hf
hf (heart failure)
hf as an independent risk factor for stroke, systemic embolism, mortality
hf hospitalization
hf hospitalization (re‑hospitalization)
hf hospitalizations
hf incidence
hf mortality
hf nurses
hf readmission / rehospitalization
hf registry participation
hf risk scoring
hf self‑care
hf staging
hf transplant centers
hf with improved ef (hfimpef)
hf with mildly reduced ef (hfmref)
hf with preserved ef (hfpef)
hf with preserved ejection fraction (hfpef)
hf with reduced ef (hfref)
hf with reduced ejection fraction (hfref)
hf – heart failure
hfa‑peff diagnostic algorithm (heart failure association – european society of cardiology)
hfmref (heart failure with mildly reduced ejection fraction)
hfpef (heart failure with preserved ejection fraction)
hfpef (heart‑failure with preserved ejection fraction)
hfpef – heart failure with preserved ejection fraction
hfref (heart failure with reduced ejection fraction)
hfref (heart‑failure with reduced ejection fraction)
hfref – heart failure with reduced ejection fraction
hfsa (heart failure society of america)
hfsa (heart failure society of america) guideline
hfsa heart failure guideline
hf‑action (heart failure: a controlled trial investigating outcomes of exercise training)
hf‑action predictive risk score
hibernating myocardium
high bleeding risk
high bleeding risk estimators
high bleeding‑risk procedures
high blood cholesterol
high blood pressure
high blood pressure (bp)
high blood pressure (hypertension)
high blood pressure / hypertension in adults
high blood pressure / hypertension management
high blood pressure prevention
high cardiovascular risk
high cha₂ds₂‑vasc score (>5)
high ef with diastolic dysfunction (≥40 %)
high gastrointestinal bleeding risk
high la pressure
high mortality
high or prohibitive surgical risk
high physical performance occupations (law enforcement, firefighters)
high pressure (right‑sided or left‑sided)
high procedural risk
high pulmonary vascular resistance (pvr)
high success rate
high surgical risk
high thrombotic risk
high-grade lvot gradients (80–100 mm hg)
high-volume aortic center
high-volume surgeon
highly penetrant risk
highly resistant organisms
high‐value economic therapy
high‑altitude exposure
high‑burden atrial fibrillation
high‑carbohydrate diet
high‑complexity coronary artery disease (cad)
high‑cost therapies
high‑degree atrioventricular (av) block
high‑density lipoprotein (hdl)
high‑density lipoprotein cholesterol (hdl‑c)
high‑dose aspirin
high‑dose aspirin (162‑325 mg)
high‑dose aspirin therapy
high‑dose diuretics
high‑dose glucocorticoid induction
high‑dose glucocorticoids
high‑flow oxygen in suspected acute coronary syndrome
high‑grade atrioventricular block
high‑gradient as
high‑gradient severe as
high‑impact area (improving patient outcomes)
high‑intensity anticoagulation
high‑intensity endurance training (≥3 h/day)
high‑intensity exercise‑based cardiac rehabilitation
high‑intensity immunosuppressive therapy
high‑intensity interval training
high‑intensity interval training (exercise)
high‑intensity interval training (hiit)
high‑intensity interval training (hit)
high‑intensity or competitive exercise
high‑intensity statin
high‑intensity statin therapy
high‑negative predictive value (>99.5 %)
high‑output heart failure
high‑output state
high‑potency (high‑intensity) statin
high‑pressure inlet chamber (rv)
high‑quality communication
high‑quality integrated multidisciplinary care
high‑quality, drug‑specific evidence for cardiotoxicity screening and monitoring
high‑risk acs (lvef ≤ 40 %, hypertension, diabetes mellitus, anterior stemi)
high‑risk anatomy (aaoca)
high‑risk anatomy (ostial/proximal stenosis, slit‑like orifice, acute angle of takeoff, intramural course)
high‑risk aortopathies (high‑risk cardiac conditions)
high‑risk aortopathy
high‑risk ascvd
high‑risk cardiac conditions
high‑risk cardiac disease in pregnancy
high‑risk cardiac surgery
high‑risk cardiovascular profile
high‑risk clinical findings
high‑risk clinical scenarios (comorbid conditions, social factors)
high‑risk conditions
high‑risk conditions for ascvd (age ≥ 65, familial hypercholesterolemia, prior coronary interventions, etc.)
high‑risk drinking
high‑risk features
high‑risk features (e.g., ventricular arrhythmias, atrioventricular conduction abnormalities)
high‑risk features (in myocarditis)
high‑risk features (in uncomplicated cases)
high‑risk features for adverse aortic events
high‑risk features for myocarditis
high‑risk features of rupture
high‑risk imaging features
high‑risk imaging findings
high‑risk left‑sided valve disease
high‑risk non‑cardiac surgery
high‑risk pathways
high‑risk patient populations (male predominance, older age)
high‑risk patient selection for aortic procedures
high‑risk patients
high‑risk plaque
high‑risk procedures during pregnancy
high‑risk reintervention (e.g., porcelain aorta, prior radiation)
high‑risk surgery
high‑risk, moderate‑risk, high‑probability categories
high‑sensitive cardiac troponin t (ctnt)
high‑sensitivity cardiac troponin (hs‑ctn)
high‑sensitivity crp ≥ 2.0 mg/l
high‑sensitivity c‑reactive protein (hscrp)
high‑sensitivity c‑reactive protein (hs‑crp)
high‑sensitivity troponin
high‑sensitivity troponin (tnt / tni)
high‑sensitivity troponin t (hs‑tnt)
high‑value clinical interventions
high‑velocity severe as (stage d1)
high‑volume aortic center
high‑volume aortic/heart‑valve center
high‑volume surgeons / high‑volume centers
high‑volume transplant centers with achd accreditation
high‑volume valve‑surgery centers
high‑volume versus low‑volume surgeons
high‑volume vs. low‑volume surgical centers
high blood cholesterol
hinge points for ascending aorta (≥ 5.25 – 5.75 cm)
his bundle displacement
his bundle pacing
hispanic/latino populations
histiocytes
histologic diagnosis (in myocarditis)
histopathologic criteria (dallas criteria)
history and physical examination
history of coa (coarctation of the aorta)
history of major bleeding
history of stroke
history of tia
his‑bundle pacing
his‑bundle pacing (his‑sp) / his‑bundle correction
hiv
hiv infection and cardiovascular risk
hiv‑associated cardiac disease
hiv‑associated cardiovascular disease risks (e.g., abacavir, protease inhibitors, ritonavir, dolutegravir)
hlhs (hypoplastic left heart syndrome)
hoarseness (recurrent laryngeal nerve compression)
holodiastolic flow reversal in abdominal aorta
holosystolic eccentric jet mr
holter monitor
holter monitor (24‑hour, 10‑day)
holter monitoring
holter‑based electrocardiographic monitoring
holt‑oram syndrome
holt‑oram syndrome (tbx5)
home or community setting for exercise
homelessness
home‑based cardiac rehabilitation
home‑based cr programs
home‑based exercise program
home‑based exercise programs
home‑based exercise training program
home‑based mobile cardiac rehabilitation
home‑based walking exercise
home‑based walking program
home‑delivered meals
homocysteine
homocysteine‑lowering therapy (folic acid & b‑vitamins)
homograft (aortic or pulmonary)
homograft aortic root replacement
homograft valve
homografts
hope study (heart outcomes prevention evaluation)
hope trial
hope trial (ramipril)
hope‑2 trial (heart outcomes prevention evaluation‑2)
hormonal contraception & risk of venous thromboembolism
hormonal contraception cardiovascular risk
hormonal influences on cardiac rhythm (e.g., elevated progesterone)
hormonal therapies → growth hormone, testosterone
hormonal therapy
hormone replacement therapy in achd patients
hormone therapy (estrogen, estrogen‑progesterin, oral contraceptives, hormonal contraceptives)
horner’s syndrome (sympathetic chain compression)
hospice care
hospice enrollment
hospice referral for advanced hf with <6 month survival
hospital admission outcomes for af/flutter
hospital cost analysis in aortic surgery
hospital discharge / early after discharge management
hospital discharge criteria
hospital discharge in acs management
hospital discharge planning
hospital length of stay
hospital length of stay (as outcome of rate‑control efficacy)
hospital morbidity/mortality
hospital mortality rate
hospital or outpatient facility setting for exercise
hospital performance metrics (30‑day all‑cause readmission)
hospital procedural volume
hospital procedural volume (quintiles)
hospital readmission
hospital readmission / re‑hospitalization
hospital volume
hospital volume outcomes
hospitalization
hospitalization & mortality rates (related to hf management)
hospitalization (all‑cause, cardiovascular, hf)
hospitalization (all‑cause, hf‑specific)
hospitalization (cardiac, hf, acs)
hospitalization (hf hospitalization, hfh)
hospitalization (hf‑related)
hospitalization / hospitalisations
hospitalization / readmission
hospitalization / rehospitalization
hospitalization and readmission (rehospitalization)
hospitalization due to heart failure
hospitalization due to heart failure (hf)
hospitalization for antiarrhythmic initiation
hospitalization for heart failure
hospitalization for hf
hospitalization for ischemia or hf
hospitalization for unstable angina
hospitalization for worsening heart failure
hospitalization rate (hf hospitalizations)
hospitalization rates for hf
hospitalization risk
hospitalization trends & health‑resource utilization
hospitalizations
hospitalizations (all‑cause)
hospitalized heart failure
hospitalized patients with af and rvr
hospital‑based discharge medication program
hospital‑based stemi care
hospital‑to‑home initiative
hospital‑to‑home initiatives
host‑exam trial
hot cafe trial
housing insecurity
housing instability
housing stability
housing status
how to treat chronic atrial fibrillation (hot cafe)
hps2‑thrive trial (niacin + laropiprant)












hrs (heart rhythm society)
hrs expert consensus on arrhythmogenic cardiomyopathy
htad (heritable thoracic aortic disease)
htad (heritable thoracic aortic disease) incidence among reintervention patients
htx – heart transplant
human immunodeficiency virus (hiv)
human immunodeficiency virus (hiv) (as a cardiovascular risk factor)
human leukocyte antigen (hla)
human leukocyte antigen class ii (hla‑ii) associations
human leukocyte antigen haplotypes
hurst’s the heart online
hybrid and convergent ablation procedures
hybrid approach
hybrid approach (combining endovascular and open methods)
hybrid approaches (combined surgical/endovascular)
hybrid arch exclusion (zone 0‑0)
hybrid cardiac rehabilitation (cr)
hybrid cardiovascular procedures
hybrid catheterization laboratory
hybrid cr models
hybrid endovascular approach
hybrid epicardial‑endocardial ablation
hybrid imaging (pet/spect with ct, mri)
hybrid operating room
hybrid operating room (or) laboratory
hybrid or bridging approach
hybrid percutaneous coronary intervention (pci)
hybrid procedure
hybrid procedure (closed‑chest epicardial + endocardial ablation)
hybrid procedure (combination of open and endovascular)
hybrid programs (facility‑based & community/home‑based)
hybrid repair (endovascular + open)
hybrid repair of aortic aneurysm
hybrid revascularization
hybrid revascularization strategies
hybrid surgery (endovascular + open)
hybrid surgical repair of coa
hybrid technique
hybrid techniques
hybrid techniques (open, percutaneous, or combined)
hydralazine
hydralazine + nitrate therapy
hydralazine and isosorbide dinitrate
hydralazine and isosorbide dinitrate (hydral‑nitrates)
hydralazine and isosorbide dinitrate therapy for hfref in black or african american patients
hydralazine‑isosorbide dinitrate (h‑isdn)
hydralazine‑isosorbide dinitrate combination
hydralazine‑isosorbide dinitrate for black patients with heart failure
hydralazine‑isosorbide therapy in hf (african american and non‑african american)
hydration (pre‑contrast)
hydration status
hydrochlorothiazide
hydrocortisone
hydroxychloroquine (dmard)
hyperacute aortic dissection
hyperbaric oxygen therapy
hypercholesterolemia
hypercholesterolemia (as a risk factor)
hypercholesterolemia (high cholesterol)
hypercholesterolemia (primary severe hypercholesterolemia)
hypercholesterolemia / familial hypercholesterolemia
hypercoagulability
hypercoagulable state
hypercoagulable state (e.g., active malignancy, genetic thrombophilia)
hypercoagulable state in hf
hypercoagulable states
hypercoagulable syndromes
hyperkalemia
hyperkalemia (serum potassium >5.0 meq/l)
hyperkalemia (serum potassium ≥ 5.5 meq/l)
hyperlipidemia
hyperlipidemia (high ldl‑c, low hdl‑c)
hypersensitivity syndrome
hypertelorism
hypertension
hypertension (antihypertensive therapy)
hypertension (arterial hypertension)
hypertension (as a cardiovascular comorbidity)
hypertension (as a risk factor for aortic dissection)
hypertension (as a risk factor)
hypertension (blood‑pressure control)
hypertension (high blood pressure)
hypertension (high blood pressure) management
hypertension (high blood pressure) – includes systolic bp (sbp), diastolic bp (dbp)
hypertension (htn)
hypertension (immunology and neurohumoral effects)
hypertension (post‑coa)
hypertension (pre‑existing and pregnancy‑related)
hypertension (resting bp >140/90 mm hg or treated)
hypertension (risk factor)
hypertension (systemic and exercise‑induced)
hypertension (systolic >140 mm hg)
hypertension / blood pressure (bp)
hypertension / blood pressure management
hypertension / high blood pressure
hypertension / high blood pressure (bp)
hypertension / high blood pressure (hbp)
hypertension / uncontrolled hypertension
hypertension as a cardiovascular risk factor
hypertension control
hypertension definition (seventh report/jnc7)
hypertension guideline
hypertension in aortic stenosis
hypertension in hfpef
hypertension management (beta‑blockers, acei/arb)
hypertension management (restenosis‑free)
hypertension management in elderly/elderly consensus documents
hypertension management in pregnancy
hypertension prevalence in black patients
hypertension screening (office, home, ambulatory)
hypertension‑associated aortic disease (htad)
hypertensive cardiomyopathy
hypertensive diseases of pregnancy
hypertensive disorders of pregnancy
hypertensive therapy
hyperthyroidism
hyperthyroidism (cardiac effects)
hyperthyroidism / thyrotoxicosis
hyperthyroidism‑related hf
hypertriglyceridemia
hypertriglyceridemia (≥500 mg/dl)
hypertrophic cardiomyopathy
hypertrophic cardiomyopathy (hcm)
hypertrophic cardiomyopathy registry (hcmr)
hypertrophic obstructive cardiomyopathy
hypertrophic subaortic stenosis
hypertrophic subaortic stenosis (sas)
hypertrophied muscle bundles
hypertrophied papillary muscles
hyperuricemia
hyperventilation
hyperviscosity
hyperviscosity management (rehydration, iron replacement, phlebotomy)
hyperviscosity symptoms
hyperviscosity symptoms (headache, visual disturbance)
hyperviscosity syndrome
hyper‑ or hypothyroidism
hypoattenuation of valve leaflets
hypocoagulability
hypoglycemia risk
hypokalaemia
hypokalemia
hypokinetic hypertrophic cardiomyopathy
hypomagnesemia
hyponatremia
hyponatremia (serum sodium < 134 meq/l)
hyponatremia? (not in the excerpt)
hypoperfusion
hypoperfusion (resting, low pulse pressure)
hypoplasia of the proximal segment
hypoplastic aorta
hypoplastic aortic root
hypoplastic left heart syndrome (hlhs)
hypoplastic left heart syndrome (hlhs) – norwood repair
hypoplastic right or left ventricle
hyporesponder status
hypotension
hypotension (as a side‑effect of rhythm‑control drugs)
hypotension (drug‑induced)
hypotension (refractory, leading to cardiac arrest)
hypotension (sbp < 100 mm hg)
hypotension (symptomatic)
hypotension (systemic and pulmonary)
hypotension / shock
hypotensive events
hypotensive management in hf
hypothermic circulatory arrest
hypothyroidism
hypothyroidism (cardiac effects)
hypothyroidism‑related hf
hypovolemia
hypoxemia
hypoxemia (mild, moderate, severe)
hypoxemia (resting spo₂ ≤ 92 %)
hypoxia (oxygen saturation < 90 %)
hypoxia (tissue oxygenation inadequate)
hypo‑ or hyperthyroidism
h₂fpef score (diagnostic composite score for hfpef)
h₂fpef score components (obesity, af, age, antihypertensive meds, e/e′, pa pressure)















iabp‑shock ii study
iabp‑shock ii trial
iatrogenic dissection of right coronary artery
iatrogenic etiologies (device leads, endomyocardial biopsy)
ibrutinib (bruton’s tyrosine kinase inhibitor)
ibrutinib‑associated atrial fibrillation
ibuprofen
ibutilide
ibutilide (class iii agent)
ica‑l (l‑type ca²⁺ channel)
icd
icd (implantable cardioverter‑defibrillator)
icd (implantable cardioverter‑defibrillator) therapies
icd and crt indications
icd cost‑effectiveness
icd implantation for primary prevention
icd implantation in adults and children
icd lead failure / lead infection
icd placement for sports participation (contraindicated)
icd programming
icd shock
icd shock rates
icd shocks
icd shocks (appropriate and inappropriate)
icd shocks (appropriate icd shocks)
icd shocks (appropriate/inappropriate)
icd shocks (inappropriate)
icd therapies reduction
icd therapy (appropriate shocks)
icd therapy compliance
icd utilization
icd – implantable cardioverter‑defibrillator
icosapent ethyl
icosapent ethyl (eicosapentaenoic acid ethyl ester)
icosapent ethyl (epa ethyl ester)
icosapent ethyl (epa)
icosapent ethyl (purified epa)
icosa­pent ethyl (epa‑only formulation)
icu (intensive care unit)
icu/multidisciplinary team (mdt) involvement
id (indeterminate entry tear, e.g., i9)
idarucizumab
idarucizumab (dabigatran antidote)
idarucizumab (dabigatran reversal agent)
ideal cardiovascular health
identification of health disparities in pad (qm‑5)
idiopathic dilated cardiomyopathy
idiopathic dilated cardiomyopathy (dcm)
idiopathic giant cell myocarditis
idiopathic hypertrophic subaortic stenosis
idiopathic pulmonary arterial hypertension
idorsia
ife (immunofixation electrophoresis)
ifr‑guided pci (instantaneous wave‑free ratio > 0.89)
ik1 (inward rectifier k⁺ current)
ikach (acetylcholine‑activated k⁺ channel)
ikr (rapid delayed rectifier k⁺ current)
ikr inhibitor
iks (slow delayed rectifier k⁺ current)
ikur (ultra‑rapid delayed rectifier k⁺ current)
iliac access
iliac access parameters
iliac artery aneurysm
iliac artery aneurysm (common, internal, external)
iliac artery conduit
iliac artery graft conduit
iliac artery recanalization
iliac artery stenting
iliac artery/iliofemoral access
iliac seal diameter
iliac stenting
iliofemoral bypass
iloprost
iloprost therapy
imagine trial
imaging and engineering advances for valve diagnosis and treatment.
imaging assessment of neopulmonary outflow tract obstruction
imaging assessment of pulmonary stenosis and regurgitation
imaging biomarkers
imaging diagnostic criteria for stenosis severity
imaging diagnostics: fdg‑pet/ct, ct angiography, mri, indium‑labeled wbc scan
imaging evolution (ct follow‑up)
imaging features: high‑risk, focal intimal disruption, tiny intimal disruption
imaging for aortic disease (ct, mri, echocardiography)
imaging for assessment of laao efficacy
imaging for lv thrombus detection
imaging for pad (angiography, duplex ultrasound, etc.)
imaging for reinfection (axial imaging, identification of inflammatory changes, fluid or air collections, pseudoaneurysm formation)
imaging frequency guidelines (cmr imaging every 1–5 years)
imaging guidance in pci
imaging in large‑vessel vasculitis (e.g., pet, ct, mr)
imaging in loeys‑dietz syndrome
imaging interval based on aortic diameter and growth rate
imaging intervals (5‑year, 10‑year, 2‑3‑year, annual)
imaging intervals based on aortic size and progression
imaging intervals for long‑term surveillance
imaging laboratory records
imaging modalities
imaging modalities (ct, cmr, pet, mpi)
imaging modalities (mri, ct, angiography)
imaging modalities for aortic surveillance
imaging modalities:
imaging modalities: 2‑d echocardiography, 3‑d echocardiography, cardiac mri (cmr)
imaging modalities: computed tomography (ct), magnetic resonance imaging (mri), transthoracic echocardiography (tte)
imaging modalities: ecg, chest x‑ray, tte, ct, cmr, stress testing, tee, cardiac catheterization
imaging modality
imaging modality for myocardial hypertrophy pattern (apical, atypical, etc.)
imaging modality for pannus detection
imaging of postsurgical aorta
imaging of the aorta (ct, mri, tee)
imaging phenotype
imaging studies
imaging surveillance
imaging surveillance (ct, mri, pet‑ct, tee)
imaging techniques (ct, mri, echocardiography, intravascular ultrasound, abdominal ultrasound)
imaging: computed tomography (ct)
imaging: magnetic resonance imaging (mri)
imaging: transthoracic echocardiogram (tte)
imaging‑only evidence of malperfusion
imatinib
immediate (early) surgical outcomes
immediate (single‑procedure) multivessel pci
immediate mortality risk (per hour)
immediate revascularization
immune checkpoint blockade
immune checkpoint inhibitors
immune checkpoint inhibitors (ici)
immune checkpoint inhibitors (treatment implications)
immune checkpoint‑inhibitor‑associated myocarditis
immune phenotyping
immune polarization
immune tolerance
immune‑checkpoint inhibitors
immune‑checkpoint‑inhibitor–induced myocarditis
immune‑checkpoint–related myocarditis
immune‑mediated inflammatory reaction
immunization (vaccine recommendations)
immunization for cardiovascular risk reduction (e.g., influenza vaccine, pneumococcal vaccine)
immunizations (in the context of cardiovascular risk)
immunocompromised hosts (fungal or tuberculous aortitis)
immunofixation electrophoresis (ife)
immunogenicity
immunoglobulin g4‑related disease
immunologic phenomena (immune complex deposition, rheumatoid factor)
immunological tolerance
immunomodulators
immunomodulatory drugs (lenalidomide, interleukin‑2)
immunophenotyping
immunosuppressive drugs (cyclosporine, tacrolimus, everolimus, sirolimus)
immunosuppressive therapies
immunosuppressive therapy
immunosuppressive therapy (e.g., for sarcoidosis, eosinophilic, giant‑cell myocarditis)
immunosuppressive therapy in myocarditis
impact of coronary artery anatomy on surgical outcomes
impact‑af program (computerized decision support for af care).
impaired chronotropic response (chronotropic incompetence)
impella device
implantable cardiac devices
implantable cardiac monitor
implantable cardiac monitor sensitivity for af
implantable cardiac monitors
implantable cardioverter defibrillator (icd)
implantable cardioverter-defibrillator (icd) therapy
implantable cardioverter‑defibrillator
implantable cardioverter‑defibrillator (icd)
implantable cardioverter‑defibrillator (icd) implantation
implantable cardioverter‑defibrillator (icd) in achd
implantable cardioverter‑defibrillator (icd) infection
implantable cardioverter‑defibrillator (icd) outcomes
implantable cardioverter‑defibrillator (icd) placement
implantable cardioverter‑defibrillator (icd) placement counseling for hfref
implantable cardioverter‑defibrillator (icd) shocks
implantable cardioverter‑defibrillator (icd) – shock risk
implantable cardioverter‑defibrillator leads
implantable cardioverter‑defibrillator lead–induced tricuspid regurgitation
implantable cardioverter‑defibrillator programming and testing
implantable cardioverter‑defibrillator shock appropriateness in repaired tof
implantable cardioverter‑defibrillator therapy
implantable cardioverter‑defibrillators
implantable cardioverter‑defibrillators (icd)
implantable cardioverter‑defibrillators (icds)
implantable cardioverter–defibrillator (icd)
implantable cardioverter–defibrillators (icds)
implantable cardio‑defibrillator (icd)
implantable defibrillator
implantable defibrillator complications
implantable defibrillator therapy
implantable devices
implantable devices (including cardiac resynchronization)
implantable electrical interventions (e.g., multipoint pacing, non‑excitatory electrical impulses)
implantable loop recorder
implantable loop recorder (implantable recorder)
implantable loop recorder clinical yield in af detection
implantable loop recorders
implantable cardioverter‑defibrillator (icd)
implantation timing of icd
implantation‑related complications
implanted defibrillator (icd)
implanted device
implanted electronic devices (icds, crt‑ds)
implementation science
implementation strategies
impless‑stic study (impella plus iabp for cardiogenic shock)
implicit bias in clinical decision‑making
implicit bias training in healthcare
impotence
improve‑it study (clinical trial)
improve‑it trial
improve it trial
in situ graft repair
in situ reconstruction
in situ venous reconstruction
in vitro fertilization with preimplantation genetic diagnosis (pgd)
in-hospital morbidity and outcomes
in-line blood flow
ina (sodium channel)
inadequate housing conditions
inadequate or excessive anticoagulation
inadequate social support
inappropriate icd shock
inappropriate icd shocks (e.g., in tetralogy of fallot)
inappropriate shock
inappropriate shocks
inappropriate vasodilatation
inari medical
inari medical (vascular interventions)
ina‑l augmentation
incarda
incidence
incidence (of cardiovascular conditions)
incidence of af
incidence of drug use–associated ie
incidence of heart failure
incidence of valve deterioration after 10 years
incidence/size thresholds for rupture or dissection
incident atrial fibrillation
incident heart failure (hf)
incident hf risk
inclisiran
inclisiran (monoclonal antibody)
inclisiran (small interfering rna pcsk9 inhibitor)
inclusion in clinical trials
inclusion of diverse patient groups
inclusion‑wrap technique
income level
incomplete penetrance
incomplete revascularization
inconvenience of monitoring
increased filling pressures
incremental cost‑effectiveness ratio
incremental cost‑effectiveness ratio (icer)
incremental decrease through aggressive lipid lowering (ideal) study
incremental increases in walking intensity
index of microcirculatory resistance (imr)
index of microvascular resistance (imr)
indexed right ventricular end‑diastolic volume (rvedv)
indexed right ventricular end‑systolic volume (rvesv)
indications for surgery based on lung biopsy in vsd/pda with severe ph
individual‑patient data meta‑analysis.
indomethacin therapy for pericarditis
inducible atrial fibrillation
inducible atrial fibrillation (at ablation)
inducible sustained ventricular arrhythmia
inducible ventricular arrhythmia
infant of mother with gestational diabetes
infarct size
infarction anterior cerebral artery
infarction middle cerebral artery
infarction posterior cerebral artery
infarct‑related artery
infected aneurysm
infected aortic aneurysm
infection
infection (advanced or bone/soft‑tissue involvement)
infection (as a precipitant for af)
infection (infective endocarditis, ie) – contraindication to transcatheter therapy, requires antibiotics before surgery
infection (prosthetic valve endocarditis)
infection management
infection management in pad patients
infection prevention guidelines for infective endocarditis
infection‑related complications
infection‑related heart disease indicators (fever >38 °c, vascular phenomena, immunologic phenomena)
infectious aneurysm
infectious aortitis
infectious aortitis (mycotic aneurysm)
infectious disease
infectious disease specialist
infectious disease specialists (mdt)
infectious disease specialists (role in ie care)
infective endocarditis
infective endocarditis (ie)
infective endocarditis (ie) prophylaxis
infective endocarditis (post‑valve or post‑repair)
infective endocarditis (risk factor)
infective endocarditis (valvular vegetation)
infective endocarditis (with vsd involvement)
infective endocarditis prophylaxis
infective endocarditis risk factors
infective material limiting valve occluder motion
inferior infarction
inferior vena cava (ivc) diameter
inferior vena cava (ivc) stenosis
infiltrative cardiac disease (amyloid, sarcoid, hemochromatosis)
infiltrative cardiomyopathies
infiltrative cardiomyopathies (e.g., amyloid)
infiltrative cardiomyopathy (e.g., amyloidosis)
infiltrative disorders
inflammation
inflammation (and inflammatory markers)
inflammation (as a cardiovascular risk factor)
inflammation (e.g., il‑6)
inflammation / metabolic derangement
inflammation and oxidative stress
inflammation biomarkers (related to heart failure prognosis)
inflammation‑induced ion channel dysfunction
inflammatory aortitis
inflammatory arthritis (cardiovascular events)
inflammatory biomarkers (e.g., crp, esr)
inflammatory bowel disease (acute coronary syndrome risk)
inflammatory cardiomyopathy
inflammatory cardiomyopathy (chronic)
inflammatory cells (within thrombus)
inflammatory cytokines
inflammatory cytokines (exercise‑induced)
inflammatory disease of the heart
inflammatory infiltrate (on emb)
inflammatory infiltrate classification
inflammatory infiltrate risk for vas
inflammatory infiltrates
inflammatory mechanisms (e.g., crp elevation, nlrp3 inflammasome)
inflammatory pathways
inflammatory response
inflammatory signaling
inflammatory signalling
inflammatory state
inflammatory aortitis
inflow disease
inflow lesions













influenza vaccination
influenza vaccination (as a preventive measure for cardiovascular risk)
influenza vaccination as secondary prevention for cardiovascular disease
influenza vaccination in heart failure
influenza vaccination status
influenza vaccine
infragenicular arterial bypass
infrainguinal autogenous vein bypass grafts
infrainguinal bypass graft
infrapopliteal arterial disease
infrapopliteal arterial segment
infrapopliteal arteries (tibial, pedal)
infrapopliteal balloon angioplasty
infrapopliteal bypass
infrapopliteal disease
infrapopliteal intervention
infrarenal aaa
infrarenal aorta
infrarenal aortic ulcer therapy
infra‑popliteal disease
infra‑popliteal procedures
infundibular right ventricular outflow obstruction / double‑chamber right ventricle
infundibulotomy
infundibulum (outflow tract)
infuse‑ami trial
inhaled iloprost
inhaled nitric oxide (pre‑operative test)
inheritable cardiomyopathies
inherited cardiomyopathies
inherited cardiomyopathy genes
inherited channelopathies (e.g., brugada, catecholaminergic polymorphic ventricular tachycardia)
inherited connective‑tissue disorders with cardiac manifestations (e.g., marfan syndrome, hypertrophic cardiomyopathy)
inherited heart disease
inherited ion‑channel disorders
inherited vascular connective tissue disorder
injection drug use (risk factor for ie)
injection drug users (idu)
injection drug use–associated ie
injection‑site reaction (adverse effect of pcsk9 therapies)
injury after pci
inner‑edge measurement
inner‑edge to inner‑edge measurement
innominate artery
innominate artery cannulation
inoperable severe aortic stenosis
inotersen (drug for attrv)
inotersen therapy
inotrope dependence
inotrope strategies
inotropes
inotropes (intravenous)
inotrope‑dependent advanced hf
inotropic agents
inotropic agents (milrinone, dobutamine, dopamine, epinephrine, norepinephrine)
inotropic infusion
inotropic support
inotropic support (e.g., dobutamine, milrinone)
inotropic support / inotropes
inotropic support trials
inotropic therapy
inotropic therapy (intravenous inotropes)
inotropic/pressor support
inoue balloon‑dilation method
inpatient care setting – cardiovascular care context
inpatient monitoring of heart failure
inr (international normalized ratio)
inr goal (2–3)
inr monitoring
inr target ranges
inr target ranges (1.5‑2.0, 2.5, 2.0‑3.0)
insertable cardiac monitor
insomnia and risk of cardiovascular disease
inspiratory muscle strength
inspiratory muscle training
instantaneous wave‑free ratio (ifr)
instantaneous wave‑free ratio (ifr)
instead (investigation of stent grafts in patients with type b aortic dissection)
institutional expertise in congenital heart disease (chd)
institutional imaging availability
institutional volume
insufficient blood flow to the heart muscle
insulin resistance
insulin sensitivity
insurance barriers
insurance reimbursement for exercise therapy
insurance status / health insurance coverage
intact ventricular septum
integrated cardio‑oncology framework
integrated chronic care models
integrated lifestyle and risk‑factor modification programs (lrfm)
integrated systems biology models for hf diagnosis, prognosis, and therapy targeting.
intense endurance exercise
intensity rating of breathlessness
intensive blood pressure lowering
intensive blood‑pressure control
intensive blood‑pressure control (sprint)
intensive blood‑pressure lowering
intensive blood‑pressure management
intensive blood‑pressure reduction
intensive blood‑pressure reduction studies
intensive bp control
intensive bp control (<120 mm hg)
intensive cardiac rehabilitation
intensive care setting
intensive care unit
intensive care unit (icu)
intensive care unit (icu) admission
intensive care unit (icu) coverage
intensive care unit (icu) monitoring
intensive care unit (icu) organization
intensive care unit (icu) patients with cardiac rhythm issues
intensive care unit (icu) services (as a readmission risk factor)
intensive care unit (icu) specialized in acute aortic/heart disease management
intensive care unit (icu) stay
intensive glucose lowering
intensive lifestyle intervention (diet, exercise)
intensive lipid lowering
intensive sbp goal (<120 mm hg)
intensive statin intensity (moderate‑intensity, high‑intensity)
intensive/statistically significant risk reduction
intensivists
interarterial course of coronary artery
interatrial baffle
interatrial conduction time
interatrial shunt
interfacility transfer of patients with acute type a aortic dissection
interleukin (il)
interleukin‑17 (il‑17)
interleukin‑2 receptor (soluble il‑2r)
interleukin‑37 (il‑37)
interleukin‑4 (il‑4)
interleukin‑6 (il‑6)
interleukin‑6 receptor (il‑6r)
intermacs
intermacs (interagency registry for mechanically assisted circulatory support)
intermacs profiles
intermacs profiles (1–7, interagency registry for mechanically assisted circulatory support)
intermacs profiles (cardiogenic shock, inotropic dependence, etc.)
intermacs profiles of advanced hf
intermacs profiling
intermacs registry for adult chd patients on mcs
intermediate care unit
intermediate care unit (icu)
intermediate risk (≥7.5 %–<20 %)
intermediate, high, and low risk of ischemic events
intermediate‑risk patients
intermittent claudication
intermittent claudication management
intermittent pneumatic compression
intermittent pneumatic compression device (arterial pump)
intermittent walking
internal iliac artery
internal iliac artery exclusion
internal mammary coronary artery anastomosis
internal medicine specialist
international classification of diseases (icd)
international guidelines (e.g., circulation acs guideline)
international journal of cardiology
international multicenter angina exercise (image) study
international normalised ratio (inr)
international normalized ratio (inr)
international normalized ratio (inr) monitoring
international paediatric and congenital cardiac code
international registry of acute aortic dissection
international registry of acute aortic dissection (irad)
international registry of acute aortic dissection (irad) score
international registry of patients with tgfbr1/tgfbr2 mutations (montalcino aortic consortium).
international society for adult congenital heart disease (isachd)
international society for heart lung transplantation (ishlt) listing criteria
international society for the advancement of cardiovascular surgery (isachd)
international society of heart & lung transplantation (ishlt) guidelines
international standardization of diagnostic criteria for microvascular angina
international standardization of diagnostic criteria for vasospastic angina
internet‑based education
interpersonal safety
interposition graft
interposition grafting
interposition grafts
interrupted aortic arch
interrupted aortic arch type b
intersectionality (combined risk factor impact)
intersocietal accreditation commission (iac)
intersocietal accreditation commission (iac) accreditation
intersocietal accreditation commission (iac) echocardiography laboratory accreditation
interstitial changes
interstitial edema
interstitial fibrosis
interstitial fibrosis (conduction heterogeneity)
interstitial lung disease
interstitial space characteristics
interval change
intervention (cardiac care)
intervention criteria in congenital heart conditions
intervention threshold
intervention threshold (≥10 cm²/m)
intervention thresholds (e.g., lvesd >50 mm, indexed >25 mm/m²)
intervention thresholds for valve repair/replacement
interventional and cardiovascular programs
interventional candidates
interventional cardiac systems
interventional cardiologist
interventional cardiologists
interventional cardiology
interventional cardiology in achd
interventional cardiology techniques
interventional cardiovascular procedures
interventional closure of ventricular septal defect
interventional echocardiographer (formalized role)
interventional echocardiographer (imaging guidance)
interventional procedures
interventional procedures (e.g., septal reduction)
interventional radiology
interventional radiology for aortic disease
interventional radiology for vascular disease
interventional radiology in aortic disease management
interventional techniques (arterial embolization, endovascular therapy)
interventional therapy (surgical or transcatheter lvot stenosis relief)
interventionist procedures for chd
interventions
interventions / policies
intervention‑free survival
interventricular septal thickness in diastole
intima
intima (intimal tear)
intimal defect
intimal disruption
intimal flap mobility
intimal injury
intimal medial hematoma (imh)
intimal tear
intimate partner violence
intraatrial placement of mitral prosthesis
intracardiac abscess
intracardiac arrhythmias
intracardiac conduit
intracardiac device
intracardiac echocardiography
intracardiac electrocardiograms (ecgs)
intracardiac mass
intracardiac mural thrombi
intracardiac pressures
intracardiac prosthetic materials (pacemaker leads)
intracardiac repair
intracardiac repair of congenital defects
intracardiac rhythm devices
intracardiac shunt
intracardiac shunt (e.g., patent foramen ovale)
intracardiac shunts
intracardiac shunts (other than apvc)
intracardiac surgery
intracardiac thrombi
intracardiac thrombosis
intracardiac thrombosis / embolism
intracardiac thrombus
intracavitary gradients
intracavitary pressure
intracellular sodium overload
intracerebral hemorrhage
intracerebral hemorrhage (ich)
intracerebral hemorrhage (iph)
intracoronary (ic) blockade
intracoronary abciximab
intracoronary drug delivery
intracoronary glycoprotein iib/iiia inhibitors
intracoronary imaging
intracoronary imaging (general)
intracoronary imaging (plaque assessment & regression)
intracoronary imaging guidance
intracoronary infusion of abciximab
intracoronary ultrasound‑enhancing contrast
intracoronary versus intravenous drug administration
intracranial aneurysm
intracranial aneurysm screening
intracranial aneurysm screening (mri/ct)
intracranial aneurysms (brain mri/ct angiography)
intracranial aneurysms screening
intracranial bleeding
intracranial haemorrhage (ich)
intracranial hemorrhage
intracranial hemorrhage (as a contraindication to fibrinolysis)
intracranial hemorrhage (ich)
intracranial hemorrhage recurrence risk
intracranial hemorrhage risk score
intracranial hemorrhage survivors
intracranial malignancy
intractable pain
intragastric (intracaval) imaging terms related to vascular pathology.
intralaminar hematoma (imh)
intralaminar intimal tear
intraluminal imaging
intraluminal thrombus
intramural arterioles (density)
intramural blood pool
intramural coronary artery abnormalities
intramural coronary course
intramural hematoma
intramural hematoma (imh)
intramyocardial muscle bundles
intraoperative atrial fibrillation
intraoperative decision making
intraoperative echocardiographic guidance
intraoperative echocardiography
intraoperative tee
intraoperative transesophageal echocardiography
intraoperative transesophageal echocardiography (tee)
intraoperative trans‑esophageal echocardiography (tee)
intraparenchymal bleeding
intrapericardial lvad
intraplaque hemorrhage (implied by bleeding risk contexts)
intraprocedural anticoagulation strategies
intraprocedural echocardiography
intraprocedural guidance
intraprocedural intravenous anticoagulation
intraprocedural ischemic events
intraprocedural myocardial contrast echocardiography
intraprocedural outcomes
intrapulmonary hemorrhage
intrathecal papaverine
intravascular catheter–associated bacteremia
intravascular complications (e.g., pulmonary vein stenosis)
intravascular filling defects (e.g., thrombus, dissection flap)
intravascular imaging
intravascular imaging‑guided pci
intravascular magnesium
intravascular pressure measurements
intravascular procedure
intravascular ultrasound
intravascular ultrasound (ivus)
intravascular ultrasound (ivus) for graft assessment
intravascular ultrasound (ivus) guidance
intravascular ultrasound assisted sizing
intravascular ultrasound imaging
intravenous (iv)
intravenous (iv) drug administration
intravenous (iv) platelet blockade
intravenous amiodarone
intravenous antiarrhythmic therapy
intravenous antibiotic treatment
intravenous anticoagulation
intravenous antimicrobial therapy
intravenous anti‑arrhythmic therapy
intravenous beta‑blocker use prior to reperfusion
intravenous beta‑blockers (e.g., esmolol, metoprolol, labetalol)
intravenous bolus
intravenous calcium channel blockers
intravenous cangrelor during pci
intravenous cangrelor trials (rcts 1–3)
intravenous catheter–associated bacteremia.
intravenous digoxin (digitalis glycoside)
intravenous diltiazem
intravenous diuretics
intravenous diuretics (bolus or continuous infusion)
intravenous drug delivery
intravenous drug use–associated endocarditis
intravenous drug use–related endocarditis
intravenous esmolol
intravenous flecainide
intravenous glycoprotein iib/iiia inhibition
intravenous glycoprotein iib/iiia inhibitors
intravenous heparin
intravenous heparin infusion (continuous or slow‑infusion)
intravenous ibutilide
intravenous ibutilide therapy
intravenous infusion
intravenous infusion of abciximab
intravenous infusion of eptifibatide
intravenous infusion of tirofiban
intravenous inotropes
intravenous inotropic agents
intravenous inotropic support
intravenous iron replacement for iron deficiency in hf
intravenous iron therapy
intravenous iron therapy (ferric carboxymaltose)
intravenous loading of sotalol
intravenous loop diuretics
intravenous magnesium
intravenous magnesium (as rate‑control therapy)
intravenous magnesium sulfate
intravenous methylprednisolone
intravenous nitroglycerin
intravenous nitroprusside
intravenous non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem)
intravenous p2y12 inhibition
intravenous pressure gradient (within rv)
intravenous procainamide
intravenous propafenone
intravenous prostacyclin
intravenous sotalol
intravenous sotalol therapy
intravenous streptokinase
intravenous thrombolysis
intravenous vasodilators (e.g., nicardipine, clevidipine, sodium nitroprusside)
intravenous verapamil
intravenous vitamin k
intravenous vitamin k
intravenous vs oral p2y12 inhibition
intravenous/intravenous drug hold (drug “hold” of 48 h)
intravenous/oral factor xa inhibitors (e.g., rivaroxaban)
intraventricular gradients
intraventricular myocardial stiffness
intra‑abdominal surgery
intra‑annular rv pacemaker or implantable cardioverter‑defibrillator leads
intra‑aortic balloon counterpulsation
intra‑aortic balloon counterpulsation (iabc)
intra‑aortic balloon counterpulsation (iabp)
intra‑aortic balloon pump
intra‑aortic balloon pump (iabp)
intra‑aortic balloon pump/support
intra‑aortic debris










intra‑atrial reentrant arrhythmias
intra‑atrial reentrant tachycardia (iart)
intra‑atrial re‑entrant tachycardia
intra‑atrial re‑entrant tachycardia (scar‑mediated)
intra‑cranial tumor / vascular abnormality
intra‑mural course
intra‑operative imaging
intrinsic cardiac risks
intrinsic coronary flow reserve (crf)
intrinsic flow compromise in myocardium
intrinsic mitral valve disease
intrinsic myocardial performance
intrinsic pulmonary vascular disease
invasive approach (routine invasive strategy)
invasive bacterial pathogens
invasive cardiac evaluation (catheterization)
invasive cardiac procedures
invasive cardiology
invasive coronary angiography
invasive coronary angiography (ica)
invasive coronary angiography prior to discharge
invasive coronary function testing (cormica trial)
invasive coronary physiology testing
invasive electrophysiology procedures
invasive hemodynamic assessment
invasive hemodynamic assessment (cardiac catheterization)
invasive hemodynamic characteristics
invasive hemodynamic evaluation
invasive hemodynamic measurement (rest or exercise)
invasive hemodynamic measurements
invasive hemodynamic monitoring
invasive hemodynamics
invasive lvot gradient measurement.
invasive lvoto evaluation
invasive management
invasive management of acute mi complicated by cardiogenic shock
invasive management of acute mi with cardiogenic shock (specific to acute mi)
invasive management of acute myocardial infarction
invasive management of obstructive hcm
invasive measurement (direct invasive measurement)
invasive measurement (of pah)
invasive measurements of pulmonary artery pressures
invasive monitoring
invasive pressure measurements
invasive procedure
invasive procedures
invasive risk stratification
invasive srt
invasive srts (myectomy, alcohol septal ablation)
invasive strategy
invasive strategy (angiography, revascularization)
invasive strategy for acs (including pci)
invasive treatment decisions (revascularization, amputation)
invasive treatment for obstructive hcm (e.g., surgical myectomy, alcohol septal ablation)
invasive versus non‑invasive treatment strategy
invasive vs. selective invasive strategy (routine invasive approach)
invest (international verapamil‑srv trandolapril) study
invest trial (international recommendations for bp management)
investigational device exemption (ide)
investigational devices
investigational stent graft devices
invictus trial
inward current (automaticity / early afterdepolarization)
inward rectifier potassium currents (i<sub>ka</sub>)
in‑hospital and 30‑day mortality (<1%)
in‑hospital mortality
in‑hospital mortality rate
in‑hospital stay
in‑situ reconstruction
in‑stent restenosis
in‑stent re‑stenosis
iodinated contrast
iodinated contrast agent
iodinated contrast allergy
iodinated contrast media
iodinated contrast nephrotoxicity (from ct)
ion channelopathy genes
ionis
ionizing radiation exposure
ionizing radiation exposure (from ct)
ipragliflozin
irad database
irad risk score
irbesartan
iron deficiency
iron deficiency (annual screening)
iron deficiency anemia
iron deficiency anemia in achd
iron deficiency therapy
iron metabolism & homocysteine levels
iron overload
iron studies (serum iron, total iron‑binding capacity, ferritin)
iron supplementation
ironout hf trial
ironwood
iron‑deficiency anemia
irreversible hepatic disease
irreversible neurological disease
irreversible renal disease
isachd (international society for adult congenital heart disease)
isar‑safe trial
ischaemia
ischaemic cardiomyopathy
ischaemic heart failure
ischaemic mitral regurgitation
ischemia
ischemia (e.g., myocardial or limb ischemia)
ischemia (general term encompassing myocardial, limb, and other tissue ischemia)
ischemia (general)
ischemia (heart ischemia)
ischemia (identified by myocardial perfusion imaging)
ischemia (irreversible, prolonged)
ischemia (limb and systemic)
ischemia (vascular‑related tissue hypoxia)
ischemia / severe recurrent ischemia
ischemia burden
ischemia extent
ischemia severity
ischemia severity (noninvasive testing)
ischemia trial
ischemia trial (stable cad, ischemia)
ischemia trial results
ischemia with no obstructive coronary artery disease (inoca)
ischemia with nonobstructive coronary arteries (inoca)
ischemia with non‑obstructive coronary arteries
ischemia with non‑obstructive coronary arteries (inoca)
ischemia with non‑obstructive coronary artery (inoca)
ischemia‑ckd study (invasive vs medical treatment for ckd)
ischemia‑driven revascularization
ischemia‑driven target vessel revascularization
ischemia‑reperfusion injury
ischemia without obstructive coronary artery disease (inoca)
ischemic adverse events
ischemic and bleeding risk assessment
ischemic burden
ischemic cardiomyopathy
ischemic cardiomyopathy / ischemic left‑ventricular dysfunction
ischemic cardiovascular events
ischemic changes on ecg
ischemic chronic secondary mr
ischemic colitis
ischemic events
ischemic events (myocardial infarction, stroke)
ischemic events (non‑fatal ischemia, myocardial infarction)
ischemic events / ischemic efficacy
ischemic foot ulcer in diabetic patients
ischemic heart disease
ischemic heart disease (ihd)
ischemic heart disease (stable ischemic heart disease)
ischemic heart failure
ischemic hf
ischemic insult
ischemic left ventricular dysfunction
ischemic limb
ischemic limb outcomes
ischemic mitral regurgitation
ischemic mr
ischemic myocardium
ischemic neurologic events
ischemic outcomes
ischemic rest pain
ischemic risk
ischemic skin changes
ischemic skin changes (wounds, ulceration)
ischemic stroke
ischemic stroke (relevant contraindication)
ischemic stroke in hcm
ischemic stroke risk
ischemic symptoms
ischemic symptoms (moderate‑to‑severe claudication pain)
ischemic symptoms assessment
ischemic time
ischemic cardiomyopathy
ischemix (ischemic vascular therapy)
isolated branch pulmonary artery stenosis
isolated or concomitant tricuspid valve repair or replacement
isolated pulmonary regurgitation
isolated pulmonary stenosis
isolated systolic hypertension
isolated tr (associated with af, preserved lvef)
isolated tricuspid regurgitation
isolated tricuspid regurgitation surgery
isolated tricuspid valve surgery
isolated ventricular septal defect
isolated pulmonary regurgitation
isometric exercise
isometric exercise training
isometric exercise training for blood‑pressure management
isometric resistance exercise
isoproterenol challenge
isosorbide dinitrate
isosorbide dinitrate (iso)
isosorbide dinitrate plus hydralazine (fixed‑dose combination)
isosorbide mononitrate
isotonic fluid replacement.
isthmus (crista terminalis)
ito (transient outward k⁺ current)
ivabradine
ivabradine (i‑channel inhibitor)
ivabradine therapy (targeting heart rate ≥ 70 bpm)
i‑aκ (mhc ii molecule on apcs)
i‑preserve (irbesartan in heart failure with preserved ejection fraction) study
i‑preserve score (irbesartan in heart failure with preserved ejection fraction study)













jacc (journal of the american college of cardiology)
jacc review topic of the week (cardiac shock care centers)
jacc state‑of‑the‑art review on cardiovascular drugs in pregnancy
jama (medical journal covering cardiovascular topics)
janeway lesions
janssen pharmaceuticals
janus kinase inhibitors
jcpm (joint commission on practice‑mediated)
jet velocities
jet width (percentage of lvot)
jnk2 signaling
johnson & johnson
joint british societies (jbs3) consensus
joint committee on clinical practice guidelines** (guideline‑development body)
joint committee on performance measures
journal of cardiovascular pharmacology
journal of clinical lipidology
journal of the american college of cardiology (jacc)
jugular venous distention
jugular venous pressure (jvp)
jump extension grafts
jupiter (justification for the use of statins in prevention) trial
juxtarenal aorta
j‑curve risk pattern for vigorous activity
j‑point definition
j‑shaped relationship (alcohol vs. cardiovascular outcomes)
j‑shaped relationship between alcohol and cardiovascular risk














kaneka pharma america llc
kansas city cardiomyopathy questionnaire (kccq)
kaplan‑meier method (used for af recurrence analysis)
kawasaki disease
kawasaki disease (congenital coronary involvement)
kawasaki disease (coronary sequelae)
kawashima procedure
kcnq1 (potassium voltage‑gated channel subfamily q member 1) variants
ketoacidosis (perioperative)
ketoconazole
key biomarkers
key clinical concepts from the text:
key clinical trials mentioned
key crt trials: companion, madit‑crt, reverse, block‑hf, care‑hf, raft, mustic‑af, spare, pave
key guideline terms
key heart disease–related terms
key heart disease–related terms extracted
key heart‑/vascular‑disease terms extracted from the guideline text
key heart‑disease related terms
key heart‑disease related terms (from the provided guideline text)
key heart‑disease related terms extracted
key heart‑disease related terms extracted from the document
key heart‑disease related terms extracted from the guideline text
key heart‑disease related terms extracted from the guidelines text
key heart‑disease related terms extracted from the provided text
key heart‑disease related terms extracted from the text
key heart‑disease related terms found in the text
key heart‑disease related terms from the guideline excerpt
key heart‑disease related terms from the text
key heart‑disease related terms identified in the text
key heart‑disease terms (from the hcm guideline excerpt)
key heart‑disease terms extracted
key heart‑disease terms extracted from the guideline
key heart‑disease terms extracted from the guideline text
key heart‑disease terms extracted from the guidelines
key heart‑disease terms extracted from the guidelines and cited studies
key heart‑disease terms extracted from the text
key heart‑disease terms extracted:
key heart‑disease terms found in the guideline excerpt
key heart‑disease terms identified
key heart‑disease terms identified in the excerpt
key heart‑disease terms identified in the guideline excerpt
key heart‑disease terms identified in the guideline text
key heart‑disease terms identified in the text
key heart‑disease terms mentioned in the text
key heart‑disease‑related terms
key heart‑disease‑related terms extracted from the guideline text
key heart‑disease–related terms
key heart‑disease–related terms extracted
key heart‑disease–related terms extracted from the guideline
key heart‑disease–related terms extracted from the text
key heart‑disease–related terms identified
key heart‑disease–related terms identified in the guideline excerpt
key heart‑disease–related terms identified in the text
key heart‑vascular terms extracted from the text
key medical‑device and pharmaceutical entities:
key terms related to heart (aortic) disease:
key terms related to heart (cardiovascular) disease in the guideline text
key terms related to heart disease
key terms related to heart disease (and vascular complications) in the guideline:
key terms related to heart disease (as extracted from the guideline excerpt)
key terms related to heart disease (as extracted from the guideline text)
key terms related to heart disease (as extracted from the provided text)
key terms related to heart disease (from the excerpt provided):
key terms related to heart disease (from the provided guideline excerpt)
key terms related to heart disease (from the provided text)
key terms related to heart disease (peripheral artery disease & related care):
key terms related to heart disease (primarily peripheral artery disease)
key terms related to heart disease (valvular and hemodynamic):
key terms related to heart disease (vascular/ischemic disease) extracted from the guideline text
key terms related to heart disease / cardiovascular care:
key terms related to heart disease extracted from the guideline text
key terms related to heart disease extracted from the guideline text:
key terms related to heart disease extracted from the guideline:
key terms related to heart disease extracted from the text
key terms related to heart disease found in the text
key terms related to heart disease found in the text:
key terms related to heart disease in the guideline
key terms related to heart disease in the text
key terms related to heart disease:
kidney disease / chronic kidney disease
kidney disease as a risk factor for cardiovascular disease
kidney disease management guidelines (neoerica, etc.)
kidney disease progression (as a benefit)
kidney excretion
kidney failure / end‑stage renal disease
kidney function (for dose adjustment and monitoring)
killip class
killip class (ii–iv)
killip class ii‑iv acute heart failure
klinefelter syndrome
klinefelter syndrome (47,xxy) – patent ductus arteriosus, asd, mitral valve prolapse
knowledge chunk format
knowledge of lifelong cardiac care
knowledge‑chunk format for cardiovascular guideline presentation
kommerell diverticulum (aneurysmal dilation of anomalous subclavian artery)
kommerell’s diverticulum












l-type ca²⁺ current
la (left atrium)
la anterior‑posterior dimension
la appendage excision
la appendage occlusion / exclusion
la appendage occlusion/exclusion/amputation
la compliance
la ejection fraction
la emptying fraction
la emptying function
la end‑diastolic volume
la enlargement
la non‑compliance
la strain
la thrombus
la volume / left atrial volume
laa (left atrial appendage)
laa closure
laa device implantation (plaao)
laa occlusion (laao)
laao (left atrial appendage occlusion)
laaos iii trial
laaos study
laaos iii (left atrial appendage occlusion study)
labetalol
labetalol (intravenous)
labile inr
labile inr (time in therapeutic range < 60%)
lack of contractile reserve / flow reserve
lack of social support
lactate (elevated lactate)
lactate metabolism
lactation
lactmed (lactation medications database)
lake louise criteria (cmr findings)
lake louise criteria (2009 & 2018)
laminated (in‑situ) thrombi
lamp2 (danon disease)
lamp2 cardiomyopathy
landing zone
landing zone 0 (0a, 0b, 0c)
landing zone assessment
lansoprazole
laplace’s law in aortic wall stress
large anterior infarction
large area of myocardium at risk
large cohort study
large infarct territory
large septal defects
large sheath access
large thrombus burden
large vessel vasculitis
large vessel vasculitis (lvv)
large‑bore access
large‑vessel vasculitis
large‑vessel vasculitis (lvv)
laryngeal nerve palsy
laser capture microdissection
laser doppler flowmetry
laser speckle imaging
late aortic complications
late aortic rupture (incidence >5% through 8 years)
late assessment of thrombolytic efficacy (late) study
late atrial tachycardia
late complications
late coronary artery complications post‑arterial switch
late death
late gadolinium enhancement
late gadolinium enhancement (lge)
late gadolinium enhancement cardiovascular magnetic resonance
late gadolinium enhancement imaging
late gadolinium enhancement on cardiac mri
late gadolinium‑enhancement cmr
late graft infection (>3 months)
late heart failure
late intervention
late mortality
late mortality associated with bioprosthetic valves
late myocardial ischemia
late outcomes
late phase sodium currents
late postoperative complications
late post‑closure pah
late pregnancy assessment
late presentation of myocardial infarction
late presenters (12‑24 hours after symptom onset)
late reintervention
late results of vsd closure (30–35 years)
late rupture
late sodium current
late sodium current (ina,l)
late sodium current (mechanism of ranolazine)
late thrombotic events
late/ delayed myocardial enhancement quantification
latent lvoto detection
lateral e′ velocity
lateral medullary syndrome
lateral velocity ratio threshold (≤0.25)
late‑onset complete heart block
lbbb (left bundle branch block)
lbbb – left bundle branch block
lcz696 (lcz)
lcz696 (sacubitril/valsartan)
ldl cholesterol
ldl cholesterol lowering
ldl testing / monitoring
ldlr
ldl‑c (low‑density lipoprotein cholesterol)
ldl‑c / ldl
ldl‑c level targets
ldl‑c lowering efficacy (≥50 %, 30‑49 %, <30 %)
ldl‑c lowering strategy (rapid, intensive)
ldl‑c reduction
ldl‑c reduction goals (≥ 50 % with high‑intensity statin)
ldl‑c target levels
ldl‑c target ≤ 70 mg/dl
ldl‑c threshold for therapy intensification (≥ 70 mg/dl, persistent ≥ 100 mg/dl)
ldl‑c thresholds: ≥70 mg/dl, <70 mg/dl, <50 mg/dl
ldl‑c ≥ 190 mg/dl (≥ 4.9 mmol/l)
ldl‑cholesterol (ldl‑c)
ldl‑cholesterol (ldl‑c) management
ldl‑cholesterol lowering
ldl‑cholesterol target levels
ldl‑lowering therapy guidelines
lead dislodgement
lead extraction
lead failure
lead placement
leader trial
leading‑edge measurement
leadless atrioventricular synchronous pacing
leadless pacemaker implantation
leaflet abnormalities (excessive leaflet length, anomalous papillary muscle insertion)
leaflet calcification
leaflet calcification / aortic‑valve calcium
leaflet degeneration
leaflet flail
leaflet length (ct measurement for tavi planning)
leaflet mobility
leaflet number
leaflet perforation
leaflet prolapse
leaflet restriction
leaflet tear / perforation
leaflet tethering
leaflet tethering height
leaflet thinning/calcification/tear
leaflet thrombosis
lean mass
lecompte maneuver
leflunomide (dmard)
left anterior descending (lad) artery
left anterior descending (lad) artery disease
left anterior descending artery
left anterior descending artery (lad)
left anterior descending artery (lad) involvement
left atrial (la)
left atrial (la) appendage ligation
left atrial (la) compliance
left atrial (la) dilatation
left atrial (la) dilation
left atrial (la) mechanics
left atrial (la) pressure
left atrial (la) size
left atrial (la) size / thrombus
left atrial (la) size and function
left atrial (la) size/volume
left atrial (la) thrombus
left atrial (la) volume
left atrial (la)–esophageal fistula
left atrial appendage
left atrial appendage (laa)
left atrial appendage (laa) closure
left atrial appendage (laa) function and anatomy
left atrial appendage (laa) imaging
left atrial appendage (laa) thrombus / laa stunning
left atrial appendage closure
left atrial appendage closure devices
left atrial appendage exclusion
left atrial appendage isolation
left atrial appendage occlusion
left atrial appendage occlusion (laao)
left atrial appendage occlusion (laao) devices
left atrial appendage occlusion / closure
left atrial appendage occlusion devices
left atrial appendage stunning
left atrial appendage thrombus
left atrial appendage thrombus resolution on follow‑up tee
left atrial blood flow characteristics
left atrial compliance
left atrial diameter
left atrial diameter z‑score
left atrial dilatation
left atrial dysfunction
left atrial enlargement
left atrial enlargement (lae)
left atrial enlargement / left atrial size
left atrial functional measures (strain, volume)
left atrial functional recovery
left atrial hypertension
left atrial mechanical function
left atrial membrane
left atrial noncompliance
left atrial or left atrial appendage thrombus (la/ laa)
left atrial posterior wall ablation
left atrial pressure
left atrial remodeling
left atrial remodeling / enlargement
left atrial scar
left atrial signal loss
left atrial size
left atrial size / left atrial volume index
left atrial size reduction
left atrial strain
left atrial thrombus
left atrial thrombus / left atrial appendage thrombus
left atrial volume
left atrial volume / diameter
left atrial volume index (lavi)
left atrioventricular valve regurgitation
left atrium (la)
left atrium and left atrial appendage anatomy (stroke implications)
left bundle area pacing
left bundle branch area pacing
left bundle branch area pacing leads
left bundle branch block (lbbb / lbbb)
left bundle branch block (lbbb)
left bundle branch block (lbbb) pacing
left bundle branch block management
left bundle‑area pacing
left bundle‑branch block (lbbb)
left cardiac sympathetic denervation (lcs)
left circumflex occlusion
left heart bypass
left heart bypass circuit
left heart disease
left heart enlargement / dilation
left internal mammary artery (lima)
left internal mammary artery (lima) coronary bypass graft
left internal mammary artery (lima) graft
left internal thoracic artery graft
left main artery lesions
left main coronary artery cad (≥50% luminal diameter reduction)
left main coronary artery disease
left main coronary artery lesion
left main coronary artery stenosis
left main coronary disease
left main disease
left main disease / left main cad
left main stenosis
left mitral isthmus flutter
left subclavian artery
left subclavian artery coverage
left superior vena cava
left upper‑extremity dialysis access
left ventricle
left ventricle (lv)
left ventricle (lv) dysfunction
left ventricle ejection fraction (lvef ≤ 40%)
left ventricle strain imaging
left ventricle‑to‑aorta baffle
left ventricular (lv)
left ventricular (lv) afterload
left ventricular (lv) anatomy
left ventricular (lv) chamber dilatation
left ventricular (lv) compliance
left ventricular (lv) diastolic pressure
left ventricular (lv) dilation
left ventricular (lv) dilation / chamber size
left ventricular (lv) dilation / volume overload
left ventricular (lv) dysfunction
left ventricular (lv) dysfunction (post‑tof)
left ventricular (lv) dysfunction / lv function
left ventricular (lv) dysfunction / severe lv dysfunction
left ventricular (lv) function
left ventricular (lv) function assessment
left ventricular (lv) hypertrophy
left ventricular (lv) mass
left ventricular (lv) mass / lv mass index
left ventricular (lv) outflow tract diameter/area
left ventricular (lv) outflow tract obstruction
left ventricular (lv) outflow tract obstruction (lvoto)
left ventricular (lv) pressure overload
left ventricular (lv) remodeling
left ventricular (lv) response to overload
left ventricular (lv) size
left ventricular (lv) size and function
left ventricular (lv) structural/functional alterations
left ventricular (lv) systolic dysfunction
left ventricular (lv) systolic function
left ventricular (lv) systolic function / left ventricular ejection fraction (lvef)
left ventricular (lv) systolic function / lv dysfunction
left ventricular (lv) thrombus
left ventricular (lv) thrombus after mi
left ventricular (lv) volume
left ventricular (lv) volume overload
left ventricular (lv) volumes
left ventricular (lv) wall thickness
left ventricular apical aneurysm
left ventricular assist device
left ventricular assist device (lvad)
left ventricular assist device support in transposition of the great arteries
left ventricular assist device trends and outcomes
left ventricular cardiomyopathy
left ventricular compliance
left ventricular diastolic dysfunction
left ventricular diastolic dysfunction assessment
left ventricular diastolic function
left ventricular diastolic pressure
left ventricular dilatation and remodeling
left ventricular dilation / dilatation
left ventricular dysfunction
left ventricular dysfunction (ischemic)
left ventricular dysfunction (lv dysfunction)
left ventricular dysfunction (lvd)
left ventricular dysfunction (lvef < 50 %)
left ventricular dysfunction / lv dysfunction
left ventricular dysfunction / lv dysfunction / left ventricular systolic dysfunction
left ventricular dysfunction / systolic dysfunction
left ventricular dysfunction assessment
left ventricular dysfunction, asymptomatic
left ventricular ejection fraction
left ventricular ejection fraction (ef)
left ventricular ejection fraction (ef) < 50%
left ventricular ejection fraction (lvef)
left ventricular ejection fraction (lvef) / ef < 40%
left ventricular ejection fraction (lvef) / ejection fraction (ef)
left ventricular ejection fraction (lvef) < 40 %
left ventricular ejection fraction (lvef) < 50%
left ventricular ejection fraction (lvef) – >40 %
left ventricular ejection fraction (lvef) – threshold <50 %
left ventricular ejection fraction (lvef) ≤ 35%
left ventricular ejection fraction (lvef) ≤ 35 %
left ventricular ejection fraction (lvef) < 50%
left ventricular ejection fraction (lv ef)
left ventricular ejection fraction (reduced & preserved)
left ventricular ejection fraction (reduced vs preserved)
left ventricular end‑diastolic diameter (lvedd)
left ventricular end‑diastolic dimension (lvedd)
left ventricular end‑diastolic volume (lvedv)
left ventricular end‑systolic diameter
left ventricular end‑systolic diameter (lvesd)
left ventricular end‑systolic dimension
left ventricular end‑systolic dimension (lvesd)
left ventricular end‑systolic volume
left ventricular enlargement
left ventricular failure (lvf)
left ventricular filling
left ventricular filling pressures
left ventricular free‑wall rupture
left ventricular function
left ventricular function (systolic & diastolic)
left ventricular function recovery
left ventricular global longitudinal strain (gls)
left ventricular hypertrophy
left ventricular hypertrophy (interventricular septum)
left ventricular hypertrophy (lvh)
left ventricular longitudinal strain
left ventricular longitudinal strain (lvls)
left ventricular mass
left ventricular mass and geometry assessment
left ventricular mass index (lvmi)
left ventricular mid‑range preserved ejection fraction
left ventricular morphology / wall thickness
left ventricular outflow obstruction
left ventricular outflow tract (lvot)
left ventricular outflow tract (lvot) disease
left ventricular outflow tract (lvot) gradient
left ventricular outflow tract (lvot) obstruction
left ventricular outflow tract (lvot) obstruction (lvoto)
left ventricular outflow tract gradient
left ventricular outflow tract gradients
left ventricular outflow tract obstruction
left ventricular outflow tract obstruction (lvoto)
left ventricular pacing
left ventricular performance
left ventricular performance post‑surgery
left ventricular posterior wall thickness
left ventricular pressure gradient
left ventricular recovery
left ventricular recovery (lv recovery)
left ventricular relaxation
left ventricular relaxation abnormalities
left ventricular remodeling
left ventricular remodeling / reverse remodeling
left ventricular reverse remodeling
left ventricular strain
left ventricular strain, speckle‑tracking echocardiography
left ventricular systolic dysfunction
left ventricular systolic dysfunction (ef < 50 %)
left ventricular systolic dysfunction (lvsd)
left ventricular systolic function
left ventricular systolic function / depressed left ventricular function
left ventricular systolic volume
left ventricular systolic‑diastolic coupling
left ventricular thrombosis
left ventricular thrombus
left ventricular thrombus management
left ventricular volume
left ventricular volume overload
left ventricular volumes
left ventricular wall thickness
left ventricular wall thickness measurement
left ventricular–based cardiac stimulation post‑av nodal ablation
left ventriculography
left vertebral artery
left-valvar morphology (mitral)
left ventricular dysfunction
left‐main coronary artery disease
left‑atrial compliance
left‑atrial cox maze iii procedure
left‑axis deviation pattern
left‑bundle‑area pacing
left‑heart obstructive lesions
left‑heart valve surgery














left‑main coronary artery disease
left‑main coronary artery revascularization outcomes
left‑main equivalent coronary artery disease
left‑sided chamber size
left‑sided endocarditis
left‑sided failure (exertional dyspnea, coughing, fatigue, orthopnea, paroxysmal nocturnal dyspnea)
left‑sided filling pressures
left‑sided heart failure (hf) / pulmonary edema
left‑sided icd implant
left‑sided infective endocarditis
left‑sided infective endocarditis (ie)
left‑sided mechanical prosthetic heart valve
left‑sided obstructive lesions
left‑sided obstructive lesions (e.g., mitral and aortic stenosis)
left‑sided prosthetic valve
left‑sided regurgitant lesions (mitral regurgitation, aortic regurgitation)
left‑sided valve
left‑sided valve disease
left‑sided valve regurgitation
left‑sided valve surgery
left‑sided valve surgery (mitral, aortic)
left‑to‑right atrial k<sup>+</sup> gradient
left‑to‑right atrial shunt
left‑to‑right shunt
left‑to‑right shunt (clinical significance)
left‑to‑right shunt (qp:qs ratio)
left‑to‑right shunt (qp:qs)
left‑to‑right shunt defects
left‑to‑right shunting
left‑to‑right shunting (shunts)
left‑ventricle characteristics
left‑ventricular (lv) diastolic dysfunction
left‑ventricular (lv) dysfunction
left‑ventricular (lv) remodeling (regional/global)
left‑ventricular (lv) systolic dysfunction
left‑ventricular (lv) systolic pressure
left‑ventricular (lv) volume overload
left‑ventricular assist device (lvad)
left‑ventricular compliance
left‑ventricular diastolic dysfunction
left‑ventricular dilatation / hypertrophy
left‑ventricular dilation
left‑ventricular dysfunction
left‑ventricular dysfunction (systolic or diastolic)
left‑ventricular dysfunction / ejection fraction
left‑ventricular ejection fraction
left‑ventricular ejection fraction (lvef)
left‑ventricular function / cardiac output
left‑ventricular hypertrophy / hypertrophic cardiomyopathy
left‑ventricular hypertrophy pathophysiology
left‑ventricular outflow tract (lvot) obstruction
left‑ventricular outflow tract (lvot) stenosis / obstruction
left‑ventricular outflow tract obstruction (lvot obstruction)
left‑ventricular outflow tract obstruction (lvoto)
left‑ventricular pacing
left‑ventricular remodeling
left‑ventricular remodeling (reverse remodeling)
left‑ventricular systolic dysfunction
left‑ventricular systolic dysfunction prevalence (11–40%)
left‑ventricular systolic function
left‑ventricular volume overload
left‑ventricular–based cardiac stimulation (pave)
left atrial thrombus
left ventricular ejection fraction (lvef)
leg edema
leg ischemia
leg pressure monitoring
leg symptoms
legal and ethical considerations (state laws, medicare eligibility)
leg‑lift maneuver
length of hospital stay
length of hospitalization
lenient rate control
lesion complexity
lesion length
lethal arrhythmic events
level of evidence
level of evidence (b‑nr, c‑eo, etc.)
level of evidence (clinical research grading)
level of evidence (c‑eo, b‑nr, c‑ld, b‑r, c‑ld)
level of evidence (e.g., class 1, 2, 3)
level of evidence (loe)
level of evidence in cardiovascular guidelines
level of evidence: b‑r
levosimendan therapy
lge (late gadolinium enhancement)
lge (late gadolinium enhancement) on cmr
lge extent and location
lge mid‑wall localization
lge persistence/reciprocal changes (increase, decrease, resolution)
lge present (late gadolinium enhancement)
lge without edema (predictor of adverse events)
lge – late gadolinium enhancement
lge‑cmr (late gadolinium‑enhanced cardiovascular magnetic resonance)
lianbio
liberal transfusion strategy
lidocaine
life expectancy
life expectancy / actuarial tables
life expectancy / longevity
life expectancy < 1 year
life expectancy considerations
life expectancy increase (>1.4 years)
life simple 7
lifelong anticoagulation
lifelong clinical and imaging follow‑up for coa patients
lifelong continuum of congenital heart disease care
lifelong or extended prophylaxis (≥ 10 years or until 40 years of age)
lifelong serial imaging (echocardiography, cmr, ct)
lifelong specialized chd care by achd cardiologists
lifelong surveillance
lifelong surveillance imaging
lifelong surveillance imaging for endoleaks
lifelong surveillance imaging of the aorta
lifelong surveillance
lifespan risk of cardiovascular disease
lifestyle
lifestyle / exercise / training / walking
lifestyle / physical activity
lifestyle and activity modification
lifestyle and risk factor modification (lrfm) for af
lifestyle changes
lifestyle considerations for hcm (recreational physical activity, competitive sports)
lifestyle counseling
lifestyle counseling (diet, exercise)
lifestyle disease prevention
lifestyle factors
lifestyle factors impacting cardiovascular risk
lifestyle factors: diet, exercise, physical activity
lifestyle goal setting (dietary modification, exercise plans)
lifestyle improvements (diet, exercise, smoking cessation)
lifestyle interventions
lifestyle interventions (e.g., hartcoach, proactive heart, moodcare)
lifestyle interventions (heart‑healthy lifestyle, diet, exercise)
lifestyle interventions for blood‑pressure control (aerobic exercise, isometric training, potassium supplementation)
lifestyle interventions for cardiovascular health
lifestyle management
lifestyle management (diet, exercise)
lifestyle management (dietary counseling, smoking cessation, weight control)
lifestyle management to reduce cardiovascular risk
lifestyle modification
lifestyle modification (diet, exercise, smoking cessation)
lifestyle modification (e.g., smoking cessation)
lifestyle modification (risk factor reduction)
lifestyle modification / dietary behavior changes
lifestyle modification for aortic disease
lifestyle modification for cardiovascular health
lifestyle modifications
lifestyle modifications (diet, exercise)
lifestyle modifications (smoking cessation, physical activity)
lifestyle modifications (weight loss, heart‑healthy diet, sodium reduction, physical activity, alcohol moderation)
lifestyle optimization (diet, activity, tobacco avoidance)
lifestyle physical activities (e.g., gardening, office‑based movement, stair climbing)
lifestyle preventive therapies
lifestyle risk factors (e.g., smoking cessation, diet, exercise tolerance, alcohol and substance use, environmental exposures)
lifestyle risk factors (e.g., smoking, hypertension)
lifestyle therapy
lifestyle‑focused interventions (diet, exercise, weight management)
lifestyle‑related blood‑pressure factors
lifetime ascvd risk
lifetime costs
lifetime major adverse cardiovascular events reduction ("fewer lifetime mace")
lifetime qalys
lifetime risk of ascvd
lifetime risk of cardiovascular disease
life‑expectancy reduction
life‑extending therapies in hf
life‑sciences technology
life‑space mobility
life‑sustaining therapies (initiation, continuation, deactivation)
life‑sustaining treatments (hospitalization, tube feeding, medication)
life‑table analysis for late hf
life‑threatening arrhythmia
life‑threatening arrhythmias
life‑threatening bleeding
life‑threatening bradycardia with verapamil in neonates
life‑threatening conditions
life‑threatening hyperkalemia
life‑threatening ventricular arrhythmias
life‑threatening ventricular tachyarrhythmia
life‑threatening/uncontrolled bleeding
life‑time risks of valve therapy
life’s essential 8 (aha)
life’s essential 8 (aha lifestyle recommendations)
life’s essential 8 (cardiovascular health metrics)
life’s simple 7 (cardiovascular metrics)
life’s simple 7 (ideal cardiovascular health metrics)
ligament of marshall
ligation/closure of coronary artery at the pulmonary artery level
light chain (al) amyloidosis
light‑chain (al) amyloidosis
light‑chain amyloidosis
light‑chain amyloidosis (al‑cm)
light‑intensity physical activity
light‑to‑moderate alcohol consumption (5–25 g/d)
likely pathogenic variant
likely pathogenic variant (in htad genes)
limb amputation
limb ischemia
limb ischemia (ischemic complications)
limb loss
limb loss (prevention)
limb outcomes
limb preservation/limb salvage
limb salvage
limb salvage rate
limb survival
limb viability
limb‑ischaemia evaluation and device deployment
limb‑preservation strategies
limb‑salvage procedures
limb‑threatening infection
limb‑threatening ischemia
limited english proficiency
limited life expectancy (<1‑2 years)
linagliptin
linear dimensions
lipid
lipid clinic (cardiovascular disease prevention)
lipid disorders
lipid goals (ldl‑c, hdl‑c, triglycerides)
lipid levels
lipid lowering therapy
lipid management
lipid management (statins, etc.)
lipid management (statins, ldl‑c reduction)
lipid management / dyslipidemia
lipid management / statins
lipid management guidelines
lipid management post‑acs
lipid metabolomics
lipid monitoring (fasting lipids, triglycerides)
lipid monitoring / lipid testing
lipid presence
lipid profile
lipid profile (cholesterol, triglycerides)
lipid profile / dyslipidemia
lipid profile measurement
lipid screening (family members)
lipid targets (ldl, hdl, triglycerides)
lipids
lipids (total cholesterol, ldl, hdl, triglycerides)
lipids / dyslipidemia
lipid‐lowering intensity
lipid‑increasing effect of statins (ldl‑c lowering)
lipid‑lowering (statin) therapy
lipid‑lowering agents
lipid‑lowering agents (e.g., ezetimibe, pcsk9 inhibitors)
lipid‑lowering agents (e.g., pravastatin, atorvastatin, rosuvastatin, simvastatin)
lipid‑lowering medication
lipid‑lowering therapy
lipid‑lowering therapy (high‑intensity statins)
lipid‑lowering therapy (statins, ezetimibe, combination therapy)
lipid‑lowering therapy (statins, ezetimibe, pcsk9 inhibitors)
lipid‑lowering therapy (statins, ezetimibe, rosuvastatin)
lipid‑lowering therapy (statins, pcsk9 inhibitors)
lipid‑lowering therapy (statins, pcsk9 inhibitors, etc.)
lipid‑lowering therapy for pad (high‑intensity statins) (pm‑5)
lipid‑lowering therapy guidelines.
lipid‑profiling methods (friedewald formula, direct ldl measurement)
lipid‑risk scoring
lipoprotein (a)
lipoprotein (ldl) cholesterol
lipoprotein apheresis
lipoprotein apheresis (used in familial hypercholesterolemia)
lipoprotein profile
lipoprotein(a)
lipoprotein(a) (lp(a))
lipoprotein(a) / lp(a)
lipoprotein(a) [lp(a)]
lipoproteins
liraglutide
lisinopril
lite (low intensity exercise intervention in pad) trial
literature review
lithotripsy (intravascular lithotripsy)
lithotripsy for calcified iliacs
liver biopsy
liver cancer
liver cirrhosis
liver congestion
liver disease
liver disease (anticoagulation considerations)
liver disease (cirrhosis)
liver disease (cirrhosis, hepatic impairment, non‑alcoholic fatty liver disease)
liver disease severity (cirrhosis)
liver dysfunction
liver fibrosis
liver fibrosis (assessment via biopsy)
liver fibrosis / cirrhosis
liver function testing
liver metabolism
liver nodules
lmna (lamin a/c) variants
loading dose
loading dose (300 mg then 75 mg daily)
loading dose (aspirin, clopidogrel, prasugrel, ticagrelor)
lobar intraparenchymal hemorrhage (iph)
local anesthesia
local anesthesia (preferred to reduce peri‑operative mortality in cardiac patients)
local inflammatory response
local quality improvement initiatives
lodoco trial
lodoco2 trial
loeys‑dietz syndrome
loeys‑dietz syndrome (lds)
loeys‑dietz syndrome with smad3 mutation
loeys‑dietz syndrome with tgfb2 mutation
loeys‑dietz syndrome with tgfb3 mutation
loeys‑dietz syndrome with tgfbr1 mutation
loeys‑dietz syndrome with tgfbr2 mutation






lone af
long duration of diabetes (≥10 yr for t2dm; ≥20 yr for type 1)
long life expectancy
long qt syndrome
long stent length
longitudinal cardiac screening
longitudinal cohort studies of aortic surgery outcomes
longitudinal evaluation of hcm patients
longitudinal follow‑up
longitudinal follow‑up for pad
longitudinal imaging surveillance (transthoracic echocardiography, cmr, ct angiography)
longitudinal spending on aortic repair
longitudinal strain by echocardiography
longitudinal strain of the systemic right ventricle
long‑acting nitrate (e.g., isosorbide dinitrate, nitroglycerin)
long‑acting nitrates
long‑acting thiazide diuretics
long‑chain n‑3 polyunsaturated fatty acids (protective factor for heart disease)
long‑standing persistent af
long‑standing persistent atrial fibrillation
long‑term anticoagulation
long‑term anticoagulation complications
long‑term anticoagulation in acs
long‑term behavior / outcomes
long‑term beta blockers
long‑term beta‑blocker use (> 1 year)
long‑term chromosomal damage
long‑term clinical outcome of antithrombotic therapy
long‑term clinical outcomes
long‑term complications
long‑term complications of congenital heart disease
long‑term complications of icd therapy
long‑term continuous monitoring
long‑term cvd outcomes (mortality, morbidity)
long‑term durability of revascularization
long‑term effect of goal‑directed weight management in atrial fibrillation
long‑term follow‑up
long‑term follow‑up of patients undergoing pulmonary‑ventricle to pulmonary artery conduits
long‑term follow‑up outcomes
long‑term follow‑up studies (10‑year, 3‑year)
long‑term heart failure after radiotherapy
long‑term maintenance of sinus rhythm
long‑term maintenance of sinus rhythm (rhythm‑control strategy)
long‑term mortality
long‑term myocardial infarction outcomes in adults with congenital heart disease
long‑term natural history of pulmonary stenosis after surgical repair
long‑term oral anticoagulation
long‑term oral antihypertensive regimens
long‑term outcome
long‑term outcome after atrioventricular valve surgery following modified fontan operation
long‑term outcomes
long‑term outcomes (8‑year freedom from ie)
long‑term outcomes (mechanical prosthesis durability, valve repair durability)
long‑term outcomes (up to 25–40 years)
long‑term outcomes (≤ 50 years)
long‑term outcomes after heart transplantation.
long‑term outcomes after pci vs cabg in octogenarians
long‑term outcomes of unrepaired papvr with intact atrial septum
long‑term outcomes of valve interventions
long‑term outcomes of vsd repair
long‑term pah therapies
long‑term pah therapy
long‑term patency / long‑term success (angioplasty/bypass)
long‑term prognosis
long‑term prognosis after myocardial infarction
long‑term prognosis of neo‑aortic root
long‑term rate control
long‑term rate control in af
long‑term risk
long‑term secondary prevention
long‑term surveillance
long‑term surveillance after endovascular repair
long‑term surveillance imaging of the aorta
long‑term survival
long‑term survival / actuarial survival
long‑term survival / prognosis
long‑term survival after aortic aneurysm repair
long‑term survival after arterial switch
long‑term survival after atrial switch / arterial switch
long‑term survival after fontan procedure
long‑term survival and freedom from coronary artery reintervention post‑arrest
long‑term survival in hcm
long‑term survival of valve‑repair patients
long‑term survival rates (e.g., 91–94 % at 15–30 years)
long‑term survival, mortality, and morbidity after heart transplantation in chd
long‑term valve survival
long‑term ventricular function
long‑term vka anticoagulation
long‑term vka therapy
loop diuretic
loop diuretic (furosemide)
loop diuretic dose
loop diuretics
loop diuretics (bumetanide, furosemide, torsemide)
loop diuretics (e.g., furosemide, torsemide, torasemide)
loop diuretics (intravenous)
loop of henle
losartan
losartan (angiotensin ii type‑1 receptor blocker)
losartan (angiotensin receptor blocker)
loss of atrial rhythm
loss of coaptation
loss of pregnancy
loss of pulses in an extremity
loss of sinus rhythm
loss to care
loss to care (attrition)
lovastatin
lovastatin (20 mg, 40 mg, 80 mg)
lovastatin (40–80 mg)
lovastatin (40 mg; 20 mg)
low birth weight
low bleeding risk
low bleeding‑risk procedures
low blood pressure (sbp ≤ 90 mm hg)
low blood pressure in hfref
low cardiac index
low cardiac output
low cardiac output state / cardiogenic shock risk
low early morbidity
low ef threshold (≤35 %, ≤30 % in esc criteria)
low flow (graft compromise indicator)
low hdl‑cholesterol
low health literacy (as a risk factor for poor self‑care)
low household income / low socioeconomic status
low molecular weight heparin (lmwh)
low output
low peak vo₂ (< 14–16 ml/kg/min)
low risk
low surgical risk
low systemic blood pressure
low systolic blood pressure (≤90 mm hg)
low-dose rivaroxaban
low-volume surgeon
low/reduced abi
lower extremity
lower extremity amputation
lower extremity amputation (amputation, major amputation)
lower extremity arterial disease
lower extremity arterial revascularization
lower extremity bypass
lower extremity bypass grafting
lower extremity edema
lower extremity functioning
lower extremity gangrene
lower extremity hypoperfusion
lower extremity hypotension
lower extremity ischemia
lower extremity manifestations of pad
lower extremity non‑healing wounds
lower extremity pad
lower extremity peripheral artery disease
lower extremity pulse assessment (femoral, popliteal, dorsalis pedis, posterior tibial)
lower extremity revascularization
lower extremity surveillance after revascularization
lower extremity surveillance procedure
lower extremity threatened limb
lower extremity threatened limb classification system
lower extremity vein bypass graft surveillance
lower limb wound healing
lower morbidity
lower procedural risk (surgical morbidity & mortality)
lower‑extremity amputation
lower‑extremity amputations
lower‑extremity amputations – reduction strategies
lower‑extremity arterial disease
lower‑extremity arterial waveform nomenclature
lower‑extremity arteries
lower‑extremity bypass revascularization
lower‑extremity ischemia
lower‑extremity malperfusion
lower‑extremity pad
lower‑extremity peripheral arterial disease
lower‑extremity peripheral artery disease
lower‑extremity pulse examination
lower‑extremity rest pain
lower‑extremity revascularization
lower‑extremity surveillance after revascularization (qm‑7)
lower‑extremity thrombosis
lower‑limb aerobic exercise
lower extremity peripheral artery disease
low‑attenuation plaque
low‑attenuation plaque (mean ct < 30 hu)
low‑calorie sweetened beverages
low‑carbohydrate diet
low‑carbohydrate diets
low‑density lipoprotein
low‑density lipoprotein (ldl)
low‑density lipoprotein (ldl) cholesterol
low‑density lipoprotein (ldl) target <70 mg/dl
low‑density lipoprotein cholesterol
low‑density lipoprotein cholesterol (ldl‑c)
low‑density lipoprotein cholesterol (ldl‑c) goals
low‑dose aspirin
low‑dose aspirin (75–100 mg daily)
low‑dose aspirin (75–100 mg)
low‑dose aspirin (75–162 mg daily)
low‑dose aspirin (75–162 mg/d)
low‑dose aspirin (aspirin + rivaroxaban)
low‑dose aspirin (pregnancy safety)
low‑dose colchicine therapy
low‑dose diuretics for congestion in hcm
low‑dose dobutamine echocardiography
low‑dose dobutamine stress testing
low‑dose dopamine therapy
low‑dose dual‑source ct for ventricular function
low‑dose infusion strategies
low‑dose lmwh (low‑molecular‑weight heparin)
low‑dose oral diuretics
low‑dose rivaroxaban
low‑dose thrombolytic therapy
low‑dose warfarin
low‑flow aortic stenosis
low‑flow as
low‑flow low‑gradient aortic stenosis
low‑flow states
low‑flow versus high‑flow states in as
low‑flow, low‑gradient aortic stenosis
low‑flow, low‑gradient severe aortic stenosis (as)
low‑flow, low‑gradient severe as
low‑gradient aortic stenosis
low‑gradient as
low‑gradient severe mitral stenosis
low‑income populations
low‑intensity anticoagulation
low‑intensity lifestyle activity (walking breaks, reduced sedentary time)
low‑intensity statin
low‑intensity statin therapy
low‑intensity vs. high‑intensity anticoagulation
low‑molecular‑weight heparin
low‑molecular‑weight heparin (anticoagulation)
low‑molecular‑weight heparin (enoxaparin)
low‑molecular‑weight heparin (enoxaparin, dalteparin)
low‑molecular‑weight heparin (lmwh)
low‑molecular‑weight heparin (lmwh) – alternative anticoagulant (not directly mentioned but relevant)
low‑molecular‑weight heparin (lmwh) – dalteparin
low‑molecular‑weight heparin (lmwh) – e.g., enoxaparin
low‑output low‑gradient aortic stenosis
low‑pressure outlet chamber (rv outflow)
low‑right atrial isthmus flutter
low‑risk ascvd
low‑risk chest pain evaluation
low‑risk favourable metrics (lrfm) programme
low‑risk features for myocarditis
low‑risk patients
low‑salt diet
low‑sodium diet
low‑to‑moderate‑risk patients
low‑voltage areas
low‑voltage ecg findings
lox
lox gene mutation
lox mutation (lysyl oxidase)
lumbar spinal stenosis
lumbosacral dural ectasia (co‑existing condition)
luminal stenosis
lumiracoxib
lung biopsy utility in congenital heart disease management
lung disease (concomitant)
lung function & gas exchange in pah/eisenmenger
lung transplantation (with cardiac repair)
lung ultrasound (in acs)
lv (left ventricle)
lv (left ventricular)
lv (left ventricular) filling pressures
lv afterload
lv and left atrial (la) reverse remodeling
lv aneurysm
lv apical aneurysm
lv cavity dimensions
lv cavity size / dimensions (e.g., ≥46‑50 mm)
lv chamber dilation
lv compliance
lv diastolic dysfunction
lv diastolic function
lv dilatation
lv dilation
lv dilation / end‑systolic diameter >40 mm
lv dilation / left ventricular dilation
lv disease (left‑ventricular disease)
lv dysfunction
lv dysfunction from chronic pressure overload
lv dysfunction thresholds for teer
lv ejection fraction (lvef)
lv end‑diastolic diameter (lvedd)
lv end‑diastolic dimension (lvedd)
lv end‑diastolic dimension/volume (lvedd/lvedv)
lv end‑diastolic pressure
lv end‑diastolic volume
lv end‑diastolic volume <50 ml/m² (small cavity definition)
lv end‑systolic diameter (lvesd)
lv end‑systolic dimension (lvesd)
lv end‑systolic dimension index (mm²/m²)
lv end‑systolic volume (lvesv)
lv fibrosis
lv filling
lv filling pressures
lv function
lv functional thresholds (lvef ≤ 60 %, lvesd ≥ 40 mm)
lv hypertrophy
lv hypertrophy (cardiomyocyte hyperplasia)
lv lge extent
lv longitudinal strain
lv mass
lv non‑compaction
lv outflow obstruction (post‑mitral viv)
lv outflow tract (lvot)
lv outflow tract obstruction (lvoto)
lv posterior wall thickness
lv pressure overload
lv remodeling
lv remodeling (hypertrophy, fibrosis, impaired relaxation, impaired compliance, impaired contractility)
lv remodeling (left‑ventricular remodeling)
lv remodeling (proportionate vs. disproportionate mr)
lv remodeling (ventricular cavity enlargement, wall thinning)
lv remodeling and its effect on mr
lv reverse remodeling
lv segment involvement
lv size
lv size (volumes vs. dimensions)
lv strain (function)
lv strain (speckle‑track)
lv stroke volume
lv stroke volume <30 ml/m² (small cavity definition)
lv systolic dysfunction
lv systolic dysfunction (ef < 50 %)
lv systolic dysfunction (lvef ≤55%)
lv systolic dysfunction (lvef ≤ 55%)
lv systolic dysfunction (lvef ≤ 40%)
lv systolic dysfunction / severe lv dysfunction (ejection fraction ≤ 35%)
lv systolic function
lv volume overload / lv volume measurements
lv volumes
lv wall thickness
lv wall thickness measurement in any segment
lv wall thickness ≥ 14 mm
lv wall‑thickness measurement
lvad (left ventricular assist device)
lvad recovery
lvad – left ventricular assist device
lvef
lvef (<50%)
lvef (left ventricular ejection fraction)
lvef (left ventricular ejection fraction) < 45 %
lvef < 50%
lvef measurement in various modalities (echo, cmr, ct, radionuclide)
lvef on initial cmr
lvef recovery
lvef thresholds (≤ 35 % and ≤ 40 %) predictive of icd benefit
lvef trajectories and monitoring
lvef ≤ 35%
lvef ≤ 40 % (left‑ventricular ejection fraction)
lvef < 50 %
lvef ≤ 30 %
lvef ≤ 35 %
lvef ≤ 40 %
lvesd index (indexed lvesd, mm/m²)
lvh (left ventricular hypertrophy)
lvot (left ventricular outflow tract) obstruction
lvot gradient
lvot gradient (peak ≥50 mm hg, mean ≥40 mm hg)
lvot gradient (≥30 mm hg)
lvot gradient / lvot peak gradient
lvot gradient reduction post‑ablation
lvot gradients
lvot obstruction
lvot obstruction (lvoto)
lvot peak gradient ≥ 50 mm hg
lvot stenosis
lvoto (left ventricular outflow tract obstruction)
lvsd – left ventricular systolic dysfunction
lyme carditis
lymphatic abnormalities (fontan)
lymphatic fistula
lymphocytic myocarditis
lymphopenia
lyon diet heart study
lyon diet heart study (mediterranean diet intervention)
lysosomal storage disease
lysosomal storage diseases
lytic agent (used in thrombolysis)
l‑type calcium channel activity

























mace (major adverse cardiac events)
mace (major adverse cardiovascular events)
mace risk reduction
machine learning in risk prediction
machine‑learning assessment of systemic right ventricle
machine‑learning‑based trials
machine‑learning–based imaging analysis for aortic assessment
macitentan
macitentan (endothelin‑1 receptor antagonist)
macitentan therapy
macitentan therapy for pulmonary hypertension
macroalbuminuria
macrolide or azalide antibiotics (for penicillin‑allergic patients)
macronutrient intake
macroreentrant atrial arrhythmias
macroreentrant atrial tachycardia
macroreentrant atrial tachycardia (at)
macroreentrant circuit
macrovascular blood flow
macrovascular outcomes
madit (multicenter automated defibrillator implantation trial)
madit‑crt trial
madit‑ii (multicenter automatic defibrillator implantation trial ii)
madit‑ii trial
madit ii (multicenter automatic defibrillator implantation trial)
maf‑app (mobile health technology)
maggic (meta‑analysis global group in chronic heart failure)
maggic (meta‑analysis global group in chronic heart failure) risk calculator
maggic risk score
maggic score
magnesium
magnesium infusion (prophylaxis for torsades de pointes)
magnesium sulfate (intravenous)
magnetic navigation & robotic ablation (atrial tachyarrhythmias)
magnetic resonance
magnetic resonance (mr)
magnetic resonance (mr) angiography
magnetic resonance angiography
magnetic resonance angiography (mra)
magnetic resonance elastography
magnetic resonance imaging
magnetic resonance imaging (four‑dimensional)
magnetic resonance imaging (mri)
magnetic resonance imaging (mri) / mra
magnetic resonance imaging (mri) in cardiac imaging
magnetic resonance imaging (mri) of the aorta
magnetic resonance imaging (mri) of the brain
magnetic resonance imaging (mri) of the thoracic aorta
magnetic resonance imaging (mri) – (implied by imaging discussions)
magnetic resonance imaging (mri) – high diagnostic accuracy for endoleaks, requires plain radiograph for stent strut assessment
magnetically levitated left ventricular assist device (lvad)
maintenance dose
maintenance dose (aspirin, clopidogrel, prasugrel, ticagrelor)
maintenance of sinus rhythm
major adverse cardiac events (mace)
major adverse cardiovascular event (mace)
major adverse cardiovascular events
major adverse cardiovascular events (mace)
major adverse event rate
major adverse events
major adverse limb event (male)
major adverse limb events
major adverse limb events (male)
major amputation
major arterial branches
major bleeding
major bleeding / life‑threatening bleeding
major bleeding complications
major bleeding risk with mcs devices
major cardiovascular events
major cardiovascular events (stroke, myocardial infarction, heart failure)
major coronary event
major coronary events
major depression therapy (escitalopram, sertraline)
major histocompatibility complex (mhc)
major limb amputation (mla)
major noncerebral bleeding
major pulmonary artery anomalies
major vascular complications
major vascular events
major/minor bleeding criteria
maladaptive cardiac remodeling
malaise
malapposition
male sex
malignancy
malignant arrhythmia risk stratification (share score)
malignant arrhythmias
malignant arrhythmias (e.g., sustained ventricular tachycardia)
malnutrition
malnutrition / nutritional index (predicts mortality post‑pci)
malnutrition / obesity
malperfusion
malperfusion (clinical evidence)
malperfusion (malperfusion syndrome)
malperfusion resolution
malperfusion syndrome
malperfusion syndromes
malperfusion syndromes associated with aortic dissection
management
management of acute aortic dissection (surgical vs endovascular)
management of anticoagulation (vitamin k antagonist)
management of anticoagulation in cardiac patients
management of aortic aneurysm
management of aortic diseases (guideline recommendations)
management of blood cholesterol
management of comorbidities
management of comorbidities in hcm
management of concomitant cardiac conditions in hcm
management of congenital heart disease
management of hcm and af
management of heart failure
management of heart failure guidelines
management of high bleeding risk patients (master dapt trial)
management of intramural hematoma (acute and subsequent)
management of lower extremity pad
management of pad
management of patients at risk for and with left ventricular thrombus (acc/aha)
management of patients with af and ich.
management of patients with chronic coronary disease
management of patients with left ventricular thrombus
management of patients with vhd
management of refractory angina
management of right atrial strain
management of rv‑to‑pa conduit failure
management of symptoms in hcm
management of valvular heart disease
management of venous/arterial access in cardiac patients
management strategies
mantra‑af study
manual labor / heavy lifting occupational consideration
manufacturer’s instructions for use (ifu)
marfan surgical outcomes (early and 1‑year)
marfan syndrome
marfan syndrome (aortic root evaluation)
marfan syndrome (mfs)
marfan syndrome (mild systemic features)
marfan syndrome – a connective‑tissue disorder affecting the aorta
marijuana / cannabis / medical marijuana
markov decision analysis
markov decision model
martin/hopkins method (ldl‑c calculation)
massive left ventricular hypertrophy
massive lvh
massive lvh (≥ 30 mm in any lv segment)
mat2a mutation
maternal adverse outcome
maternal and fetal cardiac risk
maternal and fetal complications of pregnancy
maternal and fetal morbidity/mortality
maternal and fetal risk balance
maternal and fetal safety
maternal cardiac death
maternal cardiac disease
maternal cardiac outcomes (in pregnancy)
maternal cardiac risk
maternal cardiac risk management
maternal complications during pregnancy
maternal cor triatriatum management during pregnancy
maternal counseling
maternal death
maternal heart disease
maternal hemorrhage risk
maternal morbidity
maternal morbidity / mortality
maternal morbidity and mortality
maternal mortality
maternal mortality in hcm pregnancy (very low)
maternal mortality risk (~1 %)
maternal outcomes
maternal outcomes in congenital heart disease‑associated pulmonary hypertension
maternal rubella exposure
maternal thrombotic complications
maternal/fetal risk assessment
maternal‑fetal medicine (specialist care coordination)
maternal‑fetal medicine / obstetric cardiology
maternal‑fetal medicine obstetricians
maternal‑fetal medicine specialist
maternal‑fetal medicine surveillance
maternal‑fetal medicine team
maternal‑fetal mri
maternal‑fetal outcomes
maternal–fetal decision making in aortopathy
maternal–fetal outcome optimization
matrix metalloprotease‑9
matrix metalloproteinase (mmp) activity
matrix metalloproteinases (mmp‑2, mmp‑9)
matrix metalloproteinase‑9 (mmp‑9)
matrix remodeling
matrix remodeling biomarkers (related to heart failure prognosis)
matrix trial
mavacamten
mavacamten (contraindicated in pregnancy)
mavacamten (myosin inhibitor)
mavacamten (myosin inhibitor) for obstructive hcm
mavacamten (myosin‑inhibitor drug)
maximal aortic diameter
maximal aortic diameter (> 40 mm)
maximal instantaneous lvot gradient
maximal left ventricular (lv) wall thickness
maximal left‑ventricular wall‑thickness measurement
maximal tolerated statin therapy
maximal workload
maximally tolerated doses (of acei/arb/arni)
maximally tolerated statin therapy
maximum aortic diameter
maximum diameter
maximum pau depth
maximum pau diameter
maximum tolerated statin
maximum velocity
maximum velocity (vmax)
maze operation
maze procedure
maze procedure (atrial maze)
mcha2ds2‑vasc score
mean arterial pressure (map)
mean arterial pressure targets
mean gradient
mean mitral gradient
mean mitral valve gradient > 15 mm hg during exercise
mean pressure gradient
mean pressure gradient (mm hg)
mean pressure gradient (δp)
mean pressure gradient ≥ 40 mm hg
mean pulmonary artery pressure (mpap)
mean pulmonary artery pressure > 20 mm hg
mean systolic pressure gradient (∆pmean)
mean transvalvular gradient
mean transvalvular gradient >10 mm hg
mean δp ≥40 mm hg or <20 mm hg
measurement
measurement attributes (evidence‑based, reliability, validity, feasibility)
measurement protocols (electrocardiographic‑synchronized, perpendicular to flow axis, multiplanar reformats)
measurement techniques (leading‑edge to leading‑edge, inner‑wall to inner‑wall)
measurement variability
mechanical aortic root replacement
mechanical aortic valve replacement
mechanical aortic valve replacement (avr)
mechanical aortic valve replacement in women of childbearing age
mechanical atrial systole
mechanical bileaflet avr
mechanical bridge to definitive treatment
mechanical circulatory support
mechanical circulatory support (bridge to transplant, lvad)
mechanical circulatory support (bridge‑to‑transplant)
mechanical circulatory support (e.g., lvad)
mechanical circulatory support (e.g., temporary circulatory support devices)
mechanical circulatory support (e.g., ventricular assist devices)
mechanical circulatory support (impella, short‑term mechanical support)
mechanical circulatory support (lvad, vad)
mechanical circulatory support (mcs)
mechanical circulatory support (mcs) devices
mechanical circulatory support (mcs) in achd (intermacs, unos)
mechanical circulatory support device
mechanical complications (e.g., mechanical valve failure, ventricular rupture)
mechanical complications (of the heart)
mechanical complications of acs
mechanical complications of acute myocardial infarction
mechanical complications of acute myocardial infarction (e.g., rupture, pseudo‑aneurysm)
mechanical complications of ami
mechanical complications of mi
mechanical complications of mi (e.g., lv free‑wall rupture, papillary muscle rupture)
mechanical complications of mi (e.g., ventricular septal defect, free‑wall rupture)
mechanical complications of myocardial infarction
mechanical disc prosthesis
mechanical dyssynchrony (detected by echocardiography)
mechanical heart valve
mechanical heart valve (bileaflet)
mechanical heart valve prosthesis
mechanical heart valves
mechanical heart valves (mechanical valvular prostheses)
mechanical mitral valve
mechanical mitral valve replacement
mechanical mitral‑valve replacement
mechanical prostheses
mechanical prosthesis
mechanical prosthesis monitoring
mechanical prosthetic aortic valve
mechanical prosthetic heart valves
mechanical prosthetic valve
mechanical prosthetic valve complications
mechanical prosthetic valve thrombosis
mechanical prosthetic valves
mechanical reperfusion
mechanical support
mechanical support utilization trends
mechanical therapy
mechanical valve
mechanical valve (prosthetic)
mechanical valve (surgical)
mechanical valve dysfunction
mechanical valve implantation
mechanical valve leaflet imaging
mechanical valve prostheses
mechanical valve prosthesis
mechanical valve replacement
mechanical valve stenosis
mechanical valve surgery
mechanical valve thrombogenicity
mechanical valve thrombosis
mechanical valve thrombosis management during pregnancy
mechanical valve thrombosis prevention
mechanical valved conduit
mechanical valves
mechanical valve‑associated bleeding risk
mechanical ventricular assist device
mechanical vs. bioprosthetic valve durability in young women
mechanisms of action (ina inhibition, ikr inhibition, late ina augmentation)
med-oriented and surgery strategies for multivessel coronary artery disease (mass ii)
media
medial degeneration
medial degeneration of the aortic wall
medial radiation effects on cardiac surgery
medial smooth muscle
mediastinal hematoma
mediastinal widening
medical device manufacturers related to cardiac care:
medical devices
medical devices for heart disease
medical management (antihypertensive therapy, anticoagulant clearance, etc.)
medical management of aneurysm disease
medical management of aortic aneurysm/dissection
medical management of sporadic or degenerative aortic aneurysm
medical management/therapy
medical surveillance (aortic)
medical therapy
medical therapy (best medical treatment)
medical therapy (e.g., diltiazem)
medical therapy (for pad)
medical therapy (including guideline‑directed medical therapy, gdmt)
medical therapy (optimal management)
medical therapy (optimal medical therapy)
medical therapy after avr (ventricular and vascular function)
medical therapy alone
medical therapy for aortic aneurysm disease
medical therapy for aortic disease
medical therapy for aortic dissection management
medical therapy for loeys‑dietz syndrome
medical therapy for progressive valve disease (stage b)
medical therapy for relief of angina
medical therapy for systemic right ventricle
medical therapy for valve disease
medical therapy optimization
medical therapy to prevent cardiovascular events
medical therapy uptitration (hf)
medical therapy: guideline‑directed medical therapy (gdmt)


















medical treatment
medical, percutaneous, or surgical intervention
medically and surgically managed loeys‑dietz syndrome patients
medicare beneficiaries
medicare claims registry data
medicare coverage of exercise therapy
medicare coverage of set
medication adherence
medication adherence / medication‑taking
medication adherence / non‑adherence in hf
medication adherence and optimization
medication adherence interventions
medication adherence/ compliance in cardiac disease
medication interactions
medication management for pad
medication non‑adherence
medication optimization / reconciliation
medication reconciliation
medication therapy
medication therapy for stable coronary disease
medication therapy management
medications (rx)
medications alone
medications associated with myocarditis:
medications with negative inotropic effect (e.g., verapamil)
mediterranean diet
mediterranean diet (extra‑virgin olive oil, nuts)
mediterranean diet and aneurysm prevention
mediterranean‑style diet (primary & secondary prevention of cvd)
mediterranean‑type dietary plan (plant‑based, lean protein, fish)
mediter­rainian dietary pattern (high‑score mediterranean diet)
medium‑ and large‑vessel vasculitis
medium‑term functional status
medtronic
medtronic (cardiovascular device manufacturer)
medtronic (cardiovascular devices)
medtronic (device manufacturer for heart conditions)
medtronic (device manufacturer for heart valve procedures)
medtronic (device manufacturer relevant to cardiovascular therapy)
medtronic talent stent graft (device-based term)
medtronic** (heart‑device manufacturer)
med‑ahf study
melody valve
membrane orifice
membranous obstruction (subaortic obstruction)
men >40 years
mendelian genetic variants
mendelian randomization (mr) findings
mendelian randomization studies (genetic determinants)
mental component summary (mcs)
mental health (comorbidity)
mental health (depression)
mental health (for ccd)
mental health / psychosocial stressors
mental health conditions (depression, anxiety, anger/hostility, general distress, type d personality)
mental health disorders and aortic dissection
mental health screening (phq‑4, etc.)
mental illness (comorbid)
mental retardation
mental‑health screening in achd clinics
mentation (altered mentation)
merck
merit‑hf
merit‑hf (metoprolol in patients with heart failure)
merlin trial
merlin‑timi 36 trial
merlin‑timi 36 trial (cardiac biomarker assessment)
mesa (multi‑ethnic study of atherosclerosis)
mesenteric (visceral) malperfusion
mesenteric artery stenosis
mesenteric malperfusion
metabolic abnormalities
metabolic acidosis
metabolic and energetic abnormalities in hcm.
metabolic complications (acidosis, liver function tests)
metabolic disorders affecting the heart
metabolic equivalent (met)
metabolic equivalent-hours per week
metabolic equivalents (mets)
metabolic equivalents (mets) – light, moderate, vigorous
metabolic equivalents of task (mets)
metabolic risk
metabolic risk profile
metabolic stress
metabolic syndrome
metabolic syndrome, heart disease risk
metabolic therapies
metabolic transformation (liver biotransformation)
metabolism pathways (cyps, p‑gp)
meta‑analyses
meta‑analysis
meta‑analysis (individual patient data)
meta‑analysis (individual‑patient data, randomized trial)
meta‑analysis / systematic review
meta‑analysis / systematic review (methodology in cardiology)
meta‑analysis and systematic review (reference to methodology)
meta‑analysis findings on mortality
meta‑analysis of acs trials
meta‑analysis of af incidence post‑ablation
meta‑analysis of clopidogrel in acs undergoing pci
meta‑analysis of individual patient data for aaa
meta‑analysis of mcs devices
meta‑analysis of obesity and atrial fibrillation
meta‑analysis of pad interventions
meta‑analysis of randomised controlled trials concerning cardiovascular risk
meta‑analysis of randomized controlled trials (rcts)
meta‑analysis of randomized trials
meta‑analysis of reperfusion strategies
meta‑analysis on clopidogrel pretreatment
meta‑analysis studies
meta‑synthesis of women’s experiences with cardiac disease in pregnancy
metformin
metformin (first‑line therapy for diabetes)
metformin (implied via glycemic control)
methamphetamine abuse
methamphetamine use
methamphetamine‑associated cardiomyopathy
methicillin‑resistant *staphylococcus aureus* (mrsa)
methicillin‑resistant staphylococcus aureus (mrsa)
methicillin‑sensitive staphylococcus aureus (mssa)
methodology manual
methotrexate
methotrexate (cardiovascular risk modifier)
methotrexate (dmard)
methotrexate (mtx)
metolazone
metolazone (thiazide‑like diuretic)
metoprolol
metoprolol (cr/xl, extended‑release)
metoprolol (dose escalation)
metoprolol cr/xl
metoprolol high‑dose iv/po therapy
metoprolol succinate
metoprolol succinate (merit‑hf)
metoprolol tartrate
mets (metabolic equivalents)
mexiletine
mhealth education interventions for heart failure
mi
mi (myocardial infarction)
microalbuminuria
microaxial flow pump
microaxial flow pump (intra‑aortic balloon pump, v‑ax, impella, etc.)
microaxial flow pump (mcp)
microaxial intravascular flow pump (microaxial pump)
microaxial lvad (impella lp5.0)
micronutrient deficiency
micronutrient intake
micronutrient supplementation
micronutrient‑deficiency screening
microreentry circuit
microrna
micrornas (e.g., mmu‑mir‑721)
micrornas (mmu‑mir‑721)
microrna‑155 (mir‑155)
microrna‑21 (mir‑21)
microvascular
microvascular angina
microvascular angina (mva)
microvascular blood flow
microvascular complications
microvascular disease
microvascular disease (retinopathy, neuropathy, nephropathy)
microvascular dysfunction
microvascular ischemia
microvascular outcomes
microvascular resistance (high)
midterm mortality rate
midterm outcomes
midventricular obstruction
mid‑range ejection fraction
mid‑range lvef (40 – 49%)
mid‑rv obstruction
mid‑term outcomes (10–20 years)
mid‑to‑late systolic jets
mid‑wall lge
migalastat (small‑molecule therapy for fabry)
mild ar
mild to moderate aortic stenosis
mild, moderate, and severe mr definitions
mild/moderate heart failure
mildly reduced ejection fraction
mild‑to‑moderate intensity exercise
milrinone
milrinone (oral)
milrinone (phosphodiesterase inhibitor)
milrinone infusion
mineral oil placebo
mineralocorticoid receptor antagonist
mineralocorticoid receptor antagonist (mra)
mineralocorticoid receptor antagonist (mra) therapy for hfref
mineralocorticoid receptor antagonists
mineralocorticoid receptor antagonists (mra)
mineralocorticoid receptor antagonists (mras)
mineralocorticoid receptor antagonists (mras) – spironolactone
mineralocorticoid receptor antagonists (spironolactone)
mineralocorticoid‑receptor antagonist – e.g., spironolactone, eplerenone
mineralocorticoid‑receptor antagonists
mineral‑corticoid receptor antagonists (for af)
minerva study
minimally interrupted anticoagulation
minimally invasive approach
minimally invasive direct coronary artery bypass
minimum stent area (msa)
minimum training duration (≥12 weeks)
minimum vessel diameter (>2.5 mm)
minneapolis heart institute
minnesota living with heart failure questionnaire (mlhfq)
minor amputation (inframalleolar level)
minor and major amputation (foot, digit)
minor bleeding
minor procedures (e.g., dental extraction, cataract removal)
minorities (racial/ethnic representation)
minority communities
minute ventilation to co₂ production (ve/vco₂)
miracl trial
miracle score
miscarriage
mission: lifeline stemi system
mistral study
mitochondrial density and activity
mitochondrial disorders
mitochondrial myopathies
mitraclip (transcatheter mitral valve repair)
mitraclip device
mitraclip therapy
mitral (left atrioventricular) valve regurgitation
mitral annular calcification
mitral annular dilation
mitral annular dilation and valve adaptation
mitral annulus calcification
mitral commissurotomy
mitral insufficiency
mitral intervention (repair or replacement)
mitral leaflet‑base calcification
mitral pressure half‑time
mitral prosthesis
mitral regurgitation
mitral regurgitation (functional mr)
mitral regurgitation (functional/secondary)
mitral regurgitation (in combined valvular studies)
mitral regurgitation (mr)
mitral regurgitation (mr) associated with lvoto
mitral regurgitation (mr) – moderate or greater, normal lv systolic function, pulmonary artery systolic pressure < 50 mm hg
mitral regurgitation (mr) – secondary
mitral regurgitation (mr) ≤ 2 +
mitral regurgitation (progression)
mitral repair for primary mr (posterior leaflet)
mitral stenosis
mitral stenosis (ms)
mitral stenosis (ms) – rheumatic, moderate or greater, pulmonary artery systolic pressure < 50 mm hg
mitral stenosis (shared pathophysiology)
mitral subvalvular apparatus
mitral transcatheter edge-to-edge repair
mitral transcatheter edge‑to‑edge repair (teer)
mitral valve
mitral valve (and its components: commissures, leaflets)
mitral valve (mv)
mitral valve (mv) area
mitral valve (mv) clipping
mitral valve abnormalities
mitral valve abnormalities (mitral regurgitation, papillary muscle insertion)
mitral valve anatomy
mitral valve anatomy and function
mitral valve annuloplasty
mitral valve annulus calcification
mitral valve apparatus
mitral valve area
mitral valve area (mva)
mitral valve area measurement
mitral valve area score
mitral valve area ≤ 1.5 cm²
mitral valve area ≤ 1.5 cm²
mitral valve attachments
mitral valve disease
mitral valve disease / mitral valve repair
mitral valve disease associated with tgfb2 mutations
mitral valve endocarditis
mitral valve gradient
mitral valve injury
mitral valve insufficiency (due to papillary muscle infarction)
mitral valve intervention
mitral valve leaflet abnormalities
mitral valve leaflet calcification
mitral valve leaflet scallops
mitral valve leaflets malcoaptation
mitral valve lesions
mitral valve morphology
mitral valve morphology score
mitral valve orifice geometry
mitral valve plication
mitral valve prolapse
mitral valve regurgitation
mitral valve regurgitation (mr)
mitral valve repair
mitral valve repair (surgical)
mitral valve repair feasibility
mitral valve repair strategies
mitral valve replacement
mitral valve replacement (mvr)
mitral valve replacement (mv replacement)
mitral valve replacement (within 1 year of procedure)
mitral valve replacement strategy
mitral valve replacement vs repair
mitral valve resistance
mitral valve stenosis
mitral valve stenosis progression
mitral valve structural abnormalities
mitral valve surgery
mitral valve surgery (repair or replacement)
mitral valve surgery (repair, commissurotomy, replacement)
mitral valve surgery (repair, replacement)
mitral valve surgery (repair/replacement)
mitral valve surgery / repair
mitral valve surgery with ablation
mitral valve systolic anterior motion (sam)
mitral‑aortic discontinuity
mitra‑fr study
mitra‑fr trial
mitra‑fr trial outcomes













mixed aortic stenosis (as) and aortic regurgitation (ar)
mixed dyslipidemia
mixed mitral stenosis and aortic regurgitation (ms‑ar)
mixed mitral stenosis and aortic stenosis (ms‑as)
mixed mitral stenosis and mitral regurgitation (ms‑mr)
mixed moderate as/ar
mixed pulmonary valve disease
mixed severe as and mitral regurgitation (mr)
mixed valve disease
mixed valve disease (combined mr + aortic stenosis)
mixed valvular disease
mobile atheroma
mobile electrocardiogram
mobile health (mhealth) technologies
mobile health devices
mobile health technology for af
mobile telemetry
mobile‑health–delivered educational interventions
mobility challenges
mobility impairment
mobility issues / procedural risk
mode of delivery (in pregnancy context)
mode of delivery in aortic disease
model duration
moderate aortic stenosis
moderate ar
moderate ar (stage b)
moderate ischemic mitral regurgitation
moderate la enlargement
moderate mr (ero ≥ 20 mm²)
moderate or greater mitral stenosis
moderate pulmonary regurgitation
moderate regurgitation
moderate stenosis
moderate to severe heart failure
moderate to severe rheumatic mitral stenosis
moderate tricuspid regurgitation
moderate/high‑intensity statin
moderate‑intensity aerobic activity
moderate‑intensity aerobic exercise (≥150 min/week)
moderate‑intensity aerobic physical activity
moderate‑intensity continuous training
moderate‑intensity exercise
moderate‑intensity physical activity
moderate‑intensity statin
moderate‑intensity statin therapy
moderate‑sodium diet
moderate‑to‑vigorous exercise
moderate‑to‑vigorous physical activity
moderation of alcohol intake
modifiable cardiovascular risk factors
modifiable risk factors
modified bentall procedure
modified duke criteria
modified duke criteria (major and minor criteria for ie diagnosis)
modified duke criteria (major and minor criteria)
modified frailty index
modified konno procedure
modified konno procedure (high‑risk children)
modified who risk classification
modified world health organization (who) classification system
modularity in guideline presentation (knowledge chunk format)
molecular autopsy
molecular autopsy for sudden death
molecular diagnosis
molecular genetic testing / pathogenic variant detection
molecular profiling
monitoring
monitoring and management of cardiovascular disease during labor, delivery, and postpartum.
monitoring of anticoagulation
monitoring of anti‑xa trough levels >0.6 iu/ml
monitoring of coronary artery patency
monitoring of exercise progress
monitoring of pulmonary artery anatomy
monitoring of valve function
monitoring of ventricular function
monoamine oxidase inhibitor (mao‑i)
monoclonal antibodies to pcsk9
monoclonal antibody (rituximab)
monocyte chemoattractant protein‑1 (mcp‑1)
monogenic disease
monomorphic ventricular tachycardia
monomorphic ventricular tachycardia (vt)
monomorphic ventricular tachycardia
monophasic waveform
monotherapy
monotherapy in pah
monotherapy, dual therapy, triple therapy (gdmt combinations)
monounsaturated fat
monounsaturated fatty acids
morbid obesity
morbidity
morbidity (cardiovascular morbidity)
morbidity (disease burden)
morbidity and mortality
morbidity and mortality (cardiovascular outcomes)
morbidity and mortality associated with pad
morbidity and mortality discussions
morbidity and mortality in eisenmenger syndrome
morbidity and mortality rates
morbidity and mortality related to heart failure
morbidity reduction
morbidity related to af and other cardiac events
moricizine
morphine
morphologic tricuspid valve
morphological domain
mortality
mortality & morbidity (associated with surgical/endovascular intervention)
mortality (all‑cause death)
mortality (all‑cause, cardiovascular)
mortality (all‑cause, cardiovascular, hf‑specific)
mortality (all‑cause, cardiovascular, sudden cardiac death)
mortality (all‑cause, hf‑specific, short‑ and long‑term)
mortality (aorta‑related and all‑cause)
mortality (cardiac and all‑cause)
mortality (cardiac‑related)
mortality (cardiovascular mortality)
mortality (cardiovascular)
mortality (death from stroke, heart disease, or other vascular disease)
mortality (death)
mortality (elective surgery)
mortality (hf‑related)
mortality (high rates of mortality associated with ali)
mortality (in-hospital and long‑term)
mortality (in‑hospital, short‑term, 1‑year, long‑term)
mortality (short‑ and long‑term)
mortality (short‑term, 1‑year, 5‑year, overall)
mortality / death
mortality / morbidity in adult fontan patients
mortality / survival outcomes
mortality / survival rate
mortality advantage with multidisciplinary programs
mortality and morbidity
mortality and morbidity in acs
mortality and morbidity in aortic regurgitation
mortality and morbidity risks
mortality and survival analysis
mortality and transplant event rates in complicated vs. fulminant myocarditis.
mortality benefit (in cabg context)
mortality benefit of cabg over gdmt
mortality following ventricular arrhythmia suppression
mortality from heart failure
mortality in ebstein’s anomaly
mortality outcomes
mortality post‑myocardial infarction
mortality prediction
mortality prediction / risk models
mortality prediction in cardiogenic shock
mortality prediction in hf patients
mortality predictors in endocarditis
mortality rate
mortality rate (30‑day, midterm)
mortality rate (30‑day, overall)
mortality rate (age‑adjusted death rate)
mortality rate (in-hospital)
mortality rate (increase to 20% by day 2, 25% by day 30)
mortality rate post‑avr
mortality rates
mortality reduction
mortality reduction at >20–25 or >50 procedures per year
mortality related to aortic disease
mortality risk
mortality risk associated with af and cardiovascular conditions
mortality risk associated with moderate mixed disease
mortality risk associated with valvular lesions
mortality risk in pad patients
mortality risk score
mortality – cardiovascular, all‑cause
most study
motion artifact
motivational interviewing
mount sinai
moyamoya disease
mr
mr angiography
mr imaging
mr severity (effective regurgitant orifice area)
mra (mineralocorticoid receptor antagonist)
mra therapy (mineralocorticoid‑receptor antagonist)
mri (aortic imaging)
mri (magnetic resonance imaging)
mri angiography (non‑contrast, free‑breathing)
mri scan
mrna‑based covid‑19 vaccination
muffled closing clicks
multicenter automatic defibrillator implantation trial (madit)
multicenter clinical trials (e.g., capricorn, albatross)
multicenter cohort studies
multicenter diltiazem post‑infarction trial
multicenter diltiazem post‑infarction trial (mdpit)
multicenter pregnancy outcome registries (ropac, registry of pregnancy and cardiac disease)
multicenter prospective study
multicenter randomized clinical trial (acute study)
multicenter randomized trials in aortic surgery
multicenter registry
multicenter study
multicenter un‑sustained tachycardia trial (must)
multicentre study
multicomponent integrated care (combination of quality improvement strategies)
multidetector computed tomography (ct) angiography – wall thickness, coronary anatomy
multidetector computed tomography (mdct)
multidetector computed tomography coronary angiography
multidetector ct angiography (imaging of aortic stenosis)
multidetector ct imaging
multidetector ct scanners
multidetector‑row computed tomography (ct)
multidisciplinary achd team
multidisciplinary aortic team
multidisciplinary aortic teams
multidisciplinary approaches
multidisciplinary cardiac care
multidisciplinary cardiac surgical procedures (non‑transplant)
multidisciplinary cardio‑obstetric care
multidisciplinary cardio‑obstetrics team
multidisciplinary cardio‑oncology team
multidisciplinary care
multidisciplinary care / team
multidisciplinary care in vascular disease
multidisciplinary care program
multidisciplinary care strategy
multidisciplinary care team
multidisciplinary care teams
multidisciplinary care teams (hf, critical care, interventional cardiology, cardiac surgery)
multidisciplinary collaboration (achd, anesthesiology, surgery, ep)
multidisciplinary collaborative approach (cardiology, obstetrics, neonatology, genetics)
multidisciplinary discussion (treatment approach)
multidisciplinary expertise
multidisciplinary hcm centers
multidisciplinary heart failure team
multidisciplinary heart team
multidisciplinary heart valve team
multidisciplinary heart valve team (mdt)
multidisciplinary heart‑failure management
multidisciplinary heart‑failure team (cardiologist, surgeon, nurse, pharmacist, dietitian, palliative specialist, social worker)
multidisciplinary interventions
multidisciplinary interventions for heart failure
multidisciplinary management strategies for hf
multidisciplinary management team (e‑team)
multidisciplinary risk assessment and management
multidisciplinary shock team
multidisciplinary subspecialties (pulmonary medicine, gastroenterology)
multidisciplinary team
multidisciplinary team (cardiologists, interventionalists, cardiac anesthesiologists, obstetricians)
multidisciplinary team (complex‑care decision making)
multidisciplinary team (mdt)
multidisciplinary team (mdt) evaluation
multidisciplinary team (mdt) involvement
multidisciplinary team approach (mda)
multidisciplinary team evaluation
multidisciplinary team evaluation (for clti)
multidisciplinary team evaluation for clti patients (qm‑8)
multidisciplinary team follow‑up
multidisciplinary team for pregnancy management
multidisciplinary transplant committee
multidisciplinary transplant team
multidisciplinary valve team
multidisciplinary vascular care teams
multidisciplinary vascular team
multidisciplinary wound‑care team (for clti)
multidisciplinary/team‑based care for chronic limb‑threatening ischemia
multidrug immunosuppression
multidrug‑resistant microorganisms
multifocal enhanced external counterpulsation study (must‑eecp)
multigenerational families with thoracic aortic aneurysms and dissections
multigenerational family history of tad
multileaf lesion
multilevel disease
multimodal imaging
multimodal pharmacologic therapy (e.g., beta‑blockers, calcium channel blockers, antiarrhythmic drugs)
multimodality cardiovascular imaging
multimodality imaging
multimodality imaging (echocardiography, cmr, ct, scintigraphy)
multimodality imaging during follow‑up care of congenital heart disease
multimodality imaging for cor triatriatum sinister
multimodality imaging guidelines (echocardiography, cmr, ct)
multimodality imaging guidelines (echocardiography, mri, ct)
multimorbidity
multimorbidity in acs patients
multimorbidity in hf (≥2 chronic conditions)
multimorbidity, frailty, cognitive impairment in hf patients
multinucleated giant cells
multiorgan dysfunction
multiorgan failure
multiorgan phenotype
multiorgan transplantation
multiorgan transplantation (heart‑lung, heart‑kidney, heart‑liver)
multiparameter severity grade
multiple comorbidities
multiple lesions
multiple operative interventions
multisite pacing
multislice computed tomography
multislice computed tomography (ct)
multisociety guideline for prevention, detection, evaluation, and management of high blood pressure in adults
multispecialty / multisocietal collaboration
multispecialty care team
multispecialty care team (vascular, wound care, cardiology)
multispecialty care team / team‑based care for clti
multispecialty heart valve team
multispecialty, team‑based care for pad
multivalve disease
multivalve operations
multivariable analysis
multivariable risk scores
multivariate risk scores
multivessel cad
multivessel coronary artery disease
multivessel coronary artery disease (cad)
multivessel coronary artery disease (mvd)
multivessel coronary disease
multivessel coronary disease management in acs
multivessel disease
multivessel disease (mvd)
multivessel pci
multivessel pci vs culprit‑only pci comparison
multivessel percutaneous coronary intervention (pci)
multivessel revascularization
multivitamin supplementation
multivitamin‑mineral supplementation
multi‑center clinical studies
multi‑ethnic study of atherosclerosis (mesa)
multi‑organ transplantation in achd
multi‑specialty care team
multi‑system disease
multi‑valve disease
multi‑vessel coronary disease
multi‑vessel disease
mural thrombus
murmur
mus musculus microrna (mmu‑mir)
muscle fiber adaptations
muscle flaps
muscle‑related adverse effects (increased with concomitant statins)
muscular dystrophy
muscular dystrophy (cardiac involvement)
musculoskeletal limitations
mustard operation (surgical correction of transposition of great arteries)
mustt (multicenter unsustained tachycardia trial)
mv transcatheter edge‑to‑edge repair
mwho (modified world health organization) cardiac risk classification
mybpc3
mycophenolate mofetil
mycotic (infectious) aortic aneurysm
mycotic aneurysm
mycotic aneurysms
mycotic aortic aneurysm
myectomy
myectomy (surgical myectomy)
myectomy outcomes
myeloperoxidase (mpo)
myeloperoxidase (mpo) activity
myeloperoxidase activity












myh11
myh11 mutation (myosin heavy chain 11)
myh11‑associated aortopathy
myh6 (myosin heavy chain 6) variants
myh7
myh7 (myosin heavy chain 7) variants
myh7 gene
myl2
myl2 (myosin light chain 2)
myl3
myl3 (myosin light chain 3)
mylk
mylk mutation
mylk mutation (myosin light chain kinase)
mylk variant
mylk‑associated aortopathy
myocardial
myocardial arterial blood supply
myocardial blood flow at stress
myocardial blood flow reserve (mbfr)
myocardial bridging
myocardial collagen turnover (diastolic hf evidence)
myocardial contractility
myocardial contraction
myocardial crypts
myocardial damage
myocardial dysfunction
myocardial dysfunction / left‑ventricular dysfunction
myocardial edema
myocardial energetics
myocardial energy impairment during exercise
myocardial fibrosis
myocardial fibrosis assessment
myocardial fibrosis assessment (cmr)
myocardial function assessment
myocardial hibernation
myocardial hypertrophy
myocardial infarction
myocardial infarction (ami)
myocardial infarction (heart attack)
myocardial infarction (mi / ami)
myocardial infarction (mi)
myocardial infarction (mi) / acute coronary syndrome (acs)
myocardial infarction (mi) / acute myocardial infarction
myocardial infarction (mi) / heart attack
myocardial infarction (mi) / myocardial infarct
myocardial infarction (mi) / reinfarction
myocardial infarction (mi) size
myocardial infarction (mi) – previous and new
myocardial infarction (mi, sometimes referred to as ami)
myocardial infarction (non‑obstructive)
myocardial infarction / infarction
myocardial infarction after alcohol binge
myocardial infarction outcome measures
myocardial infarction risk
myocardial infarction with nonobstructive coronary arteries (minoca)
myocardial infarction with non‑obstructive coronary arteries (minoca)
myocardial infarction with non‑obstructive coronary artery disease (minoca)
myocardial infarction with normal coronary arteries
myocardial infarction, acute
myocardial infarction, chronic
myocardial infarction, evidence‑based interventions
myocardial infarction, non‑st‑elevation (nstemi)
myocardial infarction, revascularization outcomes
myocardial infarction, st‑elevation (stemi)
myocardial inflammation
myocardial injury
myocardial injury biomarkers
myocardial injury/death (procedure‑related)
myocardial ischemia
myocardial ischemia / ischemic changes
myocardial ischemia and transfusion (mint) trial
myocardial ischemia attributable to aaoca
myocardial ischemia detection
myocardial mass quantification
myocardial metabolism
myocardial necrosis
myocardial necrosis (myonecrosis)
myocardial oxygen demand
myocardial oxygen demand reduction (via heart rate, blood pressure, contractility)
myocardial oxygen supply
myocardial oxygen supply‑demand mismatch
myocardial performance
myocardial performance index (mpi)
myocardial perfusion
myocardial perfusion imaging
myocardial perfusion imaging (mpi)
myocardial perfusion reserve
myocardial perfusion single‑photon emission computed tomography (spect)
myocardial replacement fibrosis
myocardial revascularization
myocardial salvage
myocardial scar
myocardial scar / late‑gadolinium enhancement
myocardial scar heterogeneity
myocardial scarring
myocardial stiffness
myocardial strain abnormalities
myocardial strain imaging
myocardial stress perfusion mri (regadenoson)
myocardial structure
myocardial stunning
myocardial viability
myocardial work analysis (biventricular performance)
myocardial infarction
myocarditis
myocardium
myocardium (myocardial structure/function)
myocyte necrosis
myofibroblast activity
myofilament protein degradation
myokardia
myokardia (myocardial therapy)
myonecrosis
myopathic process in ebstein anomaly
myopathy (muscle disease)
myopathy, rhabdomyolysis
myopericarditis
myosin heavy chain 6 (myh6)
myosin inhibitor
myosin inhibitor (e.g., mavacamten)
myosin inhibitors
myosin‑binding protein c3 (mybpc3)
myxomatous changes
myxomatous degeneration
myxomatous disease
myxomatous mitral valve





















n-acetylprocainamide (napa)
n-terminal pro-bnp (nt‑probnp)
n-terminal pro‑brain natriuretic peptide (nt‑probnp)
n-terminal pro–b-type natriuretic peptide (nt‑probnp) – (implicit in hf assessment)
nadolol (oral)
naltrexone/bupropion (weight‑loss drug)
napkin‑ring sign
naproxen
narrow therapeutic range
nasogastric tube deviation
national academy of medicine (formerly institute of medicine) – cardiology standards
national behavioral risk factor surveillance system (brfss)
national cardiogenic shock initiative
national cardiovascular data registries
national cardiovascular data registry (ncdr)
national cardiovascular data registry (ncdr) action registry
national cardiovascular data registry (ncdr) – pvi registry
national center for catastrophic sports injury research
national cholesterol education program (ncep) adult treatment panel iii
national cholesterol education program adult treatment panel iii (ncep atp iii)
national forum for heart disease & stroke prevention (heart‑related focus)
national guidelines (aortic disease guideline)
national health and nutrition examination survey (nhanes)
national heart association/american college of cardiology guidelines (e.g., acc/aha)
national heart, lung, and blood institute (nhlbi)
national heart, lung, and blood institute (nhlbi) gentac registry
national heart, lung, and blood institute (nhlbi) – heart disease funding
national heart, lung, and blood institute (nhlbi) – key cardiovascular research institute
national institutes of health (nih)
national lipid association (nla)
national lipid association expert panel on familial hypercholesterolemia
national minority cardiovascular alliance
national physical activity plan (american heart association)
national registries and cohort studies (e.g., af‑risk, pinnacle, cabana)
national registry of nontraumatic amputations
national surgical quality improvement program (nsqip) data on aortic aneurysm
national trends in hf hospitalization and readmission
national/american heart association (aha), american college of cardiology (acc), heart rhythm society (hrs) guideline documents
nationwide registry data (e.g., dutch, japanese, uk national registries)
native american and alaskan native populations
native aortic infection
native valve
native valve disease
native valve endocarditis
native valve endocarditis (nve)
native valve heart disease (excluding rheumatic mitral stenosis)
native valve repair
native valves in pregnancy
native valvular heart disease, excluding mitral stenosis
native valvular regurgitation
native‑valve endocarditis
natriuretic peptide
natriuretic peptide (np)
natriuretic peptide biomarker
natriuretic peptide biomarkers
natriuretic peptide levels
natriuretic peptides
natriuretic peptides (bnp)
natriuretic peptides (bnp, nt‑probnp)
natriuretic peptides (bnp/nt‑probnp)
natriuretic peptides (e.g., bnp, nt‑probnp)
natural history
natural history (of pau and imh)
natural history of aortic aneurysm
natural history of aortic disease
natural history of aortic root aneurysm in marfan syndrome
natural history of arteriosclerosis
natural history of congenital ventricular septal defect
natural history of mitral regurgitation
natural history of moderate mixed vhd
nausea
navigate** (cardiac navigation system)
neat‑hfpef trial
nebivolol
neck angulation
neck length
necrotizing vasculitis on arterial biopsy
nect (n/a)
need for achd cardiac anesthesia and icu support
negative atrial remodeling
negative dromotropic agents
negative inotropes (verapamil, diltiazem, disopyramide)
negative inotropic effects
negative pressure wound therapy (npwt)
negative risk markers (e.g., cac=0)
negative u waves
neighborhood deprivation
neighborhood deprivation index (adi)
neighborhood disadvantage
neighborhood environment
neighborhood environment / access to facilities
neoaorta
neoaortic diameter
neoaortic dilation
neoaortic insufficiency
neoaortic insufficiency (regurgitation)
neoaortic obstruction
neoaortic regurgitation
neoaortic regurgitation (insufficiency)
neoaortic root dilation
neoaortic root intervention
neoaortic root replacement
neoaortic size/diameter
neoaortic valve stenosis
neoaortic valvular dysfunction
neoaortic‑root pathology
neochord (transcatheter mitral valve repair system)
neointimal hyperplasia
neonatal and pediatric outcomes after arterial switch
neovasc medical inc.
neo‑aortic insufficiency
neo‑aortic regurgitation
neo‑aortic root diameter
neo‑aortic root growth
neo‑intimal hyperplasia
nephrogenic systemic fibrosis
nephrogenic systemic fibrosis (nsf)
nephron blockade
nephropathy
nephrotoxic exposure
neprilysin inhibition
neprilysin inhibitor
net adverse clinical events
net atrial‑ventricular compliance
net atrioventricular compliance (nac)
net clinical benefit
net clinical benefit (mace + bleeding)
net clinical benefit / harm
net clinical outcome
net clinical outcomes (stroke, transient ischemic attack)
net harm (prasugrel vs clopidogrel in certain subgroups)
net left‑to‑right shunt
net left‑to‑right shunt (qp:qs ≥ 1.5:1)
net right‑to‑left shunt
network meta‑analysis
neuraxial anesthesia
neuraxial local anesthetic agents
neuraxial local anesthetics
neurocognitive adverse effects
neurocognitive and mental‑health considerations in achd (depression, anxiety, ptsd, cognitive decline, frailty)
neurocognitive and psychological outcomes in adults with corrected d‑tga
neurocognitive decline
neurocognitive dysfunction
neurocognitive events
neurocognitive screening in achd
neurodevelopmental evaluation in chd
neurodevelopmental outcomes
neurodevelopmental outcomes for individuals with congenital heart disease
neurodevelopmental outcomes in congenital heart disease
neuroendocrine activation
neurofibromatosis
neurohormonal
neurohormonal activation (targeted by neprilysin inhibitor)
neurohormonal activation in heart failure
neurohormonal antagonists
neurohormonal antagonists (e.g., acei, arbs, beta‑blockers, mras)
neurohormonal blockade
neurohormonal modulation (gdmt)
neurohormonal therapies for cardioprotection
neurohormonal therapy
neurohumoral and hemodynamic effects of lower body negative pressure
neuroischemic wounds
neurologic complications (brain abscess, stroke)
neurologic complications (perfusion‑related, stroke)
neurologic deficits
neurologic events
neurologic recovery / prognosis
neurologic toxicity (neurologic)
neurological outcomes
neurological toxicity
neurologist
neurology stroke team
neuromodulation
neuromuscular assessment
neuropathy
neuroprotection
neurosurgical monitoring
neurosurgical procedures
neuro‑hormonal guideline‑directed medical therapy (gdmt)
neuro‑modulation
neuro‑psychological complications
neutropenia
new cardiovascular horizons
new heart failure treatment strategies (sglt2 inhibitors, arni)
new or increased left‑sided valve regurgitation
new oral anticoagulants (doacs)
new partial dehiscence of prosthetic valve
new pharmacological therapy for heart failure
new york heart association
new york heart association (nyha)
new york heart association (nyha) class
new york heart association (nyha) class ii symptoms
new york heart association (nyha) class iii symptoms
new york heart association (nyha) class ii‑iv
new york heart association (nyha) class ii–iv
new york heart association (nyha) class i‑ii
new york heart association (nyha) class i–ii
new york heart association (nyha) class i–iii symptoms
new york heart association (nyha) class ii, iii, iv
new york heart association (nyha) class ii–iii
new york heart association (nyha) class iv
new york heart association (nyha) class ≥ iii/iv
new york heart association (nyha) functional class
new york heart association (nyha) functional class ii, iii, iv
new york heart association (nyha) functional class iii–iv
new york heart association (nyha) functional classes iii & iv heart failure
new york heart association (nyha) functional classes i–iv
new york heart association (nyha) functional classification
new york heart association (nyha) functional class iii/iv
new york heart association class (nyha)
new york heart association functional class (nyha fc)
newborn metabolic screening
new york heart association (nyha) class
new york heart association (nyha) functional classes ii–iv, iii–iv, iv
new york heart association (nyha) functional class iii/iv
new york heart association (nyha)
new york heart association (nyha) classification
new‑generation anticoagulants
new‑generation direct oral anticoagulants (doacs)
new‑guideline recommendations (ng)
new‑onset af (<1 year)
new‑onset af (within 3 months of valve surgery)
new‑onset af burden
new‑onset af diagnostic trials (e.g., east‑afnet 4)
new‑onset atrial arrhythmias
new‑onset atrial fibrillation
new‑onset heart failure
new‑onset heart failure (nyha classes iii–iv)
new‑onset myocardial infarction (mi)
new‑onset postoperative af
new‑tarry “high‑value” cardiac therapeutic economics (qaly)
new‑york heart association (nyha) class
new‑york heart association (nyha) class (i–iv)
new york heart association (nyha) functional class
new york heart association (nyha) functional classification
new york heart association (nyha) class
new york heart association (nyha) classification
new york heart association (nyha) functional class
new york heart association (nyha) functional class (ii–iii)
new york heart association (nyha) functional classes i–iv
new york heart association (nyha) class
new york heart association (nyha) class i–iv
new york heart association (nyha) classification
new york heart association (nyha) functional classification
nf‑κb (nuclear factor kappa‑b)
nhlbi (national heart, lung, and blood institute)
niacin
niacin (with or without laropiprant)
nicardipine
nicotine
nicotine dependence / addiction
nicotine replacement therapy
nicotine replacement therapy (nrt)
nicotine replacement therapy (patch, gum, lozenge)
nicotine‑replacement therapy
nicotine‑replacement therapy (nrt)
niemann‑pick c1‑like 1 protein (npc1l1)
nifedipine
nifedipine (long‑acting)
night‑time or weekend surgical effect
nih (national institutes of health)
nih (national institutes of health, many cardiovascular research programs)
nikaidoh procedure
nitrate medications
nitrate therapy
nitrates
nitrates (e.g., isosorbide mononitrate)
nitrates (e.g., nitroglycerin)
nitrates (pharmacologic therapy)
nitrates (routine use contraindicated, class iii)
nitrate‑responsive angina
nitric‑oxide release
nitroglycerin
nitroglycerin (nitroglycerin spray, sublingual tablets, intravenous)
nitroglycerin consumption
nitroglycerin spray
nitroglycerin‑sildenafil interaction (tadalafil, avanafil, sildenafil citrate)
nitroprusside
nitro‑sodic‑acid‑dependent peptides (dpp‑4) inhibitors
nitro‑vasodilators
nkx2‑5 mutation
nla (national lipid association)
nlrp3 (nod‑lrr‑pyrin domain containing protein 3)
nlrp3 inflammasome
nlrp3‑blocking drugs
noac (novel oral anticoagulant)
noble trial
nocebo effect (patient expectation of harm with statin)
nocturnal oximetry abnormalities
nocturnal oxygenation
nomograms
nonapical site pacing
noncardiac conditions
noncardiac surgery in vhd patients
noncompaction cardiomyopathy
noncompressible abi (> 1.40)
noncompressible vessels
nondihydropyridine calcium channel blocker
nondihydropyridine calcium channel blockers
nondihydropyridine calcium channel blockers (e.g., verapamil, diltiazem)
nondihydropyridine calcium channel blockers (verapamil, diltiazem)
nondihydropyridine calcium‑channel blocker
nondihydropyridine calcium‑channel blockers
nondihydropyridine calcium‑channel blockers (diltiazem, verapamil)
nonfamilial hcm
nonfatal mi
nonfatal stroke
nonfulminant myocarditis
nonhealing wounds
nonimaging parameters (serum markers, novel approaches)
nonintact circle of willis
noninvasive cardiac imaging
noninvasive cardiac testing
noninvasive diagnostic testing
noninvasive doppler interrogation
noninvasive imaging
noninvasive imaging (e.g., doppler echocardiography)
noninvasive risk markers
noninvasive stress imaging
noninvasive stress testing
nonischemic cardiomyopathy
nonischemic cardiomyopathy (nicmp)
nonischemic intermediate lesions
nonlethal arrhythmias
nonobstructive coronary arteries
nonobstructive coronary artery disease (nonobstructive cad)
nonobstructive hcm
nonobstructive hcm with preserved ejection fraction (ef)













nonparoxysmal atrial fibrillation
nonpharmacological interventions
nonpharmacological interventions for hypertension
nonpharmacological treatment
nonprescription nutrition/dietary supplements
nonrheumatic calcific mitral stenosis
nonsteroidal anti‑inflammatory drugs (nsaids)
nonsustained ventricular tachycardia (nsvt)
nonsustained ventricular tachycardia (nsvt) episodes
nonsyndromic heritable thoracic aortic aneurysm (nshtad)
nonsyndromic heritable thoracic aortic disease
nonsyndromic heritable thoracic aortic disease (nshtad)
nonsyndromic htad
nonthrombogenic valve surfaces
nonthrombogenic valves
nontraumatic amputation
nontraumatic lower extremity amputation
nontraumatic lower‑extremity amputation
nonvalvular atrial fibrillation
non‑adherence and subtherapeutic drug levels
non‑alcoholic fatty liver disease (nafld)
non‑aortic cardiovascular events
non‑arrhythmic deaths following icd implantation or mi
non‑aspirin non‑steroidal anti‑inflammatory drugs (nsaids) – their impact on mace risk
non‑a‑non‑b dissection (european consensus)
non‑calcified plaque
non‑calcified plaque burden
non‑cardiac comorbidities affecting treatment choice.
non‑cardiac organ dysfunction
non‑cardiac procedures
non‑cardiac procedures at achd centers
non‑cardiac surgery
non‑cardiac surgery (in the context of cardiac risk)
non‑cardiac surgery (perioperative context)
non‑cardiac surgery in high‑risk populations (ap classes ic–d, iia–d, iiia–d)
non‑cardiac surgery in vhd patients
non‑cardioembolic stroke
non‑cardiothoracic surgery
non‑cardiovascular death
non‑coding rnas (e.g., microrna)
non‑competitive β‑blocker
non‑conclusive tte → tee or cmr
non‑contrast mri
non‑coronary atherosclerotic disease
non‑coronary revascularization procedure
non‑culprit lesion
non‑culprit lesion pci
non‑deferrable major surgery on dapt
non‑dental invasive procedures (transthoracic/ transesophageal echocardiography, esophagogastroduodenoscopy, colonoscopy, cystoscopy)
non‑dihydropyridine calcium channel blocker (ndcc)
non‑dihydropyridine calcium channel blockers
non‑dihydropyridine ccb (verapamil, diltiazem)
non‑familial hypertrophic cardiomyopathy
non‑fatal cardiac failure
non‑fatal events
non‑fatal mi
non‑fatal myocardial infarction (mi)
non‑fatal reinfarction
non‑fatal stroke
non‑fibrin‑specific agents
non‑hdl cholesterol
non‑hdl‑c
non‑hdl‑c (total cholesterol – hdl‑c)
non‑hdl‑cholesterol
non‑healing ischemic ulcers
non‑healing lower extremity wound
non‑healing lower‑extremity wounds
non‑hyperemic pressure ratios
non‑infarct‑related arteries
non‑inferiority trial design
non‑invasive diagnostic testing before discharge
non‑invasive evaluation of valvular disease
non‑invasive filling pressure assessment (diastolic imaging)
non‑invasive global and regional ventricular function
non‑invasive imaging
non‑invasive imaging limitations (parallel intercept angle, image quality)
non‑invasive imaging-assisted management
non‑invasive management of acs
non‑invasive modalities (e.g., myocardial perfusion imaging, stress testing)
non‑invasive respiratory monitoring for congenital heart disease.
non‑invasive risk stratification
non‑invasive scd risk assessment
non‑invasive stress imaging
non‑invasive stress testing
non‑invasive testing (e.g., doppler, ultrasound)
non‑invasive testing (nuclear imaging, stress echo)
non‑invasive testing prior to discharge
non‑invasive vascular assessment
non‑ischemic cardiomyopathy
non‑ischemic chronic secondary mr
non‑ischemic dilated cardiomyopathy (non‑ischemic heart failure)
non‑ischemic hf
non‑ischemic mr
non‑ischemic myocardial inflammation
non‑laminar blood flow
non‑lbbb pattern
non‑left bundle branch block (non‑lbbb)
non‑major clinically relevant bleeding
non‑obstructive cad
non‑obstructive coronary arteries
non‑obstructive coronary arteries (inoca)
non‑obstructive coronary artery disease
non‑obstructive coronary artery disease (minoca)
non‑obstructive coronary artery disease (nocad)
non‑obstructive hcm
non‑obstructive hypertrophic cardiomyopathy
non‑pci‑capable hospital
non‑pharmacologic interventions
non‑pharmacologic therapy for mental health
non‑prescription dietary supplement
non‑q‑wave myocardial infarction
non‑randomized comparative studies
non‑reconstructable peripheral arterial disease
non‑restrictive ventricular septal defect
non‑restrictive vsd
non‑restrictive vsds (large, associated with eisenmenger)
non‑salvageable limb
non‑segregating heritable thoracic aortic disease (nshtad)
non‑selective beta‑blockers
non‑shockable rhythm (asystole, pulseless electrical activity)
non‑st elevation myocardial infarction (nstemi)
non‑statin lipid‑lowering therapies
non‑statin lipid‑lowering therapy
non‑stemi (implied as other acs presentations)
non‑stemi (nstemi)
non‑stemi acute coronary syndromes (nste‑acs)
non‑steroidal anti‑inflammatory drug (nsaid)
non‑steroidal anti‑inflammatory drug (nsaid) use
non‑steroidal anti‑inflammatory drugs (nsaids)
non‑steroidal anti‑inflammatory drugs (nsaids) for pericardial effusion
non‑steroidal selective mineralocorticoid receptor antagonists (mra) in hf
non‑st‑elevation acs (nste‑acs)
non‑st‑elevation acute coronary syndrome (nste‑acs)
non‑st‑elevation acute coronary syndromes
non‑st‑elevation acute coronary syndromes (nste‑acs)
non‑st‑elevation acute coronary syndromes (nst‑acs)
non‑st‑elevation mi
non‑st‑elevation myocardial infarction (nstemi)
non‑st‑segment elevation acs (nstemi)
non‑st‑segment elevation acs (nste‑acs)
non‑st‑segment elevation acute coronary syndrome (nste‑acs)
non‑st‑segment elevation acute coronary syndrome / nstemi (nste‑acs)
non‑st‑segment elevation acute coronary syndromes (nste‑acs)
non‑st‑segment elevation myocardial infarction (nstemi)
non‑st‑segment elevation myocardial infarction (nstemi/nste‑acs)
non‑st‑segment‑elevation myocardial infarction (nstemi)
non‑st‑segment–elevation acs (nste‑acs)
non‑sustained ventricular tachycardia
non‑sustained ventricular tachycardia (nsvt)
non‑syndromic aneurysm
non‑syndromic hereditary thoracic aortic disease (nshtad)
non‑syndromic heritable thoracic aortic disease (nshtad)
non‑syndromic thoracic aortic aneurysm
non‑traditional risk factors
non‑traditional risk markers
non‑valvular af
non‑valvular atrial fibrillation
non‑viable myocardium
non‑vitamin k antagonist oral anticoagulants
non‑vitamin k antagonist oral anticoagulants (noacs)
non‑vitamin k oral anticoagulant (doac)
non‑vitamin k oral anticoagulants (noacs)
non‑vitamin‑k antagonist oral anticoagulants trial (noah)
non‑vitamin‑k oral anticoagulant (noac)
non‑vitamin k antagonist oral anticoagulant (noac)
non‑vitamin k antagonist oral anticoagulants (noacs)
non‑vitamin k oral anticoagulant (noac)
non–st-elevation myocardial infarction (nstemi)
non–st‑elevation acute coronary syndrome (nst‑acs) / acute coronary syndrome (acs)
non–st‑segment elevation acs (nste‑acs)
non–st‑segment elevation acute coronary syndromes (nste‑acs)
non–st‑segment–elevation myocardial infarction (nstemi)
noonan syndrome
noonan syndrome (ptpn11, kras, sos1, raf1, nras, braf, map2k1) – pulmonary stenosis, asd, hypertrophic cardiomyopathy, avsd
noradrenaline (norepinephrine)
norcaad (nordic consortium for acute type a aortic dissection)
nordistemi study
norepinephrine
normal abi (1.00–1.40)
normal coaptation
normal coronary arteries
normal saline (for aki prevention)
normal sinus rhythm (nsr)
normotension (normal blood pressure)
northwestern university
norwood repair
norwood repair (hlhs/norwood)
norwood repair (stage 1)
nosocomial s. aureus bacteremia
notch1 gene mutation
notch1 mutation
note:** these terms encapsulate the core concepts, disease processes, interventions, complications, and diagnostic strategies relevant to cardiovascular (aortic) disease discussed in the provided guideline excerpts.
novartis
novartis (cardiovascular therapeutics)
novel agents for diabetes, obesity, and hyperlipidemia
novel cardiovascular risk‑reduction therapies
novel lipid‑lowering drugs (for pad)
novel lipid‑lowering drugs for pad (qm‑4)
novel oral anticoagulants
novel oral anticoagulants (noacs)
novo nordisk
no‑clamp technique
no‑reflow
no‑reflow phenomenon
nsaids (non‑steroidal anti‑inflammatory drugs)
nsr (normal sinus rhythm)
nstemi (non‑st‑elevation myocardial infarction)
nste‑acs (non‑st‑segment elevation acute coronary syndrome)
nt-probnp (biomarker)
nt‑probnp
nt‑probnp (biomarker for hf severity)
nt‑probnp (biomarker)
nt‑probnp (n‑terminal pro b‑type natriuretic peptide)
nt‑probnp (n‑terminal pro‑b‑type natriuretic peptide)
nt‑probnp level ≥ 5314 pg/ml (high‑risk subgroup)
nt‑probnp levels
nuclear cardiology
nuclear factor‑kappa b (nf‑κb)
nuclear imaging (myocardial perfusion)
nuclear magnetic resonance imaging (nmri)
nuclear myocardial perfusion imaging
nuclear myocardial perfusion imaging (mpi)
nuclear perfusion scans
nuclear scintigraphy
null‑please score
number needed to treat (nnt)
nupulse cv (cardiovascular technology)
nurse
nurse navigator
nurse practitioner / physician assistant
nurses with exercise training experience
nurse‑led af clinics
nurse‑led care programs
nurse‑led interventions
nutraceuticals / supplements → coenzyme‑q10, l‑carnitine, taurine, thiamine
nutrient‑related risk of cardiovascular disease
nutrition
nutrition (including supplements)
nutrition / diet
nutrition and diet (heart‑healthy diet)
nutrition and supplements
nutritional adequacy
nutritional counseling
nutritional counseling (cachexia, malnutrition)
nutritional management (diet, sodium, fluid)
nutritional risk factors (low‑carbohydrate diet, caloric reduction)
nutritional status
nutritional status / malnutrition in pad patients
nutritionist / dietitian
nuts and seeds
nuvasive
nyha (new york heart association)
nyha (new york heart association) classification
nyha (new york heart association) class
nyha (new york heart association functional classification)
nyha (new york heart association)
nyha class
nyha class (i–iv)
nyha class (new york heart association functional classification)
nyha class i
nyha class ii
nyha class ii & iii
nyha class iii
nyha class iii and iv heart‑failure (hf) symptoms
nyha class iii heart failure
nyha class iii–iv
nyha class ii‑iv symptoms
nyha class ii–iv heart failure
nyha class iv
nyha class ii or iii heart failure
nyha class iii
nyha class iv
nyha functional class
nyha functional class (i–iv)
nyha functional class i and iii
nyha functional class iii/iv
nyha functional class iii‑iv
nyha functional class iii–iv heart failure
nyha functional class ii–iv
nyha functional class i‑ii
nyha functional class i–iv
nyha functional classes (i, ii, iii, iv)
nyha functional classification
nyha functional classification (i–iv)
nyha functional class iii–iv
nyha ii‑iii symptoms / nyha class
nyha – new york heart association class
n‑3 polyunsaturated fatty acids (omega‑3)
n‑acetyl‑l‑cysteine (nac)
n‑of‑1 trial (caffeine)
n‑terminal probnp (nt‑probnp)
n‑terminal prohormone of b‑type natriuretic peptide (nt‑probnp)
n‑terminal pro‑b natriuretic peptide (nt‑probnp)
n‑terminal pro‑b type natriuretic peptide (nt‑probnp)
n‑terminal pro‑b-type natriuretic peptide (nt‑probnp)
n‑terminal pro‑bnp (nt‑probnp)
n‑terminal pro‑brain natriuretic peptide (nt‑probnp)
n‑terminal pro‑b‑natriuretic peptide (nt‑probnp)
n‑terminal pro‑b‑type natriuretic peptide
n‑terminal pro‑b‑type natriuretic peptide (nt‑probnp)
n‑terminal pro–brain natriuretic peptide (nt‑probnp)
n‑terminus pro‑bnp (nt‑probnp)



















oac (oral anticoagulant)
oac monotherapy
oasis, atoll, futura/oasis‑8, stenic, bright, gusto‑iib, etc. (key clinical trials/registries)
oasis‑5 trial
oasis‑6 trial
obesity
obesity & cardiac remodeling in hcm
obesity (as a risk factor)
obesity (bmi ≥ 30 kg/m²)
obesity (bmi ≥ 30 kg/m²)
obesity (class iii)
obesity (dose adjustment)
obesity (increased transthoracic impedance)
obesity (overweight/obese patients)
obesity (reduces bnp/nt‑probnp levels, impacting hf diagnosis)
obesity (risk factor)
obesity (weight, bmi)
obesity / cachexia / nutritional status – hf risk factors
obesity / elevated body mass index (bmi)
obesity / metabolic syndrome
obesity / overweight
obesity / weight control
obesity / weight loss (overweight)
obesity epidemic
obesity paradox in heart failure
obesity, social obstacles, substance use (barriers to transplant)
obesity‑mediated structural atrial changes
obesity‑related suppression of bnp
objective exercise capacity
objective exercise intolerance
objective limb‑threat classification tools
objective measures of cardiac dysfunction
obligates carriers
oblique imaging
obliquely arranged myocytes
observational and registry data
observational cohort studies
observational cohort studies on peripartum cardiomyopathy outcomes
observational studies
observational studies (cohort, registry)
observational studies on af and heart rate
observational studies vs randomized controlled trials (rcts)
observational studies/trials
observation‐based therapeutic strategies
obstetric and anesthesia coordination for anticoagulation
obstetric anesthesia
obstetric anticoagulation strategy (e.g., warfarin shift, lmwh use)
obstetric cardiac surveillance (cardiac monitoring during pregnancy)
obstetric outcomes
obstruction (clinical threshold for intervention)
obstructive cad
obstructive cad (≥ 50 % diameter stenosis, ffr ≤ 0.80)
obstructive cardiomyopathy
obstructive hcm
obstructive hcm / lvoto (left ventricular outflow tract obstruction)
obstructive hypertrophic cardiomyopathy
obstructive physiology
obstructive sleep apnea
obstructive sleep apnea (osa)
obstructive sleep apnea (pulmonary/ cardiac impact)
obstructive sleep apnea (risk factor for ph)
obstructive uropathy
obstructive vs. non‑obstructive hcm classification
occluded artery trial (oat)
occlusion
occlusive lesions
occlusive vascular disease
occlutech
occult (silent) atrial fibrillation
occult left ventricular dysfunction
occupation
occupational considerations for patients with hcm
occupational therapist
octogenarian surgery outcomes
odds ratio
odds ratio (or)
odyssey outcomes study (clinical trial)
odyssey outcomes trial
odyssey outcomes trial (evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab)
odyssey outcomes trial
office‑based abi measurement
offloading
off‑pump bypass
off‑pump coronary bypass
off‑pump myocardial revascularization
off‑the‑shelf branched repair
ohca score (out‑of‑hospital cardiac arrest score)
older adults
older adults (≥ 80 years, ≥ 65 years)
older age
older age (aging)
older age (≥75 years)
older age (≥ 75 years)
older‑adult heart disease risk
oliguria
omapatrilat
omapatrilat (neprilysin inhibitor/acei combination)
omecamtiv mecarbil for advanced (stage d) hfref
omega‑3 fatty acid supplements
omega‑3 fatty acids
omega‑3 fatty acids (epa, dha)
omega‑3 fatty acids (fish oil)
omega‑3 fatty acids (n‑3 fatty acids)
omega‑3 fatty acids (n‑3 polyunsaturated fatty acids, marine omega‑3)
omega‑3 polyunsaturated fatty acids
omega‑3 polyunsaturated fatty acids (omega‑3 pufa)
omega‑3 polyunsaturated fatty acids (pufa)
omental coverage
omeprazole
omics and molecular markers for hf diagnosis and prognosis
ongoing ischemia
ontarget (ongoing telmisartan alone and in combination with ramipril global endpoint trial)
ontarget (telmisartan alone and in combination with ramipril)
on‑x aortic valve
on‑x avr
open (surgical) repair
open aneurysm repair
open aortic aneurysm repair
open aortic reconstruction
open aortic repair
open aortic surgery
open aortic surgery (open repair)
open bypass
open commissurotomy
open distal anastomosis
open heart surgery
open infrainguinal bypass
open infrarenal aortic repair
open mitral commissurotomy (oc)
open repair
open repair (surgery, aortic cross‑clamping)
open repair of the aorta
open repair technique
open repair versus endovascular repair
open surgery
open surgical aortic repair
open surgical cutdown
open surgical intervention
open surgical repair
open surgical repair (arch or ascending aorta)
open surgical repair (in situ reconstruction, aortic resection)
open surgical repair (osr)
open surgical repair of aaa
open surgical repair of aorta
open surgical repair of coa
open surgical repair of the aorta
open surgical replacement
open surgical revascularization
open‑distal technique
open‑label trial (comparative efficacy of prasugrel vs. ticagrelor)
operability assessment in adult congenital heart disease
operating room (or)
operative and mortality risk in valve surgery
operative intervention (aortic surgery)
operative mortality
operative mortality (8–20 %)
operative mortality / operative risk
operative mortality rate
operative repair of type a aortic dissection
operative risk (low, intermediate, high)
operative risk models (irad score)
operative risk reduction (advanced surgical techniques)
operative survival (5‑year actuarial survival)
operative volume & surgical learning curve
operator/institutional case volume
ophthalmologic procedures
opiate medications
opioid substitution therapy
opioid substitution treatment (ost)
opioid use
opioid use (including opioid‑associated out‑of‑hospital cardiac arrest)
opioids
opioids (adjunct)
opioid‑dependent patients
optic neuropathy
optic neuropathy (amiodarone‑associated)
optic trial (optimal pharmacological therapy in cardioverter defibrillator patients)
optical coherence tomography (oct)
optical frequency domain imaging (ofdi)
optimal beta‑blocker duration in preserved lvef patients.
optimal blood pressure targets after valve intervention
optimal bp thresholds
optimal dosing
optimal exercise protocols
optimal gdmt
optimal medical management (study term)
optimal medical therapy (omt)
optimal timing of intervention
optimize‑hf (organized program to initiate lifesaving treatment in hospitalized patients with heart failure)
optimize‑hf registry
optimize‑hf study
optim‑um registry (surgically ineligible patients)
optmize‑hf registry (organized program to initiate lifesaving treatment in hospitalized patients with heart failure)
oral amiodarone
oral antibiotic treatment
oral anticoagulant
oral anticoagulant (oac)
oral anticoagulant discontinuation
oral anticoagulant therapy
oral anticoagulants
oral anticoagulants (doacs)
oral anticoagulants (e.g., rivaroxaban, direct oral anticoagulants)
oral anticoagulants (e.g., warfarin, doacs)
oral anticoagulants (oac)
oral anticoagulants (oacs)
oral anticoagulation
oral anticoagulation (oac)
oral anticoagulation (oac) therapy
oral anticoagulation / anticoagulant therapy
oral anticoagulation therapy
oral anticoagulation with a vka (vitamin k antagonist)
oral anti‑xa agents
oral aspirin
oral beta‑blockers
oral bioavailability
oral diuretics
oral dofetilide safety
oral factor xa inhibitors
oral gdmt
oral gdmt (guideline‑directed medical therapy)
oral glucose‑lowering agents in heart disease
oral health / oral hygiene (brushing teeth, flossing)
oral health maintenance
oral iron repletion
oral iron supplementation
oral loading dose (propafenone, flecainide)
oral p2y12 inhibitor
oral p2y12 inhibitors
oral p2y12 inhibitors (clopidogrel, ticagrelor, prasugrel, etc.)
oral prostacyclin analog selexipag
oral prostacyclin receptor analogs
oral sotalol
oral suppressive antimicrobial therapy (lifelong)
oral suppressive therapy
orbita medication‑adherence sub‑study
orbita trial
orbit‑af ii registry
orbit‑af trial
organ dysfunction (renal, hepatic, lymphatic)
organ hypoperfusion
organ malperfusion
organ meats
organ system compromise
organic mitral regurgitation
organisation of care for pregnancy in congenital heart disease
orthopedic surgeon
orthopedic surgery
orthopedics
orthopnea
orthotics
orthotopic branched endovascular arch repair
orthotopic heart transplantation
ortner’s syndrome
oscillating intracardiac mass
osler’s nodes
osteoplasty (coronary)
osteoplasty (surgical technique)
ostia of a branch vessel
ostial stenosis
ostium primum asd
outcome measures
outcome measures: survival, hospitalization, quality of life
outcome of atrioventricular valve surgery post‑fontan
outcome prediction
outcome prediction in hcm patients
outcome studies
outcome tracking
outcomes after specialty care for pah
outcomes of ablation in hcm patients
outcomes of atrial tachycardia ablation in fontan patients
outcomes of pacing
outcomes of percutaneous transluminal coronary angioplasty in chronic renal failure
outcomes of staged procedures (tavi → teer)
outcomes studies of arterial switch operation
outcomes studies of biventricular right‑ventricle–pulmonary‑artery conduits
outcomes studies of double‑root translocation
outcomes studies of nikaidoh/rev procedures
outcomes studies of pulmonary‑to‑pulmonary conduits
outcomes studies of rastelli repair
outcomes: mortality at 30 days, 6 months, 1 year, 6 years
outcomes: mortality, reduced mace, bleeding rates, rehospitalisation.
outer‑edge to outer‑edge measurement
outflow disease
outflow lesions
outflow tract gradient
outflow tract gradient variability
outflow tract obstruction
outflow tract‑to‑aortic velocity ratio
outlet vsd
outpatient ambulatory rhythm monitoring
outpatient antiarrhythmic therapy
outpatient care setting
outpatient care setting – cardiovascular care context
outpatient follow‑up
out‑of‑hospital cardiac arrest
out‑of‑hospital cardiac arrest management guidelines
out‑of‑hospital cardiovascular event
out‑of‑pocket costs
overall survival
oversensing (post‑exercise)
overt dosing (over‑dosing)
overt right ventricular failure
overweight
overweight and obesity in adults
overweight/obesity
over‑ or underestimation of risk by pce
oxidative stress
oxidative stress biomarkers (related to heart failure prognosis)
oxidative‑stress‑associated kinases (e.g., camkii, jun‑kinase)
oxidized low‑density lipoprotein















oxygen consumption
oxygen consumption measurements
oxygen consumption/oxygen uptake (vo₂)
oxygen saturation
oxygen saturation (spo₂)
oxygen saturation measurement (oximetry)
oxygen saturations
oxygen therapy
oxygen therapy effect on exercise performance
oxygen uptake (vo₂)
oxygen uptake / peak vo₂
oxygenation / ventilation parameters
oxygenation strategies in acute myocardial infarction
oxygen‑free radicals











p/lp (pathogenic/likely pathogenic) variants
p/lp genetic variants (predisposing pathogenic/likely pathogenic variants)
p2y12 antagonist
p2y12 inhibitor
p2y12 inhibitor (clopidogrel, ticagrelor, etc.)
p2y12 inhibitor therapy
p2y12 inhibitors
p2y12 inhibitors (clopidogrel, prasugrel, ticagrelor)
p2y12 inhibitors (e.g., clopidogrel, ticagrelor)
p2y12 inhibitors (oral & parenteral)
p2y12 inhibitors (oral and intravenous)
p2y12 receptor antagonists
pa catheter monitoring
pa hypoplasia
pa systolic pressure >35 mm hg
pac (premature atrial contraction)
pace score
pace termination
pacemaker
pacemaker (av junction ablation, vvir)
pacemaker (permanent)
pacemaker (pm)
pacemaker endocarditis
pacemaker implantation
pacemaker implantation (before age 65)
pacemaker implantation (right‑ventricular pacing, biventricular pacing)
pacemaker implantation / ventricular pacing effects
pacemaker implantation for post‑operative complete heart block
pacemaker implantation risk
pacemaker lead
pacemaker lead–induced tricuspid regurgitation
pacemaker lower‑rate programming (80–90 bpm)
pacemaker or defibrillator infection
pacemaker placement
pacemaker therapy
pacemakers
pacemakers and defibrillators
paces risk score
pace‑support rate setting
pacing
pacing (general term for cardiac pacing)
pacing algorithm
pacing algorithms (general)
pacing burden
pacing complications
pacing method (e.g., vvir, cardiac resynchronization therapy)
pacing percentage (≥ 98 % biventricular pacing)
pacing strategies
pacing strategies (rv pacing, crt pacing)
pacing strategies (systemic right ventricle / fontan)
pacing thresholds
pacing‑related atrioventricular dysfunction
packer et al. emperor‑preserved (2021)
paclitaxel‑coated devices
paclitaxel‑eluting stent
paclitaxel‑eluting stents
pad
pad (peripheral artery disease)
pad guideline (2024 acc/aha/aacvpr/apma/abc/scai/svm/svn/svs/sir/vess)
pad national action plan
pad “at risk” population pulse examination
pad “at‑risk” pulse examination
pad‑specific quality of life (padqol)
paf (paroxysmal atrial fibrillation)
paf or persistent af
pah crises (post‑partum)
pah progression
pah‑directed medications
pah‑directed therapy
pain control (analgesia)
pain control (for ischemic rest pain)
pain levels (moderate to severe claudication pain)
pain‑free walking distance
pain‑induced rest periods
pallas trial
palliated single ventricle physiology
palliation
palliative and supportive care (advanced hf)
palliative and supportive care in heart failure
palliative care
palliative care (in the context of advanced heart failure)
palliative care (limb)
palliative care for advanced heart failure
palliative care for heart disease
palliative care for patients with hf
palliative care in hf
palliative care in prohibitive surgical risk patients
palliative care interventions (e.g., pal‑hf)
palliative care team
palliative inotropic therapy
palliative medicine specialist
palliative‑care referral
palm (provider assessment of lipid management) registry
palpitations
palpitations (symptom of af)
palpitations (symptom)
pannus formation
pannus ingrew
pantoprazole
pao₂ (oxygen partial pressure)
papillary muscle abnormalities
papillary muscle displacement
papillary muscle insertion (antero‑mitral leaflet)
papillary muscle morphology
papillary muscle rupture
papillary muscle tear
papillary muscles (abnormal positioning, insertion)
papillary‑muscle rupture
paq (peripheral artery questionnaire) – assessment of limb function
parachute mitral valve
paradigm‑hf
paradigm‑hf (prospective comparison of arni with ace inhibitor in heart failure)
paradigm‑hf trial
paradigm‑hf trial (prospective comparison of angiotensin ii antagonist–drug interventions in the management of heart failure)
paradise‑mi trial
paradise‑mi trial (nt‑probnp prognostication)
paradoxical emboli
paradoxical embolism
paradoxical embolism (right‑to‑left shunts)
paradoxical embolism prevention (asd closure)
paradoxical embolization
paradoxical low‑flow severe as
paraganglioma
paragon‑hf study
paragon‑hf trial
paralysis (neurologic complication)
paramount‑hf trial
paraparesis
paraplegia
parasympathetic nerve remodeling
parasympathetic stimulation
paravalvular abscess
paravalvular extension
paravalvular infection
paravalvular invasion
paravalvular leak
paravalvular leak / regurgitation
paravalvular leakage
paravalvular regurgitation
para‑anastomotic aneurysm (post‑open aaa repair)
para‑anatomorrhatic aneurysm
parenteral antibiotics
parenteral anticoagulation
parenteral anticoagulation (heparin, enoxaparin, etc.)
parenteral anticoagulation strategies
parenteral vasodilator therapy
paris risk score
paroxysmal af
paroxysmal atrial fibrillation
paroxysmal supraventricular tachycardia (svt)
partial anomalous pulmonary venous connection
partial anomalous pulmonary venous drainage
partial anomalous pulmonary venous return
partial anomalous pulmonary venous return (papvr)
partial avsd (incomplete atrioventricular canal / primum asd)
partial defect closure (fenestrated closure)
partial oral treatment of endocarditis (poet) trial
partial/transition av septal defect
partially hydrogenated oils
parvovirus b19 infection
par‑anastomotic aneurysm
passive leg‑raising maneuver
passive smoking (second‑hand smoke)
patch angioplasty
patch leaks (vsd repair)
patency
patency (vascular graft patency)
patency rate
patency rates
patent ductus arteriosus
patent ductus arteriosus (pda)
patent ductus arteriosus closure (surgical & transcatheter)
patent foramen ovale
patent foramen ovale (implied in shunting context)
patent foramen ovale (pfo) closure
pathogenesis
pathogenic cardiac sarcomere genetic variant
pathogenic sarcomeric variant
pathogenic variant
pathogenic variant (in htad genes)
pathogenic variants
pathogenic variants in aortic disease genetics
pathogenic/likely pathogenic (p/lp) variants
pathogens: staphylococcus aureus, streptococcus pneumoniae, escherichia coli, salmonella, candida, aspergillus, mycobacterium tuberculosis
pathophysiologic mechanisms
pathophysiology
pathophysiology of functional mr
pathway (ablation)
pathway obstruction
patient activation
patient age
patient and caregiver goals
patient care (in the context of cardiovascular practice)
patient counseling and education
patient decision aids
patient demographics
patient education
patient education (for ccd)
patient education (on symptom management, lifestyle, medications)
patient education (symptom monitoring, return to daily routine, psychosocial considerations)
patient education and readiness
patient education and social determinants of health (contextual factors influencing care)
patient education strategies in acs
patient engagement
patient engagement and retention
patient engagement in cardiac treatment planning
patient health questionnaire – phq‑9 / phq‑8
patient height ratio (aortic root area to height)
patient monitoring
patient outcomes
patient out‑of‑pocket costs
patient preference
patient preference (vascular access)
patient registries for heart‑failure quality improvement
patient registry studies
patient selection for icd placement
patient self‑care education for hf
patient sex
patient values and preferences
patient-centered outcomes research institute (pcori)
patients and family members (care coordination)
patient‑centered approaches
patient‑centered care
patient‑centered decision making
patient‑centered outcomes
patient‑centered research
patient‑centered transition education
patient‑centered transitional care for hospitalized heart failure
patient‑centered treatments
patient‑centeredness
patient‑centric recommendations
patient‑characteristics influencing mcs outcomes
patient‑engagement tools
patient‑prosthesis mismatch
patient‑reported health status
patient‑reported health status measures
patient‑reported measures
patient‑reported outcome and health status measurement in hf
patient‑reported outcomes
patient‑reported outcomes (pros)
patient‑reported pre‑procedural physical and mental health
patient‑reported quality of life (rate‑af trial)
patient‑specific biomechanical simulation of stent‑graft deployment
patient–caregiver decision delegation
patient–prosthesis mismatch
patiromer (potassium binder)
patisiran (drug for attrv)
patisiran therapy (rna interference)
pause protocol
pause study
pave study
payors (insurance carriers)
pay‑for‑performance (p4p) programs
pay‑for‑performance programs
pce (pooled cohort equations)
pci (percutaneous coronary intervention)
pci strategies
pci‑capable facility
pci‑capable hospital
pcna (prevention of cardiovascular disease network)
pcna (preventive cardiovascular nurses association)
pcna (primary care cardiovascular nursing association)
pcp‑hf (pooled cohort equations to prevent hf)
pcr (polymerase chain reaction) as a diagnostic tool in myocarditis
pcsk9 inhibition (evolocumab)
pcsk9 inhibitor
pcsk9 inhibitor therapy
pcsk9 inhibitor therapy (alirocumab, evolocumab)
pcsk9 inhibitors
pcsk9 inhibitors (evolocumab, alirocumab)
pcsk9 inhibitors (monoclonal antibodies)
pcsk9 monoclonal antibody
pcsk9 monoclonal antibody (e.g., alirocumab, evolocumab)
pcsk9 monoclonal antibody (pcsk9 mab)
pcsk9 monoclonal antibody therapy
pcsk9‑directed small interfering rna (inclisiran)
pcv13 (pneumococcal conjugate vaccine)
pda insertion point
peace trial
peak and mean pressure gradients across aortic stenosis
peak aortic wall stress
peak doppler gradients (≥ 50 mm hg)
peak exercise oxygen consumption
peak gradient
peak gradient (mm hg, m/s)
peak lvot gradient
peak oxygen consumption
peak oxygen consumption (peak vo₂)
peak oxygen consumption (vo₂ peak)
peak oxygen consumption (vo₂)
peak oxygen consumption (vo₂ peak)
peak oxygen uptake (vo₂ max)
peak oxygen uptake (vo₂ peak)
peak rate‑pressure product
peak transvalvular jet velocity
peak vo₂
peak vo₂ (< 14 ml/kg/min or < 50 % predicted)
peak vo₂ (cardiac exercise capacity)
peak vo₂ (peak oxygen consumption/uptake)
peak vo₂ (peak oxygen uptake)
peak vo₂ improvement.
peak vo₂ post‑operative
peak vo₂ pre‑operative
peak vo₂ ≤ 12 ml/kg/min with beta‑blocker therapy (transplant cutoff)
peak vo₂ ≤ 14 ml/kg/min (transplant cutoff)
peak vo₂ ≤17 ml/kg/m²
pearl study
pearl‑hf trial
pearl‑hf trial (rly5016 potassium binder)
ped-fog (edifoligide prevention study)
pedal acceleration time
pediatric & congenital electrophysiology (paces) – related to cardiac conduction
pediatric and adult outcomes after coarctation repair
pediatric aortic dilation
pediatric aortic root replacement
pediatric arrhythmic events
pediatric atrial tachyarrhythmia
pediatric cardiology
pediatric cardiology / paediatric cardiology
pediatric cardiology/heart centers
pediatric cardiomyopathy
pediatric electrophysiology
pediatric exercise testing (≥ 7–8 years old)
pediatric hcm
pediatric hcm management strategies
pediatric hcm risk indicators (e.g., maximal wall thickness z‑score ≥ 20, age ≤ 50 yr for family history)
pediatric hypertrophic cardiomyopathy
pediatric icd decision‑making (cor 2b)
pediatric icd implantation
pediatric risk assessment
pediatric risk calculator
pediatric subvalvular aortic stenosis risk factors
pediatric vs. adult surgical indications
pediatric‑specific risk markers
peer review
pegasus‑timi 54 trial
pegasus‑timi 54 trial
pelvic floor exercise
pelvic surgery
penentrating atherosclerotic ulcer (pau)
penetrance
penetrance (high/low)
penetrance of hypertrophic cardiomyopathy
penetrating aortic ulcer
penetrating aortic ulcer (pau)
penetrating atherosclerotic ulcer
penetrating atherosclerotic ulcer (pau)
penetrating atherosclerotic ulcer of the thoracic aorta
penicillin g benzathine (intramuscular)
penicillin v potassium (oral)
pentoxifylline
penumbra

















peptic ulcer disease
pep‑chf
percutaneous / off‑label endovascular devices
percutaneous access
percutaneous alcohol ablation
percutaneous aortic balloon dilation
percutaneous aortic balloon dilation (balloon aortic valvuloplasty)
percutaneous aortic imaging
percutaneous aortic valve balloon dilation
percutaneous atrial fibrillation interventions
percutaneous atrial septal defect (asd) closure
percutaneous balloon aortic valvuloplasty (pba)
percutaneous balloon commissurotomy
percutaneous balloon dilatation
percutaneous balloon dilatation of the aortic valve
percutaneous balloon dilatation vs. surgical correction
percutaneous balloon dilation of the mitral valve
percutaneous balloon mitral commissurotomy (pmbc)
percutaneous balloon mitral valvuloplasty (pbmv)
percutaneous balloon valvuloplasty
percutaneous balloon valvuloplasty (balloon pulmonary valvuloplasty)
percutaneous circulatory assist device
percutaneous closure
percutaneous closure devices
percutaneous closure procedures
percutaneous coronary angioplasty
percutaneous coronary intervention
percutaneous coronary intervention (pci)
percutaneous coronary intervention (pci) / angioplasty
percutaneous deep vein arterialization (pdva)
percutaneous device closure
percutaneous device closure of vsd
percutaneous femoral access
percutaneous fenestrated asd closure
percutaneous intervention
percutaneous intervention in hcm
percutaneous intervention outcomes for coarctation
percutaneous interventions
percutaneous laao (plaao)
percutaneous laser myocardial revascularization
percutaneous lead & external power supplies (device complications)
percutaneous lead extraction
percutaneous left atrial appendage closure
percutaneous left atrial appendage occlusion (laao)
percutaneous lvad (plvad)
percutaneous mechanical thrombectomy
percutaneous mitral balloon commissurotomy
percutaneous mitral balloon commissurotomy (pmbc)
percutaneous mitral balloon dilation
percutaneous mitral clip
percutaneous mitral commissurotomy (pmc)
percutaneous mitral valve dilatation
percutaneous mitral valve repair
percutaneous mitral valve repair (e.g., mitraclip)
percutaneous mitral valve repair (tmr)
percutaneous mitral valvuloplasty
percutaneous paravalvular leak closure
percutaneous revascularization registry data
percutaneous structural intervention
percutaneous translational angioplasty
percutaneous transluminal angioplasty
percutaneous transluminal angioplasty (pta / balloon angioplasty)
percutaneous transluminal angioplasty (pta)
percutaneous transluminal angioplasty (ptca)
percutaneous transluminal balloon angioplasty
percutaneous treatment
percutaneous valve repair
percutaneous valve repair / replacement
percutaneous valve therapies
percutaneous vascular access
percutaneous ventricular assist devices (vad)
percutaneous coronary intervention (pci)
perforation (of myocardium)
perforation during angioplasty
performance attribution
performance improvement initiative
performance measure (pm)
performance measurement / quality metrics in heart failure care
performance measures
performance measures (cardiovascular performance metrics)
performance measures (cardiovascular/vascular)
performance measures (class i recommendations)
performance measures (pm) for hf
performance measures (pm‑1 to pm‑6)
performance measures (pm‑1 to pm‑7)
performance‑measure benchmarks (real‑time feedback)
perfusion
perfusion adequacy
perfusion assessment
perfusion cmr
perfusion imaging
perfusion imaging techniques
perfusion to the wound bed
perianeurysmal obstruction
periaortic hematoma
pericardial disease (implicit in heart failure context)
pericardial effusion
pericardial effusion / fluid
pericardial tamponade
pericardiectomy
pericardiotomy
pericardioversion thromboembolic event
pericarditis
pericarditis (acute & late)
pericarditis (acute)
pericarditis after myocardial infarction
pericarditis after myocardial infarction (mi)
pericarditis diagnostic criteria
pericardium
perimembranous ventricular septal defect
perimembranous vsd
perimount bioprosthesis
perimount pericardial bioprosthesis
perinatal (pregnancy continuum) hf management strategies
perinatal cardiac outcomes in valvular disease
perindopril
perindopril (ace inhibitor)
perindopril (in elderly hf)
periodic echocardiographic and electrocardiographic screening for relatives
periodic imaging
periodic imaging after valve intervention
periodic imaging schedule
periodic imaging surveillance
periodic longitudinal evaluation (cmr)
periodic monitoring and patient education
periodic reassessment of scd risk
periodical reassessment (first 2 years and yearly thereafter)
periop2 trial
perioperative antibiotic suppression
perioperative atrial fibrillation
perioperative bridging anticoagulation
perioperative cardiovascular evaluation
perioperative cardiovascular evaluation and management
perioperative cardiovascular evaluation and management (acc/aha 2014)
perioperative cardiovascular management
perioperative cardio‑vascular evaluation and management
perioperative complications
perioperative complications (in the context of heart disease)
perioperative considerations/management for non‑cardiac surgery
perioperative death
perioperative death/mortality (in cardiac surgical context)
perioperative events
perioperative hemorrhagic conversion
perioperative management
perioperative management of as patients.
perioperative management of pulmonary hypertension
perioperative morbidity
perioperative morbidity and complications of aortic repair
perioperative morbidity and mortality
perioperative mortality
perioperative mortality (10–25 %)
perioperative mortality rate
perioperative mortality rates
perioperative mortality risk
perioperative outcomes
perioperative outcomes of aortic repair
perioperative period / peri‑operative hemodynamics
perioperative risk
perioperative stroke
perioperative valve outcomes
peripartum cardiomyopathy
peripartum cardiomyopathy (cause and targeted therapies)
peripartum cardiomyopathy (ppcm)
peripheral access (ct peripheral)
peripheral aneurysm
peripheral arterial bypass
peripheral arterial cannulation (femoral, axillary)
peripheral arterial disease
peripheral arterial disease (pad)
peripheral arterial disease (pad) – implied by “atherosclerotic disease”
peripheral arterial disease (pad) – the overarching vascular disorder linked to coronary disease
peripheral arterial disease epidemiology
peripheral arterial disease severity
peripheral arterial occlusive disease
peripheral artery disease
peripheral artery disease (as a manifestation of cvd)
peripheral artery disease (lower extremity)
peripheral artery disease (pad)
peripheral artery disease measures
peripheral artery disease quality‑of‑care improvement and patient‑reported outcomes
peripheral artery disease risk factors (hypertension, diabetes, dyslipidemia)
peripheral artery disease – pad
peripheral artery intervention (endovascular)
peripheral artery questionnaire (paq)
peripheral atherosclerotic vascular disease
peripheral cardiovascular complications (e.g., perioperative af)
peripheral dissection
peripheral edema
peripheral embolization
peripheral neuropathy
peripheral neuropathy (associated with phenocopies)
peripheral neuropathy (in patients with diabetes)
peripheral neuropathy – a neurological complication often secondary to vascular disease
peripheral occlusive disease
peripheral oxygen extraction
peripheral percutaneous coronary intervention (pci)
peripheral pulmonary artery stenosis
peripheral resistance
peripheral vascular complications
peripheral vascular disease
peripheral vascular disease (broader term)
peripheral vascular disease (claudication, aortic or limb interventions, arterial/venous thrombosis)
peripheral vascular disease (general term)
peripheral vascular disease (pvd)
peripheral vascular resistance (pvr)
peripheral vascular surveillance testing
peripheral vascular ultrasound
periprocedural anticoagulation
periprocedural antithrombotic therapy
periprocedural bleeding
periprocedural care
periprocedural cerebral thromboembolism
periprocedural complications
periprocedural events
periprocedural management
periprocedural phase
periprocedural planning
periprocedural planning in cardiac patients
periprocedural risk
periprocedural stroke risk
periprosthetic leak
periprosthetic leakage
perivalvular abscess
peri‑cardioversion anticoagulation
peri‑device leak
peri‑graft air
peri‑operative complications
peri‑operative morbidity in fontan surgery
peri‑operative mortality
peri‑operative outcomes
peri‑operative risk
peri‑pregnancy intervention for vhd
peri‑procedural ischemic events
permanent af
permanent atrial fibrillation
permanent pacemaker
permanent pacemaker (ppm)
permanent pacemaker (ppm) implantation
permanent pacemaker implantation
permanent pacemaker insertion
permanent pacemaker leads
permanent pacemaker risk
permanent pacing
permanent pacing / pacemaker
permanent/persistent af
permissive hypotension
permissive hypotension (used in hemodynamically unstable cardiac/vascular emergencies)
peroxisome proliferator‑activated receptor‑γ (ppar‑γ)
peroxisome proliferator‑activated receptor γ (ppar‑γ)
perpendicular measurement to aortic axis
persistent af
persistent atrial fibrillation
persistent chest pain symptoms
persistent infection
persistent infection (bacteremia, fevers >5 days)
persistent inflammation
persistent inflammation in myocarditis
persistent left superior vena cava
persistent shunts (right‑to‑left shunts)
personal history of arrhythmic syncope
personal history of cardiac arrest or sustained ventricular arrhythmias
pet (positron emission tomography)
pet/ct imaging
pfizer
pfizer (cardiovascular drugs)
ph (pulmonary hypertension)
pharmaceutical companies with cardiac indications:
pharmacist
pharmacist interventions in cardiovascular care
pharmacist involvement
pharmacists
pharmacist‑administered intervention
pharmacist‑led interventions
pharmacodynamic variability
pharmacodynamics of oral antiplatelet therapy
pharmacogenomics (xpnpep2 polymorphism)
pharmacoinvasive strategy
pharmacokinetics (half‑life, liver/kidney elimination, crcl)
pharmacokinetics in pregnancy (absorption, volume of distribution, protein binding, clearance, uteroplacental flow, fetal metabolism)
pharmacologic (optimal medical) management
pharmacologic agents for af prevention (e.g., mras, acei/arb)
pharmacologic antiarrhythmics (e.g., amiodarone, amiodarone vs icd)
pharmacologic delay of p2y12 inhibitor effects by opioids (morphine, fentanyl)
pharmacologic interventions for aneurysm prevention
pharmacologic management of atrial fibrillation
pharmacologic management of heart failure
pharmacologic management of obstructive hcm
pharmacologic management of symptomatic patients with obstructive hcm
pharmacologic modulation of preload and afterload in hcm therapy.
pharmacologic therapies
pharmacologic therapy
pharmacologic therapy (beta‑blockers, ace inhibitors, arbs, diuretics, anticoagulants)
pharmacologic therapy (beta‑blockers, etc.)
pharmacologic therapy for hcm
pharmacologic therapy for mental health
pharmacologic therapy in heart failure guidelines
pharmacologic treatment
pharmacologic treatment options
pharmacological cardioversion
pharmacological interventions (e.g., iron, ace inhibitors, beta‑blockers, arni)
pharmacological management for exercise capacity
pharmacological smoking cessation therapies (nicotine patch, varenicline, bupropion)
pharmacological therapy for cardiovascular risk reduction
pharmacological treatment
pharmacological treatments
pharmacomechanical thrombectomy
pharmacotherapy for tobacco cessation
pharmaco‑invasive approach (fibrinolysis followed by pci)
pharmaco‑invasive strategy
phase ii re‑align study (dabigatran vs. warfarin in valve replacement)
phendimetrazine
phenocopies of hypertrophic cardiomyopathy (hcm)
phenocopy (mimic) of hcm
phenotype
phenotype conversion
phenotype negative
phenotype severity assessment
phenotype‑negative / genotype‑positive status for hcm
phenotype‑specific risk algorithms
phenotype–genotype correlation in cardiomyopathy
phenotypic expression
phenotypic heterogeneity
phenotypic spectrum
phenotypic spectrum of tgfb3 disease‑causing variants
phenprocoumon anticoagulation
phentermine
phenylephrine
phenylephrine (intravenous vasoconstrictor)
phenylephrine, norepinephrine (vasopressors)
phenytoin
pheochromocytoma
pheochromocytoma / paraganglioma
pheochromocytoma‑associated cardiomyopathy















philips
philips healthcare** (cardiac imaging equipment)
phlebitis
phosphodiesterase iii inhibitor
phosphodiesterase inhibition
phosphodiesterase type 5 inhibitors (pde5i)
phosphodiesterase‑5 (pde5) inhibitors
phosphodiesterase‑5 inhibition (e.g., sildenafil)
phosphodiesterase‑5 inhibitor
phosphodiesterase‑5 inhibitor (tadalafil)
phosphodiesterase‑5 inhibitor therapy
phosphodiesterase‑5 inhibitors
phosphodiesterase‑5 inhibitors (class iii)
phosphodiesterase‑5 inhibitors (e.g., sildenafil)
phosphodiesterase‑5 inhibitors (pde‑5i)
phosphodiesterase‑type 5 inhibitors
phosphodiesterase 3 inhibitors (pde3)
phospholamban regulation
photoplethysmographic af inference
photoplethysmographic waveform
photoplethysmography
photoplethysmography (ppg)
photoplethysmography (smartphone / smartwatch)
photosensitivity
phpvd (pulmonary hypertension with pulmonary vascular disease)
phrenic nerve paralysis
physical activity
physical activity (exercise)
physical activity (general)
physical activity (moderate‑intensity, vigorous)
physical activity / exercise
physical activity / exercise prescription
physical activity / exercise prescription for aortic disease patients
physical activity counseling
physical activity guidelines for adults and children
physical activity guidelines for americans
physical activity guidelines for ccd
physical activity intensity levels (mets) (e.g., 1.6–2.9 mets for light, 3.0–5.9 mets for moderate, ≥6 mets for vigorous)
physical activity level
physical activity promotion
physical activity recommendations for aortic disease
physical activity, exercise, sports participation
physical activity/exercise
physical component summary (pcs)
physical exam of pulses
physical examination
physical examination (pulse palpation)
physical examination findings (weight change, exam signs of congestion)
physical examination findings in tr
physical exercise training (within cr)
physical fitness
physical functioning
physical inactivity
physical inactivity / sedentary lifestyle
physical medicine and rehabilitation clinician
physical performance / endurance
physical signs of fluid retention
physical therapist
physical, mental, and emotional health impact of aortic disease
physician and patient preferences
physician education / patient education
physician market concentration
physician‑ and industry‑sponsored clinical trials
physician‑estimated outcomes
physiologic pacing
physiologic pacing versus right ventricular pacing evaluation
physiological assessment (e.g., fractional flow reserve) of non‑culprit stenosis
physiological changes
physiological impact / assessment
physiological repair (surgical or transcatheter)
physiological stage (a, b, c, d) in achd classification.
physiological stage (a–d)
physiological stages (a, b, c, d) in achd follow‑up
physiological stages of follow‑up (stages a–d)
physiological tests of myocardial perfusion
physiologically significant cad
physiology‑guided pci
physiopathology
ph‑specific therapies
pico[ts] structure (clinical question format)
pill‑in‑the‑pocket (pitp) approach
pill‑in‑the‑pocket strategy
pill‑in‑the‑pocket therapy
piloting an aircraft (occupational consideration)
pinnacle flx trial
pioglitazone
pioneer af‑pci
pioneer trials (not explicitly mentioned but implied by pcsk9 inhibitors)
pioneer‑hf (prospective study of arni in acute heart failure)
pioneer‑hf trial
pioneer‑hf trial (phase ii/iii study evaluating novel therapies in decompensated heart failure)
pitavastatin
pitavastatin (1‑4 mg)
pitavastatin (1–4 mg)
pitavastatin (statin therapy)
pitp (pill‑in‑the‑pocket)
pitp strategy (pulmonary‑influenced termination protocol)
pivotal (positive impact of endovascular options for treating aneurysm early)
pivotal doac trials (e.g., averroes, aristotle, spaf iii)
pkcβ (protein kinase c beta)
plaao (percutaneous left atrial appendage occlusion)
placebo comparison
placental crossing of medication
plain chest x‑ray
plakophilin‑2 (pkp2)
planimetric area
plant protein
plant protein (e.g., nuts, whole‑grain breads)
plant‑based diet
plant‑based diets
plaque
plaque burden
plaque contents exposure
plaque erosion
plaque index
plaque instability
plaque length
plaque regression / plaque components
plaque rupture
plaque stabilization
plaque volume
plasma concentration
plasma fractionated metanephrines
plastic surgery
platelet activation
platelet activation (in drug‑induced cardiac events)
platelet activation / aggregation
platelet activation / inhibition
platelet activation pathways
platelet adenosine diphosphate receptor (p2y12)
platelet adenosine diphosphate receptor (p2y12) agents
platelet aggregation
platelet aggregation inhibition
platelet antiplatelet therapy (apt)
platelet count (thrombocytopenia)
platelet count/function
platelet dysfunction (in the context of noonan syndrome)
platelet function assays
platelet function testing
platelet inhibition
platelet inhibition (irreversible)
platelet inhibition / pharmacodynamic response
platelet inhibition loading dose
platelet inhibition variability in clopidogrel
platelet microparticles
platelet reactivity
platelet‑activated receptor‑1 (par‑1)
platelet‑activating factor p2y12 receptor inhibitors
platelet‑leukocyte interaction
plato trial
plato trial (p2y12 inhibitor study of ticagrelor vs. clopidogrel)
pleiotropic effects of statins
plethysmographic pulse volume recording (pvr)
pleural coverage
pleural effusion
pleuritic chest pain
pm2.5 (particulate matter ≤ 2.5 µm)
pneumococcal polysaccharide vaccination (as a preventive measure for cardiovascular risk)
pneumococcal polysaccharide vaccine (ppv)
pneumococcal vaccination
pneumonia
pneumonia (post‑procedure)
pocket hematoma
podiatrist
podiatry
podiatry / podiatrist
poet study (patient outcome evaluation)
point‑of‑care cardiac ultrasound
point‑of‑care lung ultrasound
point‑of‑care ultrasound
policies and procedures for transfer, referral, and tracking of patients
policy development
policy impact on mortality and outcomes
policy recommendations for pad
policy statement
polyester graft
polygenic and monogenic contributions to af risk
polygenic risk scores
polygenic susceptibility
polymerase chain reaction (pcr)
polymorphic pvcs
polymorphic ventricular tachycardia (vt)
polypharmacy
polypharmacy, multimorbidity, cognitive decline, frailty
polytetrafluoroethylene (ptfe) grafts
polytetrafluoroethylene (ptfe) prosthetic graft
polyunsaturated fat
polyunsaturated fatty acid (pufa)
polyunsaturated fatty acids
polyunsaturated fatty acids (pufa)
polyvascular disease
polyvascular disease (disease in ≥2 arterial beds)
pooled cohort equation (pce)
pooled cohort equations (acc/aha)
pooled cohort equations (pce)
pooled cohort equations (pce) – ascvd risk estimation
pooled individual patient data
pooled individual patient data analysis
poor adherence to pharmacotherapy
poor candidate for rehabilitation
poor-quality runoff
poorly controlled hypertension
popliteal artery
popliteal entrapment/ aneurysm
popliteal pulse
population attributable fraction (paf) for af
population health management (hf risk stratification)
population screening
population screening / risk stratification
population‑based analysis
population‑based cohorts
population‑based data collection
population‑based study
population‑based study of wpw syndrome
porcelain aorta
portal hypertension
portal hypertension (cause of ph)
portrait pad registry
positive airway pressure therapy
positive family history of cardiomyopathy
positive remodeling (remodeling index > 1.1)
positron emission tomography
positron emission tomography (pet)
positron emission tomography (pet) with fdg
positron emission tomography (pet) – myocardial perfusion
positron emission tomography myocardial perfusion imaging
positron emission tomography myocardial perfusion imaging (pet mpi)
positron emission tomography‑based myocardial perfusion imaging
positron emission tomography‑ct (pet‑ct)
positron emission tomography–computed tomography (pet‑ct)
post-treatment surveillance of lvot gradients
postcapillary pulmonary hypertension
posterior circulation
posterior circulation perfusion
posterior leads (v7–v9)
posterior leaflet pathology
posterior left pericardiotomy
posterior left pericardiotomy (atrial fibrillation prevention)
posterior mediastinum
posterior stemi
posterior tibial pulse
postmenopausal hormone therapy
postmenopausal hormone therapy and cardiovascular outcomes
postmenopausal women
postmortem genetic testing
postmortem testing / molecular autopsy
postnatal genetic testing
postoperative atrial fibrillation
postoperative atrial fibrillation (poaf)
postoperative outcomes
postoperative outcomes.
postoperative surveillance
postoperative β‑blocker use
postpartum aortic complications
postpartum cardiac decompensation
postpartum cardiomyopathy
postpartum cardiovascular outcomes
postprandial exercise
postprandial exercise stress testing
postprocedural care
posttest genetic counseling
posttraumatic stress disorder (ptsd)
post‑ablation blanking period complications
post‑acute care planning
post‑acute management of acs
post‑acute mi complications
post‑capillary pulmonary hypertension
post‑cardiac arrest care
post‑cardioversion thromboembolic risk
post‑closure hemodynamic assessment
post‑conversion bradycardia
post‑discharge antiplatelet therapy
post‑discharge follow‑up
post‑discharge mortality
post‑discharge prescription medications
post‑discharge prognosis
post‑discharge risk
post‑exercise abi
post‑hoc analyses
post‑implant monitoring
post‑infarction mechanical complications
post‑infarction mitral regurgitation
post‑it registry
post‑marketing retrospective studies
post‑mi management
post‑mi pericarditis
post‑myocardial infarction (post‑mi) patients
post‑operative adhesions
post‑operative af
post‑operative af after vhd intervention
post‑operative anticoagulation
post‑operative arrhythmias after fontan operation
post‑operative atrial fibrillation
post‑operative atrial fibrillation (after cardiac surgery)
post‑operative cardiac complications
post‑operative cardiac event
post‑operative complications
post‑operative fontan physiology
post‑operative heart failure
post‑operative hemodialysis
post‑operative hemodynamic instability
post‑operative imaging for vascular ring/pa sling
post‑operative left ventricular function
post‑operative mortality
post‑operative outcomes
post‑operative outcomes for repair of truncus arteriosus, dorv, and fontan surgeries
post‑operative outcomes in asymptomatic patients with lv dysfunction
post‑operative outcomes of pulmonary valve replacement
post‑operative pain
post‑operative pericardial effusion
post‑operative prognosis
post‑operative quality of life in aortic patients
post‑operative risk factors
post‑operative survival
post‑partum aortic dissection risk
post‑partum cardiovascular disease
post‑pci
post‑pericardiotomy syndrome
post‑prandial hemodynamics
post‑prandial upright exercise echocardiography
post‑pregnancy cardiovascular management
post‑procedural care
post‑procedural complications of coronary interventions
post‑procedural residual leak assessment
post‑procedure combination therapies
post‑repair mitral stenosis
post‑revascularization arrhythmic risk
post‑savr survival
post‑stroke mortality
post‑tavi mitral repair potential
post‑tavi survival
post‑therapy imaging
post‑transplant outcomes
post‑traumatic stress disorder (ptsd) in achd
post–cardiac arrest care
potassium
potassium binders (patiromer, sodium zirconium cyclosilicate)
potassium binders to optimize guideline‑directed medical therapy (gdmt)
potassium intake
potassium intake / potassium supplementation
potassium levels
potassium‑sparing diuretics (spironolactone)
poultry
pparα modulator (pemafibrate)
ppsv23
pr index (pulmonary regurgitation index)
pr interval
pr interval / first‑degree heart block
pr interval > 0.24 ms
practice patterns for adult congenital heart disease management
prague‑17 trial
praise‑1 (prospective randomized amlodipine survival evaluation‑1)
praise‑2 (prospective randomized amlodipine survival evaluation‑2)
prasugrel
prasugrel (p2y12 inhibitor)
pravastatin
pravastatin (10 mg, 20 mg, 40 mg, 80 mg)
pravastatin (40‑80 mg; 10‑20 mg)
pravastatin (40–80 mg)
precipitants (of af)
precise and individualized hf management
precision medicine
precision medicine and patient‑centered care for aortic disease
precision medicine in cardiology
precision medicine in heritable thoracic aortic disease
precision medicine/genetic testing in hf management
preclinical hcm
preclose technique (percutaneous closure)
precombat trial
preconception counseling
preconception evaluation
preconception genetic counseling & testing for heritable cardiac conditions
preconception management of valvular disease
preconception transthoracic echocardiography (tte)
preconceptional genetic counseling
prediabetes
predicted 1‑year mortality (> 20 %)
predicted maximum heart rate
predicted survival
prediction of outcomes after valve intervention
predictive biomarkers for heart failure
predictive model for hfpef (e.g., h2f‑peff).
predictive model for long‑term survival
predictive risk scores (5‑year scd risk)
predictive scores (e.g., wilkins, integrated approach)
predictive value of cardiac biomarkers for incident hf
predictors of cerebrovascular events in valvular heart disease
predictors of disease progression
predictors of heart failure progression
predictors of major af endpoints
predictors of mortality
predictors of post‑discharge outcomes in acute heart failure
predimed study
predimed trial
















prednisone
prednisone therapy for pericarditis
preeclampsia
preeclampsia (shared risk with ppcm)
preeclampsia prevention
preexcitation
preexcitation syndromes
preexcited atrial fibrillation (af)
preexisting cardiomyopathy
pregnancy
pregnancy (in eisenmenger)
pregnancy (in hcm)
pregnancy (obstetric considerations for hcm)
pregnancy and cardiovascular disease program
pregnancy and lactation labeling rule
pregnancy anticoagulation dilemma
pregnancy cardiovascular risk tools
pregnancy counseling
pregnancy heart team
pregnancy in aortic disease
pregnancy in cardiomyopathy
pregnancy in chd patients
pregnancy in pah
pregnancy in vhd (management/anticoagulation)
pregnancy in women with cardiomyopathy
pregnancy in women with ischemic heart disease
pregnancy in women with severe valve disease
pregnancy management in hcm
pregnancy outcomes
pregnancy outcomes in eisenmenger syndrome
pregnancy outcomes in heart disease
pregnancy outcomes in women with heart disease
pregnancy outcomes in women with heart disease (carpreg)
pregnancy risk assessment (including who class iv)
pregnancy risk assessment/management
pregnancy risk category iii (world health organization)
pregnancy with heart failure
pregnancy‑associated aortic complications
pregnancy‑associated aortic disease
pregnancy‑associated cardiac risk
pregnancy‑associated cardiovascular changes (blood volume, heart rate, stroke volume, cardiac output)
pregnancy‑associated heart disease
pregnancy‑associated scad
pregnancy‑focused obstetric–cardiologic outcomes
pregnancy‑related acute aortic dissection
pregnancy‑related anticoagulation
pregnancy‑related anticoagulation considerations
pregnancy‑related aortic dissection
pregnancy‑related aortic risk
pregnancy‑related cardiac complications
pregnancy‑related cardiac risk in hcm
pregnancy‑related cardiovascular complications
pregnancy‑related cardiovascular complications (in vascular ehlers‑danlos and turner’s syndrome)
pregnancy‑related cardiovascular risk in connective‑tissue disorders
pregnancy‑related complications (iugr, hypertensive disorders of pregnancy, gestational diabetes)
pregnancy‑specific anticoagulation strategy
pregnant individuals with heart disease
pregnant women with mechanical prostheses
prehospital
prehospital 12‑lead electrocardiography (ecg)
prehospital assessment and management
prehospital assessment and management of suspected acs
prehospital notification/advance notification
prehospital serial ecgs
prehospital setting
prehospital stemi care
preimplantation genetic testing
prejudice
preload
preload / afterload management
preload optimization
preloading / pre‑administration of p2y12 inhibitors
preloading of oral p2y12 inhibitors (loading dose prior to angiography)
premature atrial contraction (pac)
premature atrial contractions (pacs)
premature coronary artery disease
premature death (associated with ascvd)
premature menopause (before age 40)
premature mortality
premature ventricular complexes (pvc)
premature ventricular complexes (pvcs)
premature ventricular contraction (pvc)
premature ventricular contractions (pvcs)
premier trial
prenatal genetic counseling
preoperative assessment of vein adequacy
preoperative cardiovascular evaluation
preoperative coronary angiography for cardiac surgery
preoperative echocardiography
preoperative fasting in cardiac patients
preoperative left ventricular dysfunction
preoperative planning
preoperative predictors (e.g., fractional shortening, lv dimensions)
preoperative predictors of death
preoperative renal dysfunction
preoperative renal insufficiency / stage 3 chronic kidney disease (ckd)
preoperative symptoms
preoperative trial of anticoagulation
preoperative β‑blockers
preprocedural evaluation
preprocedural glycemic control
preprocedural planning for surgical or catheter‑based interventions (srt)
presence of apical aneurysm on imaging
preserved ef (hfpef)
preserved ejection fraction
preserved ejection fraction (ef)
preserved ejection fraction (hfpef)
preserved ejection fraction heart failure
preserved heart function
preserved left ventricular ejection fraction (lvef)
preserved lvef
preserved lvef (≥ 50 %)
pressure drop/flow slope
pressure gradient
pressure gradient (rvot)
pressure gradient across the aortic valve
pressure half‑time
pressure half‑time (pht)
pressure offloading
pressure offloading devices (non‑removable vs removable)
pressure overload
pressure overload (hypertension, athletic conditioning)
pressure recovery
preterm delivery
pretest genetic counseling
pretest probability of cad
pretreatment (loading dose)
pretricuspid shunt
prevail study
prevail trial
prevalence
prevalence (of cardiovascular conditions)
prevalence of angina or chd
prevalence of atrial fibrillation
prevalence of chd
prevalence of peripheral arterial disease
prevent
prevent iii study
prevention
prevention (of af and related cardiovascular conditions)
prevention and risk reduction guidelines (e.g., aha/acc/accp/aspc/nla/pcna chronic coronary disease guideline)
prevention guidelines
prevention of af after cardiac surgery.
prevention of amputation
prevention of cardiovascular disease
prevention of cardiovascular disease in adults
prevention of cardiovascular disease in women
prevention of complications (e.g., need for permanent pacing, endocarditis, thromboembolic events)
prevention of events with ace inhibition (peace)
prevention of heart disease
prevention of heart failure
prevention of postoperative atrial fibrillation
prevention of progression of arterial disease and diabetes (popadad) trial
prevention of sudden death in williams‑beuren syndrome
prevention of valve disease
prevention strategies
prevention strategies in specialty populations (rheumatoid arthritis, diabetes)
prevention, detection, evaluation, and management of high blood pressure in adults
prevention‑achd acronym (icb‑vsd)
prevention‑achd risk score
preventive angioplasty
preventive cardiology
preventive cardiovascular nurses association (pcna)
preventive foot care
preventive foot care (in pad)
preventive foot care for pad (qm‑3)
preventive icd therapy
preventive medical therapy
preventive strategies (e.g., acei/arb, β‑blockers, carvedilol, spironolactone)
preventive strategies (e.g., indoor air purifiers, n95 masks)
preventive surgery
previous anthracycline exposure
previous bleeding
previous cardiac surgery with at‑risk grafts
previous chest irradiation
previous chest radiation
previous infective endocarditis (ie)
previous stroke
previous stroke or transient ischemic attack (tia)
pre‑capillary pulmonary hypertension
pre‑cise dapt (risk score)
pre‑cuffed ptfe vs. vein‑cuffed ptfe graft
pre‑eclampsia
pre‑excitation syndromes
pre‑excited atrial fibrillation
pre‑excited atrial fibrillation (e.g., wolff‑parkinson‑white)
pre‑hf (stage b)
pre‑hf (stage b)
pre‑hospital abciximab
pre‑hospital ecg
pre‑hospital fibrinolysis
pre‑hospital ticagrelor
pre‑operative arrhythmia management
pre‑operative cardiac imaging
pre‑operative catheterization for shunt feasibility
pre‑operative coronary angiography assessment
pre‑operative criteria for surgery
pre‑operative evaluation
pre‑operative functional capacity assessment
pre‑operative left ventricular function
pre‑operative optimization for cardiac risk
pre‑operative pah therapy
pre‑operative renal insufficiency
pre‑operative resting 12‑lead ecg
pre‑operative risk factors
pre‑participation athletic screening
pre‑pci pretreatment
pre‑pregnancy assessment (echocardiography)
pre‑pregnancy counseling for heart disease
pre‑reperfusion era trials
pre‑risk stratification / risk scores for cardiac patients in pregnancy
pre‑term delivery
pre‑therapy lvef assessment
pre‑transplant cardiac evaluation
pre‑treated p2y12 inhibitors
pre‑tricuspid shunts
pre‑vention and control of hypertension
primary (degenerative) mr
primary and secondary prevention of cardiovascular disease
primary angioplasty
primary ascvd prevention
primary care clinician role
primary clinical cardiologist
primary disorders of the tricuspid apparatus
primary endpoint of death or hospitalization
primary hcm center
primary hcm centers
primary hypercholesterolemia
primary mitral regurgitation
primary mitral regurgitation (mr)
primary mr
primary mr (organic mitral valve disease)
primary mr stages (b–d)
primary myocardial disease
primary or comprehensive heart valve center
primary patency
primary pci
primary pci (ppci)
primary pci triage strategy
primary pci versus thrombolysis
primary percutaneous coronary intervention
primary percutaneous coronary intervention (pci)
primary percutaneous coronary intervention (ppci / ppci)
primary percutaneous coronary intervention (ppci or ppci)
primary percutaneous coronary intervention (ppci)
primary percutaneous coronary intervention (ppci) / pci
primary percutaneous coronary intervention (primary pci)
primary prevention
primary prevention (cardiovascular disease)
primary prevention (secondary prevention)
primary prevention for hf stages a/b
primary prevention icd criteria (lvef > 0.35, <3 months of gdmt)
primary prevention of arrhythmias
primary prevention of ascvd
primary prevention of cad
primary prevention of cardiovascular disease
primary prevention of cardiovascular diseases
primary prevention of cvd
primary prevention of cvd/ascvd
primary prevention of drug‑induced cardiomyopathy
primary prevention of stemi/pcr
primary prophylactic implantable cardio‑electrical defibrillator (icd) implantation
primary regurgitation
primary severe mr
primary stenosis
primary tr
primary valve center
primary valve center, comprehensive valve center, valve surveillance programs
primary/comprehensive heart valve center
primary/secondary chordal support
primary‑care aortic aneurysm screening
primary‑care clinicians
primary‑prevention icd
primary‑prevention icd placement
primary‑prevention implantable cardioverter‑defibrillator (icd)
prime‑ffr study
primordial prevention
prior infective endocarditis
prior mediastinal radiation
prior mitral valve surgery
prior revascularization
prior sternotomy
prior stroke
prism‑plus trial
prkag2 (glycogen‑storage disease)
prkg1
prkg1 mutation
prkg1 mutation (protein kinase g)
prkg1‑associated aortopathy
proact xa trial
proactive intervention strategy
proarrhythmia
proarrhythmia (drug‑induced arrhythmia)
proarrhythmic effects
proarrhythmic events
probable myocarditis
procainamide
procedural / device terms
procedural aspects of pad care
procedural complications
procedural complications of ablation (2–5%)
procedural mi (type 4a)
procedural mortality
procedural optimization
procedural or surgical risk of savr/tavi
procedural planning
procedural risk
procedural risk‑scoring systems
procedural success
procedural treatment
procedural treatments
procedural treatments (surgical or interventional procedures)
procedural type 4a mi
procedural type 4b mi
procedural type 4c mi
procedural volume
process measures
processed meats (cured bacon, hot dogs)
processed meats (e.g., bacon, salami, ham, hot dogs, sausage)
processed meats (smoked, cured, salted)
processed red meat
process‑of‑care measures
procoagulant and hypofibrinolytic state
professional societies (guideline authors)
prognosis
prognosis (hf)
prognosis in hf
prognosis of asymptomatic left‑ventricular dysfunction
prognosis of heart failure
prognosis of hypertrophic cardiomyopathy
prognosis studies
prognostic assessment after primary angioplasty
prognostic biomarkers
prognostic determinants
prognostic discussions (“hope for the best, plan for the worst”)
prognostic factors
prognostic factors (age, atrial size, fibrosis)
prognostic factors for aortic complications in marfan syndrome.
prognostic factors for residual lesions after surgery
prognostic impact of lv function in aortic stenosis
prognostic implications
prognostic implications of arrhythmias
prognostic implications of imaging findings
prognostic implications of left‑ventricular strain
prognostic implications of valvular dysfunction
prognostic importance of aortic dilation
prognostic importance of quantitative exercise doppler
prognostic indicators
prognostic information (from emb)
prognostic markers
prognostic medications (gdmt)
prognostic predictors
prognostic relevance
prognostic risk scores (e.g., seattle heart failure model, rematch, etc.)
prognostic risk scores (e.g., syntax score, ischemia, heart team decision tools)
prognostic risk stratification tools
prognostic score
prognostic significance
prognostic significance of aortic root dilation pattern
prognostic significance of exercise testing
prognostic significance of heart failure stages
prognostic value
prognostic value in asymptomatic valve disease
prognostic value of bnp/nt‑probnp ratios
prognostic value of cmr
programming antitachycardia pacing
progression of atrial fibrillation
progressive af
progressive aneurysmal dilation
progressive aortic dilation
progressive atherosclerosis
progressive decline in lvef
progressive decline in lvef (to 55‑60%)
progressive exercise intolerance
progressive heart failure
progressive increase in aortic velocity
progressive lv dilation (lvedd >65 mm)
progressive lv enlargement
progressive stenosis
progressive systemic rv dysfunction
progressive training to 30‑45 min of active walking
progressive valve dysfunction
prohibit trial






















prolactin cleavage (cathepsin‑d cleaved prolactin)
prolapse of the right coronary cusp (aortic valve)
proliferation‑signal inhibitor
prolonged av conduction
prolonged continuous monitoring
prolonged dual antiplatelet therapy
prolonged hv interval
prolonged intubation (>24 h)
prolonged qtc
prominent trial
promise minimal‑risk tool
promise trial
promis‑plus‑hf (patient‑reported outcomes measurement information system‑plus‑heart failure)
propafenone
propafenone (antiarrhythmic)
propensity‑matched analysis
propensity‑matched comparison
propensity‑matched comparison studies in aortic surgery
prophylactic antibiotics
prophylactic aortic repair
prophylactic aortic replacement
prophylactic aortic root replacement
prophylactic aortic surgery
prophylactic aspirin (low‑dose/high‑dose)
prophylactic fasciotomy
prophylactic implantable cardioverter‑defibrillator (icd) implantation
prophylactic intervention
prophylactic repair
prophylactic root replacement
prophylactic surgery
prophylactic surgical replacement (aortic root/ascending aorta)
proportional hazards regression
proportionate functional mitral regurgitation
propranolol
propranolol (oral and iv)
propranolol therapy
proprotein convertase subtilisin/kexin type 9 (pcsk9)
proprotein convertase subtilisin/kexin type 9 (pcsk9)
proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors
prospective and retrospective cohort studies on achd outcomes
prospective comparison of arni with acei to determine impact on global mortality and morbidity in heart failure (paradigm‑hf)
prospective epidemiological study of myocardial infarction (prime)
prospective multicenter rct (aortic)
prospective multicenter study
prospective observational studies
prospective observational study
prospective randomised trial
prospective randomized controlled trial (rct)
prospective randomized open‑label study
prospective randomized study
prospective randomized trial
prospective study
prospective study (prevention‑achd)
prostacyclin analogs
prostacyclin analogs / receptor agonists
prostacyclin therapy
prostacyclin therapy (inhaled, subcutaneous, intravenous)
prostacyclin therapy (inhaled/subcutaneous)
prostaglandin therapy
prostanoids (in the context of clti)
prostanoids (pharmacologic agents in arterial disease)
prostanoids (prostacyclin, iloprost)
prosthesis‑patient mismatch
prosthesis–patient mismatch
prosthetic (mechanical) heart valves
prosthetic aortic graft
prosthetic aortic graft infection
prosthetic aortic valve
prosthetic bypass failure
prosthetic bypass graft
prosthetic bypass grafts
prosthetic cardiac valves
prosthetic conduit (prosthetic graft material)
prosthetic graft
prosthetic graft allograft replacement
prosthetic heart valve
prosthetic heart valve (phv)
prosthetic heart valve complications
prosthetic heart valves
prosthetic material for valve repair (annuloplasty rings, chords, clips)
prosthetic mechanical heart valves
prosthetic mitral valve
prosthetic mitral valve; prosthetic aortic valve
prosthetic patch or prosthetic device
prosthetic rehabilitation / ambulation
prosthetic valve
prosthetic valve deterioration
prosthetic valve durability
prosthetic valve dysfunction
prosthetic valve endocarditis
prosthetic valve endocarditis (pve)
prosthetic valve endocarditis (see section 12.3)
prosthetic valve evaluation
prosthetic valve obstruction
prosthetic valve paravalvular leak closure
prosthetic valve regurgitation
prosthetic valve regurgitation (transvalvular & paravalvular)
prosthetic valve replacement versus medical therapy
prosthetic valve selection factors (durability, anticoagulation risk, patient preference)
prosthetic valve stenosis
prosthetic valve thrombosis
prosthetic valves
prosthetics
protease inhibitors
protease inhibitors (drug interaction impacting cardiovascular drugs)
protect af study
protect trial (renal function in acute hf)
protective factors
protective footwear / therapeutic footwear
protect‑af trial
protect af trial
protein restriction
proteinase‑3 (pr‑3)
proteinuria
proteinuria (>150 mg/24 h)
protein‑based biomarkers
protein‑losing enteropathy
protein‑losing enteropathy (ple)
proteolysis of the extracellular matrix
proteolysis pathways
proteomics
prothena
prothesis graft (surgical context)
prothrombin complex concentrate
prothrombin complex concentrate (pcc)
prothrombin complex concentrate (used in reversal of anticoagulation)
prothrombin time (pt)
prothrombotic changes in the la
prothrombotic state
prothrombotic states
proton pump inhibitor (ppi)
proton pump inhibitors (ppis)
proton‑pump inhibitor (ppi) therapy
proved trial (digoxin withdrawal in chf)
prove‑it‑timi 22 study
prove it‑timi 22 trial
provocative maneuvers (valsalva, squat‑to‑stand, standing)
provocative maneuvers for lvot gradient assessment
provocative stimuli (acetylcholine, ergot)
proximal aortic dilatation
proximal aortic surgery
proximal cad (≥70% luminal diameter reduction)
proximal control with clamp or balloon
proximal coronary artery disease
proximal descending aorta dilation
proximal isovelocity surface area (pisa)
proximal sealing zone
proximal thoracic aortic surgery
proximal tubular ascending aorta
pro‑bnp (biomarker)
pro‑bnp (n‑terminal pro‑brain natriuretic peptide)
pro‑vegetarian food pattern (protective factor for heart disease)
pseudoaneurysm
pseudoaneurysm formation after coa repair
pseudomonas aeruginosa
pseudo‑coarctation of the aorta
pseudo‑myocardial‑infarction pattern
psoriasis
psoriasis (as a cardiovascular risk factor)
psychiatry
psychoeducation
psychological distress (in the context of hf management)
psychological functioning in icd patients
psychological health in cardiovascular disease (mind‑heart connection)
psychological impact of icd implantation
psychological interventions
psychological outcomes and interventions for congenital heart disease
psychological outcomes in congenital heart disease
psychological status and cardiovascular health
psychological support (depression & anxiety screening)
psychological trauma related to icd shocks
psychologist
psychosocial care for inherited cardiovascular disease
psychosocial deprivation
psychosocial management
psychosocial stressors
psychosocial support (limitations)
psychosocial well‑being
ptfe bypass (peripheral bypass)
pthlh gene locus (chromosome 12p11.22)
public health
public health initiative
public policy for cardiovascular disease
public reporting
public reporting of performance measures
publicly available controlled‑temperature environments
pubmed
pulmonary arterial hypertension
pulmonary arterial hypertension (low‑risk, intermediate‑risk, high‑risk)
pulmonary arterial hypertension (mean pa pressure ≥ 20 mm hg, pawp ≤ 15 mm hg, pvr ≥ 2 wu)
pulmonary arterial hypertension (pah)
pulmonary arterial hypertension (pulmonary hypertension)
pulmonary arterial hypertension guidelines (pah guidelines)
pulmonary arterial hypertension guidelines for adults
pulmonary arterial hypertension related to congenital heart disease
pulmonary arterial hypertension risk categories (3‑strata)
pulmonary arterial pressure
pulmonary arterial pressures
pulmonary arterial pressures (pa pressures)
pulmonary arterial resistance
pulmonary arterial saturation
pulmonary arterial thrombosis
pulmonary arterial trunk
pulmonary arterial wedge pressure
pulmonary arterial wedge pressure ≤ 15 mm hg
pulmonary arteries (pas)
pulmonary arteriovenous malformation
pulmonary artery
pulmonary artery (pa)
pulmonary artery (pa) catheterization
pulmonary artery (pa) line
pulmonary artery (pa) pressure
pulmonary artery (pa) pressures
pulmonary artery (pa) sling
pulmonary artery (pa) stenosis
pulmonary artery (pa) systolic pressure
pulmonary artery catheter
pulmonary artery catheterization (pa catheter)
pulmonary artery catheterization / pulmonary artery pressure monitoring
pulmonary artery compliance
pulmonary artery diastolic pressure (padp)
pulmonary artery evaluation
pulmonary artery gradient
pulmonary artery hemodynamic monitoring
pulmonary artery hypertension
pulmonary artery pressure
pulmonary artery pressure (pap)
pulmonary artery pressure gradient
pulmonary artery pressure measurement
pulmonary artery pressure monitoring catheter
pulmonary artery pressure ≥ 50 % of systemic
pulmonary artery pulsatility index (papi) <1.0
pulmonary artery pulse index (papi)
pulmonary artery sling
pulmonary artery sling repair
pulmonary artery slings
pulmonary artery stenosis (pas)
pulmonary artery stenosis after arterial switch
pulmonary artery stiffness
pulmonary artery systolic pressure
pulmonary artery systolic pressure (pasp)
pulmonary artery systolic pressure (≥ 50 mm hg)
pulmonary artery systolic pressure > 50 mm hg
pulmonary artery thrombosis
pulmonary artery wedge pressure
pulmonary artery wedge pressure > 25 mm hg
pulmonary atresia
pulmonary atresia (all forms)
pulmonary atresia with intact ventricular septum
pulmonary atresia with intact ventricular septum (pa‑ivs)
pulmonary autograft (ross procedure)
pulmonary balloon valvuloplasty
pulmonary blood flow
pulmonary blood flow measurement
pulmonary branch stenosis
pulmonary capillary wedge pressure
pulmonary capillary wedge pressure (pcw)
pulmonary capillary wedge pressure (pcwp)
pulmonary circulation
pulmonary circulation pressure
pulmonary circulatory support
pulmonary complications (covid‑19, pneumococcal pneumonia) as cardiovascular event risk enhancers
pulmonary congestion
pulmonary congestion (clinical, cxr, lung us)
pulmonary disease
pulmonary disease (comorbidity)
pulmonary edema
pulmonary edema (postpartum, labor, pregnancy)
pulmonary embolism
pulmonary embolism (cardiovascular event)
pulmonary embolism (pe)
pulmonary embolism (pulmonary embolic–related cardiac strain)
pulmonary embolism response team (pert)
pulmonary embolism / inherited thrombophilia (implied by embolism context)
pulmonary fibrosis
pulmonary function testing
pulmonary homograft
pulmonary hypertension
pulmonary hypertension (> 50 mm hg)
pulmonary hypertension (commonly associated with heart disease)
pulmonary hypertension (general)
pulmonary hypertension (group 2)
pulmonary hypertension (implied in thoracic aortic disease)
pulmonary hypertension (moderate)
pulmonary hypertension (pah)
pulmonary hypertension (ph)
pulmonary hypertension (post‑capillary, pre‑capillary, combined)
pulmonary hypertension (primary or secondary to left‑sided heart disease)
pulmonary hypertension (relevant for cardiovascular risk)
pulmonary hypertension / pulmonary vascular disease
pulmonary hypertension / right hf
pulmonary hypertension association
pulmonary hypertension expertise
pulmonary hypertension guidelines
pulmonary hypertension in chd
pulmonary hypertension in congenital heart disease
pulmonary hypertension management
pulmonary hypertension management (post‑ and precapillary)
pulmonary hypertension management strategies.
pulmonary hypertension specialist
pulmonary hypertension specialist care
pulmonary hypertension specialists
pulmonary hypertension therapies (pharmacologic)
pulmonary hypertensive crisis
pulmonary mitral balloon commissurotomy (pmbc)
pulmonary or systemic venous congestion
pulmonary or urinary tract infections (as precipitants of hf)
pulmonary outflow tract obstruction (poto)
pulmonary outflow tract obstruction (pvr)
pulmonary overcirculation
pulmonary over‑pressure
pulmonary perfusion testing
pulmonary pressures
pulmonary pressures (mean pulmonary artery pressure, systolic, diastolic)
pulmonary pressures / pulmonary hypertension
pulmonary regurgitation
pulmonary regurgitation (conduit related)
pulmonary regurgitation (if applicable)
pulmonary regurgitation (pr)
pulmonary regurgitation (pulmonary insufficiency)
pulmonary regurgitation after repair of pulmonary stenosis
pulmonary sarcoidosis (cardiac involvement)
pulmonary sequestration
pulmonary stenosis
pulmonary stenosis (associated defect)
pulmonary stenosis (ps)
pulmonary stenosis severity (moderate/severe)
pulmonary stump
pulmonary systolic pressure
pulmonary toxicity
pulmonary toxicity (lung)
pulmonary translocation
pulmonary translocation (surgical technique)
pulmonary valve
pulmonary valve (pv)
pulmonary valve and aortic root translocation / en‑bloc rotation procedures
pulmonary valve atresia
pulmonary valve conduit stenting
pulmonary valve disease
pulmonary valve dysfunction
pulmonary valve dysfunction (moderate pr, pr >25% by cmr)
pulmonary valve function
pulmonary valve gradients
pulmonary valve implantation
pulmonary valve insufficiency
pulmonary valve intervention
pulmonary valve regurgitation
pulmonary valve regurgitation quantification
pulmonary valve replacement
pulmonary valve replacement (in tof)
pulmonary valve replacement (pvr)
pulmonary valve replacement (surgical & transcatheter)
pulmonary valve replacement (surgical or transcatheter)
pulmonary valve replacement (surgical)
pulmonary valve replacement (transcatheter)
pulmonary valve replacement risks and complications
pulmonary valve replacement timing
pulmonary valve stenosis
pulmonary valve stenosis (pvs)
pulmonary vascular disease
pulmonary vascular disease (phpvd)
pulmonary vascular obstructive disease
pulmonary vascular resistance
pulmonary vascular resistance (pvr)
pulmonary vascular resistance (pvr) > 2 wood units
pulmonary vascular resistance (pvr) – wood units
pulmonary vascular resistance (≤ 2 wood units; 2–5 wood units)
pulmonary vascular resistance ratio (pvr to systemic resistance)
pulmonary vasculature
pulmonary vasodilators
pulmonary vasodilatory therapy efficacy
pulmonary vasomodulators
pulmonary vein (pv) isolation
pulmonary vein (pv) stenosis
pulmonary vein ectopy / ectopic action potentials
pulmonary vein isolation
pulmonary vein isolation (pvi)
pulmonary vein isolation (pvi) effectiveness in afl
pulmonary vein isolation techniques
pulmonary vein stenosis
pulmonary vein stenosis / baffle stenosis
pulmonary veins
pulmonary veins (pvs) as af drivers
pulmonary veins (pvs) of the left atrium (la)
pulmonary vein‑driven af genesis (haïssaguerre et al. finding)
pulmonary venous congestion
pulmonary venous connections
pulmonary venous flow reversal
pulmonary venous pathway stenosis
pulmonary venous pathways
pulmonary venous stasis
pulmonary/renal comorbidity (e.g., renal insufficiency)
pulmonary‑mural balloon commissurotomy (pmbc)
pulmonary‑to‑systemic blood flow ratio (qp:qs)
pulmonary‑to‑systemic blood flow ratio (qp:qs) ≥ 1.5
pulmonary‑vein isolation (for af)
pulmonary artery dilation
pulmonary hypertension
pulmonary valve dysfunction
pulmonary valve intervention
pulmonary valve replacement (surgical / transcatheter)
pulmonic autograft (ross procedure)
pulmonic homograft
pulmonic regurgitation
pulmonic stenosis
pulmonic valve disease
pulse deficit
pulse deficits (absent, diminished, normal, bounding)
pulse examination for pad “at risk” patients (qm‑2)
pulse flow (direct revascularization)
pulse palpation
pulse pressure
pulse volume recording (pvr)
pulse wave analysis
pulsed field ablation
pulsed‑wave doppler
pulseless electrical activity (pea)
pulse pressure
pulse‑wave and conduction abnormalities (heart block, permanent pacing)
pump mechanisms (mechanically assisted circulatory support)
pump thrombosis
pump thrombus
pure study (prospective urban rural epidemiology)
pursuit risk score
pv (pulmonary veins)
pv-to-la reconnection
pvcs (premature ventricular complexes)
pvi (pulmonary vein isolation)
pvi registry (peripheral vascular intervention)
pvr (pulmonary vascular resistance)
pvr wood units (e.g., 2–5, <5, <10, >8, >10)
pyp (pyrophosphate) scintigraphy
p‑2y12 inhibitors
p‑glycoprotein
p‑glycoprotein (p‑gp)
p‑glycoprotein inhibitors
p‑gp (p‑glycoprotein) substrate/inhibitor activity
p‑wave dispersion















qaly (quality‑adjusted life year)
qalys (quality‑adjusted life years)
qol (quality of life)
qol (quality of life) improvement
qol (quality of life) – health outcome metric
qp:qs (pulmonary to systemic flow ratio)
qp:qs (pulmonary‑to‑systemic blood flow ratio)
qp:qs ratio
qp:qs ratio (left‑to‑right shunt ratio)
qp:qs ratio (pulmonary to systemic flow)
qp:qs ratio (pulmonary/systemic flow ratio)
qp:qs ≥ 1.5
qrisk / jbs3
qrs complex / width
qrs duration
qrs duration & qrs width (>130 ms, >150 ms)
qrs duration (narrow qrs, <120 ms; 120–130 ms; non‑lbbb 120–149 ms)
qrs duration (≥120 ms)
qrs duration (≥150 ms)
qrs duration <120 ms
qrs duration <150 ms
qrs duration > 180 ms
qrs duration and fragmentation
qrs duration ≥120 ms
qrs duration ≥180 ms
qrs fragmentation
qrs morphology (e.g., right bundle branch block)
qrs prolongation (>120 ms)
qrs‑based outcome prediction
qt dispersion ≥70 ms
qt interval
qt interval monitoring
qt interval prolongation
qt interval prolongation (qtc prolongation)
qt interval prolongation / qtc prolongation
qt prolongation
qtc interval
qtc interval prolongation
qtc prolongation
qtc prolongation / qt‑prolonging agents
quality & health it (related to cardiovascular care)
quality control in echocardiographic measurement
quality improvement / performance measures
quality improvement initiatives
quality improvement metrics
quality improvement projects
quality indicators
quality measure (qm)
quality measure (qm‑7)
quality measure (qm‑8)
quality measurement
quality measures
quality measures (clinical practice guideline‑based)
quality measures (qm) for hf
quality measures (qm‑1 to qm‑8)
quality measures (qm‑3 to qm‑8)
quality measures for pad care
quality metrics and patient‑reported outcomes
quality of care
quality of care in heart failure
quality of care metrics
quality of life
quality of life (af‑related)
quality of life (cardiac context)
quality of life (qol)
quality of life (qol) and functional capacity in hf
quality of life (qol) data
quality of life (qol) enhancement
quality of life (qol) improvement
quality of life (qol) improvement in hf care
quality of life (qol) in cardiovascular patients
quality of life (qol) measures
quality of life (qol) measures in hf/af patients
quality of life (qol) outcomes
quality of life (qol) outcomes in limb loss
quality of life after aortic surgery
quality of life in atrial fibrillation
quality of life in cardiac care
quality of life in cardiac patients
quality of life in icd patients
quality of life in peripheral vascular disease
quality of life outcomes
quality of life (qol)
quality of treatment decisions (hf)
quality outcomes
quality‑adjusted life year
quality‑adjusted life year (qaly)
quality‑adjusted life years (qaly)
quality‑adjusted life years (qalys)
quality‑adjusted life‑year (qaly)
quality‑adjusted life‑years (qalys)
quality‑improvement programs
quality‑of‑life (qol) in af patients
quality‑of‑life considerations post‑intervention
quality‑of‑life improvement
quality‑of‑life outcomes after neonatal arterial switch operation
quantification of lge (≥ 15 % lv mass)
quantitative doppler assessment
quantitative exercise doppler
quantitative exercise doppler echocardiography
quantitative kappa and lambda free‑light‑chain assays
quantitative risk estimation
quidel (diagnostics)
quinapril
quinidine
quinidine sulfate
quitline (telephone‑based smoking cessation resource)
q‑symbio (coenzyme q₁₀ as adjunctive treatment of chronic heart failure)
q‑symbio trial (coenzyme q10)
q‑waves













r wave prominence or r/s ratio >1
r3f registry
raas inhibitors (raasi)
race 3 trial
race 4 trial
race and ethnicity in hf outcomes
race ii study
race, ethnicity, and gender/sex disparities in af outcomes
race/ethnicity related risk variation
race ii study (lenient vs. strict rate control)
race‑specific risk estimation (non‑hispanic white, non‑hispanic black, other ethnic groups)
race 3 trial (targeted therapy for underlying conditions)
racial and ethnic differences in heart disease outcomes
racial and ethnic disparities (hispanic, black, white, american indian)
racial and ethnic disparities in af management
racial and ethnic disparities in cardiovascular risk
racial and ethnic disparities in hcm prevalence
racial and ethnic minority populations
racial and sex disparities in acs care
racial disparities
racial disparities in cardiovascular care
racial disparities in endovascular aortic repair
racial disparities in peripheral artery disease
racial/ethnic disparities in cardiovascular outcomes
racial/ethnic disparities in heart‑failure outcomes (e.g., non‑hispanic black, non‑hispanic white, hispanic, asian/pacific islander)
radial access
radial access (for pci)
radial access (pci)
radial access (radial artery approach)
radial access approach (radial artery)
radial access vs. femoral access (transradial vs. transfemoral approach)
radial approach for coronary angiography
radial artery
radial artery access
radial artery graft vs. saphenous vein graft
radial vascular access
radiating groin pain
radiation dose/exposure
radiation dose‑reduction strategies (low‑dose ionizing radiation)
radiation exposure
radiation exposure (ct)
radiation exposure / ionizing radiation dose
radiation exposure from ct
radiation exposure risks
radiation heart disease
radiation‑induced cardiovascular disease
radiation‑induced heart disease
radiation‑induced mitral stenosis
radiation‑induced tr
radiofrequency ablation
radiofrequency catheter ablation
radiofrequency irrigation
radiofrequency perforation & balloon decompression
radiographic contrast media safety
radiologic findings
radiologic protocols (avoid false‑negative/false‑positive)
radiological assessment of aortic annulus, sinuses, and ascending aorta
radiological findings
radiology
radiomics
radiomics in cardiac imaging
radionuclide imaging
radionuclide imaging (indirectly referenced via radiation concerns)
radionuclide ventriculography
radionuclide ventriculography (rvg)
radiotherapy‑associated heart disease
raft study
raft trial
raft‑af (rhythm control–catheter ablation with or without anti‑arrhythmic drug control of maintaining sinus rhythm versus rate control with medical therapy and/or atrio‑ventricular junction ablation and pacemaker treatment for atrial fibrillation)
raft‑af trial
ramipril
ramipril (ace inhibitor)
randomised clinical trial
randomized aldactone evaluation study (rales)
randomized clinical trial
randomized clinical trials
randomized clinical trials (rcts)
randomized clinical trials on quality of life after aortic repair
randomized controlled trial
randomized controlled trial (rct)
randomized controlled trial (rct) evidence on ppcm and bromocriptine
randomized controlled trial (rct) – in the context of cardiovascular studies
randomized controlled trials
randomized controlled trials (rcts)
randomized controlled trials (rcts) in cardiology
randomized controlled trials (rcts) in pad therapy evaluation
randomized controlled trials of bromocriptine in peripartum cardiomyopathy
randomized double‑blind study
ranges of coronary artery disease severity
ranolazine
ranolazine therapy
rapid aneurysm growth
rapid aneurysm growth (≥ 0.5 cm/y)
rapid aortic growth
rapid aortic growth (≥ 0.3 cm/y)
rapid aortic growth (≥ 0.3 cm/year)
rapid aortic growth (≥ 0.5 cm / year)
rapid aortic growth ≥ 0.3 cm/year
rapid aortic root growth
rapid atrial flutter (1:1 afl)
rapid bedside bnp testing
rapid coverage of the descending aorta
rapid fluid resuscitation for torso trauma
rapid infusion systems in trauma care
rapid rule‑out strategies
rapid ventricular rate
rapid ventricular rate control
rapid ventricular response
rapid ventricular response (rvr)
rare genetic variants in cardiomyopathy and arrhythmia genes
ras/erk signaling pathway
rash
rasmussen cardiovascular disease prevention center
rasopathies
rasopathies (e.g., neurofibromatosis, noonan syndrome)
rastelli procedure
rastelli repair
rastelli repair/operation
rate control
rate control (rate‑control strategies)
rate control (target <100 bpm)
rate control in af
rate control strategies
rate control strategy
rate control therapies
rate control therapy
rate of aortic dilation
rate‑control drugs
rate‑control medications
rate‑control strategy
rate‑slow‑ing agents
rct (randomized controlled trial)
reach (reduction of atherothrombosis for continued health)
reach registry
reactive oxygen species
readiness and utilization of cardiac rehabilitation
readiness for transfer of care
readmission
readmission (30‑day readmission)
readmission (clinical outcome)
readmission / rehospitalization
readmission / rehospitalization after acs
readmission burden
readmission for heart failure
readmission prediction for heart failure
readmission rates
readmission risk
readmissions
real‑time 3‑d tee
real‑time 3‑d transesophageal echocardiography
real‑world outcomes after transfusion strategies (reality trial)
reboa (resuscitative endovascular balloon occlusion of the aorta)
reboa contraindication
reboot‑cnic
rebound anticoagulation after cessation
recent major surgery or trauma (within 30 days)
recent myocardial infarction (mi)
recipient mortality
recoarctation
recombinant tissue plasminogen activator (rt‑pa) / tissue plasminogen activator (tpa)
reconstruction options
recreational physical activity
recreational physical activity (moderate–vigorous intensity)
recreational substance use (cocaine, marijuana)
recumbent stepping
recurrence rate of afl post‑ablation
recurrent acute coronary syndromes (acs)
recurrent aortic reintervention
recurrent aortic stenosis (post‑repair)
recurrent arrhythmia / recurrence of atrial arrhythmia
recurrent atrial arrhythmias (af or svt)
recurrent atrial fibrillation
recurrent atrial fibrillation (recurrent af)
recurrent atrial tachyarrhythmias after ablation
recurrent cardiac events
recurrent cardiovascular events
recurrent coronary artery stenosis or suboptimal flow
recurrent coronary events
recurrent dcrv
recurrent endocarditis
recurrent fever
recurrent gradients
recurrent heart failure
recurrent hemorrhage
recurrent ie
recurrent ischemia
recurrent ischemic events
recurrent ischemic symptoms
recurrent mace
recurrent mi
recurrent mitral regurgitation
recurrent morbidity and mortality rates
recurrent myocardial infarction
recurrent myocardial infarction (mi)
recurrent or residual functional regurgitation
recurrent outflow tract obstruction
recurrent pericarditis
recurrent scad
recurrent stroke
recurrent valve thrombosis
recurrent ventricular arrhythmias
red and processed meat (risk factor for heart disease)
red blood cell transfusion
red meat
red meats
redirection of care to interventional strategies
redo aortic valve surgery
redo sternotomies
reduced ef (<40%)
reduced ef (<50%)
reduced ef / hfref
reduced egfr (<45 ml/min/1.73 m²)
reduced ejection fraction
reduced ejection fraction (ef)
reduced ejection fraction (hfref)
reduced ejection fraction heart failure
reduced exercise capacity (in achd patients)
reduced functional capacity
reduced left ventricular ejection fraction
reduced left ventricular ejection fraction (lvef < 50 %)
reduced left‑ventricular function
reduced left‑ventricular systolic function
reduced lvef (<50%)
reduced lvef (≤40%/≤50%)
reduced mortality in heart failure trials (cha‑rm, topcat)
reduced valve motion due to pannus or thrombus
reduce‑it (reduction of cardiovascular events with icosapent ethyl)
reduce‑it trial
reduce‑it trial (icosapent ethyl)
reduce‑swedeheart
reentrant arrhythmia
reentrant supraventricular tachyarrhythmias (svts)
reentry (arrhythmic circuit)
reentry mechanism
reentry tear
reevaluation of long‑term anticoagulation
referral for advanced imaging beyond local expertise
referral for cardiothoracic surgery
referral for diagnostic/interventional therapies
referral for electrophysiology studies
referral for transplant evaluation
referral for worsening heart failure
referral pathways
referral policies to achd care
refined carbohydrates
refined carbohydrates (white bread, white rice, refined cereals)
refined european guidelines instrument for risk prediction in pah
refined grains
refractory angina
refractory arrhythmias
refractory heart failure
refractory hypertension
refractory or recurrent angina
refractory pain (symptom of acute dissection)
refractory pain duration (> 12 h)
refractory ventricular arrhythmias
regadenoson stress cmr perfusion
regards study
regards study (reasons for geographic and racial differences in stroke)
regeneron
regional cardiac autonomic remodeling
regional stemi care
regional stemi care systems
regional stemi system
regional wall motion
regional wall motion abnormalities
regionalization of stemi care
registered dietitian / nurse‑coached dietetic intervention
registered nurse
registries
registries: lombardy registry, itamy (italian study in myocarditis)
registry data
registry data (e.g., ropac, share) in hcm research
registry data on peripartum cardiomyopathy
registry data on preloading efficacy
registry study (great, medpar)
registry‑based research
registry‑based thresholds for aortic repair in female patients
regression tree (cart) model
regular exercise
regular physical activity
regulatory approval of cardiac drugs and devices in the united states.
regulatory compliance (us approval status)
regulatory support
regulatory t cells (treg)
regulatory/industry advisory organizations:
regurgitant flow
regurgitant fraction
regurgitant fraction (%)
regurgitant fraction (rf)
regurgitant lesions
regurgitant orifice area
regurgitant orifice area (ero)
regurgitant volume
regurgitant volume (ml/beat)
regurgitant volume (rvol)
regurgitant volume (≥45 ml)
regurgitant volume quantification
regurgitation
regurgitation (moderate or severe)
regurgitation (valvular)
rehabilitation
rehabilitation protocols
rehabilitation strategies
rehospitalization
rehospitalization (cardiovascular & non‑cardiovascular)
rehospitalization for cardiovascular causes
rehospitalization for ischemia
rehospitalization risk
reimplantation (aortic valve)
reimplantation technique
reinfarction
reinitiation of anticoagulation after bleeding
reintervention
reintervention (rv‑to‑pa reoperation)
reintervention / reoperation
reintervention outcomes
reintervention rate after tevar
reintervention rates
reintervention risk
reinterventions
rein‑2 trial













relapse/recurrence of heart failure
relapsing polychondritis
relative risk
relative risk (rr)
relative risk reduction (e.g., 15 %, 19 %)
relative risk reduction (rrr)
relative wall thickness (rwt)
relax trial
relevant industry / technology terms (often linked to heart disease management)
remission (clinical criteria)
remodeling (aortic root)
remodeling technique
remote algorithm‑based cardiovascular risk management
remote cardiac rehabilitation
remote disease‑management programs
remote monitoring
remote monitoring / telemonitoring
remote monitoring data
remote patient monitoring / telemonitoring
remote patient‑monitoring devices (wearables, smart devices)
renal artery stenosis
renal artery stenting
renal branch grafts
renal clearance (crcl)
renal comorbidities
renal denervation
renal denervation (for af)
renal denervation (renal sympathetic modulation)
renal disease
renal disease / kidney dysfunction
renal dysfunction
renal dysfunction & cardiovascular outcomes after myocardial infarction
renal dysfunction (comorbidity)
renal dysfunction (crcl)
renal dysfunction (high serum creatinine, dialysis, kidney transplant)
renal dysfunction (kidney disease)
renal dysfunction (post‑operative)
renal dysfunction (right‑hf‑related)
renal dysfunction in advanced heart failure
renal dysfunction in heart failure
renal excretion (crcl‑dependent dosing for dofetilide)
renal failure
renal failure (associated risk in pci)
renal failure (cardiovascular comorbidity)
renal failure (contrast‑related)
renal failure with neuropathy
renal function
renal function (baseline kidney health)
renal function (ckd stages)
renal function (crcl)
renal function (creatinine clearance)
renal function (e.g., serum creatinine, egfr)
renal function (glomerular filtration, kidney disease)
renal function (impact on anticoagulant dosing)
renal function (renal insufficiency)
renal function (worsening renal function, tubule injury)
renal function / creatinine
renal function / creatinine clearance (crcl)
renal function / glomerular filtration rate (gfr)
renal function assessment (crcl)
renal function considerations
renal function indices (egfr, crcl)
renal function monitoring
renal function testing
renal impairment monitoring
renal injury (post‑operative)
renal injury after cardiac surgery
renal insufficiency
renal insufficiency (as risk factor for hf)
renal insufficiency / chronic kidney disease (ckd)
renal malperfusion
renal outcomes
renal protection during thoracoabdominal aneurysm repair
renal protection strategies
renal replacement therapy
renal replacement therapy (as outcome endpoint)
renal replacement therapy (used in advanced hf)
renal replacement therapy / kidney failure in pci context
renal toxicity / contrast‑induced nephropathy
renin‑angiotensin system
renin‑angiotensin system agents
renin‑angiotensin system blockade (ace inhibitors, arbs)
renin‑angiotensin system inhibition
renin‑angiotensin system inhibitors
renin‑angiotensin‑aldosterone inhibitors (raasi)
renin‑angiotensin‑aldosterone system (raas)
renin‑angiotensin‑aldosterone system (raas) antagonists
renin‑angiotensin‑aldosterone system (raas) inhibitor therapy
renin‑angiotensin‑aldosterone system (raas) inhibitors
renin‑angiotensin‑aldosterone system (raas) inhibitors (ace inhibitors, arbs, aldosterone antagonists)
renin‑angiotensin‑aldosterone system (ras) effects
renin‑angiotensin‑aldosterone system blockade
renin‑angiotensin‑aldosterone system inhibitor (raasi)
renin‑angiotensin‑aldosterone system inhibitors (raas inhibitors)
renin‑angiotensin‑aldosterone system inhibitors (raasi)
renin‑angiotensin‑inhibitor safety
renin–angiotensin system blocker
renin–angiotensin system blockers
renin–angiotensin system inhibition
renin–angiotensin‑aldosterone system (raas) inhibition
renin–angiotensin–aldosterone system (raas)
renin–angiotensin–aldosterone system (raas) antagonists
renin–angiotensin–aldosterone system (raas) blockade
renin–angiotensin–aldosterone system (raas) drugs
renin–angiotensin–aldosterone system (raas) inhibition
renin–angiotensin–aldosterone system (raas) inhibitors
renin–angiotensin–aldosterone system inhibitors (raasi)
reoperation
reoperation (late re‑intervention, redo surgery)
reoperation (post‑surgical)
reoperation (surgical recurrence)
reoperation / reintervention
reoperation / repeat intervention
reoperation after aortic repair
reoperation for lvot obstruction
reoperation outcomes
reoperation risk
reoperation risk (reoperation frequency, freedom from reoperation)
reoperation with isolated tricuspid valve surgery
reoperative avr
reoperative cardiac surgery outcomes
reoperative mortality
reoperative savr (surgical aortic valve replacement)
reoperative surgery mortality and morbidity
reoperative tricuspid surgery
reoperative valve surgery
repair quality
repair threshold (≥5.5 cm for men, ≥5.0 cm for women)
repaired coa
repaired congenital heart disease with residual shunts or valvular regurgitation
repaired native valves
repaired tetralogy of fallot
repaired tetralogy of fallot (arrhythmias)
repaired tof
repaired vs unrepaired congenital defects
repeat echocardiography (tte/tee)
repeat hospitalization
repeat intervention risk
repeat procedure rate for srts
repeat revascularization
repeat tee (before completion of oral therapy)
repeated hospitalizations
reperfusion
reperfusion benefit
reperfusion delay
reperfusion injury
reperfusion metabolites
reperfusion modality
reperfusion strategy
reperfusion syndrome
reperfusion therapy
reperfusion therapy (pci, thrombolysis)
reperfusion time
reperfusion timing metrics
replacement fibrosis
repolarization changes
repolarization duration
reproducibility issues with nyha classification
reproductive health (pregnancy & contraception)
reproductive health education
reproductive health in congenital heart disease
reproductive health, pregnancy, and contraception (cardiovascular considerations)
reproductive health, pregnancy, and delivery
reproductive issues & pregnancy considerations in valve disease
reproductive options (informed decision‑making)
rescue angioplasty / rescue pci
rescue or bail‑out therapy
rescue pci
research / implementation terms
residual anatomic sequelae
residual anatomical abnormalities post‑repair
residual aortic disease monitoring
residual aortopathy / aortopa
residual baffle leaks
residual cardiovascular risk
residual coronary/arterial gradients
residual gradients
residual heart disease
residual leak (≤5 mm, >5 mm)
residual lesions / residual disease
residual lesions / residual shunt
residual mitral regurgitation (moderate or greater)
residual mr
residual regurgitation
residual regurgitation assessment post‑device placement
residual risk
residual sam post‑myectomy or ablation
residual shunt
residual shunts
residual shunts after repair
residual thrombus monitoring
residual unrevascularized coronary artery disease (cad)
residual valve dysfunction
residual ventricular septal defects (vsds)
residual vsd
residual ventricular septal defects (vsds)
resistance (strength) training (≥2 days/week)
resistance exercise
resistance training
resistance training (muscle‑strengthening)
resistance training (strength training)
resistive training with light weights
respect‑epa (randomized trial for evaluation in secondary prevention efficacy of combination therapy – statin and eicosapentaenoic acid)
respiratory symptoms
respiratory‑related fluctuations
respire study (sleep apnea incidence in pacemakers)
rest or provoked left ventricular outflow tract (lvot) gradient <50 mm hg
rest pain
rest pain (ischemic pain at rest)
restenosis
restenosis (stent restenosis)
restenosis‑related mi (type 4c)
resting abi
resting echocardiographic findings
resting electrocardiogram (ecg)
resting heart rate
resting heart rate (j‑shaped relationship with af)
resting hypoxemia / cyanosis
resting lvot gradient
resting oxygen saturation
resting peak lvot gradient < 50 mm hg
resting vs. provoked pressure gradients
resting, exercise, and ambulatory hypertension
restrictive cardiomyopathy
restrictive diastolic filling
restrictive lung disease in chd
restrictive physiology
restrictive physiology / restrictive cardiomyopathy phenotype
restrictive rv physiology
restrictive transfusion strategy
restrictive valve involvement
restrictive vsd
restrictive vsds (pressure‑ and/or volume‑restrictive)
rest‑ventricular ejection fraction (lvef)
resuscitated cardiac arrest
resuscitative endovascular balloon occlusion of the aorta
resuscitative endovascular balloon occlusion of the aorta (reboa)
retained valves
reteplase
reteplase (rpa)
retinopathy
retransplantation
retrograde extension of dissection
retrograde perfusion obstruction (implied in malperfusion)
retrograde propagation
retrograde type a aortic dissection
retrograde type a dissection
retrospective analysis
retrospective cohort study
retrospective outcomes (10‑year follow‑up)
retrospective series / case study data (guideline evidence)
retro­active studies on bav outcomes
return of spontaneous circulation (rosc)
return‑to‑play protocols for athletes with heart disease
revascularisation
revascularisation (pci/cabg)
revascularization
revascularization (both endovascular and open surgical)
revascularization (e.g., coronary revascularization)
revascularization (e.g., endovascular or surgical)
revascularization (e.g., pci, cabg)
revascularization (e.g., percutaneous coronary intervention – pci)
revascularization (e.g., percutaneous coronary intervention)
revascularization (early, routine, optimal)
revascularization (endovascular and surgical)
revascularization (endovascular or surgical)
revascularization (endovascular, surgical)
revascularization (endovascular, surgical, hybrid)
revascularization (endovascular, surgical, infrainguinal bypass)
revascularization (endovascular/surgical)
revascularization (for pad)
revascularization (including cabg and pci)
revascularization (interventional/surgical)
revascularization (pci vs cabg)
revascularization (pci, cabg)
revascularization (stenting, cabg)
revascularization (surgical & endovascular)
revascularization (surgical bypass, endovascular)
revascularization (surgical or catheter‑based)
revascularization (surgical or endovascular)
revascularization (urgent/refractory)
revascularization (vascular)
revascularization (when not an option)
revascularization + set combination therapy
revascularization / valve replacement options (mitral valve replacement)
revascularization as standard therapy for clti
revascularization benefits (pci, cabg)
revascularization decision‑making with ffr
revascularization failure
revascularization for coronary artery disease (cad)
revascularization guidelines
revascularization guidelines (acc/aha/scai)
revascularization indications (categories i, iia, iib)
revascularization of vertebral artery
revascularization planning
revascularization planning strategy
revascularization procedures
revascularization procedures (e.g., angioplasty, bypass, endovascular therapy)
revascularization readmissions
revascularization strategies
revascularization strategies in cardiogenic shock
revascularization strategy
revascularization strategy recommendations (cabg vs pci)
revascularization techniques
revascularization therapy
revascularization, coronary revascularization
reversal agents
reversal drugs
reversal of anticoagulation
reversal of pah
reversal of vasomotor paralysis
reverse bernheim effect (ventricular‑ventricular interaction)
reverse remodeling
reverse remodeling (left ventricular/left atrial)
reverse remodeling after surgical repair
reverse study
reverse trial
reverse typical afl (clockwise circuit)
reverse‑edge ventricular outflow tract (rev) procedure
reverse‑typical atrial flutter
reversible factor management
revived‑bcis 2 trial
reynolds risk score
re‑ablation
re‑align trial
re‑coarctation
re‑coarctation (restenosis of aortic isthmus)
re‑dual pci
re‑hospitalization with mi
re‑infarction (reinfarction)
re‑infarction risk reduction
re‑initiation of anticoagulation
re‑ly, rocket af (pivotal doac trials)
re‑occlusion
re‑operative cardiac procedures
re‑stenosis (post‑interventional)
re‑thoracotomy
rf (radiofrequency)










rhabdomyolysis
rheumatic disease
rheumatic fever
rheumatic fever prophylaxis
rheumatic heart disease
rheumatic heart disease‑associated atrial fibrillation
rheumatic mitral disease
rheumatic mitral stenosis
rheumatic mitral stenosis (ms)
rheumatic mitral valve disease
rheumatic valve changes
rheumatic valve disease
rheumatic valvular disease
rheumatoid arthritis
rheumatoid arthritis (inflammatory cardiovascular risk)
rheumatoid arthritis (ra)
rheumatoid arthritis and cardiovascular events
rheumatologic or autoimmune disease
rhythm
rhythm abnormalities
rhythm and rate control in af
rhythm control
rhythm control (rhythm‑control strategies)
rhythm control in af
rhythm control of atrial fibrillation (af)
rhythm control strategies
rhythm control strategies (pharmacologic, ablation, electrical cardioversion)
rhythm control strategy
rhythm control therapies
rhythm control therapy
rhythm conversion (to sinus rhythm)
rhythm evaluation for anticoagulation with continuous monitoring (reactcom)
rhythm management
rhythm monitoring
rhythm monitoring tools
rhythm‑af study
rhythm‑control drugs
rhythm‑control strategies
rhythm‑control strategy
rhythm‑control therapy
rhythm‑restoration outcomes
rhythm control strategy
ribonucleic acid (rna)
rifampin
rifampin‑impregnated prosthetic graft
rifampin‑soaked graft
rifampin‑soaked grafts
right atrial (ra)
right atrial (ra) dilation
right atrial (ra) pathology in repaired complex achd
right atrial area
right atrial contraction
right atrial dysfunction
right atrial enlargement
right atrial enlargement (rae)
right atrial function
right atrial involvement in avsd
right atrial pressure
right atrial size
right atrial strain
right bundle branch block
right coronary artery
right heart anatomy
right heart catheterization
right heart dysfunction
right heart failure
right heart function
right heart overcirculation
right hemiarch replacement
right internal mammary artery (rima) graft
right subclavian artery
right ventricle
right ventricle (rv)
right ventricle (rv) size
right ventricle‑to‑pulmonary artery (rv‑to‑pa)
right ventricle‑to‑pulmonary artery (rv‑to‑pa) conduit
right ventricle‑to‑pulmonary artery conduits
right ventricular (rv)
right ventricular (rv) dilation
right ventricular (rv) dimensions
right ventricular (rv) dysfunction
right ventricular (rv) dysfunction (systolic and diastolic)
right ventricular (rv) dysfunction / dilatation
right ventricular (rv) failure
right ventricular (rv) function
right ventricular (rv) hypertension
right ventricular (rv) involvement
right ventricular (rv) pacing
right ventricular (rv) pressure
right ventricular (rv) pressure load
right ventricular (rv) pressure overload
right ventricular (rv) response to overload
right ventricular (rv) size
right ventricular (rv) size and function
right ventricular (rv) systolic dysfunction
right ventricular (rv) systolic function
right ventricular (rv) systolic pressure
right ventricular (rv) thinning/fatty replacement
right ventricular activation
right ventricular cavity
right ventricular dilatation
right ventricular dilation
right ventricular dilation / enlargement
right ventricular dimensions
right ventricular dysfunction
right ventricular dysfunction / failure
right ventricular dysfunction secondary to tricuspid regurgitation
right ventricular ejection fraction (rvef)
right ventricular ejection fraction (rvef) – threshold <46 %
right ventricular end‑diastolic volume (referenced)
right ventricular end‑diastolic volume (rvedv)
right ventricular end‑diastolic volume (rvedv) – indexed rvedv (rvedvi)
right ventricular end‑systolic volume (>80 ml/m²)
right ventricular end‑systolic volume index (rvesvi)
right ventricular enlargement
right ventricular enlargement (rve)
right ventricular failure
right ventricular failure (implied in fontan context)
right ventricular fibrosis
right ventricular filling pressure
right ventricular free‑wall strain
right ventricular function
right ventricular function / rv systolic dysfunction
right ventricular function evaluation
right ventricular hypertension
right ventricular hypertrophy
right ventricular infarction
right ventricular infarction (rv infarction)
right ventricular involvement
right ventricular loading
right ventricular outflow tract (rvot)
right ventricular outflow tract (rvot) dysfunction
right ventricular outflow tract (rvot) obstruction
right ventricular outflow tract dysfunction
right ventricular outflow‑tract dysfunction / akinetic length
right ventricular pacing
right ventricular pacing (rvp)
right ventricular pressure
right ventricular remodeling
right ventricular size
right ventricular size assessment
right ventricular systolic function
right ventricular systolic pressure (rvsp)
right ventricular to pulmonary arterial coupling
right ventricular unloading
right ventricular volume
right ventricular volume / left ventricular volume ratio
right ventricular volume overload
right ventricular volume/pressure overload
right ventricular/left ventricular function parameters
right ventricular–to‑pulmonary artery (rv‑to‑pa) conduit
right ventriculography
right ventriculotomy
right vertebral artery
right-sided chamber enlargement
right/left coronary artery involvement
right‑atrial maze procedure
right‑heart catheterization
right‑heart chamber enlargement
right‑heart decompression
right‑heart monitoring
right‑heart pressure / right‑ventricular dysfunction
right‑heart pressure assessment
right‑sided diastolic pressures
right‑sided endocarditis
right‑sided failure (elevated central venous pressure, hepatomegaly, dependent edema)
right‑sided filling pressures
right‑sided heart failure
right‑sided heart failure (hf)
right‑sided heart remodeling
right‑sided hf signs and symptoms
right‑sided icd implant
right‑sided ie
right‑sided infective endocarditis
right‑sided prosthetic valve
right‑sided staphylococcus aureus endocarditis
right‑to‑left atrial shunt
right‑to‑left shunt
right‑to‑left shunt / bidirectional shunting
right‑to‑left shunting
right‑ventricular (rv) dysfunction
right‑ventricular (rv) failure
right‑ventricular (rv) pacing
right‑ventricular (rv) pressure overload
right‑ventricular (rv) remodeling
right‑ventricular (rv) shock
right‑ventricular (rv) strain
right‑ventricular (rv) systolic dysfunction
right‑ventricular afterload (pulmonary vascular resistance)
right‑ventricular assist device (rvad)
right‑ventricular compliance
right‑ventricular dilation
right‑ventricular dysfunction
right‑ventricular ejection fraction (rvef)
right‑ventricular failure
right‑ventricular function (ejection fraction, volumes)
right‑ventricular heart failure (rv hf)
right‑ventricular mass, volume and function assessment
right‑ventricular measures (cvp >15 mm hg, cvp‑pcw >0.6)
right‑ventricular outflow tract (rvot)
right‑ventricular pacing
right‑ventricular strain and deformation
right‑ventricular systolic dysfunction
right‑ventricular systolic dysfunction prevalence (50–80%)
right‑ventricular volume overload
right‑ventricular/biventricular pacing (rv/bivp)
right atrial size
right ventricular (rv) volumes
right ventricular dysfunction
right ventricular outflow tract (rvot)
rime (randomized ischemic mitral evaluation) trial
ring annuloplasty (aortic root)
riociguat
riociguat (sgc stimulator)
risk
risk amplifiers (clinical definitions for pad)
risk amplifiers (≥ 1 of the above factors)
risk amplifiers for pad (guideline‑defined)
risk analysis index
risk assessment
risk assessment (dissection risk)
risk assessment (for cardiovascular risk)
risk assessment / risk stratification
risk assessment and management (pulmonary hypertension specialists)
risk assessment and therapeutic decision‑making
risk assessment for thrombolysis
risk assessment frequency (every 4–6 years)
risk assessment tools
risk assessment tools (e.g., 3‑strata, 4‑strata models)
risk calculators
risk calculators (e.g., pce, framingham, reynolds, score, qrisk/jbs3)
risk calibration
risk categories: low, intermediate, high risk
risk discrimination
risk discrimination and calibration in prediction models
risk discussion
risk discussion / shared decision making
risk estimation
risk estimation tools (e.g., ascvd risk estimator, pce, 30‑year/lifetime risk estimator)
risk estimators (e.g., pooled cohort equations – pce)
risk evaluation and mitigation strategy
risk factor
risk factor (tobacco use)
risk factor algorithms for specific populations (e.g., veterans affairs, women’s health initiative, china‑par, korean risk model)
risk factor burden at age 50
risk factor burden at age 70
risk factor clustering (age, sex, smoking, diabetes, hyperlipidemia, hypertension)
risk factor control (lipids, blood pressure, diabetes)
risk factor education and counseling
risk factor evaluation for af complications
risk factor for aortic dissection
risk factor for reoperation
risk factor identification
risk factor management
risk factor modification
risk factor modification (e.g., smoking cessation, physical activity, healthy diet)
risk factor modification (smoking, cholesterol, blood pressure)
risk factor optimization
risk factor prediction models
risk factors
risk factors (e.g., for af, scd)
risk factors (for cardiovascular disease)
risk factors (general)
risk factors for aortic dilation
risk factors for aortic disease
risk factors for arrhythmia in achd
risk factors for avr timing
risk factors for cardiovascular disease
risk factors for claudication
risk factors for development of vhd
risk factors for dissection
risk factors for familial tad (age < 60 y, family history, sudden death)
risk factors for hf
risk factors for infective endocarditis
risk factors for loss to follow‑up
risk factors for mechanical complications post‑mi
risk factors for pad (e.g., diabetes, smoking, hyperlipidemia)
risk factors for peripheral artery disease
risk factors for rupture (endoleak, sac enlargement)
risk factors for sudden death
risk factors for valve degeneration (younger age, diabetes, renal failure)
risk factors for valve disease
risk factors: maternal age >30 yr, african ancestry, multiparity, multigestation, preeclampsia/eclampsia, anemia, diabetes, obesity, prolonged tocolysis
risk factors: young age (<60 yr), smoking, diabetes mellitus, chronic kidney disease, initial mean gradient ≥15 mm hg, valve type.
risk model
risk modelling
risk modifiers (stroke risk)
risk of adverse aortic events (dissection, rupture, sudden death)
risk of adverse events (rupture, dissection, death)
risk of af
risk of aortic rupture
risk of bleeding in p2y12 inhibitor therapy
risk of cardiomyopathy with family history
risk of death or renal failure with multivessel pci
risk of graft failure
risk of major adverse cardiac events (maces) in pad
risk of noncardiac intervention
risk of operative intervention
risk of progression from left‑ventricular dysfunction to overt heart failure
risk of recurrent ich
risk of rupture
risk of systemic thromboembolism in af
risk of thromboembolic recurrence
risk prediction
risk prediction (aortic disease)
risk prediction factors and stratification categories
risk prediction functions
risk prediction model
risk prediction models
risk prediction models (e.g., vascular study group of new england)
risk prediction models for af
risk prediction models for children with hcm
risk prediction models for peripartum cardiomyopathy
risk prediction models for scd
risk prediction performance (validity, calibration, discrimination)
risk prediction tools (tool‑specific)
risk ratio & confidence interval (statistical outcomes)
risk reclassification
risk reclassification & discrimination
risk reduction
risk reduction discussion
risk reduction of cardiovascular events
risk reduction strategies
risk reduction therapy
risk score
risk score (predicting death or need for surgery)
risk score / risk factors
risk score application for ventricular arrhythmia & scd
risk score assignment (0–3 points)
risk score development
risk score for af
risk score recalibration / customization
risk scores
risk scores (comprehensive, contemporary)
risk scores (e.g., cha₂ds₂‑vasc, chads‑vasc)
risk scores (e.g., for need of intensive care, predicting length of stay)
risk scores for death/recurrent mi prediction
risk scoring (e.g., precise‑dapt, paris)
risk scoring for major clinical events (post‑atrial switch)
risk scoring system for prosthetic valve procedures
risk stage a (patients at risk of hf)










risk stratification
risk stratification (e.g., cha₂ds₂‑vasc, has‑bled)
risk stratification (for ccd)
risk stratification (for icd decision‐making)
risk stratification (ischemic risk, bleeding risk)
risk stratification (pediatric and adult)
risk stratification (serious comorbidities, advanced age)
risk stratification / mortality prediction models
risk stratification / prognostic assessment
risk stratification after myocardial infarction
risk stratification and early diagnosis of aortic disease
risk stratification and population screening for af
risk stratification by exercise testing
risk stratification for achd patients
risk stratification for aortic disease
risk stratification for cardiac patients
risk stratification for icd placement
risk stratification for mortality and major events
risk stratification for pah
risk stratification for scd
risk stratification for sudden cardiac death
risk stratification for sudden cardiac death (scd)
risk stratification for vt/scd
risk stratification in coronary disease
risk stratification in heart failure
risk stratification models
risk stratification of asymptomatic valvular disease
risk stratification of sudden cardiac death
risk stratification scores
risk stratification scores (validated risk models)
risk stratification scores – conventional risk‑factor analysis, clinical risk scores
risk stratification tools
risk stratification tools (e.g., timi, grace scores)
risk stratification using cpet variables
risk thresholds (low < 5 %, borderline 5 %–< 7.5 %, intermediate ≥ 7.5 %–< 20 %, high ≥ 20 %)
risk treatment discussion
risk-benefit assessment
risk-enhancing factors
risk‑adjusted annual risk (>2% risk for stroke)
risk‑adjusted mortality rate (a/p ratio)
risk‑adjusted odds ratio (or) for mortality
risk‑amplifying comorbidities
risk‑assessment tools (e.g., 6mwd, hemodynamic parameters)
risk‑based foot screening intervals (annual, every 3–6 months, every 1–3 months)
risk‑based selection of oral anticoagulation
risk‑benefit assessment
risk‑benefit calculation.
risk‑benefit ratio (tavi vs. savr)
risk‑benefit ratio for intervention
risk‑benefit ratio of aspirin
risk‑enhancing factors
risk‑enhancing factors (e.g., elevated lipoprotein (a), metabolic syndrome, inflammatory diseases, hiv, protease inhibitors)
risk‑enhancing factors (family history of premature ascvd, elevated hscrp, lipid‑rich environment)
risk‑estimate calculator (5‑year scd risk)
risk‑estimation for ascvd (10‑year ascvd risk score)
risk‑factor algorithm
risk‑factor categories (aortic dilation, bav, aortic coarctation, hypertension)
risk‑factor control
risk‑factor control/optimization: lifestyle modification, pharmacologic therapy (statins, antihypertensives, antidiabetic drugs)
risk‑factor modification
risk‑factor modification (blood‑pressure control, medication)
risk‑factor modifications (diet, exercise, smoking cessation)
risk‑stratification for anticoagulation
risk‑stratification tools
risk–benefit balance of intervention timing
risk–benefit tradeoff
ritonavir
rivaroxaban
rivaroxaban (anticoagulant drug)
rivaroxaban (direct oral anticoagulant)
rivaroxaban (full‑dose)
rivaroxaban (low‑dose)
rivaroxaban + aspirin combination
rivaroxaban therapy
rly5016 (polysorbate potassium binder)
robo4 gene mutation
robotics‑assisted epicardial left atrial appendage exclusion
roche
roche diagnostics
rocket af trial
rocket‑af trial
rocket af study (predictors of mortality)
rofecoxib
role of primary hcm centers in procedural excellence
root aneurysm
root diameter
root enlargement with avr
root phenotype aortopathy
root‑sparing ascending replacement
ropac registry
ropac registry (registry of pregnancy and cardiac disease)
ropac registry (registry on pregnancy and cardiac disease)
rose angina (rose questionnaire)
rose trial
rosiglitazone
ross operation
ross procedure
ross procedure (aortic root autograft)
ross procedure (pulmonary autograft)
ross procedure (pulmonic autograft)
rossipril (ramipril)
rosuvastatin
rosuvastatin (20‑40 mg)
rosuvastatin (20–40 mg)
rosuvastatin (5‑10 mg)
rosuvastatin (5 mg, 10 mg, 20 mg, 40 mg)
rosuvastatin (≥ 20 mg)
roth’s spots
rotor or rotor‑modulation ablation (firm, confirm, firmap)
rotors (focal drivers)
routine cesarean delivery policy
routine clinical or imaging follow‑up
routine diagnostic studies
routine follow‑up
routine follow‑up (physiological stages a–d)
routine follow‑up / monitoring
routine follow‑up coronary angiography
routine follow‑up for valvular pulmonary stenosis
routine follow‑up imaging after valve intervention
routine follow‑up intervals
routine follow‑up intervals (physical, electrocardiogram, echocardiogram)
routine follow‑up visits
routine functional stress testing
routine invasive strategy
routine invasive vs selective invasive approach in nste‑acs
routine patient‑reported health status assessment
routine versus selective stenting
routine vs. conservative oxygen administration
rubidium‑82 pet imaging
rupture
rupture (aortic)
rupture (contained rupture)
rupture (of the aorta)
rupture of aortic aneurysm
rupture protocols (early imaging, rapid transfer, imaging‑guided repair)
rupture risk
rupture threshold (≥5.5 cm men, ≥5.0 cm women)
ruptured aaa
ruptured abdominal aortic aneurysm
ruptured abdominal aortic aneurysm (raaa)
ruptured aortic aneurysm
ruptured cerebral aneurysm
rural dwelling status / urban‑rural disparities
rural health disparities in vascular care
rurality / geographic remoteness
rutherford classification
rv (right ventricle)
rv apical pacing
rv dilatation
rv dilation
rv dilation (right‑ventricular dilation)
rv dysfunction
rv end‑systolic area
rv enlargement
rv free wall
rv hypertension
rv hypertrophy
rv lge present
rv pressure
rv pressure overload
rv pressure/volume overload
rv remodeling
rv size and function assessment
rv systolic dysfunction
rv systolic function
rv systolic pressure
rv volume
rv volume loading
rv volume overload
rv volume overload (shunts/high‑output states)
rv volumes
rvot anatomy (native vs conduit)
rvot dysfunction
rvot obstruction
rvot pressure ≥47 mm hg
rvot reintervention
rvot resection
rvot obstruction
rvp (right ventricular pacing)
rv‑dependent coronary circulation
rv‑to‑pa conduit
rv‑to‑pa conduit regurgitation
rv‑to‑pa conduit stenosis
rv‑to‑pa shunt
rv‑to‑pulmonary artery (rv‑to‑pa) conduit
rv systolic function
rv systolic pressure
rwi (relationships with industry)
ryanodine receptor dysfunction









s. aureus endocarditis
s.* aureus bacteremia
saccular aaa
saccular aneurysm
saccular aneurysm morphology
sacubitril/valsartan
sacubitril/valsartan (arni)
sacubitril/valsartan (arni) in adult complex chd
sacubitril/valsartan (entresto)
sacubitril/valsartan (lcz‑696, lcz‑696)
sacubitril/valsartan therapy (heart failure)
sacubitril/valsartan use in systemic rv failure
sacubitril‑valsartan
sacubitril‑valsartan (arni)
sacubitril‑valsartan (lcz‑dppv)
sacubitril‑valsartan (valsartan‑based arni)
sacubitril–valsartan (arni)
sad, etc. (implied in references)
safety and effectiveness of antithrombotic therapy in coronary artery disease
safety and efficacy
safety and harm statements (e.g., arni/acei overlap within 36 h)
safety and outcomes of catheter ablation in achd
safety laboratory checks
safety of sheath insertion
safety profile
safety profile of verapamil and diltiazem in hcm
safety study
safety trial (af‑specific management strategy)
safe‑t trial
safe‑t trial (sotalol vs. amiodarone)
safire‑d study
safire‑d study (dofetilide trial)
salt restriction
salvageable limb
same‑day discharge
sano shunt
sanofi
sanofi‑aventis
saphenous vein
saphenous vein (autogenous conduit)
saphenous vein (great saphenous vein)
saphenous vein assessment
saphenous vein assessment before leg revascularization
saphenous vein assessment before leg revascularization (qm‑6)
saphenous vein graft
saphenous vein graft (great, small, or femoral)
saphenous vein graft occlusion
saphenous vein grafts
sapien 3 transcatheter heart valve
sapien s3 transcatheter heart valve
sarcoid (sarcoidosis)
sarcoid cardiomyopathy (cardiac sarcoidosis)
sarcoidosis
sarcoidosis (cardiac form)
sarcoidosis (cardiac involvement)
sarcoidosis‑related hf
sarcolipin regulation
sarcoma of the aorta / primary aortic tumor
sarcomere contractility inhibitors
sarcomere gene
sarcomere gene variant carriers
sarcomere gene variant.
sarcomere genes
sarcomere mutation
sarcomere mutation carriers.
sarcomere proteins
sarcomere variant
sarcomere‑related structures
sarcomeric genes
sarcomeric genetic variants
sarcomeric human cardiomyopathy registry (share)
sarcopenia
sarcopenia (predicts adverse outcomes in cad)
sarcoplasmic reticulum ca<sup>2+</sup> leak
sarcoplasmic reticulum calcium atpase (serca)
sarcoplasmic reticulum calcium load
sarcoplasmic reticulum dysfunction in af
sars‑cov‑2 infection and mrna vaccination
sars‑cov‑2 vaccination
sars‑cov‑2 vaccine effectiveness (high‑risk population)
sarver heart center
satisfactory procedural success (>95%)
saturated fat
saturated fat (< 6 % of total calories)
saturated fat intake
saturated fats
saturated fatty acids
save study (captopril after mi)
savor‑timi 53 (dpp‑4 inhibitor outcomes)
savr (surgical aortic valve replacement)
sawtooth flutter waves (ecg finding)
saxagliptin
sbp < 100 mm hg (systolic blood pressure)
scai
scai (society for cardiovascular angiography & interventions)
scai (society for cardiovascular angiography and interventions)
scai (society for cardiovascular angiography and interventions) guidelines
scai cardiogenic shock stages (a–e)
scai device‑selection guideline
scai expert consensus on shock stage classification
scai expert consensus statement on out‑of‑hospital cardiac arrest
scai grade
scai grade for cardiac arrest
scai guidelines (device selection, endovascular specialists)
scai position statement on achd interventional training
scai shock stage classification update
scai shock stages (c, d, e)
scai stage classification
scai/aats/acc/sts operator and institutional requirements
scar burden
scar formation
scar re‑entry circuits
scar tissue
scar‑mediated reentrant tachycardia
scar‑related vt
scd (sudden cardiac death)
scd rate increase with rv‑dependent circulation
scd risk assessment
scd risk assessment in adults with hcm
scd risk assessment in children/adolescents with hcm
scd risk calculator
scd risk calculator (e.g., from concor registry)
scd risk markers (clinical, imaging, electrophysiologic)
scd risk markers (e.g., lv apical aneurysm, lge, ef < 50 %)
scd risk reduction via ablation
scd‑heft (sudden cardiac death in heart failure trial)
scientific statement
scientific statement (american heart association)
scientific statement on dilated cardiomyopathy diagnostics and treatment
scientific statements
scimitar syndrome
scimitar syndrome (scimitar vein repair)
scimitar vein (variant of apvc)
score (systematic coronary risk evaluation)
scot‑heart trial
screening (for af)
screening (for aneurysm)
screening (genotype‑positive family members)
screening (ultrasound screening)
screening and referral processes
screening aortic imaging (if testing negative or vus)
screening for aaa
screening for abdominal aortic aneurysm
screening for abdominal aortic aneurysm (aaa)
screening for all risk factors (e.g., head 2 toes)
screening for aneurysms
screening for asymptomatic first‑degree relatives
screening for congenital aortic valve abnormalities
screening for coronary artery anomalies
screening for heart failure (stop‑hf)
screening for intracranial aneurysms in coarctation of the aorta
screening for mental health disorders
screening for new‑onset atrial fibrillation
screening for pad
screening for serum and urine monoclonal light chains
screening intervals:
screening of first‑degree relatives
screening recommendations for aaa
screening stratification risk prediction
screening tte in first‑degree relatives
seamless transitions from pediatric to achd
seattle angina questionnaire
seattle angina questionnaire (patient‑reported health status measure)
seattle angina questionnaire (saq)
seattle heart failure model
second trimester
secondary (functional) mr
secondary cardiovascular prevention
secondary coronary prevention
secondary erythrocytosis
secondary hyperaldosteronism
secondary mitral regurgitation
secondary mitral regurgitation (mr)
secondary mitral regurgitation (secondary mr)
secondary mr
secondary mr (chronic secondary mr)
secondary mr (lv‑remodeling‑related)
secondary patency
secondary prevention
secondary prevention (post‑discharge care)
secondary prevention (rheumatic fever, endocarditis)
secondary prevention after acs
secondary prevention in atherosclerotic disease
secondary prevention of arrhythmias
secondary prevention of ascvd
secondary prevention of atherosclerotic vascular disease
secondary prevention of cad
secondary prevention of cardiovascular disease
secondary prevention of cardiovascular disease (cvd)
secondary prevention of coronary disease
secondary prevention of coronary ischemic events
secondary prevention of cvd
secondary prevention of heart failure
secondary prevention of mi
secondary prevention of rheumatic fever
secondary prevention strategies
secondary tr
secondary tricuspid regurgitation
secondary‑prevention icd
secondhand smoke
secondhand smoke exposure
second‑ or third‑degree heart block (without pacemaker)
second‑degree atrioventricular block, mobitz type ii
second‑degree av block (mobitz i & ii)
second‑generation des
second‑generation dihydropyridine calcium channel blockers
second‑hand smoke
second‑hand smoke (passive smoking)
second‑hand smoke exposure
secundum asd
secundum atrial septal defect
sedation / patient tolerance
sedation for cardioversion
sedentary behavior
sedentary behaviour
sedentary lifestyle
sedentary time
segmental leg pressures
segmental limb pressure measurements
segmental pressures
segmental systolic pressures
selective invasive approach
selective invasive strategy
selective serotonin reuptake inhibitors (ssris)
selective treatment indications
selexipag (oral prostacyclin receptor agonist)
selexipag therapy
selexipag therapy for pulmonary hypertension
self‑care
self‑care education / self‑care
self‑care education and adherence
self‑care support for heart failure
self‑care support in heart failure
self‑expandable valve (e.g., evolut r)
self‑expanding prosthesis
self‑expanding pulmonary valve
self‑expanding tavi device
self‑expanding valve
self‑expanding valve technologies
self‑management
self‑management in heart failure patients
self‑reported health status
sellar’s criteria
semaglutide
semilunar valve interventions
semi‑supine bicycle exercise testing
seniors
seniors trial
sensory or motor dysfunction in an extremity
sensory polyneuropathy
sepsis
sepsis (from limb ischemia)
sepsis (systemic infection with cardiovascular implications)
sepsis / septic shock management
sepsis / severe sepsis (hospitalized patients)
sepsis‑associated atrial fibrillation
septal alcohol ablation
septal defects
septal e′ velocity
septal hypertrophy
septal myectomy
septal myectomy (surgical)
septal perforator injection
septal radiofrequency therapy (srt)
septal reduction therapy
septal reduction therapy (srt)
septic emboli to the lungs
septic embolism
septic pulmonary infarct
septic pulmonary infarcts
sequelae of avr on mr (improvement vs. persistence)
sequencing gdmt
sequential intervention
sequential pneumatic compression
sequential studies
sequential therapy (heparin then warfarin)
serca2 function / enhancer
serial cardiac imaging
serial clinical assessment
serial doubling of loop diuretics
serial ecg monitoring
serial echocardiograms
serial echocardiographic surveillance intervals (3–5 y, 1–2 y, 6–12 mo, 1 yr)
serial follow‑up echocardiography (every 1–2 years)
serial imaging
serial imaging studies
serial lvef monitoring
serial measurement of natriuretic peptides
serial troponin testing (0, 1–2 h)
serious cardiac complications during transplantation
serological evidence of active infection
serum biomarkers
serum brain natriuretic peptide (bnp)
serum creatinine
serum creatinine (scr)
serum digoxin concentration
serum digoxin level / concentration
serum electrolytes
serum free light chains (flc)
serum magnesium
serum monoclonal light chains
serum nt‑probnp concentrations
serum potassium
serum potassium (hyper‑kalaemia)
serum sodium
serum uric acid in eisenmenger syndrome
severe aortic regurgitation
severe aortic regurgitation (native or bioprosthetic)
severe aortic stenosis
severe aortic stenosis (as)
severe ar
severe ar (stage c1, c2, d)
severe as
severe as (asymptomatic or symptomatic)
severe asymptomatic vhd
severe bradycardia
severe burns (cardiovascular impact)
severe coronary artery disease
severe coronary artery disease (cad)
severe coronary stenosis (≥70 %)
severe dementia








severe disease
severe heart failure
severe high‑gradient as
severe hypotension (risk with pde5i + nitrates)
severe hypoxemia (spo₂ ≤ 85 %)
severe ischemic mitral regurgitation
severe kidney dysfunction (egfr < 30 ml/min/1.73 m²)
severe left ventricular dysfunction
severe lung disease
severe lung, liver, or renal disease
severe lv dysfunction (lvef ≤ 35 %)
severe mitral annular calcification (late paravalvular leak risk)
severe mitral regurgitation
severe mitral regurgitation (mr)
severe mitral regurgitation (mr) due to annular calcification
severe mitral stenosis
severe mitral valve (mv) regurgitation
severe mr (ero ≥ 40 mm² or ≥ 0.4 cm²; regurgitant volume ≥ 60 ml)
severe ms criteria (≤1.5 cm², >5 mm hg gradient)
severe native coarctation or recoarctation
severe obesity
severe or symptomatic valvular disease
severe pah with shunt reversal
severe pain (abrupt, ripping/tearing)
severe pneumonia (cardiovascular comorbidity)
severe primary mitral regurgitation (mr)
severe primary mr
severe pulmonary arterial hypertension
severe pulmonary hypertension
severe regurgitation
severe respiratory diseases
severe rvot obstruction
severe secondary mr
severe stenosis
severe symptomatic aortic stenosis (as)
severe symptomatic tricuspid regurgitation (e.g., due to device leads)
severe tricuspid regurgitation
severe tricuspid regurgitation (severe tr)
severe tricuspid regurgitation (tr)
severe valve disease
severe valvular dysfunction
severe ventricular dysfunction
severely reduced lvef (<35%)
severity grading of as and ar
severity of presentation (fulminant vs nonfulminant)
severity of vhd
severity thresholds for mr (e.g., “severe primary mr”)
sex (female)
sex category (as part of cha2ds2‑vasc score)
sex differences
sex differences in peripheral artery disease
sex differences in symptom presentation and treatment of mi
sex disparities
sex, gender, and ethnicity disparities in cardiovascular care
sex, race, and ethnicity disparities in aortic disease outcomes
sex/gender differences (female vs. male ischemia, outcomes)
sex/gender differences in af treatment and outcomes
sexual activity (as moderate exercise)
sexual activity–related cardiovascular risk
sexual dysfunction
sexual dysfunction after aortic dissection
sexual health
sex‑modified cha₂ds₂‑vasc score
sex‑specific agaston unit thresholds (1300 women, 2000 men)
sex‑specific cardiovascular risk
sex‑specific criteria for myocardial infarction diagnosis
sglt2 inhibitor
sglt2 inhibitor (sglt2i)
sglt2 inhibitor pharmacodynamics in hf
sglt2 inhibitors
sglt2 inhibitors (dapagliflozin, empagliflozin)
sglt2 inhibitors (sglt2i)
sglt2 inhibitors (sodium‑glucose cotransporter‑2 inhibitors)
sglt‑2 inhibitors
sglt‑2 inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin)
shared decision making
shared decision making (sdm)
shared decision-making
shared decision‐making process
shared decision‑making
shared decision‑making (among cardiology, primary, and specialty teams)
shared decision‑making (as a key process in risk assessment)
shared decision‑making (clinical decision process for preventive therapy)
shared decision‑making (clinical process)
shared decision‑making (for ccd)
shared decision‑making (for valve intervention)
shared decision‑making (in cardiovascular care)
shared decision‑making (in icd placement)
shared decision‑making (multidisciplinary)
shared decision‑making (sdm)
shared decision‑making (sdm) framework
shared decision‑making (sdm) in sports/physical activity
shared decision‑making for icd placement
shared decision‑making for valve therapy
shared decision‑making in aortic surgery
shared decision‑making in cardiac care
shared decision‑making in cardiovascular prevention
shared decision‑making in hcm care
shared decision‑making in hcm management
shared decision‑making in treatment choices
shared decision‑making process
shared decision‑making strategies in pad management
shared decision‑making with patients
shared‑decision making
shear stress
shfm (seattle heart failure model)
shifamed
shift trial (ivabradine treatment)
shift trial (shift) – a clinical trial on hfref
shock
shock (cardiac related)
shock (cardiogenic)
shock (shock) trial
shock energy (j)
shock index (hr/sbp)
shock index >1.0
shock severity scales (risk‑stratification tools for cardiogenic shock)
shock stage classification
shock team
shock team approach
shock teams
shock trial (cardiogenic shock after mi)
shock trial (should we emergently revascularize occluded coronaries for cardiogenic shock)
shockable rhythm (ventricular fibrillation, ventricular tachycardia)
shockwave medical
shockwave therapy
shone complex
shone complex
short stature (growth-related risk factor)
shorter dapt strategy
shortness of breath
shortness of breath / dyspnea
short‑acting nitrates
short‑acting nitrates (e.g., nitroglycerine)
short‑term and long‑term outcomes in mi
short‑term and long‑term survival
short‑term cardiac toxicity (post‑transplant)
short‑term dapt
short‑term dual antiplatelet therapy
short‑term evolution
short‑term mortality
short‑term outcomes (early results, immediate results)
short‑term survival
shunt (left‑to‑right, qp:qs)
shunt (trivial/small, hemodynamically significant)
shunt assessment
shunt closure
shunt closure complications
shunt lesions
shunt lesions (e.g., asd, vsd, patent ductus)
shunt magnitude
shunt magnitude / size
shunt palliation
shunt pre‑repair
shunt repair / closure
shunt type: secundum, primum, sinus venosus (superior/inferior), unroofed coronary sinus
shunting
sibutramine
sick sinus syndrome
sick sinus syndrome (tachycardia‑bradycardia form)
siemens
siemens healthineers** (cardiac imaging equipment)
signal void in mri (mitral regurgitation)
significant cad (>50% stenosis)
significant heart murmur
significant lv disease (chronically elevated left‑atrial pressure ≥ 15 mm hg)
signs / symptoms of heart failure
sildenafil
sildenafil (example pde5 inhibitor)
sildenafil (pde5 inhibitor)
sildenafil citrate therapy
sildenafil therapy
sildenafil therapy for pulmonary hypertension
silent / subclinical af
silent af
silent cerebral embolism
silent cerebral ischemic events
silent ischemia
silent thromboembolic lesion
silk road medical
silver‑coated graft
silver‑impregnated prosthetic graft
simple carbohydrates (e.g., high‑fructose corn syrup)
simple risk models for surgical mortality in type a dissection
simple, moderate, and complex forms of chd
simulation training for operators
simvastatin
simvastatin (10 mg, 20 mg, 40 mg)
simvastatin (20‑40 mg; 10 mg)
simvastatin (20–40 mg)
single antiplatelet therapy (sapt)
single photon emission computed tomography myocardial perfusion imaging (spect mpi)
single photon emission ct (spect)
single staged versus multistaged pci in multivessel nstemi patients (smile trial)
single ventricle (functional single‑ventricle heart)
single ventricle (univentricular)
single ventricle physiology
single-anticoagulant therapy
single‑call transfer protocol
single‑cell rna sequencing
single‑chamber icd
single‑chamber pacing
single‑coil defibrillator lead
single‑coil icd lead
single‑coil icd leads
single‑nucleus profiling
single‑photon emission computed tomography (spect)
single‑photon emission computed tomography myocardial perfusion imaging (spect mpi)
single‑ventricle
single‑ventricle anatomy (including double‑inlet left ventricle, tricuspid/mitral atresia, hypoplastic left heart)
single‑ventricle congenital heart disease
single‑ventricle palliation
single‑ventricle physiology
single‑ventricle repair
sinoatrial (sa) node
sinoatrial node
sinotubular junction
sinus node dysfunction
sinus of valsalva
sinus of valsalva aneurysm
sinus of valsalva aneurysm / prolapse
sinus rhythm
sinus rhythm (electrophysiological term)
sinus rhythm maintenance
sinus rhythm maintenance and targeted therapy in persistent atrial fibrillation
sinus rhythm restoration
sinus tachycardia
sinus venosus asd
sinus venosus atrial septal defect (svasd)
sinus venosus defect
sinuses of valsalva
sinuses of valsalva (non‑replaced) management
sinus‑based atrial maze procedure
sinus‑to‑commissure (s‑c) measurement
sinus‑to‑sinus (s‑s) measurement
sinus‑to‑sinus measurement
sir
sir (society for interventional radiology)
sir (society of interventional radiology)
sir data registry
sirolimus (rapamycin) therapy
sitagliptin
situs abnormalities, ciliary dysfunction, functional asplenia, conduction abnormalities, biliary atresia, atrioventricular septal defects (balanced/unbalanced), malposed great vessels, interrupted ivc, bilateral svc, atrial isomerism
sit‑up maneuver
six‑minute walk distance
six‑minute walk distance improvement
six‑minute walk test
six‑minute walk test (6mwt)
size threshold for repair (≥ 5.5 cm, < 5.5 cm with risk factors)
size thresholds for repair
skeletal muscle mass
skeletal muscle strength and endurance
skeletal muscle weakness or movement disorder (associated with phenocopies)
skeletal myopathy
skilled nursing facility care
skin perfusion pressure (spp)
skin pigmentation (blue‑gray)
sleep
sleep apnea
sleep apnea severity
sleep disorders
sleep disorders in heart failure
sleep disturbances / sleep deficiency
sleep duration (short sleep)
sleep hygiene (sleep quality)
sleep hygiene / short sleep duration (<6 h)
sleep study (polysomnography)
sleep‑apnea therapy
sleep‑disordered breathing
sleep‑disordered breathing (obstructive sleep apnea)
sleep‑disordered breathing (sdb)
sleep‑disordered breathing interaction with atrial fibrillation
slit‑like orifice
slow flow
slow inward calcium channels
slow pathway ablation
slow‑conducting electroanatomic isthmus
slow‑infusion thrombolysis
smac‑af trial (aggressive bp control in ablation)
smad3
smad3 (gene)
smad3 mutation
smad3 pathogenic variant
smad6 gene mutation
smad6 mutation
small aortic root / patient–prosthesis mismatch
small body size
small for gestational age infant
small left‑ventricular chamber
small prospective trial of inhaled prostacyclin in eisenmenger patients with normal lv function
small saphenous vein
small valve area
small vessel (intramural) coronary disease
small vessel ischemia
small, low‑flow, low‑gradient as
smart choice trial
smart devices
smartphone ecg
smartphone‑based tools leveraging artificial intelligence
smartwatch
smartwatch monitoring
smartwatches
smile trial
smoking
smoking (active tobacco use)
smoking (as a risk factor)
smoking (cigarette smoking)
smoking (current or former)
smoking (current/ongoing smoking)
smoking (risk factor for aaa)
smoking (risk factor)
smoking (tobacco use)
smoking / cigarette use
smoking / tobacco cessation – major cardiovascular risk factor
smoking / tobacco use
smoking / tobacco use (including other forms of tobacco)
smoking / vaping
smoking cessation
smoking cessation (behavioral and pharmacologic)
smoking cessation (cardiovascular risk modification)
smoking cessation (risk factor for heart disease)
smoking cessation (risk factor reduction)
smoking cessation / tobacco use
smoking cessation guidelines
smoking cessation pharmacotherapies
smoking cessation, physical activity, nutrition, weight management, stress reduction
smoking history (≥100 cigarettes)
smoking restrictions in homes and vehicles
smoking/tobacco use
smooth muscle cell apoptosis
smooth muscle dysfunction syndrome
smooth muscle dysfunction syndrome (acta2)
soccer trial (oxygen therapy on myocardial salvage)
social / psychosocial limitations
social determinants of ascvd risk
social determinants of cardiovascular disease
social determinants of health
social determinants of health (contextual factor)
social determinants of health (housing stability, food security, transportation)
social determinants of health (impact on hf management)
social determinants of health (medication access, cr attendance barriers)
social determinants of health (racial/ethnic disparities, socioeconomic status, rural residence)
social determinants of health (sdoh)
social determinants of health (sdoh) in af
social determinants of health (sdoh) interventions
social determinants of health (sdoh) risk factors
social determinants of health influencing cardiac disease
social engagement and chronic disease risk











social isolation
social isolation (as a risk factor for poor self‑care)
social relationships and heart failure survival
social support (individual and group)
social worker
social workers
society for cardiovascular angiography & interventions (scai)
society for cardiovascular angiography and intervention (scai)
society for cardiovascular angiography and interventions (scai)
society for interventional radiology (sir)
society for vascular medicine (svm)
society for vascular medicine (svm) guideline on aortic disease
society for vascular nursing (svn)
society for vascular surgery (svs)
society for vascular surgery abdominal aortic aneurysm guidelines
society of cardiovascular anesthesiologists (sca)
society of cardiovascular echocardiography recommendations
society of interventional radiology (sir)
society of interventional radiology virtex registry
society of thoracic surgeons (sts)
society of thoracic surgeons (sts) database
society of thoracic surgeons (sts) guideline on aortic aneurysm care
society of thoracic surgeons (sts) national database
society of thoracic surgeons (sts) score
society of thoracic surgery (sts)
society of thoracic surgery (sts) reporting
society of vascular medicine (svm)
society of vascular surgery (svs)
socioeconomic and racial disparities
socioeconomic deprivation
socioeconomic deprivation / rurality impact on cvd
socioeconomic deprivation and vascular health
socioeconomic factors
socioeconomic inequities
socioeconomic position / social deprivation status
socioeconomic status
socioeconomic status (income, education, distressed communities index)
socioeconomic status (ses)
socioeconomic status (ses) and health inequities
socioeconomic status (ses) – adverse influence on af risk
socioeconomic status and cardiovascular outcomes
socioeconomic stress (risk factor for loss to care)
socio‑demographic disparities
socio‑economic status / poverty / lack of health‑care access
sodium
sodium glucose cotransporter 2 (sglt2)
sodium intake
sodium intake (≤ 2300 mg/d, optimum 1500 mg/d)
sodium intake / dietary sodium
sodium intake / low‑sodium diet
sodium intake / sodium reduction
sodium nitroprusside
sodium nitroprusside (intravenous)
sodium reduction
sodium restriction
sodium restriction (dietary)
sodium restriction / dietary sodium restriction
sodium retention
sodium zirconium cyclosilicate (szc)
sodium zirconium cyclosilicate (zs‑9)
sodium/calcium exchanger (ncx) dysfunction
sodium‑calcium exchanger (ncx)
sodium‑glucose cotransporter 2 inhibitors (sglt2‑i)
sodium‑glucose cotransporter 2 inhibitors (sglt2i)
sodium‑glucose cotransporter‑1 inhibitors (sglt1i)
sodium‑glucose cotransporter‑2 (sglt2) inhibitor
sodium‑glucose cotransporter‑2 (sglt2) inhibitors
sodium‑glucose cotransporter‑2 (sglt2) inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin)
sodium‑glucose cotransporter‑2 (sglt‑2)
sodium‑glucose cotransporter‑2 (sglt‑2) inhibitor
sodium‑glucose cotransporter‑2 (sglt‑2) inhibitors
sodium‑glucose cotransporter‑2 (sglt‑2) inhibitors in achd
sodium‑glucose cotransporter‑2 (sglt‑2) inhibitors – cardiovascular benefit agents
sodium‑glucose cotransporter‑2 inhibitor (sglt2i)
sodium‑glucose cotransporter‑2 inhibitor (sglt2i) – e.g., dapagliflozin, empagliflozin
sodium‑glucose cotransporter‑2 inhibitor (sglt₂‑i) therapy
sodium‑glucose cotransporter‑2 inhibitor benefits in heart failure and mortality
sodium‑glucose cotransporter‑2 inhibitors
sodium‑glucose cotransporter‑2 inhibitors (sglt2i)
sodium‑glucose cotransporter‑2 inhibitors (sglt2i) in hfpef, hfmref, and hfref
sodium‑glucose cotransporter‑2 inhibitors (sglt2‑i) (mentioned in broader guideline context)
sodium‑glucose cotransporter 2 (sglt2) inhibitors (empagliflozin, dapagliflozin, canagliflozin)
sodium‑glucose co‑transporter 2 inhibitors (sglt2i)
sodium‑glucose co‑transporter‑2 (sglt2) inhibitors
sodium‑glucose co‑transporter‑2 (sglt‑2) inhibitors
sodium‑glucose co‑transporter‑2 inhibitors (sglt2i)
sodium‑glucose co‑transport‑2 (sglt2) inhibitors
sodium‑hf trial
sodium‑restricted diet
sodium‑water retention in heart failure
sodium–glucose cotransporter‑2 inhibitors (sglt2i)
soft‑tissue infections
soloist‑whf trial
soloman et al. (paradigm‑hf)
soluble guanylate cyclase (sgc) stimulator
soluble guanylate cyclase stimulator (riociguat)
soluble guanylate cyclase stimulators
soluble guanylyl cyclase stimulator
soluble guanylyl‑cyclase stimulators
soluble interleukin‑1 receptor‑like 1 (st2)
soluble st2 (sst2)
solvd (studies of left ventricular dysfunction)
sos (swedish obese subjects) study
sos (symptom‑management framework)
sotagliflozin
sotalol
sotalol (antiarrhythmic)
sotatercept therapy
south asian ancestry (high‑risk race/ethnicity)
spatial frequency domain imaging
spatial resolution
special populations (e.g., cad with valvular heart disease, hf with preserved or reduced ef)
specialist and support services
specialist care
specialist clinics for heart failure
specialized electrophysiologic care in achd
specialized pah management
specialty clinics
specialty hospitals and academic centers in cardiology:
specific antineoplastic agents highlighted as af risk factors:
specific anti‑arrhythmic agents
specific metabolic assays
speckle‑tracking echocardiography
spect (single‑photon emission computed tomography)
spect perfusion imaging
spin echo dark blood sequence
spinal cord dysfunction
spinal cord injury
spinal cord injury (sci)
spinal cord ischemia
spinal cord ischemia (sci)
spinal cord perfusion pressure
spinal cord perfusion pressure (scpp)
spinal cord protection
spinal cord protection strategies
spinal cord stimulation (scs)
spinal infection or non‑vertebral osteomyelitis
spinal ischemia
spinal ischemia (paraplegia)
spinal surgery
spiral computed tomography
spirometry as a predictive tool
spironolactone
spironolactone (aldosterone antagonist)
spirontolactone (topcat)
splanchnic nerve ablation
splenomegaly
spliced arm vein graft
spondin‑1
spontaneous abortion / miscarriage
spontaneous bleed
spontaneous coronary artery dissection
spontaneous coronary artery dissection (scad)
spontaneous coronary artery dissection (scad)
spontaneous diastolic ca²⁺ leak
spontaneous echocardiographic contrast (sec)
spontaneous mi (type 1)
spontaneous miscarriages
spontaneous myocardial infarction (mi)
sporadic taa
sports
sports cardiology
sports participation
sports participation & lifestyle changes in cardiac patients
sports participation counseling
sports‑related sudden death epidemiology
sprint
sprint (intensive vs standard bp)
sprint (systolic blood pressure intervention trial)
sprint (systolic blood pressure intervention) trial
sprint study
sprint trial
sprint trial (subpopulation)
square‑wave response to the valsalva maneuver
squat‑to‑stand maneuver
srt in pediatric and young adult patients (> 100 mm hg gradient)
srt not recommended in asymptomatic patients
st vincent’s screening to prevent heart failure (stop-hf)
st-elevation myocardial infarction (stemi)
st. vincent hospital
st. john’s wort
stability of chronic coronary syndromes
stabilized heart failure (hf)
stable angina
stable angina pectoris
stable coronary artery disease (cad)
stable coronary artery disease (stable cad)
stable coronary disease
stable ischemic heart disease
stable ischemic heart disease (sihd)
stable symptomatic presentation
stable ischemic heart disease
stage a (at‑risk) heart failure
stage a hf
stage a, b, c, d of as progression
stage a: at risk (risk factors present)
stage a: at risk for hf (risk factors, no symptoms)
stage b (pre‑clinical hf)
stage b / c1 disease (valvular disease stages)
stage b hf (pre‑hf)
stage b: pre‑hf (evidence of structural or functional abnormality without symptoms)
stage b: progressive (mild‑to‑moderate, asymptomatic)
stage c (symptomatic hf)
stage c / stage c1 (severity classification)
stage c, stage d1, d2, d3 (as staging)
stage c1, c2, and d (guideline staging).
stage c: symptomatic hf (symptoms plus structural disease)
stage d heart failure
stage d2 (low lvef)
stage d3 (normal lvef)
stage d: advanced hf (marked symptoms, recurrent hospitalizations)
staged multivessel pci
staged percutaneous coronary intervention (pci)
staged revascularization
stages a–d (valvular disease severity/management stages)
stages a–d of vhd progression
stages c2 and d disease
stages of atrial fibrillation
stages of chronic ar (stage a, b, c, d)
stages of hf (stage a, stage b, stage c, stage d)
stages of valve disease (a, b, c, d)
stages c and d of tricuspid regurgitation
stage b progressive disease definition
stage 1 hypertension (bp 130–139/80–89 mm hg)
stage a hf
stage b (medical therapy to treat or prevent disease progression)
stage b disease (progressive, no therapeutic action)
stage b heart failure
stage b hf
stage b, c, d progression (tricuspid regurgitation stages)
stage c (optimal timing of intervention)
stage c heart failure
stage c1: asymptomatic severe, lv/rv compensated
stage c2: asymptomatic severe, lv/rv decompensation
stage d (better options for intervention)
stage d disease
stage d heart failure
stage d mitral stenosis
stage d: symptomatic severe
staging of secondary mr (stages a, b, c, d)
standard 12‑lead ecg
standard blood pressure control
standard deviation (±2 sd) in regression analysis of mortality risk
standard deviations above the mean
standard guideline‑directed medical therapy (gdmt)
standard guideline‑directed medical therapy (gdmt) for hf
standard heart‑failure therapies (e.g., diuretics, mineralocorticoid antagonists)
standard therapy versus early routine pci after fibrinolysis
standardization of cardiac biomarker assays
standardized outcome measures (symptom burden, quality‑of‑life)
standing body weight
stanford classification
stanford classification (system)
stanford classification of aortic dissections
staphylococcal prosthetic valve endocarditis
staphylococcus aureus
staphylococcus aureus bacteremia
staphylococcus aureus endocarditis
staphylococcus aureus infection
stasis of blood flow
stat6 (signal transducer and activator of transcription 6)
static obstruction
statin
statin benefit
statin class
statin eligibility
statin eligibility / statin therapy
statin eligibility criteria
statin exposure (as a medication affecting cardiovascular risk)
statin initiation / continuation
statin intolerance
statin intolerance (partial/complete)
statin intolerance (requiring ≥2 statins)
statin safety
statin therapy
statin therapy (cholesterol‑lowering therapy)
statin therapy (e.g., for elevated ascvd risk or familial hypercholesterolemia)
statin therapy (e.g., pravastatin)
statin therapy (e.g., simvastatin)
statin therapy (e.g., simvastatin, pravastatin, atorvastatin)
statin therapy (high‑dose; statin‑related adverse effects)
statin therapy (high‑intensity statin)
statin therapy (high‑intensity, moderate‑intensity, low‑intensity)
statin therapy (implicitly referenced in cholesterol management)
statin therapy (moderate/high intensity)
statin therapy (moderate‑ or high‑intensity)
statin therapy (primary prevention)
statin therapy / lipid‑lowering therapy
statin therapy / severe statin‑associated side effects
statin therapy / statin prescribing
statin therapy / statin use
statin therapy / statins
statin therapy in ckd patients
statin treatment
statin use
statin use disparities in post‑mi patients
statin use during pregnancy
statin-associated muscle symptoms
statins
statins (e.g., rosuvastatin)
statins (e.g., rosuvastatin, atorvastatin)
statins (e.g., simvastatin, pravastatin, simvastatin)
statins (high‑dose statins)
statins (high‑intensity statins)
statins (high‑intensity, moderate‑intensity, low‑intensity)
statins (hmg‑coa reductase inhibitors)
statins (hydroxymethylglutaryl‑coenzyme a reductase inhibitors)
statins (incl. high‑intensity statin therapy)
statins (including high‑intensity statin therapy)
statin‑associated muscle symptoms (sams)
statin‑associated side effects
statin‑associated symptoms
statin‑intolerant patient management strategies
stationary bicycle exercise test
stationary bicycle training
steep rise in cardiac biomarkers (ongoing ischemia)
stemi (st‑segment elevation myocardial infarction)
stemi care system (regional stemi system of care)
stemi care system pathway
stemi equivalent (e.g., lbbb‑equivalent ecg)
stemi equivalent conditions
stemi network
stemi networks
stemi performance measures
stemi receiving center (src) networks
stemi recognition and activation protocol
stemi surveillance (e.g., ischemic st‑segment episodes)












stenosis
stenosis (clinical threshold for intervention)
stenosis (severe)
stenosis of fontan connection
stenosis of pulmonary and systemic venous pathways
stenotic lesions
stenotic mitral valve
stenotic murmur
stenotic valve lesions
stent (cheatham‑platinum, covered, bare)
stent (endovascular stenting)
stent creep
stent deployment
stent fracture
stent fracture‑related stenosis
stent graft
stent graft (various brands/models)
stent graft / endograft
stent graft / graft / endograft (vascular device)
stent graft fracture
stent graft migration
stent graft separation
stent implantation
stent implantation (drug‑eluting stent, bare‑metal stent)
stent implantation (pulmonary)
stent length (<15 cm)
stent malapposition
stent migration
stent or closure device (artifact in imaging)
stent patency
stent placement
stent placement (common femoral, iliac)
stent placement (intra‑vascular, baffle)
stent placement (thoracic)
stent placement in fontan pathway
stent revascularization
stent thrombosis
stent thrombosis (definite or probable)
stent trials
stent, drug‑eluting stent (des)
stenting
stenting (endovascular stent)
stenting of fontan pathway
stentless bioprosthesis
stents (pci stents)
stent‑graft collapse
stent‑graft deployment
stent‑graft design
stent‑graft fracture
stent‑graft migration
stent‑graft migration risk
stent‑graft oversizing
stent‑induced intimal hyperplasia
stent‑related mi (type 4b)
step 8 trial
sternal‑sparing surgery (cabg)
steroid therapy during myocardial infarction
steroid therapy for giant cell arteritis
steroids
stich trial
stich trial (surgical treatment for ischemic heart failure)
stiff left atrial syndrome
stiff left atrium
stop af first study (cryoballoon ablation)
stop‑dapt2 trial
straddling atrioventricular valves
strain imaging
strain‑rate imaging
stratified diagnostic tiers (acute evaluation, definitive confirmation, auxiliary diagnostics)
stream study (fdg‑pet/ct vs. mri/emb)
stream trial
stream trial (strategic reperfusion early after myocardial infarction)
strength (long‑term outcomes study to assess statin residual risk with epanova in high cardiovascular risk patients with hypertriglyceridemia)
streptokinase
strep a pharyngitis (group a streptococcus)
stress (psychological stress)
stress cardiac magnetic resonance (cmr)
stress cardiac magnetic resonance imaging (dobutamine or other)
stress cardiomyopathy
stress echocardiography
stress echocardiography (exercise doppler)
stress echocardiography in mitral stenosis
stress electrocardiogram (ecg)
stress myocardial perfusion imaging
stress nuclear/pet imaging
stress perfusion imaging
stress positron emission tomography (pet)
stress test
stress test (exercise test)
stress test (screening study)
stress testing
stress testing (dobutamine)
stress testing (exercise treadmill, stress echo)
stress testing (noninvasive)
stress testing (with or without imaging)
stress testing for lvoto or advanced hf consideration
stress, anxiety, and depressive symptoms
stress‑induced cardiomyopathy (takotsubo)
stress‑induced gradient
stress‑induced ischemia
strict rate control
stroke
stroke (as a cardiovascular event)
stroke (as a complication of aortic dissection)
stroke (as a major cardiovascular comorbidity)
stroke (as a major cardiovascular outcome)
stroke (as a related outcome)
stroke (as a vhd‑related complication)
stroke (as an af complication)
stroke (associated with atrial fibrillation)
stroke (cardioembolic)
stroke (cardio‑embolic)
stroke (carotid/vertebral artery involvement)
stroke (cerebral ischemia)
stroke (cerebral malperfusion)
stroke (cerebrovascular disease)
stroke (cerebrovascular event)
stroke (cerebrovascular, brain infarction, brain‑stem infarction)
stroke (embolic stroke)
stroke (hemorrhagic or ischemic)
stroke (high‑risk for stroke)
stroke (in relation to cardiovascular disease)
stroke (incident, ischemic, hemorrhagic)
stroke (incl. cardioembolic stroke)
stroke (including intracranial hemorrhage)
stroke (ischemic and hemorrhagic)
stroke (ischemic events related to af)
stroke (ischemic stroke)
stroke (ischemic stroke, thromboembolic stroke)
stroke (ischemic)
stroke (ischemic, intracerebral hemorrhage)
stroke (neurologic complications)
stroke (neuro‑vascular complication)
stroke (non‑fatal)
stroke (thromboembolic complication)
stroke (thromboembolic event)
stroke / cerebral hemorrhage
stroke / cerebrovascular disease
stroke / systemic embolism
stroke / systemic embolism prevention
stroke / transient ischemic attack
stroke / transient ischemic attack (tia)
stroke and bleeding risks
stroke and embolic events
stroke and mortality outcomes
stroke and mortality risk in af patients with ich
stroke and mortality risks associated with af/vhd
stroke and transient ischemic attack prevention (as a cardiac risk management strategy)
stroke in heart failure
stroke prevention
stroke prevention after cryptogenic stroke
stroke prevention guidelines
stroke prevention in af
stroke prevention in af/vhd
stroke prevention in atherosclerosis
stroke prevention in atrial arrhythmias
stroke prevention in atrial fibrillation
stroke prevention in cardiovascular disease
stroke prevention in patients with prior stroke or transient ischemic attack
stroke prevention in stroke and transient ischemic attack
stroke prevention measures
stroke prevention strategies
stroke prevention strategies in af with high bleeding risk
stroke prevention therapy
stroke rate
stroke rates (varied by cannulation strategy)
stroke registry data in hf with af
stroke risk
stroke risk (as a cardiac complication)
stroke risk (atrial fibrillation)
stroke risk (cha₂ds₂‑vasc score)
stroke risk (hcm patients)
stroke risk (high)
stroke risk (hr)
stroke risk (ischemic stroke) in the peri‑operative period
stroke risk (neurologic outcome)
stroke risk (via pad as a marker)
stroke risk / systemic embolization
stroke risk / thromboembolic risk
stroke risk / thrombo‑embolic complications
stroke risk assessment
stroke risk in af
stroke risk in atrial fibrillation
stroke risk in cyanotic disease
stroke risk in hcm patients with af
stroke risk in valvular disease
stroke risk linked to atrial fibrillation
stroke risk of antiplatelets vs warfarin
stroke risk of doacs vs warfarin
stroke risk reduction
stroke risk reduction (via bp control, anticoagulation)
stroke risk reduction therapy
stroke risk score
stroke risk score (e.g., cha₂ds₂‑vasc)
stroke risk scores
stroke risk scoring (chads2/cha₂ds₂‑vasc)
stroke risk stratification
stroke risk stratification (e.g., cha₂ds₂‑vasc)
stroke risk threshold
stroke statistics
stroke survivors
stroke volume
stroke volume (ml)
stroke volume index (ml m⁻²)
stroke volume index (svi)
stroke volume reserve (≥20% increase with dobutamine)
stroke volume support by rv
stroke/ischemic cerebrovascular event
stroke/systemic embolism risk in laao patients
stroke/tia history
stroke/tia recurrence
stroke/tia risk
stroke‑prevention therapy thresholds
stroke‑risk assessment
stroke‑risk prevention in af
stroke‑risk reduction therapies
stroke‑risk reduction therapy
stroke‑risk scores
stroke‑risk scores (e.g., cha₂ds₂‑vasc)
stroke‑risk scores (general term)
stroke‑volume index <35 ml/m²
structural abnormalities of cellular connections
structural cardiac abnormalities (mitral valve apparatus, subaortic membrane)
structural deterioration of bioprosthesis
structural deterioration probability (15‑year risk %)
structural exercise (as part of gdmt)
structural heart damage
structural heart disease
structural heart disease (apical aneurysm, mid‑ventricular obstruction)
structural heart disease (scar or fibrosis)
structural heart disease (stage c hf)
structural heart disease (implicit in definitions of lone af)
structural heart interventions
structural heart lesions (tricuspid valve dysplasia, ebstein‑like anomaly, vsd, lvot obstruction)
structural inequities in access to cardiac specialists
structural lesion (lvot stenosis, tricuspid regurgitation)
structural measures
structural measures (sm) for hf
structural racism
structural racism / chronic stress (“weathering”)
structural remodeling
structural remodeling assessment
structural remodeling of the left atrium
structural valve degeneration
structural valve degeneration (svd)
structural valve deterioration
structural valve deterioration (svd)
structural valve deterioration / failure
structured community‑based exercise program
structured community‑based exercise programs
structured community‑based exercise programs (including home‑based)
structured community‑based exercise therapy
structured comprehensive risk‑factor management
structured exercise (comparative treatment option)
structured exercise (set)
structured exercise / community‑based exercise therapy (pm‑7)
structured exercise program
structured exercise program classification
structured exercise programs
structured exercise programs for pad
structured exercise therapy
structured exercise therapy (for pad)
structured exercise training (set)
structured prehospital history and physical examination
structured telephone support
structured telephone support / telemedicine alerts
structured telephone support / telemonitoring
structured transition education
sts (society of thoracic surgeons)
sts (society of thoracic surgeons) database
sts (society of thoracic surgeons) risk calculator
sts (society of thoracic surgeons) risk‑scoring system for cardiac surgery
sts (society of thoracic surgeons) surgical risk score
sts adult cardiac surgery database
sts database
sts risk calculator (sts‑predicted risk of death)
sts/acc transcatheter valve therapies registry
sts/acc tvt registry
study / evidence descriptors
stump blowout
st‑elevation mi
st‑elevation myocardial infarction
st‑elevation myocardial infarction (stemi)
st‑segment abnormalities
st‑segment depression
st‑segment depression ≥0.5 mm in ≥2 contiguous leads
st‑segment deviation
st‑segment elevation
st‑segment elevation (definition criteria)
st‑segment elevation (in ecg)
st‑segment elevation (stemi criteria)
st‑segment elevation (st‑elevation)
st‑segment elevation acs (stemi)
st‑segment elevation myocardial infarction (stemi)
st‑segment elevation resolution criteria
st‑segment elevation ≥1 mm in ≥2 contiguous leads (j‑point)
st‑segment resolution / st‑resolution
st‑segment‑elevation myocardial infarction (stemi)
st‑segment–elevation myocardial infarction (stemi)
st jude medical prosthesis
subacute and chronic aortic dissection management
subacute aortic dissection
subacute bacterial endocarditis
subacute/chronic type b management strategies
subaortic (lv outflow tract) calcification
subaortic membrane
subaortic membrane (sam) of the mitral valve
subaortic obstruction
subaortic stenosis
subaortic stenosis (discrete subaortic stenosis)
subaortic stenosis (including discrete subvalvular aortic stenosis)
subclavian artery coverage
subclavian artery disease
subclavian artery revascularization
subclavian flap aortoplasty
subclavian/axillary access











subclinical af
subclinical af burden/duration
subclinical atrial fibrillation
subclinical atrial fibrillation (scaf)
subclinical cardiac injury
subclinical coronary anatomy complexity
subclinical coronary artery disease
subclinical hypertrophic cardiomyopathy
subclinical leaflet thrombosis
subclinical lv systolic dysfunction
subclinical myocardial damage strategies
subcutaneous enoxaparin injections
subcutaneous heparin
subcutaneous icd
subcutaneous icd (s‑icd)
subcutaneous implantable cardioverter‑defibrillator (icd)
subcutaneous treprostinil
subgroup analyses
subgroup analysis
sublingual nitroglycerin
sublingual nitroglycerin prescribing
suboptimal dose of gdmt
suboptimal valve anatomy
suboptimal valvuloplasty results
subpulmonary ef <40 %
subpulmonary stenosis
subpulmonic left‑ventricular dysfunction
subsequent medical management of aortic dissection
substance abuse
substance abuse (cocaine, amphetamines, opioids, marijuana/cannabis)
substance exposures: cocaine, amphetamines, ethanol, copper, iron, lead, venomous bites
substance use
substance‑abuse–related cardiomyopathy
substance‑use disorders (comorbidity)
substrate for re‑entry
substrate modification during ablation
subtherapeutic inr
subvalvular aortic stenosis
subvalvular apparatus
subvalvular apparatus abnormalities
subvalvular chordal fusion
subvalvular fusion/fibrosis
subvalvular mitral apparatus reconstruction
subvalvular stenosis
sudden cardiac death
sudden cardiac death (associated with coronary anomalies)
sudden cardiac death (scd)
sudden cardiac death (scd) in achd
sudden cardiac death (scd) prevention
sudden cardiac death (scd) related to coronary anomalies
sudden cardiac death (scd) risk assessment
sudden cardiac death (scd) risk stratification
sudden cardiac death in heart failure trial (scd‑heft)
sudden cardiac death prevention
sudden cardiac death risk
sudden cardiac death risk stratification
sudden death
sudden death (primary prevention)
sudden death at age < 50 years
sudden death in young athletes
sudden death risk
sudden death risk prediction
sudden unexplained death (scd)
sudden‑onset pain
sugar and high‑carbohydrate diets
sugar‑sweetened beverages
sugar‑sweetened beverages (soft drinks, energy drinks, fruit drinks)
sulfadiazine (oral)
sulfamethoxazole (dmard)
sulfonamides
superior caval‑pulmonary connections
superior mesenteric artery
superior mesenteric artery (sma)
superior qrs axis in ostium primum asd
superior sinus venosus defect
superior svasd
superior vena cava (svc)
superior vena cava (svc) pathway
superior vena cava (svc) stenosis
superior vena cava isolation
superior vena cava obstruction
superior vena cava syndrome
supervised exercise
supervised exercise therapy
supervised exercise therapy (set)
supervised exercise therapy – set
supervised exercise training
supervised exercise training (set)
supplemental oxygen therapy
supplemental oxygen use during exercise
supportive care in hf
suppressive lifelong therapy
supracristal ventricular septal defect
supratherapeutic inr (>5.0)
supravalvar aortic stenosis
supravalvar aortic stenosis (svas)
supravalvar mitral ring
supravalvar pa stenosis
supravalvar pulmonary artery stenosis
supravalvular aortic stenosis
supraventricular arrhythmia
supraventricular arrhythmias
supraventricular arrhythmias (frequent or complex repetitive forms)
supraventricular arrhythmias in pulmonary hypertension
supraventricular tachyarrhythmia
supraventricular tachyarrhythmia (atrial arrhythmias)
supraventricular tachyarrhythmias
supraventricular tachycardia
supraventricular tachycardia (svt)
supraventricular tachycardia
supra‑annular prosthesis insertion
supra‑valvar aortic stenosis
supra‑valvar mitral stenosis
surgery
surgical & endovascular intervention
surgical ablation
surgical ablation (af)
surgical ablation (atrial)
surgical ablation (cox‑maze, hybrid convergence)
surgical ablation (e.g., maze procedure)
surgical ablation in af
surgical ablation of atrial fibrillation
surgical ablation of ventricular tachycardia
surgical af ablation
surgical and endovascular management of aneurysms
surgical and transcatheter interventional risk evaluation
surgical aortic replacement
surgical aortic root replacement
surgical aortic valve bioprosthesis
surgical aortic valve replacement
surgical aortic valve replacement (savr / avr)
surgical aortic valve replacement (savr)
surgical approach
surgical atrial fibrillation ablation
surgical backup
surgical bioprosthesis
surgical bypass
surgical bypass surgery
surgical candidacy
surgical cannulation strategies (axillary vs. femoral)
surgical closure
surgical closure / repair of congenital lesions
surgical closure of vsd
surgical closure procedures
surgical considerations for cad in vhd
surgical conversion strategies for fontan patients
surgical correction of anomalous coronary artery origins.
surgical correction of aortic regurgitation
surgical correction of interarterial coronary anomaly
surgical correction of left‑to‑right shunts
surgical correction of mr
surgical debridement (for foot infections/gangrene)
surgical delay in acute severe ar
surgical durability
surgical era (pre‑1980 vs. ≥1980)
surgical expertise
surgical indication
surgical indications
surgical indications and guidelines for chronic mitral regurgitation
surgical indications: before lvef falls below 55 %
surgical ineligibility
surgical interruption of accessory pathways
surgical intervention
surgical intervention (reoperative avr, savr)
surgical intervention (repair)
surgical intervention (timing, upfront vs delayed)
surgical intervention (type a vs type b aortic dissection)
surgical intervention for aortic aneurysm
surgical intervention timing
surgical interventions for loeys‑dietz syndrome
surgical laao
surgical left atrial appendage exclusion/excision
surgical left atrial appendage obliteration
surgical left atrial appendage occlusion (s‑laao)
surgical left atrial reduction (with cardiac surgery or af ablation)
surgical ligation of the laa
surgical limb revascularization
surgical management of aortic aneurysm
surgical management of lvot obstruction
surgical management of valve disease
surgical membrane resection
surgical mitral valve repair
surgical mitral valvotomy / valve replacement
surgical mortality
surgical myectomy
surgical myectomy / papillary muscle surgical management
surgical myectomy benefit (e.g., improvement in pulmonary hypertension, exercise tolerance, reverse atrial enlargement)
surgical myectomy with concomitant af ablation
surgical or transcatheter intervention criteria
surgical outcome improvement with high case volume
surgical outcomes
surgical outcomes and repair of dcrv
surgical outcomes for chronic aortic valvular disease
surgical outcomes in aortic disease
surgical outcomes of double‑root translocation for tga with pulmonary stenosis
surgical outcomes of tricuspid valve procedures.
surgical palliation sequelae
surgical procedures for chd
surgical procedures for valve disease
surgical procedure‑specific mortality (e.g., avr, avr+cabg, mitral repair, etc.)
surgical prosthetic valve implantation
surgical pulmonary valvotomy
surgical reconstruction vs. endovascular placement
surgical reintervention
surgical relief therapy (srt) for refractory lvoto
surgical reoperation
surgical repair
surgical repair (aortic or coronary)
surgical repair (aortic root/ascending aorta)
surgical repair (aortic)
surgical repair (coronary ostial stenosis, supravalvar aortic stenosis)
surgical repair (coronary revascularization)
surgical repair (membrane resection, myectomy)
surgical repair (of avsd, shunt, valve, or lvot)
surgical repair (of dcrv)
surgical repair (open)
surgical repair (pulmonary vein repair)
surgical repair (resection of obstructive muscle bundles)
surgical repair / baffle rerouting
surgical repair / closure
surgical repair / primary repair / reoperation
surgical repair and replacement
surgical repair of aortic aneurysm/dissection
surgical repair of aortic dissection
surgical repair of asd
surgical repair of coa
surgical repair of cor triatriatum
surgical repair of coronary anomalies (e.g., translocation to the aortic root)
surgical repair of pulmonary valve atresia with coronary‑pulmonary artery fistula
surgical repair of subaortic stenosis
surgical repair of svas or valve
surgical repair of the ascending aorta
surgical repair of tof (initial surgery)
surgical repair of transposition with vsd and subpulmonary stenosis
surgical repair of tricuspid valve (repair versus replacement)
surgical repair of type a dissection
surgical repair of vascular ring/pa sling
surgical repair of ventricular septal defect
surgical repair strategies for complex transposition (double‑root, rastelli, nikaidoh, rev, etc.)
surgical repair/stent therapy
surgical resection
surgical resection (membrane removal, valve repair)
surgical revascularisation
surgical revascularization
surgical revascularization procedures
surgical risk
surgical risk (e.g., low, high)
surgical risk (high or prohibitive)
surgical risk (high, low, intermediate)
surgical risk (high, prohibitive, low)
surgical risk (low, moderate, high)
surgical risk (sts score)
surgical risk (valve surgery)
surgical risk assessment
surgical risk categories: low, intermediate, high, prohibitive
surgical risk in infective endocarditis
surgical risk models (e.g., society of thoracic surgeons)
surgical risk stratification
surgical risk stratification in young patients
surgical septal myectomy
surgical specialist
surgical superior svasd repair
surgical therapy
surgical therapy (valve replacement/repair)
surgical threshold
surgical threshold (aortic diameter)
surgical threshold (e.g., 5.0 cm, 4.5 cm, 5.5 cm)
surgical threshold (≥4.5 cm, 5.0–5.5 cm, ≥5.5 cm)
surgical threshold for aaa repair
surgical thresholds for aortic surgery
surgical thresholds for prophylactic aortic root and ascending aorta replacement.
surgical thrombectomy / atrial appendage exclusion
surgical thromboembolectomy (e.g., fogarty catheter)
surgical timing
surgical timing (>4 weeks after stroke or hemorrhage)
surgical timing for mixed valve disease
surgical treatment
surgical treatment of endocarditis
surgical treatment of valve disease
surgical valve repair
surgical valve replacement
surgical valve replacement/repair
surgical valvotomy
surgical ventricular remodeling
surgical versus endovascular comparison
surgical volume (expertise)
surgical vs interventional risk
surgical vs. endovascular therapy for chronic limb‑threatening ischemia
surgical vs. interventional risk
surgical vs. transcatheter strategies for valve disease
surmount‑1 trial
surrogate decision maker
surveillance after aortic repair
surveillance after endovascular aneurysm repair
surveillance cmr
surveillance for medical management
surveillance for thoracic aortic disease
surveillance imaging
surveillance imaging (ct, mri, duplex ultrasound)
surveillance imaging (routine aortic imaging)
surveillance imaging / annual imaging
surveillance imaging for aortic monitoring
surveillance imaging intervals
surveillance imaging schedule
surveillance interval
surveillance of small abdominal aortic aneurysms
surveillance protocols
surveillance strategy
surveillance testing
survival
survival (30‑day, 1‑year, 5‑year, 10‑year)
survival (5‑year survival, event‑free survival)
survival (long‑term, post‑ablation)
survival (mid‑, long‑term)
survival (mortality, 1‑ and 2‑year survival)
survival / mortality (surgical vs. medical)
survival advantage
survival advantage (type b vs type a)
survival advantage of cabg over medical therapy in left‑main cad
survival advantage of pci over medical therapy in left‑main cad
survival advantage with mechanical valves
survival after repair
survival after transplantation
survival after veno‑arterial ecmo (save) score
survival analysis
survival and functional results
survival and functional status after surgery
survival benefit
survival benefit (device removal)
survival benefit / cost‑effectiveness ratios (e.g., <$60,000 per year of life added)
survival benefit of elective aortic repair
survival benefit with revascularization
survival impact of stage d tr
survival of patients with congenital vsd
survival outcomes
survival outcomes in achd
survival outcomes in hf/hcm patients
survival rate
survival rate / therapy outcomes
survivors of cardiac arrest











suspected myocarditis
suspected myocarditis diagnostic criteria
sustained arrhythmia
sustained arrhythmia requiring treatment
sustained atrial fibrillation
sustained atrial flutter/fibrillation (>30 s)
sustained monomorphic ventricular tachycardia
sustained monomorphic vt
sustained ventricular tachyarrhythmia
sustained ventricular tachycardia (vt)
sustained ventricular tachycardia/fibrillation
sustained‑release metoprolol succinate
sustain‑6 trial
suture line disruption, annular disruption, endocarditis
sutureless or covered stent closure
sva (society of vascular anesthesiologists) (implicit)
svm
svm (society for vascular medicine)
svm (society of vascular medicine)
svn
svn (society for vascular nursing)
svs
svs (society for vascular surgery)
svs (society of vascular surgeons)
svs (society of vascular surgery)
svs clinical practice guidelines
svs vascular quality initiative
svs/sts 2020 classification
svt (supraventricular tachycardia)
swedeheart registry
swedish health registries
sweetened beverages
sword (survival with oral d‑sotalol)
sympathetic and parasympathetic neuron activity
sympathetic denervation
sympathetic efferent stimulation
sympathetic hyperactivity
sympathetic hyperinnervation
sympathetic nervous system stimulation
sympathetic tone / mechanical stretch interaction
sympathomimetic weight‑loss drugs
symptom assessment
symptom assessment and monitoring in hf
symptom burden
symptom evaluation (e.g., dyspnea, chest pain)
symptom improvement in atrial fibrillation
symptom management
symptom management (dyspnea, fatigue, pain, nausea, depression, anxiety)
symptom management in hf
symptom onset
symptom onset (clinical, exercise‑provoked)
symptom onset in severe as
symptom persistence despite medical therapy
symptom relief
symptom staging (stages b, c, c2, d)
symptom status
symptom status (nyha class)
symptomatic af
symptomatic aneurysm
symptomatic aortic stenosis
symptomatic as
symptomatic atrial arrhythmia (post‑ablation)
symptomatic atrial fibrillation
symptomatic atrial fibrillation (study)
symptomatic atrial fibrillation investigative research on dofetilide (safer‑d)
symptomatic coronary artery disease
symptomatic heart failure
symptomatic hf
symptomatic hypotension
symptomatic improvement
symptomatic improvement (≥1 nyha functional class)
symptomatic ischemia
symptomatic low‑gradient as with preserved lvef.
symptomatic nonsustained ventricular tachycardia
symptomatic non‑ruptured aneurysm
symptomatic pad
symptomatic pad (claudication, ischemia-related exertional symptoms)
symptomatic patient
symptomatic patients
symptomatic patients (with severe ar)
symptomatic pau
symptomatic peripheral arterial disease
symptomatic peripheral artery disease
symptomatic peripheral artery disease (abi < 0.85)
symptomatic recurrence of atrial fibrillation
symptomatic response
symptomatic severe ar
symptomatic severe as
symptomatic severe vhd
symptomatic survival benefit of avr
symptomatic versus asymptomatic aortic stenosis
symptomatic versus asymptomatic status
symptomatic vertebrobasilar insufficiency
symptomatic vs asymptomatic atrial fibrillation
symptomatic vs asymptomatic presentation
symptomatic vs. asymptomatic as
symptomatic vs. asymptomatic pad
symptomatic vs. asymptomatic patient management
symptomatic vs. asymptomatic patients
symptomatic vs. asymptomatic pulmonary stenosis
symptoms
symptoms (angina, dyspnea, fatigue)
symptoms (symptomatic disease)
symptoms and rehospitalizations (mortality)
symptoms of aneurysm expansion
symptoms of heart failure
symptom‑based indications
symptom‑based indications for intervention
symptom‑based monitoring
symptom‑based therapeutic strategy
symptom‑based treatment decisions
symptom‑driven pacing indications (symptomatic bradycardia, heart failure symptoms)
symptom‑free (asymptomatic) pad
symptom‑guided titration
symptom‑relief of lvoto
sync failure / iatrogenic ventricular fibrillation (complications of cardioversion)
synchronized cardioversion
syncope
syncope (carotid artery or cardiac tamponade)
syncope (symptom)
syncope (unexplained, arrhythmia‑related)
syncope / presyncope
syndromic aneurysm (e.g., marfan syndrome)
syndromic features
syntax score
syntax score (age‑dependent impact on mortality post‑pci)
syntax score (≥ 33 cutoff)
syntax trial
syphilitic aortitis
systematic review
systematic review and meta‑analysis
systematic review of atrial fibrillation in hcm
systematic reviews
systematic reviews of cardiac interventions
systemic and pulmonary shunts
systemic anticoagulation treatment
systemic arterial and venous thromboembolic events
systemic blood pressure
systemic blood pressure (sbp)
systemic blood pressure control (tight vs usual) in hypertensive patients
systemic congestion (peripheral edema, ascites)
systemic desaturation
systemic ef <40 %
systemic emboli
systemic embolic event
systemic embolic events
systemic embolism
systemic embolism prevention
systemic embolism risk
systemic embolization
systemic features of syndromic htad
systemic fibrinolysis
systemic hypertension
systemic hypertension (as a risk factor for af)
systemic hypotension
systemic infection
systemic inflammation
systemic inflammatory activation (post‑cardiac surgery)
systemic inflammatory disorders (ibd, sle, ra, gout, psoriatic arthritis, ankylosing spondylitis)
systemic inflammatory responses
systemic left ventricle
systemic left ventricle (lv)
systemic left ventricular (lv) dysfunction
systemic lupus erythematosus (lupus)
systemic lupus erythematosus (sle) and myocardial infarction
systemic or pulmonary venous pathway stenosis
systemic perfusion
systemic postmenopausal hormone therapy
systemic proinflammatory states
systemic resistance
systemic right ventricle
systemic right ventricle (dextro‑tga with atrial switch, cctga)
systemic right ventricle (rv) function
systemic right ventricle (srv)
systemic right ventricle with depressed function
systemic right‑ventricle (rv) dysfunction
systemic syndromes associated with cardiomyopathy (e.g., limb‑girdle dystrophy, duchenne/becker muscular dystrophy, emory‑dreifuss)
systemic thromboembolic event
systemic thromboembolism
systemic tricuspid regurgitation severity (mild vs. severe, progressive disease)
systemic tricuspid valve dysfunction / regurgitation
systemic tricuspid valve function
systemic vascular load
systemic vascular resistance
systemic vascular resistance (svr)
systemic vasodilation
systemic venous congestion
systemic venous hypertension
systemic venous pathway stenosis
systemic ventricular dysfunction
systemic ventricular dysfunction (ef < 30 %)
systemic ventricular dysfunction (post‑pacing, post‑surgery)
systemic ventricular dysfunction (right‑ventricular systolic dysfunction)
systemic ventricular dysfunction / srv failure
systemic ventricular outflow tract obstruction
systemic ventricular overload
systemic ventricular preload
systemic ventricular systolic dysfunction
systemic ventricular volume measurement
systemic ventricular volume overload
systemic/organizational factors
systemic‑to‑pulmonary arterial collaterals
systems of care
systolic (reduced‑ejection‑fraction) heart failure
systolic and diastolic rv function
systolic anterior leaflet motion
systolic anterior motion (sam)
systolic blood pressure
systolic blood pressure (bp)
systolic blood pressure (sbp)
systolic blood pressure (sbp) 60–90 mm hg
systolic blood pressure (sbp) < 120 mm hg
systolic blood pressure control
systolic blood pressure fall during exercise
systolic blood pressure intervention trial (sprint)
systolic blood‑pressure differential
systolic bp (sbp)
systolic dysfunction
systolic dysfunction (ef < 50%)
systolic dysfunction (ef < 50 %)
systolic dysfunction (lvef < 50 %)
systolic ef thresholds (≤35%, 35‑50%, ≤50%)
systolic function
systolic function assessment
systolic heart failure
systolic heart failure (hf)
systolic heart failure (hfref)
systolic heart failure trials
systolic hypertension
systolic impairment
systolic murmur (harsh crescendo‑decrescendo)
systolic pulmonary artery pressure (pa pressure)
systolic/diastolic function














t cell‑mediated inflammation
t1 mapping
t1 mapping (non‑contrast)
t1‑based imaging (t1‑mapping)
t1‑mapping
t2 mapping
t2* mri for myocardial iron overload
t2‑based imaging (t2‑mapping)
tachyarrhythmia
tachyarrhythmia detection algorithms
tachyarrhythmia management
tachyarrhythmias
tachycardia
tachycardia runs (atrial ectopy)
tachycardia‑induced cardiomyopathy
tachycardiomyopathy
tachyphylaxis
tachy‑brady syndromes
tact trial (trial to assess chelation therapy)
tadalafil
tadalafil therapy
tafamidis
tafamidis therapy
tagged white‑blood‑cell scans
tailored therapies
takayasu arteritis
takayasu’s arteritis
takeuchi repair
takotsubo (stress) cardiomyopathy
takotsubo (stress‑induced) cardiomyopathy
takotsubo syndrome
takotsubo syndrome (stress‑cardiomyopathy)
tandemheart
target anti‑xa range (0.8–1.2 u/ml)
target blood‑pressure goal <130/80 mm hg (or <120/80 mm hg in some trials)
target dose vs. lower dose of hfref medications
target doses of beta blockers, acei‑arb, arni, mra
target gdmt dose
target international normalized ratio (inr)
target lesion revascularization
target vessel failure
target vessel myocardial infarction (mi)
target vessel revascularization
targeted anterior septal thickness
targeted pah therapy
targeted pulmonary hypertension therapy
targeted temperature management
targeted therapy arrhythmias
targeted therapy to slow or reverse disease progression
target‑vessel ischemia
task force guideline
taste disturbances
taurine
tavi (transcatheter aortic valve implantation)
tavi (transfemoral)
tavi – alternative access (transthoracic, transapical, subclavian, carotid, caval)
tavr unload trial
tc (technetium) labeling
team‑based approach (for ccd)
team‑based care
team‑based care (in cardiovascular management)
team‑based care / multidisciplinary care (clinical strategy for ascvd prevention)
team‑based care for cardiac comorbidities
team‑based heart‑failure care
tear site
technetium‑99m sestamibi spect
technetium‑pyrophosphate (¹⁰¹⁹tc‑pyp)
technical success rate
tee (transesophageal echocardiogram)
tee (transesophageal echocardiography)
teer (transcatheter edge‑to‑edge repair)
telehealth
telehealth & digital interventions
telehealth (virtual visits for vascular care)
telehealth and remote rehabilitation efficacy
telehealth as a care option
telehealth cardiac rehabilitation
telehealth for pad management
telehealth implementation
telehealth in cardiovascular disease
telehealth in cardiovascular disease management
telehealth interventions
telehealth medication adherence
telehealth programs
telemedicine
telemedicine (remote ie management)
telemedicine / digital health technology
telemedicine/virtual visits for chronic hf management
telemetry capability
telemetry duration in acs management
telemetry monitoring
telemetry unit
telemetry‑based prediction of in‑hospital adverse outcomes
telephone‑delivered health coaching
tele‑health / remote patient monitoring
tele‑health interventions for acute coronary syndrome (acs)
telmisartan
temporal artery tenderness / pulse attenuation
temporal resolution
temporal trends in cardiogenic shock incidence
temporal trends in hf incidence and mortality
temporary circulatory support devices
temporary mcs
temporary mcs (e.g., implantable vascular devices)
temporary mcs / bridge therapy
temporary mcs devices
temporary mechanical circulatory support
temporary mechanical circulatory support (e.g., biventricular support)
temporary mechanical support
temporary mechanical support (e.g., intra‑aortic balloon pump, temporary peripheral ventricular assist device, ecmo)
temporary pacemaker
temporary pacemaker insertion
temporary wearable cardioverter‑defibrillator
temporary/permanent interruption of cardiotoxic agents
tenax
tendyne
tenecteplase
tenecteplase (tnk‑tpa)
teratogenicity
terminal disease/end‑stage hf
terms related to heart disease (from the guideline excerpt)
terms related to heart disease extracted from the guideline text
terms related to heart disease extracted from the text
tertiary‑care center
terumo
testosterone therapy
tetralogy of fallot
tetralogy of fallot (repaired)
tetralogy of fallot (tof)
tetralogy of fallot (tof) – repaired tof
tetralogy of fallot (tof)
tetramer stabilizer therapy (for amyloidosis)
tevar (thoracic endovascular aneurysm repair)
tevar (thoracic endovascular aortic repair)
tevar‑related reintervention rates
text messaging
text‑messaging adherence programs for chd
tgfb2
tgfb2 (gene)
tgfb2 mutation
tgfb2 pathogenic variant
tgfb3
tgfb3 (gene)
tgfb3 mutation
tgfb3 pathogenic variant
tgfbr1
tgfbr1 (gene)
tgfbr1 mutation
tgfbr1 pathogenic variant
tgfbr2
tgfbr2 (gene)
tgfbr2 mutation
tgfbr2 pathogenic variant
tgf‑beta receptor mutation (tgfbr1/tgfbr2)
tgf‑β receptor
tgf‑β receptor mutations (associated with aneurysm syndromes)
tgf‑β signaling pathway in vascular disease
tgf‑β signalling
th17 cells
th17 immune response
th2 cells
th2 immune polarization
the aristotle trial (apixaban)
therapeutic & management terms
therapeutic angiogenesis
therapeutic anticoagulation
therapeutic benefit prediction (for revascularization vs. medical therapy)
therapeutic decision‑making in af
therapeutic footwear – a preventive strategy to reduce cardiovascular‑related foot ulceration risk
therapeutic inr
therapeutic inr range
therapeutic range
therapeutic recommendations
therapeutic value of warfarin
therapy
thermodilution
thermodilution cardiac output
thiamin supplementation
thiamine
thiamine supplementation
thiazide diuretic
thiazide diuretic (add‑on)
thiazide diuretics
thiazide diuretics (chlorthiazide, chlorthalidone, hydrochlorothiazide, indapamide)
thiazide diuretics (metolazone, chlorthalidone, hydrochlorothiazide)
thiazide‑type diuretics
thiazolidinediones
thiazolidinediones (e.g., rosiglitazone, pioglitazone)
thiazolidinediones (pioglitazone, rosiglitazone)
thiazolidinediones (rosiglitazone, pioglitazone, ipratropium‑related agents)
thiazolidinediones (tzds)
thienopyridine
thiocyanate toxicity
third heart sound (s3)
third trimester
third‑degree (complete) av block
third‑degree atrioventricular (av) block
third‑degree atrioventricular block
third‑degree atrioventricular block (infranodal)
thoracic
thoracic (thoracic surgery)
thoracic aorta
thoracic aorta disease
thoracic aorta imaging
thoracic aortic aneurysm
thoracic aortic aneurysm (taa)
thoracic aortic aneurysm (taa) / descending taa
thoracic aortic aneurysm (taaa / taaa)
thoracic aortic aneurysm (taaa)
thoracic aortic aneurysm and dissection
thoracic aortic aneurysm and dissection (taad)
thoracic aortic aneurysmal disease
thoracic aortic dilation
thoracic aortic dilation (tad)
thoracic aortic disease
thoracic aortic disease (tad)
thoracic aortic disease management guidelines
thoracic aortic dissection
thoracic aortic dissection (tad)
thoracic aortic imaging
thoracic aortic injury
thoracic aortic involvement
thoracic aortic pathologies
thoracic aortic repair
thoracic aortic surgery
thoracic arch pathologies
thoracic cardiovascular surgery
thoracic endograft / endovascular repair
thoracic endovascular aneurysm repair (tevar)
thoracic endovascular aortic repair
thoracic endovascular aortic repair (tevar)
thoracic endovascular aortic repair for descending thoracic aortic aneurysms
thoracic endovascular aortic repair for penetrating ulcers
thoracic radiation therapy
thoracic spinal‑cord stimulation
thoracic surgery
thoracic surgery for aortic arch in loeys‑dietz syndrome
thoracic aortic disease
thoracoabdominal aneurysm
thoracoabdominal aorta
thoracoabdominal aorta interventions
thoracoabdominal aortic aneurysm
thoracoabdominal aortic aneurysm (taaa)
thoracoabdominal extent of aneurysm
three‑dimensional dataset
three‑dimensional echocardiography
three‑dimensional echocardiography (3‑d echo)
three‑dimensional echocardiography (3‑de)
three‑dimensional echocardiography of tricuspid/mitral valves
three‑dimensional echodoppler imaging
three‑dimensional tee
three‑dimensional trans‑echocardiographic imaging (3d tee)
three‑vessel disease
threshold gradient (e.g., ≥ 50 mm hg, ≥ 80 mm hg)
thresholds for pulmonary valve replacement (rvedv >80 ml/m², rvedv ≥2× lvedv)
thrombectomy (manual, intracoronary)
thrombin
thrombin generation
thrombin generation / activity
thrombocytopenia
thrombocytopenia (platelet count <50 × 10⁹/l)
thrombocytopenia (platelet < 50 000/µl)
thromboelastography
thromboembolic complications
thromboembolic complications (related to baffle leaks)
thromboembolic disease
thromboembolic event
thromboembolic event rates
thromboembolic event risk
thromboembolic events
thromboembolic events (e.g., stroke)
thromboembolic events / thromboembolism
thromboembolic events / thrombosis
thromboembolic prophylaxis
thromboembolic risk
thromboembolic risk (annual %)
thromboembolic risk / thromboembolism
thromboembolic risk factors
thromboembolic stroke
thromboembolism
thromboembolism (arterial/venous)
thromboembolism (clinical, cardiovascular)
thromboembolism (mechanism and prevention)
thromboembolism / stroke risk
thromboembolism / systemic embolism
thromboembolism / thromboembolic risk
thromboembolism / thrombosis
thromboembolism history
thromboembolism in hcm
thromboembolism incidence in hcm
thromboembolism prevention
thromboembolism risk
thromboembolism risk (in af)
thromboendarterectomy
thrombogenesis & arrhythmogenesis in left atrium
thrombogenesis (virchow’s triad, clot formation)
thrombogenesis / hypercoagulability
thrombogenic endocardial lesions
thrombogenic milieu
thrombolysis
thrombolysis (intra‑arterial, catheter‑directed)
thrombolysis (tissue‑type plasminogen activator, tpa)
thrombolysis / thrombolytic therapy
thrombolysis in myocardial infarction (timi)
thrombolysis in myocardial infarction (timi) risk score
thrombolysis in myocardial infarction (timi) risk score for secondary prevention (trs 2p)
thrombolytic agents (streptokinase, tissue plasminogen activator)
thrombolytic therapy
thrombolytic therapy (intravenous thrombolysis)
thrombolytic therapy for mechanical pulmonic/tricuspid valves
thrombophilia
thromboprophylaxis
thromboprophylaxis (including direct oral anticoagulants)
thromboprophylaxis for atrial arrhythmias
thrombosis
thrombosis (branch false lumen)
thrombosis (post‑repair risk)
thrombosis / atherothrombosis
thrombosis / pro‑thrombotic state
thrombosis events / thromboembolism
thrombosis in congenital heart disease
thrombosis in eisenmenger syndrome
thrombosis prevention
thrombosis prevention in prosthetic valves
thrombosis research institute
thrombosis risk
thrombosis risk (fontan population)
thrombotic biomarkers
thrombotic complications
thrombotic complications (stroke, valve thrombosis)
thrombotic disease
thrombotic events
thrombotic events (stroke, etc.)
thrombotic events / thromboembolism
thrombotic events associated with prosthetic valves.
thrombotic risk
thrombotic/embolic complications (atrial thrombosis, emboli)
thrombo‑embolism
thrombo‑prophylaxis
thrombus
thrombus (aortic)
thrombus (lv)
thrombus (valve thrombus, subclinical bioprosthetic valve thrombosis)
thrombus aspiration
thrombus burden
thrombus detection
thrombus detection before cardioversion
thrombus formation
thrombus formation (subclinical)
thrombus formation risk
thrombus on prosthetic valve
thrombus resolution rates with vka and rivaroxaban
thrombus size criteria (>10 mm) for mechanical valve thrombosis.
thrombus surveillance
thrombus visualization
thrombus vs. pannus differentiation
thyroid disease
thyroid disease (as hf precipitant)
thyroid disease (hyperthyroidism)
thyroid disease / thyroid hormones
thyroid disease – hyperthyroidism
thyroid dysfunction
thyroid dysfunction (amiodarone‑induced)
thyroid dysfunction / thyroid‑stimulating hormone (tsh)
thyroid hormone replacement therapy (levothyroxine t4, triiodothyronine t3)
thyroid hormone therapy
thyroid hormones and cardiovascular disease
thyrotoxicosis (amiodarone‑induced)















th‑17 immune response
tia (transient ischemic attack)
ticagrelor
ticagrelor (p2y12 inhibitor)
ticagrelor monotherapy
tier‑2 diagnosis of definite myocarditis
timacs trial (timing of intervention in acute coronary syndromes)
time factors
time from fmc to device activation (≤120 minutes threshold)
time from symptom onset (≤12 hours window)
time in therapeutic range (ttr)
time to first medical contact (fmc)
time to intervention (hours from onset to surgery)
time to reperfusion
time to treatment (>4 h)
timeliness, safety, effectiveness, efficiency, equity (quality domains)
time‑dependent reduction in mortality and morbidity
time‑to‑device
time‑to‑event analysis in cardiovascular trials
timi (not explicitly mentioned, but related to reperfusion)
timi (thrombolysis in myocardial infarction)
timi 3 epicardial flow grade
timi flow grade
timi frame count
timi risk score
timi study group
timi trial (thrombolysis in myocardial infarction)
timing of angiography (≤24 hours, >24 hours, immediate)
timing of anticoagulation resumption
timing of cabg after myocardial infarction
timing of infection after valve intervention.
timing of intervention
timing of intervention (early vs delayed)
timing of intervention (surgery)
timing of periodic imaging (baseline, 1 yr, 5 yr, 10 yr, annual)
timing of valve intervention
tirofiban
tirzepatide
tirzepatide (ly3298176)
tissue doppler echocardiography
tissue doppler imaging
tissue growth optimization
tissue loss
tissue plasminogen activator (t‑pa)
tissue protrusion
tissue valve (bioprosthetic)
tissue‑based molecular diagnostic system (mmdx)
tissue‑type plasminogen activator
tissue‑type plasminogen activator (tpa)
titin (ttn) gene mutations
titin loss‑of‑function variants
titin truncations
titrated intravenous (iv) nitrates (e.g., nitroglycerin)
titration and uptitration of guideline‑directed therapy
tnf‑superfamily member 12 (tnfs12)
tnni3
tnni3 (troponin i type 3)
tnnt2
tnnt2 (troponin t type 2)
tobacco
tobacco avoidance
tobacco cessation
tobacco cessation (smoking cessation)
tobacco cessation interventions
tobacco cessation treatment
tobacco cessation treatment for cardiovascular risk reduction
tobacco dependence
tobacco product regulation
tobacco products
tobacco smoke pollution
tobacco smoking
tobacco use
tobacco use (risk factor)
tobacco use / cessation
tobacco use / smoking cessation
tobacco use / tobacco treatment
tobacco use disorder
tobacco use screening and counseling
tobacco use screening and counseling (pm‑6)
tobacco use/cessation interventions
tocilizumab
tocilizumab (il‑6 receptor inhibitor)
toe pressure
toe pressure / toe‑brachial index (tbi)
toe pressures
toe‑brachial index (tbi)
toe‑brachial index (tbi) <0.70
tof (tetralogy of fallot)
toll‑like receptors (tlrs)
tomographic imaging
topas study
topcat
topcat (treatment of preserved cardiac function heart failure with an aldosterone antagonist)
topcat trial
toric study (torasemide)
torsade de pointes
torsades de pointes
torsades de pointes (tdp)
torsemide
total arch replacement
total arch replacement (tar)
total bilirubin
total cholesterol
total ischemic time
total mortality
total walking distance
tpm1
tpm1 (tropomyosin 1)
tra 2p‑timi 50 trial
trace, mild, significant, worsening tr
tracheal compression
tracheal deviation
tracheomalacia
tracking of revascularization procedures
tracking of transfer patients (via emr and databases)
traditional cardiovascular risk factors
traditional cardiovascular risk factors (e.g., age, sex, ldl‑c, hdl‑c, systolic bp, smoking)
trandolapril
trans fat
trans fat (to be avoided)
trans fat intake
trans fats
trans fatty acids
trans fatty acids (risk factor for heart disease)
trans-thoracic echocardiography (tte)
transaminase elevation
transannular patch
transaortic approach to septal myectomy
transaortic maximum velocity
transaortic myectomy
transaortic pressure gradient
transaortic pressure gradient (cardiac catheterization)
transaortic septal myectomy / extended septal myectomy (esm)
transaortic volume flow rate
transapical approach
transapical approach to septal myectomy
transapical myectomy
transapical valve implantation
transcarotid access
transcatheter (catheter‑based) closure devices
transcatheter ablation
transcatheter aortic valve (tavr)
transcatheter aortic valve implantation
transcatheter aortic valve implantation (tavi)
transcatheter aortic valve implantation (tavi/tavr)
transcatheter aortic valve implantation (tavr)
transcatheter aortic valve replacement
transcatheter aortic valve replacement (tavr / tavi)
transcatheter aortic valve replacement (tavr)
transcatheter aortic valve replacement (tavr) / implantation (tavi)
transcatheter aortic valve replacement or implantation
transcatheter aortic valve‑in‑valve implantation
transcatheter approach
transcatheter balloon dilatation of cor triatriatum
transcatheter bioprosthetic valves
transcatheter closure
transcatheter closure of asd
transcatheter closure of paravalvular defects
transcatheter coa repair / stent therapy
transcatheter device closure
transcatheter edge‑to‑edge mitral repair (mitraclip)
transcatheter edge‑to‑edge mitral valve repair
transcatheter edge‑to‑edge repair
transcatheter edge‑to‑edge repair (teer / mitraclip)
transcatheter edge‑to‑edge repair (teer)
transcatheter endovascular aortic repair (tevar)
transcatheter fistula closure (management of coronary artery fistula)
transcatheter heart valve (thv)
transcatheter heart valve thrombosis
transcatheter intervention
transcatheter interventions
transcatheter mitral edge‑to‑edge repair (teer)
transcatheter mitral valve edge‑to‑edge repair (teer) – mitraclip
transcatheter mitral valve intervention
transcatheter mitral valve repair (mitraclip)
transcatheter mitral valve replacement
transcatheter mitral‑valve repair (tmvr)
transcatheter or surgical prosthetic valves
transcatheter pacing leads
transcatheter paravalvular leak closure (catheter‑based, percutaneous repair)
transcatheter procedure
transcatheter procedures (e.g., transcatheter aortic valve, transcatheter aortic valve replacement)
transcatheter pulmonary arterial hypertension therapy
transcatheter pulmonary valve (mpv)
transcatheter pulmonary valve implantation
transcatheter pulmonary valve implantation (melody valve)
transcatheter pulmonary valve placement (balloon‑expandable platform)
transcatheter pulmonary valve replacement
transcatheter repair
transcatheter stent therapy
transcatheter therapies
transcatheter tricuspid valve interventions
transcatheter valve implantation
transcatheter valve implantation (tavi)
transcatheter valve migration
transcatheter valve placement
transcatheter valve procedures (tavr, ttvr, etc.)
transcatheter valve repair
transcatheter valve replacement
transcatheter valve‑in‑valve (viv) procedure
transcatheter valve‑in‑valve procedure
transcatheter versus surgical avr choice
transcatheter viv (valve‑in‑valve) procedure
transcatheter viv procedure
transcatheter‑implanted prostheses
transcatheter pulmonary valve replacement
transcoronary ablation of septal hypertrophy (tash)
transcranial computed tomography (ct) imaging
transcutaneous oxygen pressure (tcpo₂)
transcutaneous oxygen tension (tcpo₂)
transcutaneous partial pressure of oxygen (tcpo₂)
transesophageal echocardiogram (tee)
transesophageal echocardiography
transesophageal echocardiography (tee)
transesophageal echocardiography (tee) for valve assessment
transesophageal echocardiography (tte)
transfemoral access
transfemoral access / femoral approach
transfemoral aortic valve replacement
transfemoral approach
transfemoral delivery
transfemoral tavi
transfemoral tavi approach
transfer delays
transfer for ppci (interhospital transfer)
transfer of care from pediatric to achd providers
transfer of care policies and procedures
transfer time to pci‑capable hospital
transfer to pci‑capable center
transfer-of-care protocols
transforming growth factor‑β (tgf‑β) pathway
transfusion thresholds (restrictive vs. liberal)
transient bacteremia
transient dyspnea
transient ischemic attack
transient ischemic attack (tia)
transient ischemic attack / stroke (as a cardiac embolic event)
transient ischemic dilation ratio
transient ischemic electrocardiographic changes
transition (care/education)
transition / transitional care interventions
transition education
transition education policies
transition education procedures
transition education programs (e.g., stepstones, transition‑chd)
transition education success metrics
transition from hospital to home
transition of care
transition readiness & education programs
transition strategy from intravenous to oral p2y12 inhibition
transition study (sacubitril/valsartan initiation)
transition to adulthood (for congenital heart disease)
transition to adulthood for adolescents with congenital heart disease
transition to heart transplantation after vsr
transition trial
transitional avsd (transitional atrioventricular canal)
transitional care / discharge planning
transitional‑care services program
transitions of care
transjugular liver biopsy
translational research in cardiovascular medicine
translucent skin
transluminal septal ablation
transmitral gradient
transmitral mean gradient
transmitral mean pressure gradient
transmural pressure
transmural scar
transmural scar (identified by lge)
transmyocardial laser revascularization
transmyocardial laser revascularization (tlr)
transplant assessment
transplant cardiology
transplant center volume
transplant evaluation
transplant in myocarditis
transplant listing and timing
transplant outcomes in cardiac sarcoidosis
transplant outcomes in congenital heart disease
transplant outcomes in hypertrophic cardiomyopathy
transplant referral
transplant surgery
transplant wait‑list management
transplant wait‑list mortality
transplantation
transplantation (cardiac transplant)
transplantation (cardiac transplantation)
transplantation (cardiac/heart‑lung)
transplantation (heart‑lung, heart).
transplantation referral for thoracic organ disease
transplant‑free survival
transportation / access to care
transportation access
transportation difficulties
transposition of the great arteries
transposition of the great arteries (dextro‑tga)
transposition of the great arteries (tga)
transposition of the great arteries (tga) with systemic right ventricle
transposition of the great vessels
transposition technique
transprosthetic regurgitation severity
transpulmonary gradient
transpulmonary gradient measurement
transradial access
transradial access / radial approach
transradial approach
transradial coronary intervention
transradial or radial artery access for coronary intervention
transradial rescue pci
transseptal mitral balloon valvuloplasty
transseptal puncture
transthoracic echocardiogram
transthoracic echocardiogram (tte)
transthoracic echocardiogram (tte) follow‑up
transthoracic echocardiogram follow‑up
transthoracic echocardiography
transthoracic echocardiography (echo)
transthoracic echocardiography (tte)
transthoracic echocardiography (tte) with doppler
transthoracic echocardiography (tte) – baseline, periodic imaging
transthoracic echocardiography (tte) – imaging modality for valvular assessment
transthoracic impedance
transthyretin (ttr) amyloidosis
transthyretin amyloid (attr) subtype
transthyretin amyloid cardiomyopathy
transthyretin amyloid cardiomyopathy (attr‑cm)
transthyretin amyloidosis
transthyretin amyloidosis (attr)
transthyretin cardiac amyloidosis (attr)
transthyretin tetramer stabilizer
transthyretin‑related amyloidosis (attr)
transvalvular flow rate
transvalvular gradient
transvalvular gradients












transvalvular leak
transvalvular pressure gradient
transvalvular pressure gradients
transvalvular regurgitation (pannus, thrombus, vegetation)
transvalvular velocities
transvalvular velocity
transvenous icd
transvenous lead extraction
transvenous lead placement
transvenous pacemaker
transvenous pacemaker leads
transvenous pacemaker system
transvenous pacing leads
transverse arch repair
transwomen cardiovascular risk
trans‑aortic stroke volume
trans‑aortic velocity
trans‑echocardiographic echocardiography (tee)
trans‑esophageal echocardiography (tee)
trans‑mitral jet velocity curve
trans‑radial access (conventional & distal)
trans‑thoracic echocardiography (tte)
trans‑ulnar access
trap 2p timi 50 trial
trastuzumab
trastuzumab cardiotoxicity
trastuzumab‑associated heart failure
trastuzumab‑related cardiotoxicity
traumatic aortic injury
traumatic aortic rupture
traumatic mitral valve injury (blunt chest trauma)
traumatic thoracic aortic injury
trauma‑related aortic pathology
treadmill exercise abi
treadmill exercise test
treadmill exercise testing
treadmill exercise training
treadmill training
treadmill walking
treadmill walking (low‑intensity vs. moderate/high‑intensity)
treatment adherence
treatment approaches for chronic coronary disease
treatment arms (rescue pci, conservative care, repeat fibrinolytic therapy)
treatment cost per qaly
treatment decision / surgical indication
treatment decisions
treatment eligibility criteria
treatment guidelines for acute coronary syndromes (acs)
treatment guidelines for non‑st‑elevation acute coronary syndromes (nst‑acs)
treatment guidelines for st‑elevation myocardial infarction (stemi)
treatment of asymptomatic left‑ventricular dysfunction
treatment of concomitant coronary artery disease in hcm patients
treatment of diabetes in heart failure
treatment of early post‑myocardial infarction heart failure
treatment of heart failure with mid‑range ejection fraction (hfmref)
treatment of heart failure with preserved ejection fraction (hfpef)
treatment of heart failure, multi‑drug strategies
treatment of metabolic disorders in heart disease
treatment of post‑infarction remodeling
treatment of vascular disease
treatment options for pad
treatment outcome
treatment outcomes
treatment strategies
treatment strategy
treatments
treat‑and‑repair approach (treat‑and‑repair)
treat‑and‑repair strategy
treat‑close‑treat strategy
treat‑to‑close approach
treat‑to‑close strategy
treponema pallidum (syphilitic aortitis)
triage to pci‑capable facility
trial inclusion criteria (lvesd ≤70 mm)
trial names and acronyms:
trial of hypertension prevention (thp)
trials: revived‑bcis2, courage, bari 2d, ischemia.
triangulated, shortened action potentials (pro‑arrhythmic)
tricuspid annular dilatation
tricuspid annular dilation
tricuspid annular plane systolic excursion (tapse)
tricuspid annular systolic velocity
tricuspid annular velocity (s′)
tricuspid annuloplasty
tricuspid annulus
tricuspid annulus dilation > 4.0 cm (40 mm)
tricuspid annulus dilation > 40 mm or > 21 mm/m² indexed to bsa
tricuspid annulus dilation > 70 mm intra‑operatively
tricuspid annulus end‑diastolic diameter
tricuspid annulus end‑diastolic diameter > 4 cm
tricuspid aortic valve
tricuspid aortic valve (tav)
tricuspid aortic valve (tricuspid)
tricuspid aortic valve replacement
tricuspid prosthesis
tricuspid regurgitation
tricuspid regurgitation (tr)
tricuspid regurgitation (tr) velocity
tricuspid regurgitation (tr) – secondary
tricuspid regurgitation velocity
tricuspid repair
tricuspid stenosis
tricuspid surgery
tricuspid valve (systemic av valve)
tricuspid valve (tr)
tricuspid valve closure
tricuspid valve disease
tricuspid valve dysfunction / tricuspid regurgitation
tricuspid valve dysfunction following pacemaker/icd implantation
tricuspid valve grading scheme
tricuspid valve hypoplasia
tricuspid valve imaging
tricuspid valve intervention
tricuspid valve morphology & function
tricuspid valve procedure
tricuspid valve regurgitant gradient
tricuspid valve regurgitation
tricuspid valve regurgitation (tr)
tricuspid valve regurgitation / insufficiency
tricuspid valve repair
tricuspid valve repair (surgical / percutaneous)
tricuspid valve repair / replacement
tricuspid valve repair vs. replacement selection criteria
tricuspid valve repair/annuloplasty
tricuspid valve replacement
tricuspid valve replacement (surgical)
tricuspid valve replacement (systemic right ventricle)
tricuspid valve replacement / tricuspid regurgitation
tricuspid valve surgery
tricuspid valve surgery (repair or replacement)
tricuspid valve/isthmus
tricuspid regurgitation
tricyclic antidepressants
trigger for arrhythmic activity
triglyceride levels ≥ 500 mg/dl (cardiovascular risk)
triglycerides
triglycerides (tg)
trileaflet aortic valve
triple antiplatelet therapy
triple antithrombotic therapy
triple therapy
triple therapy (full‑intensity anticoagulation + dapt)
triple therapy (oac + p2y12 inhibitor + aspirin)
triple therapy (warfarin + aspirin + clopidogrel/ticagrelor)
triple vasodilator therapy
triple‑vessel disease
trireme medical
triton‑timi 38 trial
triton‑timi 38 trial (pragmatic comparison of prasugrel and clopidogrel)
triumph study (treatment‑resistant hypertension)
troponin
troponin (conventional, older generation)
troponin (tn)
troponin (troponin‑negative)
troponin elevation
troponin i
troponin i (cardiac biomarkers)
troponin t
troponin‑based rule‑out of acute cardiac insufficiency (tacit)
troponin‑t
troponin i
troponin t
true lumen
true lumen collapse
true lumen flow
true lumen involvement
true‑lumen flow
truncus arteriosus
trypanosoma cruzi infection
tte (transthoracic echocardiography)
tte screening for bav and aortopathy
ttn (titin) loss‑of‑function variants
ttn (titin) variants
ttr (transthyretin protein)
ttr amyloidosis (transthyretin)
tumor necrosis factor (tnf)
tumor necrosis factor (tnf) inhibitors
tumor necrosis factor inhibitors
tumor necrosis factor inhibitors (tnf)
tumor necrosis factor‑inhibitors (biologic dmards)
tumor necrosis factor‑α (tnf‑α)
turner syndrome
turner syndrome (45,x) – bicuspid aortic valve, coarctation of the aorta, aortopathies, partial anomalous pulmonary venous connection, atherosclerosis risk
turner syndrome (cardiovascular involvement)
turner's syndrome (turner’s syndrome)
twilight trial
two‑dimensional (2d) imaging
two‑dimensional echocardiogram
two‑dimensional echocardiography
type 2 diabetes mellitus
type 2 diabetes mellitus (t2dm)
type a (involves ascending aorta)
type a aortic dissection
type b (does not involve ascending aorta)
type b aortic dissection
type b aortic dissection (acute, subacute, chronic)
type i (ascending to descending aorta)
type i aortic arch
type ii (isolated ascending aorta)
type iii (descending thoracic aorta)
type iiia (isolated descending thoracic aorta)
type iiib (descending thoracic aorta extending below the diaphragm)
type ii‑a aortic arch
type ii‑b aortic arch
type 1 myocardial infarction (type 1 mi)
type 2 myocardial infarction
type 2 myocardial infarction (type 2 mi)
type 3 myocardial infarction (type 3 mi)
type 4a peri‑pci myocardial infarction (pci mi)
type 4b post‑pci myocardial infarction (stent‑related mi)
type 4c post‑pci myocardial infarction (stent restenosis)
type 5 peri‑coronary artery bypass grafting myocardial infarction (cabg mi)
type‑1 myocardial infarction (mi)
type 1 diabetes mellitus
type 2 diabetes
type 2 diabetes (in the context of ccd)
type 2 diabetes mellitus
type 2 diabetes mellitus (diabetes, prediabetes, impaired glucose tolerance)
type 2 diabetes mellitus (t2dm)
type 2 diabetes mellitus (t2dm) – interaction with hf medications
type a aortic dissection
type a aortic dissection (stanford type a)
type a imh
type b aortic dissection
type b aortic dissection (stanford type b)
type b imh
typical atrial flutter
tyrosine kinase inhibitors
tyrosine kinase inhibitor‑associated cardiovascular toxicity
tyrosine‑kinase inhibitors
tyrosine‑kinase inhibitors (ibrutinib, acalabrutinib, zanubrutinib, ponatinib, trametinib, osimertinib, nilotinib, ribociclib)
t‑helper lymphocyte (th)
t‑wave abnormalities
t‑wave inversion >1 mm in ≥2 contiguous leads













uk small aneurysm trial
uksat (uk small aneurysm trial)
ulceration / critical limb‑threatening ischemia (clti)
ulcerative plaques
ulcer‑like projection
ultrafiltration
ultrasonography / ultrasound
ultrasound
ultrasound (duplex, doppler)
ultrasound enhancing agents
ultrasound guidance (for vascular access)
ultrasound imaging
ultrasound mapping
ultrasound screening
ultrasound screening for aaa
ultrasound surveillance
ultrasound‑accelerated thrombolysis
ultrasound‑enhancing agent use (intravenous, intracardiac)
ultrasound‑enhancing agents
ultrasound‑guided femoral access
ultrasound‑guided femoral artery cannulation
ultrasound‑guided percutaneous access
ultrasound‑guided vascular access
umbrella trials
unadjusted cumulative risk of af recurrence
unanticipated conduit dysfunction
uncomplicated aortic dissection
uncomplicated intramural hematoma
uncomplicated myocarditis
uncomplicated type b aortic dissection
unconclusive abi and physiological testing.
uncontrolled arrhythmias
uncontrolled bleeding
uncontrolled cardiac arrhythmias
uncontrolled diabetes
uncontrolled hypertension
underdosing
underexpansion
under‑representation of female patients in vascular trials
under‑utilization of cardiac rehabilitation
unexplained hemolysis
unexplained sudden death
unexplained syncope
unexplored myocarditis
unfractionated heparin
unfractionated heparin (ufh)
unguided de‑escalation of dapt
unhealthy diet
unicuspid aortic valve
unilateral antegrade cerebral perfusion
unilateral cerebral perfusion
uninterrupted anticoagulation
uninterrupted doac therapy
uninterrupted health insurance coverage
uninterrupted warfarin therapy
united network for organ sharing (unos) heart transplant allocation policy
united therapeutics (pulmonary hypertension association)
univentricular hearts
universal definition and classification of heart failure
universal definition of myocardial infarction (2018)
universal trial (routine ultrasound‑guided femoral vascular access)
university of arizona
university of north carolina
university of pennsylvania
unoperated single ventricle
unos (united network for organ sharing)
unplanned heart‑failure hospitalizations
unplanned revascularization
unprotected left‑main stenosis
unrepaired asd
unrepaired coa
unrepaired cor triatriatum sinister
unrepaired cyanotic congenital heart disease
unrepaired cyanotic heart disease
unrepaired or partially palliated cyanotic congenital heart defect
unrepaired pda
unrepaired tetralogy of fallot
unrepaired vsd
unroofed right upper pulmonary vein
unruptured aaa
unsaturated fats (monounsaturated, polyunsaturated)
unsaturated fatty acids
unstable angina
unstable angina (unstable coronary artery disease)
unstable or decompensated ccd
unstructured exercise (self‑directed walking)
upfront combination pah therapy
upper extremity hypertension
upper‑limb aerobic exercise
upper‑lower extremity systolic blood pressure gradient
upper‑to‑lower extremity systolic bp gradient >20 mm hg
upright treadmill exercise testing
upstream administration
upstream therapy
upstream therapy (e.g., anti‑inflammatory approach)
urban heat island
urban heat island effect
urea nitrogen
urgent cabg
urgent coronary artery bypass grafting (cabg)
urgent coronary revascularization
urgent repair (clinical recommendation)
urgent revascularization
urinalysis markers: hemoglobin a1c (hba1c) (used in diabetes control)
urinary sodium
urinary sodium excretion
urinary tract infection
urine output (reduced urine output)
us food and drug administration (fda)
us preventive services task force recommendations (aspirin, statin use)
use of ace inhibitors or arbs for pad (pm‑2)
use of aspiration thrombectomy
use of intracoronary imaging (ivus, oct)
use of smokeless tobacco (e.g., snus, snuff)
use of vasodilators in hypertension and renal protection
use of β‑blockade with vasoconstrictor to reduce heart rate and contractility
utility assistance needs
u‑shaped oxygenation–mortality relationship


















v2–v3 lead criteria (male/female thresholds)
vaccination against respiratory illnesses
vaccine‑associated vascular complications (influenza, sars‑cov‑2)
vacuum‑assisted percutaneous mechanical thrombectomy
vagal nerve stimulation
vaginal delivery
vaginal delivery (low‑risk aortic cases)
vaginal delivery (preferred first‑choice delivery option)
vaginal delivery (when appropriate for aortic diameter <4.0 cm)
vaginal delivery with regional anesthesia
vagus nerve stimulation (vns)
val-heft (valsartan heart failure trial)
valiant study (heart failure post‑mi predictors)
valsalva maneuver
valsalva maneuver (biomarker)
valsalva maneuver (during labor)
valsalva maneuver (echo provocation)
valsalva maneuver (intense isometric exercise)
valsalva maneuver / amyl nitrite provocation
valsartan
valsartan (angiotensin ii receptor blocker) for early hcm
valsartan heart failure trial (vht)
value assessment of drug/device/intervention
valve
valve abscess
valve academic research consortium (varc) criteria
valve academic research consortium (varc) – 5‑class grading for paravalvular leak severity
valve academic research consortium‑2 (varc‑2) criteria
valve anatomy
valve anatomy (favorable/unfavorable)
valve anatomy (leaflets, chordae, annulus)
valve anatomy and hemodynamics assessment
valve anatomy and motion
valve anatomy assessment
valve apparatus
valve area
valve area (cm²)
valve area (effective orifice area)
valve area / projected valve area
valve area determination
valve area index
valve area index (cm² m⁻²)
valve area indexed to body size
valve area measurement
valve area measurement by continuity equation
valve area progression (0.1 cm²/year)
valve areas
valve bioprosthesis
valve calcification
valve calcification/fibrosis
valve center (comprehensive valve center)
valve choice
valve chords
valve clinic organization and structure
valve clip (mitral valve clip)
valve commissures
valve commissurotomy
valve coordinator (dedicated role)
valve degeneration
valve degeneration (early bioprosthetic degeneration)
valve dehiscence
valve design
valve deterioration
valve disease
valve disease / valve lesions
valve disease burden
valve disease guidelines
valve disease imaging (ct, pet/ct, echocardiography)
valve disease management
valve disease prevention (e.g., systolic blood pressure, calcific aortic stenosis)
valve disease prognosis and re‑operation risks
valve disease progression
valve disease severity
valve disease severity assessment
valve disorder
valve durability
valve durability (long‑term, >5 years)
valve durability and degeneration
valve durability data (20‑year, 5‑year)
valve durability data (≥10 years)
valve durability vs age
valve dysfunction
valve dysfunction (mild, moderate, severe)
valve echocardiographer (pre‑ and post‑procedural assessment)
valve enlargement procedures
valve evaluation
valve failure
valve failure (regurgitation of the neoaortic valve)
valve function
valve function assessment
valve function improvement
valve gradient
valve gradient ≥10 mm hg
valve gradients
valve hemodymamics
valve hemodynamics
valve imaging
valve imaging assessment
valve implantation baseline hemodynamics
valve implantation outcomes
valve infection
valve intervention
valve intervention (aortic valve replacement, avr)
valve intervention (replacement, repair)
valve intervention (timing, type, approach)
valve interventions
valve leaflet motion
valve leaflet opening/closing angles
valve leaflet pathology
valve leaflet thrombosis
valve leaflets
valve lesion
valve lesion staging (stages c, d; stage c1)
valve mobility
valve morphology
valve morphology (bicuspid, unicuspid, thickening, perforations, clefts, calcification, stenosis)
valve morphology and function (stenosis, regurgitation)
valve morphology evaluation
valve obstruction
valve outcomes
valve pathology
valve pathology and diagnostics.
valve pathology evaluation
valve perforation
valve performance
valve position (aortic, mitral)
valve position (pulmonic, aortic)
valve pressure half‑time
valve prosthesis
valve prosthesis infection
valve prosthesis maintenance
valve prosthesis mismatch
valve prosthesis selection (bioprosthetic vs mechanical)
valve prosthesis selection (mechanical vs biological)
valve regurgitation
valve regurgitation (general)
valve regurgitation (including paravalvular leak)
valve regurgitation (mitral, aortic, etc.)
valve regurgitation (severe)
valve regurgitation evaluation
valve reintervention
valve remodeling (lv remodeling)
valve reoperation risk
valve repair
valve repair (aortic)
valve repair (mitral)
valve repair criteria (lvef > 64 %, lvesd < 37 mm)
valve repair durability
valve repair freedom from reoperation
valve repair indications (≤½ posterior leaflet)
valve repair outcomes
valve repair rates
valve repair success rate
valve repair thresholds (lvesd ≈ 40 mm, lvef ≈ 60 %)
valve repair versus replacement
valve repair vs. replacement strategy
valve repair with prosthetic material
valve repair/replacement
valve repair/valve prosthesis type
valve reparability
valve replacement
valve replacement (aortic)
valve replacement (mechanical on‑x aortic valve)
valve replacement (mechanical/electronic)
valve replacement (surgical & transcatheter)
valve replacement (surgical)
valve replacement (transcatheter)
valve replacement / repair
valve replacement durability data (5‑year tavi, 20‑year bioprosthetic)
valve replacement freedom from recurrence
valve replacement in high‑risk patients
valve replacement in low‑risk patients
valve replacement indications
valve replacement outcomes
valve replacement recommendations
valve replacement strategy (savr vs. tavi)
valve replacement surgery
valve replacement timing criteria
valve resuspension
valve re‑intervention
valve selection
valve severity
valve stenosis
valve stent (bioprosthetic valve)
valve substitutes
valve surgery
valve surgery (open heart)
valve surgery (repair/replacement)
valve surgery (timing of aortic/mitral valve surgery)
valve surgery / valve replacement
valve surgery for ie
valve surgery volume
valve surgical outcomes
valve surveillance guidelines
valve tethering
valve thickening
valve thrombosis
valve thrombosis (incl. mechanical valve thrombosis)
valve thrombosis (including subclinical leaflet thrombosis)
valve thrombosis (see sections 11.6 & 11.8)
valve thrombosis prevention
valve type (aortic, mitral, bioprosthetic)
valve type and size
valve type selection
valve type selection (mechanical vs. bioprosthetic)
valve vegetation
valve-related bacteremia (e.g., staphylococcus aureus bacteremia)
valved conduit
valved prosthesis (bioprosthetic)
valved prosthesis (mechanical)
valved‐conduit aortic root replacement
valves
valve‑centric hemodynamic metrics (e.g., effective regurgitant orifice area)
valve‑in‑valve (viv)
valve‑in‑valve (viv) procedure
valve‑in‑valve (viv) procedures
valve‑in‑valve catheter intervention
valve‑in‑valve implantation
valve‑in‑valve procedure
valve‑in‑valve procedures
valve‑in‑valve tavi
valve‑in‑valve tavi (viv tavi)
valve‑prosthesis interaction
valve‑related complications
valve‑related morbidity and mortality.
valve‑related sepsis / septic shock
valve‑sparing aortic root procedures
valve‑sparing aortic root repair (david procedure)
valve‑sparing aortic root replacement
valve‑sparing aortic root replacement (vsrr)
valve‑sparing procedure
valve‑sparing procedures / valve‑spare surgery
valve‑sparing root repair
valve‑sparing root replacement
valve‑sparing root replacement (vsrr)
valve‑sparing surgery
valve replacement (surgical / transcatheter)
valvular
valvular af
valvular anatomy
valvular aortic stenosis
valvular atrial fibrillation
valvular atrial fibrillation (non‑valvular)
valvular calcification
valvular degeneration
valvular disease
valvular disease (mitral valve prolapse, pulmonary stenosis)
valvular disease management
valvular dysfunction
valvular dysfunction (e.g., mitral regurgitation)
valvular dysplasia
valvular function
valvular function evaluation
valvular heart disease
valvular heart disease (management)
valvular heart disease (mitral, aortic)
valvular heart disease (vhd)
valvular heart disease (vhd) – mild, moderate, severe
valvular heart disease in pregnancy
valvular heart disease with atrial fibrillation
valvular heart disease – valve replacement or repair for significant stenosis or regurgitation
valvular heart disease, severe aortic stenosis
valvular heart surgery
valvular insufficiency
valvular involvement
valvular lesions/valve dysfunction
valvular perforation
valvular pulmonary stenosis
valvular pulmonary stenosis (ps)
valvular regurgitant lesion
valvular regurgitation
valvular regurgitation evaluation
valvular replacement
valvular stenosis
valvular thickening.
valvular thrombosis risk (~5 %)
valvular pulmonary stenosis (moderate/severe)
valvuloplasty (general)
val‑heft trial
vaping / electronic nicotine‑delivery devices
vaping products
vardenafil
varenicline
varenicline (nicotine replacement)
varenicline (partial nicotine agonist)
varenicline (treatment)
varenicline therapy
variable early follow‑up
variable penetrance
varian medical systems
variant aortic arch anatomy
variant interpretation
variant of uncertain significance
variant of uncertain significance (vus)
variant of unknown significance (vus)
variant pathogenicity
variant reclassification
variant transthyretin (attrv)
variant transthyretin amyloidosis (attrv)
variants of unknown significance (vus)
varices
variosa‑af study (sleep apnea variability)
vasa vasorum
vascular
vascular (as a related medical specialty)
vascular (cardiovascular) disease
vascular abnormalities (extracoronary)
vascular access
vascular access (femoral artery)
vascular access approach for pci (radial vs femoral)
vascular access complications
vascular access constraints
vascular anatomy compatibility
vascular and endovascular surgery society (vess)
vascular anomalies (magnetic resonance angiographic features)
vascular assessment
vascular assessment (photoplethysmography, laser doppler flowmetry, duplex ultrasonography, ct angiography, mr angiography, angiography)
vascular bruit (epigastric, periumbilical, groin)
vascular care
vascular cause (of death or embolism)
vascular cell adhesion molecule‑1 (vcam‑1)
vascular center
vascular complications
vascular complications (access‑related)
vascular complications (access‑site, systemic)
vascular complications (wall injury, remodeling)
vascular complications from device insertion
vascular complications of cancer treatments (vascular‑related heart disease)
vascular conduit
vascular death
vascular death after ami
vascular dilator reserve impairment
vascular disease
vascular disease (general)
vascular disease (risk factor for hf)
vascular dissection
vascular dysfunction
vascular dysfunction (von willebrand factor activity)
vascular ehlers‑danlos syndrome
vascular ehlers‑danlos syndrome (veds)
vascular emboli / embolization (including stroke, septic pulmonary infarcts, mycotic aneurysm)
vascular endothelial cytoprotection
vascular event
vascular events
vascular events (general)
vascular events (including mi and stroke)
vascular examination of legs and feet
vascular follow‑up guidelines (surgery & endovascular)
vascular function














vascular graft
vascular graft infection
vascular graft infection epidemiology
vascular graft infections
vascular guidelines
vascular guidelines for chronic limb‑threatening ischemia
vascular health institute (vascular‑medicine focus)
vascular health outcomes (e.g., limb‑related events, mortality)
vascular imaging
vascular imaging (duplex ultrasound, duplex surveillance)
vascular imaging modalities
vascular imaging specialist
vascular imaging technology
vascular inspection of lower extremities
vascular instrumentation
vascular intervention
vascular interventional radiology
vascular involvement
vascular laboratory
vascular laboratory assessment
vascular laboratory setting
vascular laboratory‑based duplex ultrasound
vascular load
vascular medicine
vascular medicine in aortic disease follow‑up
vascular medicine outcomes program (vamos)
vascular morbidity
vascular mortality
vascular nursing
vascular occlusion
vascular operations
vascular outcomes study (voyager pad)
vascular outcomes study of asa (voyager pad)
vascular pathogenesis
vascular pathology
vascular quality initiative (clinical outcomes database)
vascular quality initiative (vqi)
vascular quality initiative (vqi) database
vascular quality‑of‑life questionnaire
vascular remodeling
vascular resistances
vascular revascularization
vascular review of systems (for pad)
vascular review of systems (vascular review)
vascular review of systems for lower extremity pad
vascular review of systems for lower‑extremity pad (qm‑1)
vascular ring
vascular ring anatomical classifications (complete, incomplete, double aortic arch, etc.)
vascular ring or sling
vascular ring repair
vascular rings
vascular risk
vascular risk factors
vascular risk factors (e.g., smoking, secondhand smoke)
vascular risk factors in heart disease
vascular risk levels
vascular screening
vascular screening programs
vascular specialists
vascular stiffness
vascular surgeon
vascular surgery
vascular surgery (open reconstruction)
vascular surgery (procedural specialty)
vascular surgery (svs) and thoracic surgery (sts) guidelines
vascular surgery / endovascular intervention
vascular surgery fellowship
vascular surgery follow‑up
vascular surgery outcomes studies
vascular surgery residency
vascular surgery support
vascular surveillance protocols (duplex)
vascular testing interventions
vascular tolerance (nitrate tolerance)
vascular toxicities of cancer treatments
vascular toxicity
vascular ultrasound screening (for pad)
vascular/heart‑related biotech: cytokinetics, cvrx, cyclerion, etc.
vascular‑related adverse events
vasculature
vasculitides
vasculitis (as a cause of lower‑extremity arterial disease)
vasculopathy screening
vasoactive agents
vasoactive medications
vasoactive peptides
vasoconstriction
vasoconstrictors
vasoconstrictors (non‑inotropic)
vasodilation
vasodilator stress cardiac magnetic resonance
vasodilator stress cmr
vasodilator therapy
vasodilator therapy (e.g., verapamil)
vasodilator therapy (for mr)
vasodilator therapy (hydralazine)
vasodilator therapy, nitrates
vasodilators
vasodilators (nesiritide, nitroglycerin, nitroprusside, clevidipine)
vasopressin antagonists
vasopressors
vasospastic angina
vasospastic angina (vsa)
vaughan williams class ic antiarrhythmic agents
ve/vco₂ slope
vegetables, fruits, legumes, nuts, whole grains, fish
vegetarian/vegan diet
vegetation
vegetation mobility
vegetation size
vegetation size >10 mm
vegetations
vegetations (mobile >10 mm)
vegf inhibitors (sorafenib)
vein bypass graft
vein conduit suitability
vein graft failure
vein graft vs. ptfe graft (bypass)
vein mapping
velocity pressure gradient (vpg)
velocity‑encoded cine mr imaging
vena contracta
vena contracta (cm)
vena contracta (vc)
vena contracta analysis
vena contracta width (≥0.7 cm)
venoarterial extracorporeal membrane oxygenation (va‑ecmo)
venous arterialization
venous autograft
venous hypertension (elevated fontan pressure)
venous return pathways
venous stasis
venous stenosis
venous thromboembolic disease
venous thromboembolism
venous thromboembolism (vte)
venous thromboembolism (vte) prophylaxis
venous thromboembolism (vte) prophylaxis in cancer patients
veno‑arterial extracorporeal membrane oxygenation (va‑ecmo)
veno‑venous collaterals
ventilation
ventilation strategies in achd surgery
ventilation to co₂ output slope
ventilator strategies
ventilatory anaerobic threshold
ventilatory efficiency
ventilatory efficiency (ve/vco₂ slope)
ventilatory gas exchange measurements
ventricular activation pattern
ventricular anatomy and function
ventricular and vascular function impact
ventricular and vascular interactions
ventricular arrhythmia
ventricular arrhythmia (va)
ventricular arrhythmia (va) ablation
ventricular arrhythmia / tachyarrhythmia
ventricular arrhythmia burden
ventricular arrhythmia monitoring
ventricular arrhythmia risk score
ventricular arrhythmias
ventricular arrhythmias (5.8% prevalence)
ventricular arrhythmias (aaoca presentation)
ventricular arrhythmias (atrial and ventricular)
ventricular arrhythmias (frequent or complex repetitive forms)
ventricular arrhythmias (sudden cardiac death risk)
ventricular arrhythmias (tachyarrhythmias)
ventricular arrhythmias (va)
ventricular arrhythmias (vas)
ventricular arrhythmias (vt)
ventricular arrhythmias / icd shocks
ventricular arrhythmias / malignant arrhythmias
ventricular arrhythmias in achd
ventricular arrhythmias occurring >48 hours post‑reperfusion
ventricular arrhythmias related to antiarrhythmic therapy
ventricular assist device (vad)
ventricular assist device (vad) / durable vad
ventricular assist device as a bridge to transplant
ventricular assist device therapy versus intensive medical therapy
ventricular assist devices (vads) – specifically left ventricular assist devices (lvads)
ventricular deformation imaging
ventricular depolarization pattern
ventricular diastolic function
ventricular diastolic volume
ventricular dilation
ventricular dilation / dysfunction
ventricular dimensions
ventricular dysfunction
ventricular dysfunction (general)
ventricular dysfunction (left‑ventricular systolic dysfunction)
ventricular dysfunction (mentioned in related contexts)
ventricular dysfunction (mild, moderate, severe)
ventricular dysfunction (right or left)
ventricular dysfunction (subpulmonary & systemic)
ventricular dysfunction, systolic and diastolic
ventricular dyssynchrony
ventricular end‑diastolic pressure
ventricular end‑diastolic volume
ventricular end‑systolic volume
ventricular enlargement
ventricular enlargement (mild)
ventricular enlargement after myocardial infarction
ventricular fibrillation
ventricular fibrillation (implied)
ventricular fibrillation (vf)
ventricular fibrosis
ventricular flutter
ventricular free‑wall rupture
ventricular function
ventricular function (general)
ventricular function (systemic and subpulmonary)
ventricular function assessment
ventricular function monitoring
ventricular hypertrophy
ventricular hypertrophy (rv or lv)
ventricular inflow obstruction (pulmonary venous & systemic)
ventricular involvement
ventricular outflow obstruction
ventricular outflow‑tract obstruction (left ventricular outflow‑tract obstruction)
ventricular overload
ventricular pacing
ventricular pacing burden
ventricular pacing burden (>40 %)
ventricular pacing percentage
ventricular pacing reduction
ventricular physiology after fontan
ventricular preexcitation
ventricular preload
ventricular preload, afterload, contractility
ventricular pressures
ventricular pre‑excitation
ventricular rate
ventricular rate control
ventricular rate control guidelines
ventricular rates
ventricular relaxation
ventricular remodeling
ventricular remodeling acceleration (due to exercise)
ventricular remodeling, left and right
ventricular response
ventricular response reduction
ventricular scar / fibrosis
ventricular scar detection
ventricular septal defect
ventricular septal defect (vsd)
ventricular septal defect (vsd) as a common comorbidity
ventricular septal defect closure strategy
ventricular septal defect repair techniques (patch, valve‑patch, double‑patch)
ventricular septal defects
ventricular septal geometry
ventricular septal myectomy
ventricular septal rupture
ventricular septal rupture (vsr)
ventricular septal thickness
ventricular size
ventricular size and function (subpulmonary left ventricle)
ventricular size and systolic function
ventricular synchrony
ventricular systolic dysfunction
ventricular systolic dysfunction (moderate vs. severe, residual dysfunction post‑repair)
ventricular systolic function
ventricular systolic function assessment
ventricular tachyarrhythmia
ventricular tachyarrhythmias
ventricular tachyarrhythmias (vt/vf)
ventricular tachycardia
ventricular tachycardia (monomorphic)
ventricular tachycardia (nonsustained)
ventricular tachycardia (vt)
ventricular tachycardia (vt) – monomorphic, sustained, reentrant
ventricular tachycardia / non‑sustained ventricular tachycardia
ventricular tachycardia inducibility
ventricular tachycardia isthmus
ventricular tachycardia outcomes
ventricular tachycardia risk
ventricular tachycardia substrate
ventricular tachycardia substrate characteristics
ventricular tachycardia substrate characterization
ventricular tachycardia suppression
ventricular tachycardia triggers
ventricular tachycardia/fibrillation (vt/vf)
ventricular tachycardia‑related anatomical isthmuses
ventricular volume and function
ventricular volumes
ventricular wall motion abnormalities
ventricular‑ventricular interaction
ventricular–atrial coupling
ventricular preexcitation
ventricular size
ventriculography
ventriculotomy
ventri­cular tachycardia (vt)
verapamil
verapamil (av‑nodal blocker)
verapamil (nondihydropyridine calcium channel blocker)
verapamil (nondihydropyridine calcium‑channel blocker)
verapamil therapy
verbal artery tortuosity index (vascular complication indicator)
verdict trial (very early vs deferred invasive evaluation)
vericiguat
vericiguat (soluble guanylate cyclase stimulator)
vericiguat for hfref with high natriuretic peptides
vericiguat trial (vericiguat in hfref)
vertebral arterial tortuosity
vertebral artery
vertebrobasilar insufficiency
verve therapeutics
very high‑risk ascvd (table 10)
very high‑risk definition for future ascvd events (history of multiple events or one major event plus ≥ 2 high‑risk conditions)
very severe aortic stenosis
very‑low ldl‑c
vess
vess (vascular & endovascular surgery society)
vess (vascular and endovascular surgery society)
vess (venous and vascular surgery society)
vessel patency
vessel wall inflammation in aneurysm formation
vessel wall layers (intima, media, adventitia)
vest trial (vest prevention of early sudden death)
veterans administration cooperative study (vacs)
vf (ventricular fibrillation)
vhd (valvular heart disease)
viability imaging
viable myocardium
victoria trial
vigorous exercise
vigorous‑intensity aerobic activity
vigorous‑intensity aerobic physical activity
vigorous‑intensity exercise
vigorous‑intensity physical activity
viral myocarditis
viral myocarditis (coxsackievirus b3‑induced, viral myocarditis)
viral serology: hcv, hiv, lyme borreliosis, influenza
viral titers
viral tropism
virchow’s triad
viridans streptococci endocarditis
viridans streptococci, streptococcus bovis, staphylococcus aureus, enterococci
virtex registry
virtual coaching
virtual or home‑based care delivery.
virtual surgical planning / 3‑d modelling of intracardiac baffles (dorv)
visceral adiposity
visceral artery stenting
visceral ischemia
visceral malperfusion
visceral organ protection
visceral vessel avulsion
visual disturbances
vital signs














vital‑heart failure trial (vitamin d supplementation)
vitamin b‑complex supplementation
vitamin c & e supplementation (antioxidants)
vitamin c supplementation
vitamin d deficiency / hypovitaminosis d
vitamin d supplementation
vitamin e supplementation
vitamin k antagonist
vitamin k antagonist (e.g., warfarin)
vitamin k antagonist (vka)
vitamin k antagonist (vka) therapy
vitamin k antagonist (warfarin)
vitamin k antagonists
vitamin k antagonists (anticoagulation)
vitamin k antagonists (e.g., warfarin)
vitamin k antagonists (e.g., warfarin, phenprocoumon)
vitamin k antagonists (vka)
vitamin k antagonists (vkas)
vitamin k antagonists (vkas) – warfarin
vitamin k antagonists (warfarin)
vitamin k1
vitamins (as supplements)
vitamins and nutritional supplements
vitamins c, d, e, beta‑carotene
vitamin d supplementation
vitamin‑k antagonist (vka)
vitamin‑k antagonist (vka) anticoagulation
vitamin‑k antagonist (vka) therapy
vitamin‑k guided anticoagulation strategy
vitamin c
vitamin d
vitamin d supplementation
vitamin d supplementation (serum 25‑hydroxyvitamin d)
vitamin e
vitamin e supplementation
vitamin k
vitamin k antagonist
vitamin k antagonist (vka)
vitamin k antagonists
vitamin k antagonists (e.g., warfarin)
vitamin k antagonists (vkas)
vitamin k intake
vivid registry (valve‑in‑valve international data)
vka (vitamin k antagonist) anticoagulation
vka (vitamin k antagonist)
vka (warfarin) vs doac comparison
vka anticoagulation
vka therapy
voltage mapping (bipolar endocardial voltage mapping)
volume depletion
volume overload
volume overload from valve regurgitation
volume overload impact on pulmonary circulation during pregnancy
volume resuscitation
volume status
volume status optimization
volume‑outcomes relationship for open repair
volume–outcome relationship
von willebrand factor (vwf)
vorapaxar
vorapaxar (par‑1 antagonist)
vorapaxar (thrombin receptor antagonist)
voyager pad trial
voyager trial (anticoagulation with aspirin)
vo₂ max (maximal oxygen consumption)
vo₂ max / maximal metabolic equivalent (mets)
vsd (ventricular septal defect)
vsd closure
vsd closure (surgical or percutaneous)
vt (ventricular tachycardia)
vte prophylaxis
vulnerable atherosclerotic plaques
v‑heft i (vasodilator heart failure trial)
v‑wave ltd.** (cardiac imaging/diagnostic firm)














w.l. gore (surgical/medical devices)
waist circumference
waist circumference (obesity marker)
waist‑hip ratio
waitlist mortality
waitlist outcomes
walking capacity / walking distance
walking distance
walking distance / maximal walking distance – functional capacity metric
walking distance and speed progression
walking exercise therapy
walking impairment
walking impairment / claudication
walking performance
walking performance (functional outcome)
walking performance / functional status
walking performance metrics (time to onset of symptoms, maximal walking time)
walking test (provocative maneuver)
wall motion abnormalities
wall shear stress
wall strength vs. wall stress dynamics
wall stress (saccular vs fusiform aneurysm)
wall stress and ventricular geometry
wall stress in the aorta
wall thickening / aortitis
wall thickness measurement
wall thickness ≥15 mm
wall‑motion abnormalities
wall‑motion abnormality
wall‑stress reduction strategies
warden procedure
warden procedure (repair method)
warfarin
warfarin (vitamin k antagonist, vka)
warfarin (vitamin k antagonist)
warfarin embryopathy
warfarin embryopathy / teratogenicity
warfarin therapeutic window (inr > 1.9)
warfarin therapy (in the context of graft patency)
warfarin therapy (therapeutic range)
warfarin‑associated bleeding
warfarin‑associated intracranial hemorrhage
watch trial (warfarin & antiplatelet therapy)
watchful waiting
watchful waiting (conservative management)
watchman device
watchman device (including watchman flx)
watchman device (left atrial appendage closure device)
water‑pipe (hookah) smoking
wave (warfarin antiplatelet vascular evaluation) trial
wave trial
weaning of mechanical support
wearable and remote monitoring technologies
wearable cardiac device
wearable cardioverter‑defibrillator
wearable cardioverter‑defibrillator (wcd)
wearable devices
wearable devices (e.g., smart watches)
wearable ecg monitoring
wearable heart‑monitoring devices
wearable sensors for pad‑related physiologic changes
wearable technology
wearables (remote monitoring devices)
wearables, telemonitoring, device monitoring
weight assessment
weight loss
weight loss (as a benefit)
weight loss (as prevention strategy)
weight loss (primary and secondary prevention of af)
weight loss / obesity
weight loss / weight maintenance
weight loss / weight management
weight loss / weight reduction
weight loss, sodium reduction, dietary patterns (dash)
weight loss/obesity management
weight management
weight management (obesity, bmi reduction)
weight management (pharmacologic and non‑pharmacologic therapies for cardiovascular risk)
weight management / obesity
weight management / weight loss
weight management/weight reduction
weight monitoring
weight/fluid overload
weight‑loss drugs
weight‑loss interventions
wheelchair confinement
whf (world heart federation)
white blood cell (wbc) count with differential
who cardiovascular risk classification (modified iii/iv)
who guidelines on body‑mass index for asian populations
who pulmonary hypertension groups 1, 3, 4
whole genome sequencing
whole grains
whole‑grain diet
wifi (wound‑ischemia‑foot‑infection) classification tool
wifi classification (wound, ischemia, foot infection)
wildfire smoke
wildfire smoke exposure
wild‑type transthyretin (attrwt)
wild‑type transthyretin amyloidosis (attrwt)
wild‑type transthyretin cardiac amyloidosis
wild‑type/transthyretin‑derived amyloidosis
wilkins morphology score
wilkins score (echocardiographic scoring system for mitral stenosis)
williams syndrome
williams syndrome (7q11.23 deletion) – supravalvar aortic stenosis, branch pulmonary artery stenosis, supravalvar pulmonary stenosis, coronary ostial stenosis, qtc prolongation, mid‑aortic narrowing syndrome
williams syndrome (elastin‑associated arteriopathy)
williams‑beuren syndrome
woest
wolff‑parkinson‑white (wpw) syndrome
wolff‑parkinson‑white pattern
wolff‑parkinson‑white syndrome
wolff–parkinson–white syndrome (wpw)
women (gender representation)
women‑specific ischemia risk
women’s heart clinic
women’s heart failure presentation and outcomes
wood units
wood units (measure of pulmonary vascular resistance)
wood units (unit of pvr measurement)
wood units (wu)
work and career disruptions
world health organization (who) class iv
world health organization (who) functional class
world health organization (who) risk score for pregnancy and cardiac disease
world heart federation (whf)
worsening heart failure
worsening heart failure symptoms
worsening heart‑failure symptoms (increased oxygen requirement, inotropic support)
worsening renal function
wound care
wound care, infection management, and pressure off‑loading as adjuncts
wound complications, vascular fragility, bleeding complications
wound healing
wound healing (vascular component)
wound healing / amputation‑free survival in clti
wound healing / complete wound healing
wound healing and limb salvage strategies for clti
wound healing in pad/clti
wound healing in peripheral artery disease
wound infection
wound, ischemia, and foot infection (wifi) classification
wound, ischemia, foot infection (wifi) classification
wound‑care specialist
wound‑healing therapies
wpw (wolff‑parkinson‑white)
wpw (wolff–parkinson–white) syndrome



xenograft
yale university
young adulthood (18‑26 years) chd care
zahara (zwangerschap bij aangeboren hartafwijking – pregnancy in women with congenital heart disease) study
zanchetti et al. (hypertension bp lowering)
zic3, shroom3, grk5, anks3, nodal, cfc1, lefty2, gdf1, smad2, acvr2b
zinc deficiency
zinc supplementation
zoll
zone 0–11 aortic landing zones
zone 0 thoracic endovascular aortic repair (landing zone classification)
zone 1/2 landing for thoracic stent graft
zwolle score
z‑score
z‑score for aortic diameter (turner‑specific)
α‑methyldopa
β‑1 receptor blockade
β‑adrenergic blockade
β‑adrenergic blocking drugs
β‑adrenergic receptor activation
β‑adrenoceptor antagonists
β‑blocker
β‑blocker (beta‑blocker)
β‑blocker (beta‑blocker) therapy
β‑blocker dosing, sequencing, and uptitration
β‑blocker effects (used in sotalol)
β‑blocker therapy
β‑blocker therapy / β‑blockade
β‑blockers
β‑blockers (beta blockers)
β‑blockers (cardioselective and non‑selective)
β‑blockers (e.g., bisoprolol)
β‑blockers (e.g., metoprolol, carvedilol, bisoprolol)
β‑blockers (e.g., nebivolol, bisoprolol, digoxin‑related β‑blockade)
β‑blockers (pre‑operative, postoperative)
‘no‑touch’ technique
“at risk” for hf (stage a)
“dyspnea paroxysmal”
“edema cardiac”
“pill‑in‑the‑pocket” approach
• 2021 aha/acc chest pain guideline
• aha/acc/accp/aspc/nla/pcna chronic coronary disease guideline
• bari‑2d
• courage
• ischemia
• stich
≥10 % lvef decline to <50 %
